---
document_datetime: 2023-09-21 21:10:52
document_pages: 222
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/xeljanz-h-c-004214-ii-0039-epar-assessment-report-variation_en.pdf
document_name: xeljanz-h-c-004214-ii-0039-epar-assessment-report-variation_en.pdf
version: success
processing_time: 269.9051278
conversion_datetime: 2025-12-26 17:51:14.537776
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
19 May 2022 EMA/CHMP/623552/2022

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Xeljanz

International non-proprietary name: tofacitinib

Procedure No. EMEA/H/C/004214/II/0039

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................6                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................6                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................7                       |
| 2.1. Introduction.........................................................................................................7 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................8           |
| 2.1.2. About the product............................................................................................11      |                                                                                                         |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                            | ......11                                                                                                |
| 2.1.4. General comments on compliance with GLP,                                                                             | GCP.................................................11                                                  |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................11          |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................12                                             |
| 2.2.2. Discussion on non-clinical aspects......................................................................13           |                                                                                                         |
| 2.2.3. Conclusion on the non-clinical aspects................................................................14             |                                                                                                         |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................14    |
| 2.3.1. Introduction....................................................................................................14   |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................16      |                                                                                                         |
| 2.3.1. PK/PD modelling..............................................................................................16      |                                                                                                         |
| 2.3.2. Discussion on clinical pharmacology...................................................................38             |                                                                                                         |
| 2.3.3. Conclusions on clinical pharmacology                                                                                 | .................................................................40                                     |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................40    |
| 2.4.1. Dose response study........................................................................................41        |                                                                                                         |
| 2.4.2. Main study......................................................................................................42   |                                                                                                         |
| 2.4.3. Discussion on clinical efficacy ..........................................................................           | 105                                                                                                     |
| 2.4.4. Conclusions on the clinical efficacy...................................................................              | 113                                                                                                     |
| 2.5. Clinical safety ..................................................................................................     | 113                                                                                                     |
| 2.5.1. Discussion on clinical safety ............................................................................           | 174                                                                                                     |
| 2.5.2. Conclusions on clinical safety ..........................................................................            | 179                                                                                                     |
| 2.5.3. PSUR cycle                                                                                                           | ................................................................................................... 179 |
| 2.6. Risk management plan......................................................................................             | 179                                                                                                     |
| 2.7. Update of the Product information ......................................................................               | 214                                                                                                     |
| 2.7.1. User consultation...........................................................................................         | 214                                                                                                     |
| 3. Benefit-Risk Balance............................................................................214                      |                                                                                                         |
| 3.1. Therapeutic Context .........................................................................................          | 214                                                                                                     |
| 3.1.1. Disease or condition.......................................................................................          | 214                                                                                                     |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 215                                                                                                     |
| 3.1.3. Main clinical studies                                                                                                | ....................................................................................... 215             |
| 3.2. Favourable effects ............................................................................................        | 216                                                                                                     |
| 3.3. Uncertainties and limitations about favourable effects                                                                 | ........................................... 217                                                         |
| 3.4. Unfavourable effects.........................................................................................          | 217                                                                                                     |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | ....................................... 218                                                             |
| 3.6. Effects Table....................................................................................................      | 219                                                                                                     |
| 3.7. Benefit-risk assessment and discussion...............................................................                  | 221                                                                                                     |
| 3.7.1. Importance of favourable and unfavourable effects                                                                    | ............................................ 221                                                        |

<div style=\"page-break-after: always\"></div>

3.7.2. Balance of benefits and risks  ...........................................................................  221

3.7.3. Additional considerations on the benefit-risk balance ......................................... 221

3.8. Conclusions .....................................................................................................  221

4. Recommendations ...............................................................................  221

5. EPAR changes  ......................................................................................  222

<div style=\"page-break-after: always\"></div>

## List of abbreviations

%CV

percent coefficient of variation

ACR

American College of Rheumatology

AE(s)

adverse event(s)

AS

ankylosing spondylitis

ASAS

Assessment of Spondylo Arthritis International Society

ASAS20

≥20% increase from Baseline and ≥1 unit increase in at least 3 domains on a scale of 0 to 10, and no worsening of ≥20% and ≥1 unit in the remaining domain

ASAS40

≥40% increase from Baseline and ≥2 units in at least 3 domains on a scale of 0 to 10 and no worsening at all in the remaining domain

ASDAS(CRP)

Ankylosing Spondylitis Disease Activity Score using C-Reactive Protein

ASQoL

Ankylosing Spondylitis Quality of Life

ATE

arterial thromboembolism

AUC

area under the plasma concentration-time curve over a dosing interval area under the plasma concentration-time curve over a 24-hour period bioavailability

AUC24

BA

BASFI

Bath Ankylosing Spondylitis Functional Index

BASMI

Bath Ankylosing Spondylitis Metrology Index

bDMARD

biological disease-modifying antirheumatic drug

BE

bioequivalence

BID

twice-daily

Cavg

average plasma concentration

CHMP

Committee for Medicinal Products for Human Use

Cmax

maximum plasma concentration

Cmin

minimum plasma concentration

CO

Clinical Overview

CRP

C-reactive protein

Ctrough

predose plasma concentration

CV

cardiovascular

CYP

cytochrome P450

DDI

drug-drug interaction

DMARD

disease-modifying antirheumatic drug

DVT

deep vein thrombosis

ECS

Extrudable Core System

EMA

European Medicines Agency

EPITT

European Pharmacovigilance Issues Tracking Tool

E-R

exposure-response

ESI

Emerging Safety Issue

EU

European Union

FACIT-F

Functional Assessment of Chronic Illness Therapy-Fatigue

FDA

Food and Drug Administration

GI

gastrointestinal

hsCRP

high-sensitivity C-reactive protein

HV(s)

healthy volunteer(s)

HZ

herpes zoster

IC50

concentration producing 50% of maximum inhibition

IL

interleukin

ILD

Interstitial Lung Disease

IR

immediate release

IVIVC

in vitro in vivo correlation

JAK

Janus Kinase

MA

Marketing Authorisation

MAA

Marketing Authorisation Application

MACE

major adverse cardiovascular events

MAH

Marketing Authorisation Holder

mCIA

muramyl dipeptide/collagen induced arthritis

MedDRA

Medical Dictionary for Regulatory Activities

MTX

methotrexate

NMSC

non-melanoma skin cancer

non-IR

non-inadequate response/responder

NSAID-IR

non-steroidal anti-inflammatory drug inadequate responder

<div style=\"page-break-after: always\"></div>

| PASS       | Post-Authorisation Safety Study                                      |
|------------|----------------------------------------------------------------------|
| PBRER      | Periodic Benefit Risk Evaluation Report                              |
| PCS        | Physical Component Summary                                           |
| PD         | pharmacodynamics                                                     |
| PE         | pulmonary embolism                                                   |
| PGA        | Patient Global Assessment                                            |
| PK         | pharmacokinetics                                                     |
| PL         | patient leaflet                                                      |
| PMR        | Post-Marketing Requirement                                           |
| PR         | prolonged release                                                    |
| PsA        | psoriatic arthritis                                                  |
| PsO        | psoriasis                                                            |
| PY         | Patient-Years                                                        |
| QD         | once daily                                                           |
| RA         | rheumatoid arthritis                                                 |
| RMP        | Risk Management Plan                                                 |
| SAE(s)     | serious adverse event(s)                                             |
| SAWP       | Scientific Advice Working Party                                      |
| SBP        | Summary of Biopharmaceutic Studies and Associated Analytical Methods |
| SC         | subcutaneous                                                         |
| SCE        | Summary of Clinical Efficacy                                         |
| SCP        | Summary of Clinical Pharmacology                                     |
| SCS        | Summary of Clinical Safety                                           |
| SF-36v2    | Short Form - 36 Health Survey Version 2                              |
| SmPC       | Summary of Product Characteristics                                   |
| sNDA       | supplemental New Drug Application                                    |
| STAT       | signal transducer and activator of transcription                     |
| TB         | tuberculosis                                                         |
| TEAE(s)    | treatment-emergent adverse event(s)                                  |
| TNF-  /  | tumor necrosis factor alpha/gamma                                    |
| TNFi       | TNF inhibitor                                                        |
| TNFi-IR    | TNFi-inadequate response/responder                                   |
| UC         | ulcerative colitis                                                   |
| US         | United States                                                        |
| VTE        | venous thromboembolism                                               |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Pfizer Europe MA EEIG submitted to the European Medicines Agency on 2 April 2021 an application for a variation.

The following changes were proposed:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of active ankylosing spondylitis for Xeljanz prolonged release; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 18.1 of the RMP has also been submitted.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0227/2020 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0227/2020 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with  authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Armando Genazzani

Co-Rapporteur:

N/A

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 2 April 2021      |
| Start of procedure:                                  | 18 September 2021 |
| CHMP Rapporteur Assessment Report                    | 12 November 2021  |
| PRAC Rapporteur Assessment Report                    | 18 November 2021  |
| PRAC Outcome                                         | 2 December 2021   |
| CHMP members comments                                | 6 December 2021   |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 10 December 2021  |
| Request for supplementary information (RSI)          | 16 December 2021  |
| CHMP Rapporteur Assessment Report                    | 19 April 2022     |
| PRAC members comments                                | 26 April 2022     |
| PRAC Outcome                                         | 5 May 2022        |
| CHMP members comments                                | 10 May 2022       |
| Updated CHMP Rapporteur Assessment Report            | 12 May 2022       |
| CHMP Opinion                                         | 19 May 2022       |

## 2. Scientific discussion

## 2.1. Introduction

This  Type  II  variation  seeks  approval  of  tofacitinib  11  mg  prolonged-release  tablets  (dosed  QD)  for treatment of adult patients with active AS, as an alternative to the proposed posology of the tofacitinib 5 mg IR tablet (dosed BID). The 11 mg PR formulation is an ECS osmotic delivery tablet and is currently approved for QD dosing in RA and PsA.

The registration of Xeljanz prolonged-release tablets for RA was supported by an understanding of the exposure-response (E-R) relationships from the IR development programme which established the AUC or  Cavg  as  the  relevant  parameter  for  clinical  response.  Biopharmaceutic  studies  demonstrated equivalence between tofacitinib PR 11 mg QD and tofacitinib IR 5 mg BID in terms of Cmax and AUC. These data formed the basis to bridge efficacy and safety from 5 mg IR BID to 11 mg PR QD.

A similar bridging approach is herein utilised to support the use of 11 mg PR QD for the treatment of AS.

In adult patients with active AS, the safety and efficacy of Xeljanz have been established using the IR formulation, dosed at 5 mg BID. Efficacy and safety data principally included 1 completed Phase 2 doseranging double-blind, placebo-controlled efficacy and safety trial (Study A3921119) and pivotal Phase 3, double-blind, placebo-controlled efficacy and safety trial (Study A3921120). The recommended dose of the tofacitinib IR tablet for the treatment of AS is 5 mg BID (approved with variation II/35), the same tofacitinib dose as approved for the treatment of RA and PsA.

<div style=\"page-break-after: always\"></div>

## 2.1.1. Problem statement

## Disease or condition

Ankylosing Spondylitis (AS) is a chronic inflammatory rheumatic disease primarily affecting the sacroiliac joints  and  spine  and  is  part  of  the  family  of  related  SpA  disorders,  which  also  includes  PsA.  AS  or radiographic axial SpA is defined by the presence of definitive radiographic sacroiliitis based upon 1984 Modified New York classification criteria. AS causes chronic inflammation at the insertion of ligaments and tendons in the axial skeleton (entheses) and may progress from inflammation in the sacroiliac joints to sacroiliac and spine ankylosis over time. AS is also associated with peripheral arthritis, and enthesitis, and extra-articular manifestations such as anterior uveitis, psoriasis, and IBD. Osteoporosis is a common AS comorbidity. AS is often present for many years before it is diagnosed and typically presents in people between 20 and 40 years of age, with a higher prevalence in males, leading to back pain, stiffness, fatigue, progressive disability and adverse effects on health-related quality of life

## State the claimed the therapeutic indication

The proposed indication of Tofacitinib 11 mg PR once daily is for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.

## Epidemiology and risk factors, screening tools/prevention

The incidence and prevalence of AS for a range of countries and geographical regions are provided in the following table:

Table 1. Incidence andPrevalence of AnkylosingSpondylitisbyRegion

|                                | Incidenceper 100,000PY   | Prevalence (%)   | Reference(s)   |
|--------------------------------|--------------------------|------------------|----------------|
| Region                         |                          |                  |                |
| Overall                        | 0.44-15                  | 0.01 -1.8        | 16-37          |
| NorthernEuropeand NorthAmerica | 3-15                     | 0.1-1.8          | 16,19,21-28    |
| Iceland                        | 0.44                     |                  | 17,18          |
| Asia                           | 0.48                     | 0.01-0.54        | 16,17,20,29,30 |
| EasternEurope                  |                          | 0.07-0.12        | 31-33          |
| SouthernEurope                 |                          | 0.06-1.6         | 16,34,35       |
| MiddleEast                     |                          | 0.12-0.49        | 16             |
| Sub-SaharanAfrica              |                          | 0.02             | 36             |
| Mexico                         |                          | 0.1              | 37             |

The highest incidence rates have been reported in Northern Europe and North America, while the lowest have been reported in Asia and Iceland (Table 1). The reported prevalence across geographic regions follows a similar trend to the reported incidence. Mortality rates among patients with AS are 1.5 times higher than the general population, due to respiratory complications, and consequences from spinal fractures and other fractures.

Studies consistently report that AS occurs more frequently among men than women. One study in the United  States  reported  a  four-fold  higher  incidence  in  men  than  women  and  a  similar  difference  in incidence rates between men and women was reported in the Czech Republic. The prevalence reported among men is also similarly higher than the prevalence reported among women. Studies report a male to female ratio ranging from 1.2-9 to 1.

AS usually starts in the second or third decade of life, with peak incidence occurring in the 20 to 34 age group. Studies report that the average age at onset of symptoms is between 20.9 and 32.5 years, while

<div style=\"page-break-after: always\"></div>

the average age of diagnosis is later, between 24.2 and 39.8 years.

## Biologic features, Aetiology and pathogenesis

Overall,  the  pathogenesis  of  AS  is  not  well  characterised  but  seems  to  include  both  genetic  and environmental components, which combine to elicit a chronic inflammatory response involving the innate and adaptive immune systems. A genetic link was noted in that 90 - 95% of white Western European people with AS are positive for the HLA-B27 allele, and risk increases with HLA-B27-positive relatives. Environmental factors, such as infections and mechanical stress at the entheses, have been postulated as being potential triggers of AS in genetically susceptible individuals. In AS, these entheseal stresses might activate downstream events that lead to inflammation, bone erosion and spur formation.

Key aspects of the pathology and pathogenesis of AS are listed below:

- In  the  earlier  stages  of  the  disease,  AS  primarily  involves  inflammation  of  the  entheses (enthesitis) in the axial skeleton (mainly the sacroiliac joints) and bone erosion in the vertebral bodies;
- In the later stages of the disease, syndesmophyte (spur) formation and then fusion of adjacent vertebral  bodies  and  syndesmophytes  occur.  These  processes  appear  to  be  uncoupled  from inflammation;
- The  development  of  AS  is  associated  with  specific  genes;  the  most  important  is  HLAB27; additional genes associated with AS include ERAP1, IL-23R, ANTXR2, and IL- R2;
- Key innate and adaptive immune cells involved in the initiation, progression, and modulation of inflammation in AS are reported to include dendritic cells, macrophages, NK cells, Th1 cells, Th2 cells, Th17 cells, Th22 cells, Treg cells, and T CD8+ cells. There may be a limited role for B cells.
- These  innate  and  adaptive  immune  cells  secrete  a  number  of  pro-inflammatory  cytokines implicated in the pathogenesis of AS including IL-1, IL-6, IL-7, IL-12, IL-15, IL-17 IL- 22, IL-23, IFNγ and TNFalpha.

Confirmation that TNFaplha (secreted by Th1 and T CD8+ cells) and IL-17 (secreted by Th17 and T CD8+ cells) contribute to the pathogenesis of AS has been provided by the efficacy of interventions such as TNFi and anti-IL-17 mAb. These biologic therapies directly inhibit the effect of 1 cytokine pathway. Tofacitinib, a small molecule inhibitor of JAK, interferes directly (eg, IL-23) or indirectly (eg, TNFalpha, IL-17) with the signalling of multiple AS-associated cytokines.

Tofacitinib therapy therefore has the potential to suppress the articular, as well as the extraarticular manifestations  of  AS,  without  the  drug-induced  immunogenicity  and  antidrug  neutralising  antibody formation seen with long-term monoclonal antibody use.

## Clinical presentation, diagnosis and stage/prognosis

There are no specific diagnostic tests or biomarkers for the diagnosis of AS. For the purpose of clinical trials, consistent with the EMA clinical guideline on Clinical Investigation of Medicinal Products for the Treatment of Axial Spondyloarthritis, the classification criteria based on the 1984 Modified New York Criteria for Ankylosing Spondylitis is used to define AS if the radiological criterion (pelvic radiograph) is associated with at least 1 clinical criterion. In the Phase 2 dose-ranging Study A3921119 and the Phase 3 pivotal Study A3921120, in addition to the above Modified New York criteria, a patient must have had active AS defined a s a BASDAI score of ≥4 and a back pain score (BASDAI Question 2) of ≥4 at both screening and baseline in order to be included.

<div style=\"page-break-after: always\"></div>

## Management

For many decades, the mainstay of treatment of AS has been NSAIDs and structured exercise programs including physical therapy with the aim of relieving clinical symptoms. However, gastrointestinal and other  adverse  effects  limit  the  tolerability  of  NSAIDs  including  some  COX-2  selective  inhibitors.  In addition, AS patients report insufficient control with NSAIDs alone. Treatment with csDMARDs that have shown efficacy in RA have not shown similar efficacy in AS. Sulfasalazine may provide some benefits for peripheral arthritis but does not impact axial disease. Locally administered parenteral glucocorticoids are also a treatment option for patients with active enthesitis, sacroiliitis or peripheral arthritis that have not responded fully to NSAID therapy. However, although local corticosteroid injections are widely used in clinical practice to good effect in AS patients, no c linical trials exist to support this use. TNFα antagonists or inhibitors, also known as TNFi, have demonstrated efficacy and are approved for the reduction of clinical  signs  and  symptoms,  in  patients  with  AS.  A  recent  ASAS  recommendation  stated  that  TNFi therapy  is  indicated  for  those  patients  with  persistently  high  disease  activity  despite  conventional treatment. Additional bDMARDs  that  inhibit IL-17, secukinumab  and ixekizumab, have been subsequently approved in the US and EU. However, there is a substantial proportion of patients who have an inadequate response to each of these bDMARDs and as such therapy options are administered parenterally, this may act as an additional barrier to their use. Moreover, the long-term efficacy of some TNFi and IL-17i mAb may be limited by immunogenicity. Moreover, recently, also another JAK inhibitor (Upadacitinib)  has  been  authorized  in  EU  for  the  treatment  of  active  ankylosing  spondylitis  in  adult patients who have responded inadequately to conventional therapy.

Current updates to the ASAS-EULAR axial SpA management recommendations provide initial therapy recommendations  based  upon  an  individual's  disease  activity ,  the  patient  characteristics  including comorbidities and psychosocial factors. Based on the current evidence and the considerations of ASAS and EULAR, NSAIDs and TNFi remain the primary classes of medications for the treatment of axial SpA (including  AS).  Sulfasalazine  is  considered  only  for  the  treatment  of  peripheral  arthritis.  IL-17i  are recommended  for  patients  with  active  disease  in  whom  TNFi  are  contraindicated,  and  in  primary nonresponders  to  TNFi.  The  use  of  IL-17i  should  be  avoided  in  patients  with  active  IBD,  as  TNFi monoclonal antibodies are better options.

Treatments are available to control and delay the progression of symptoms of AS. However, additional therapy options are still needed as up to 50% of patients with AS continue to have active disease despite treatment with NSAIDs or biological agents.

The use of NSAIDs is limited by gastrointestinal and other adverse events. Other effective agents for the treatment of active AS are bDMARDs, which require parenteral administration and may be limited by loss of efficacy, often due to immunogenicity. Of note, in a recent survey of patients receiving injectable bDMARDs to treat PsA, a condition related to AS, 54% found the therapy to be burdensome, with fear of injections and inconvenience amongst the most commonly reported reasons. Accordingly, there is a need for an oral tsDMARD with similar efficacy to bDMARDs for the treatment of AS.

As a number of genes and cytokines have been implicated in the pathogenesis of AS, it is likely that the etiology  of  AS  is  complex  and  has  a  plethora  of  underlying  contributory  factors.  This  implies  that additional treatment options with mechanisms of action distinct from those currently available, such as tofacitinib, are needed as options for different AS patients.

In summary, despite the advances that have been made in the last decade in the treatment of AS, a significant  number  of  patients  with  AS  still  have  active  disease  and  remain  refractory  to  currently available pharmacotherapies. Unmet medical need therefore remains for a new effective oral DMARD with a new MOA that provides a favourable benefit-risk profile and broadens the treatment options for adult patients with AS to achieve and sustain clinical benefit.

<div style=\"page-break-after: always\"></div>

## 2.1.2. About the product

## Mode of action.

Tofacitinib is a selective JAK inhibitor, with a high degree of selectivity against other kinases in the human genome. In kinase assays, tofacitinib inhibits JAK1, JAK2, JAK3, and to a lesser extent tyrosine kinase 2 (TYK2). In cellular settings where JAK kinases signal in pairs, tofacitinib preferentially inhibits signalling by heterodimeric receptors associated with JAK3 and/or JAK1 with functional selectivity over receptors that signal via pairs of JAK2.

## Pharmacological classification.

Tofacitinib belongs to the therapeutic group of Immunosuppressants (L04) and its therapeutic subgroup is L04AA29

## Previously approved indications

Xeljanz was approved in the EU at a dose of 5 mg BID (IR film-coated tablets approved on 22 Mar 2017; RA MAA procedure EMEA/H/C/004214/0000) as monotherapy or in combination with MTX in adult patients with moderate to severe active RA, who have had an inadequate response or intolerance to 1 or more DMARDs.

On 25 Jun 2018, tofacitinib was approved in the EU at a dose of 5 mg BID in combination with MTX, in adult patients with active PsA, who have had an inadequate response or intolerance to a previous DMARD treatment (procedure EMEA/H/C/004214/II/0006). Furthermore, tofacitinib was approved in the EU at a dose of 5 mg and 10 mg IR BID (26 Jul 2018; procedure EMEA/H/C/004214/X/0005/G) for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

An extension application to introduce a new pharmaceutical form (prolonged-release tablet) associated with a new strength (11 mg), was approved for RA patients on 16/12/2019

(EMEA/H/C/004214/X/0012). The same PR pharmaceutical form (11 mg) has been approved for PsA patients on 23/07/2021 (EMEA/H/C/004214/II/0027). An extension of indication in patients with AS using the 5 mg BID IR dosage (EMEA/H/C/004214/II/0035) was approved on 14 October 2021.

The review of JAK inhibitors in the treatment of inflammatory disorders has been initiated at the request of the European Commission (EC) under Article 20 of Regulation (EC) No 726/2004 and is currently on-going.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

## 2.1.4. General comments on compliance with GLP, GCP

Not applicable. This application is based on modelling approach. No new non-clinical and clinical studies have been submitted.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

<div style=\"page-break-after: always\"></div>

## 2.2.1. Ecotoxicity/environmental risk assessment

This Environmental Risk Assessment (ERA) was submitted by the MAH as part of II/35 variation seeking approval for a new indication (treatment of ankylosing spondylitis (AS) in adult patients).

The submitted ERA referred to the treatment of AS, in which the maximum recommended dosage of Xeljanz is 5 mg twice daily (IR tablet) or 11 mg once daily (MR tablet).

Tofacitinib  has  a  log  D  value  &lt;4.5  at  all  environmentally  relevant  pHs.  Screening  for  Persistence, Bioaccumulation and Toxicity (PBT) is not required.

Calculation of the Predicted Environmental Concentration in Surface Water (PECsw) Annual consumption of tofacitinib in the EU member states over the 12-month period from 1Q2019 through 4Q2019 was obtained  from  the  IQVIA™  [formerly  the  Intercontinental  Marketing  Services  (IMS)],  the  Health Management Integrity and Data Assessment System (MIDAS) database. Based on these data, total annual consumption in the EU is 117.4 kg and includes patient use of tofacitinib for treatment of the approved  indications,  RA,  PsA  and  UC.  The  highest  consumption  per  inhabitant  was  found  in Luxembourg, therefore the data from Luxembourg will be used to determine the most conservative consumption based Fpen. As per the ERA Guideline, the Fpen based on consumption is determined as follows:

<!-- formula-not-decoded -->

| Fpen                                       | Market penetration factor                  |                                            |
|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| Consumption                                | mg per year (2019)                         | 545,900 mg:yr-1                            |
| DDD                                        | Defined daily dose*                        | 10 mg:inh-1 d-1                            |
| Inhabitants                                | Luxembourg population, 2019 (Worldbank)    | 619,896                                    |
| *Lowest recommended daily dose = 10 mg/day | *Lowest recommended daily dose = 10 mg/day | *Lowest recommended daily dose = 10 mg/day |

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

Determination of PECsw, approved indications:

<!-- formula-not-decoded -->

| PECsw                                                       | Predicted environmental concentration in surface water      | -- mg/L                                                     |
|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| DOSEai                                                      | Maximum daily dose applied per inhabitant*                  | 22 mg-inh-1·d-1                                             |
| Fpen                                                        | Market penetration                                          | 0.00024 [Refined]                                           |
| WASTEWinhab                                                 | Amount of wastewater per inhabitant per day                 | 200 L·inh-·d-1 [Default]                                    |
| DILUTION                                                    | Dilution factor                                             | 10 [Default]                                                |
| *Maximum recommended daily dose = 22 mg/day (UC indication) | *Maximum recommended daily dose = 22 mg/day (UC indication) | *Maximum recommended daily dose = 22 mg/day (UC indication) |

<!-- formula-not-decoded -->

<div style=\"page-break-after: always\"></div>

PECsw = 0.0026 μg/L based on consumption attributed to RA, PsA and UC.

Determination of PECsw, new indication (AS)

<!-- formula-not-decoded -->

| PECsw       | Predicted environmental concentration in surface water   | -- mg/L                   |
|-------------|----------------------------------------------------------|---------------------------|
| DOSEai      | Maximum daily dose applied per inhabitant                | 11 mg:inh-·d-1            |
| Fpen        | Market penetration                                       | 0.01 [Default]            |
| WASTEWinhab | Amount of wastewater per inhabitant per day              | 200 L'inh-1·d-1 [Default] |
| DILUTION    | Dilution factor                                          | 10 [Default]              |

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

Total PECsw all indications (RA, PsA, UC, and AS):

<!-- formula-not-decoded -->

The PECsw value is greater than the 0.01 µg/L action limit. Based on the PECsw value, a Phase II environmental fate and effects analysis for tofacitinib is required.

PHASE II -TIER A: PHYSICAL-CHEMICAL PROPERTIES, ENVIRONMENTALFATE AND EFFECTS ANALYSIS

The  PECsurfacewater  was  not  refined  for  human  metabolism  and  excretion,  for  removal  during wastewater treatment or for biodegradation in the water-sediment environment. In this conservative estimate, the PEC is more than 4 orders of magnitude less than the lowest chronic NOEC obtained with fish. In addition, the PEC/PNEC values for surface water (2 x 10-4), groundwater (3.1 x 10-5), microorganisms (5.8 x 10-6) and sediment dwelling organisms (1.9 x 10-2), are all significantly below the respective action limits, therefore it may be concluded that tofacitinib will not present an environmental risk following patient use. No environmental concerns are apparent.

## 2.2.2. Discussion on non-clinical aspects

PECsw calculation was made by the MAH by summing up the PECsw of all indications, Fpen refinement was made by taking into consideration the annual consumption for the already approved indications (RA, PsA and UC). This is made for renewal applications, as per ERA guideline.

In case of a type II variation, specifically the addition of a new indication, the Fpen should be refined by submitting European disease prevalence data for the sought indication. Such data should be published by a reliable and independent source, as per ERA Q&amp;A.

Moreover, a PECsw of all indications was made by summing up the already approved and the new one. Also here, the PECsw of the sought indications only have to be summed to reach the PECsurface water that will be used in the ERA, as per ERA Q&amp;A.

<div style=\"page-break-after: always\"></div>

In light of these considerations, as the present submission was dealing with a type II variation, the MAH was  asked to recalculate the PECsw for the new indication (SA) only, and to refine the Fpen by submitting EU prevalence data, as per ERA Q&amp;A. For the new indication, AS, the default Fpen value of 0.01 was used  to  calculate  the  PECsw  of  0.055  μg/L,  as  per  ERA  guideline  and  Q&amp;A  documents.  Fpen  from Luxembourg was used for the previosly approved ones. Therefore, the Fpen from this member state was used for PECsw of 0.0026 μg/L. As this application i s dealing with a line extension, a total PECsw can be calculated and the ERA based on the total PECsw of 0.058 μg/L, representing contributions from newly sought and from approved indications, as originally submitted by the MAH, is appropriate for this line extension application.

## 2.2.3. Conclusion on the non-clinical aspects

Considering the above data, Tofacitinib is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

No new clinical data have been submitted for this application. The majority of AR presents data submitted and assessed for the procedure II/35.

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 2. Tabular overview of clinical studies

## Listing of All Studies

| Protocol No. (Countries)                                                                                                                                                                   | StudyDesignandObjectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Treatment Groups                                                     | No. of Subjects (by Treatment Group)a   | Demographics (sex, age, race) (No. of Subjects)                                             | Duration of Treatment       | Study Study Status Synopsis               |                             |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------|---------------------------------------------------------------------------------------------|-----------------------------|-------------------------------------------|-----------------------------|
| Efficacy and Safety Studies                                                                                                                                                                | Efficacy and Safety Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Efficacy and Safety Studies                                          | Efficacy and Safety Studies             | Efficacy and Safety Studies                                                                 | Efficacy and Safety Studies | Efficacy and Safety Studies               | Efficacy and Safety Studies |
| A3921119 (Canada, Czech Republic, Germanyb Hungary, Poland, Russia,Spain,Republic of Korea, Taiwan, United States)                                                                         | Aphase2multicenter,randomized DB, PC dose-ranging, parallel group efficacy andsafety study designed to characterize the dose-response of tofacitinib in subjects with activeAS. Study consisted of12 weeks of tofacitinibtreatmentfollowedby4 weeks off treatment. Primaryobjective:To compare the efficacy oftofacitinib, at doses of2 mgBID,5 mgBID,10 mgBID versus placebo on the ASAS20 response rate at Week12in subjects with active AS that had an inadequate response toprevious treatment.The primary analysis was byEmax | Tofacitinib 2 mgBID Tofacitinib5 mg BID Tofacitinib 10 mgBID Placebo | 52 52 52 51                             | Sex: 143 M/64 F Mean/Median Age (min/max): 41.6/39.0 (22/75) years Race: W/A/O: 168/39/0    | 12 weeks DB                 | Completed CSR Module 5.3.5.4 A3921119     |                             |
| A3921120 (Australia, Bulgaria, Canada,China,Czech Republic, France, Hungary, Poland, Russia, Republic of Korea, Turkey, Ukraine, United States)                                            | modelling. A phase 3, randomized, DB, PC, study of the efficacy and safety of tofacitinib in subjects with active AS Eligible subjects were randomized in a 1:1ratiototofacitinib5mgBIDor matching placebo BID for a total of 16weeksofblindedtreatment.Atthe Week 16visit all subjects were                                                                                                                                                                                                                                       | Tofacitinib5 mgBID Placebo (16 weeks)→ Tofacitinib 5 mg BID (32      | 133 136                                 | Sex:224M/45F Mean/Median Age (min/max): 41.1/40.0 (20/70) years Race: W/A/O: 213/55/1       | 16 weeks DB 32 weeks OL     | Completed CSR Module 5.3.5.1 A3921120     |                             |
|                                                                                                                                                                                            | assigned toreceive OL tofacitinib5 mg BID until Week 48. Primaryobjective:Tocomparethe efficacyoftofacitinib5mgBID versus placebo on the ASAS20 response rate at Week16in subjects with activeASthathad an inadequate response toprevious treatment.                                                                                                                                                                                                                                                                               | weeks)                                                               | 686                                     | Sex:316M/370F Mean/Median Age (min/max): 48.8/50.0 (18/78) years Race: W/A/B/O: 646/21/2/17 | Approximately 3yearsc       | Completed CSR Module 5.3.5.2 A3921092 LTE |                             |
| A3921092LTE (Australia, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Germany, Hungary, Mexico, Poland, Russia, Slovakia, Spain, Taiwan,United Kingdom, United                        | AnOL,LTEStudyoftofacitinibfor the treatment of PsA. Primaryobjective:Toevaluatethe long-termsafetyand tolerability of treatment with tofacitinib (5mgBID and 10 mg BID) in adult subjects with PsA.                                                                                                                                                                                                                                                                                                                                | Tofacitinib (5 or 10 mgBID)                                          |                                         | Sex:83M/96F Mean/Median Age (min/max): Race: W/A/B/O:                                       | 12 monthsd                  | Completed CSR Module 5.3.5.2              |                             |
| States) A3921092 Substudy (Australia, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Germany, Hungary, Mexico, Poland, Russia, Slovakia, Spain, Taiwan, United Kingdom, United States) | A Randomized, DB Parallel Group MTX withdrawal A3921092sub-study oftofacitinibfor the treatment ofPsA. Primary objective:To assess the efficacyoftofacitinib5mgBID monotherapy as compared to tofacitinib 5 mg BIDwith background MTXinsubjectsfromStudy A3921092whohadreceivedprior treatmentoftofacitinibin combination with MTX                                                                                                                                                                                                 | Tofacitinib 5 mg BID + MTX Tofacitinib 5 mg BID + Placebo            | 89 90                                   | 52.4/54.0 (25/77) years 170/3/0/6                                                           |                             | A3921092 Substudy                         |                             |

Note:A=Asian;AS=AnkylosingSpondylitis;ASDAS20=An improvementfromBaseline≥20%and≥1unit increasein at least 3domains on a scale of 0 to 10, and no worsening of ≥20% and ≥1 unit in the remaining domain; B = Black; BID = Twice daily; CSR=Clinical Study Report; DB = Doubleblind; F = Female; LTE= Long-term extension; M = Male; MTX = methotrexate; No = Number; O = Other; OL = Open-label; PC = Placebo-controlled; PsA = Psoriatic Arthritis; W = White.

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

No new pharmacology data was submitted in the current variation. The bridging of efficacy and safety of the IR formulation to the PR formulation in AS is based on the bridging strategy used in the previously approved RA PR submission EMEA/H/C/004214/X/0012.

Given that the efficacy of tofacitinib IR in AS has been demonstrated, the bridging of efficacy from tofacitinib IR to the PR formulation in AS, is supported by:

1. Previously provided Phase 1 studies that have demonstrated similarity of PK parameters between PR 11 mg QD and IR 5 mg BID (equivalent AUC and Cmax, and slightly lower Cmin).

2. Previously provided E-R analyses in RA that have demonstrated that a metric of overall exposure (Cav or AUC) is the relevant PK parameter to predict efficacy of tofacitinib (RA PR Module 2.7.2).

3.  Longitudinal  E-R  analyses  using  efficacy  data  for  the  IR  formulation  in  AS  patients  that  have demonstrated that Cav is the exposure metric most closely associated with efficacy.

The time delay in the attainment of tofacitinib steady-state PK versus steady-state clinical response is consistent across multiple JAK-mediated inflammatory disorders including RA, PsA and AS supporting the conclusion that a measure of overall exposure (e.g., Cav or AUC) is the relevant parameter for efficacy, regardless of indication.

## 2.3.1. PK/PD modelling

## Point 1 of the bridging strategy

Previously provided Phase 1 studies that have demonstrated similarity of PK parameters between PR 11 mg QD and IR 5 mg BID (equivalent AUC and Cmax, and slightly lower Cmin)

The supportive basis of this application includes previously submitted Phase I clinical studies conducted for Xeljanz IR application in RA and Xeljanz PR application in RA.

For tofacitinib RA IR application, results from the 25 Phase 1 studies were provided. These included 20 clinical pharmacology studies that evaluated single and/or multiple-dose PK, renal or hepatic impairment PK, drug-drug interactions, PD evaluations (ie, QT, mGFR) as well as 5 biopharmaceutics studies.

For  tofacitinib  PR  application  for  RA  7  Phase  1  clinical  pharmacology/biopharmaceutic  studies  were conducted. These included results from 4 BA studies (A3921113; A3921131; A3921132; A3921163), which evaluated PK of the pilot or initial commercial scale formulations, a food effect study (A3921180), and a single- and multiple-dose PK study with the proposed commercial formulation (A3921212) and an IVIVC study (A3921195), which investigated the relationship between in-vitro dissolution and in-vivo PK performance  of  the  PR  formulations.  The  conclusions  from  these  studies  are  provided  below  for reference:

- Studies using prototype PR formulations of tofacitinib supported the choice of the osmotic tablet at a total daily dose of 11 mg to account for a 10% difference in BA compared to the IR formulation.
- Tofacitinib PR osmotic tablets at dose strength of 11 mg, administered QD, have equivalent AUC and Cmax compared to tofacitinib IR 5 mg tablets, administered BID.
- Cmin and Ctrough at steady-state were approximately 29% and 26% lower, respectively, for PR 11 mg QD compared to IR 5 mg BID.
- Based on the equivalence demonstrated for AUC and Cmax, and E-R relationships from the RA, PsA (and submitted now for AS) IR development programs indicating Cav (or AUC) as the relevant PK

<div style=\"page-break-after: always\"></div>

parameter for efficacy, the slightly lower Cmin was not considered to have an impact on the efficacy of tofacitinib PR 11 mg QD.

- The tofacitinib PR 11 mg tablet can be administered with or without food.
- A single, Level A IVIVC model was established and validated for tofacitinib PR tablets (11 and 22 mg), confirming that in vitro dissolution is a reliable predictor of in vivo performance.

## Point 2 of the bridging strategy

Previously provided E-R analyses in RA that have demonstrated that a metric of overall exposure (Cav or AUC) is the relevant PK parameter to predict efficacy of tofacitinib

The contextualisation of efficacy in RA clinical trials using the PR formulation (A3921215 and A3921192) to  the  E-R  relationships  based  on  the  tofacitinib  IR  RA  Phase  2  studies,  as  well  as  nonclinical  E-R modelling using mCIA data from Nonclinical Dose Fractionation Study, to show efficacy between the PR 11 mg QD and IR 5 mg BID.

Cytokine signalling promotes disease through the recruitment and activation of effector cells at sites of pathologic inflammation, the pharmacological effect of tofacitinib on clinical endpoints resulting from inhibition of cytokine signalling is indirect in all diseases where efficacy has been shown.  Therefore, it is expected that clinical endpoints in these diseases, like AS, would be dependent on the overall average tofacitinib exposure over time, such as, measured by AUC or Cav (where Cav = AUC/dosing interval), and would not be significantly influenced by short-term fluctuations in plasma concentrations within the dosing interval.  This was observed in RA and further substantiated with evaluations that demonstrated that differences in the shape of the plasma-concentration profiles between IR and PR formulations were progressively less relevant for PD endpoints that were further downstream in the JAK-signalling cascade (i.e., with the 2 tofacitinib formulations, small differences were observed in the profiles of upstream biomarkers  such  as  IP-10,  whereas  no  differences  were  observed  in  the  profiles  of  downstream biomarkers such as CRP and on the clinical endpoint of DAS-28). E-R analyses that supported bridging of  efficacy  in  RA  between  the  2  formulations  on  this  basis  were  previously  provided  (procedure EMEA/H/C/004214/X/0012).

In the tofacitinib RA PR assessment, a dose mapping study for QD and BID regimens of IR tofacitinib that was conducted using the mCIA (Murine collagen induced arthritis model) was discussed to delineate the predictive values of PK parameters. These results showed concordance of E-R curves and EC50 values using Cav (ratio of EC50 values [QD/BID] ~1.8) (ie, concordance when exposure was represented by average concentration over 24 hours [ie, Cav]), and divergence with either Cmax (~4.3) or Cmin (~84), supporting the relevance of Cav in predicting nonclinical anti-inflammatory activity (Study CP 690550\\_04Nov10\\_150736).

Results from this model could be informative of the E-R relationship in AS patients, given the similarity of disease pathogenesis and indirect mechanism of action of tofacitinib between AS and RA patients.

## Point 3 of the bridging strategy

Longitudinal  E-R  analyses  using  efficacy  data  for  the  IR  formulation  in  AS  patients  that  have demonstrated that Cav is the exposure metric most closely associated with efficacy

The E-R evidence to support the bridging of efficacy from the IR formulation to the PR formulation in AS patients is described below.

<div style=\"page-break-after: always\"></div>

An ordered categorical longitudinal E-R model was used to evaluate the relationship between ASAS20 and ASAS40 response rates and tofacitinib exposure (PK) using data from the 2 AS studies, A3921119 and A3921120.

· The longitudinal E-R analysis evaluated the relationship between ASAS20 and ASAS40 response rates and tofacitinib exposure (Cav) in AS patients. Study A3921119 was a Phase 2, randomised, doubleblind, placebo-controlled, dose-ranging study of the efficacy and safety of tofacitinib in patients with active  AS,  who  have  had  an  inadequate  response  to  previous  NSAID  treatment  and  were  naive  to previous bDMARD therapy. Subjects received either placebo or tofacitinib 2 mg, 5 mg or 10 mg BID for 12 weeks. The pivotal study, A3921120 was a Phase 3, randomised, double-blinded, placebo-controlled efficacy and safety study in adult patients with active AS, who were stratified by prior treatment history of either i) bDMARD-naive (approximately 80%) or ii) TNFi-IR or bDMARD use (non-IR) (approximately 20%). Subjects received either placebo or tofacitinib 5 mg BID for 16 weeks (double-blind phase) and then continued in the open-label phase thereafter, where all subjects received tofacitinib 5 mg BID up to Week 48. Efficacy data in the double-blind phase (i.e., up to Week 16) was included in this analysis. In both studies, patients were allowed to be on background therapy of non-bDMARD (eg, methotrexate or sulfasalazine) as noted in the respective study protocols.

A  longitudinal  E-R  model  was  formulated  using  ASAS20  and  ASAS40  response  rates  and  tofacitinib exposures after administration of tofacitinib IR doses of 2 mg, 5 mg or 10 mg BID, pooled across the 2 AS studies (dose-ranging and pivotal).

The model, which consisted of baseline, placebo (or non-drug) and drug effect components, used an Emax model to describe the drug effect component. The ASAS20 and ASAS40 responder criteria used in the modelling were assessed at Week 2, 4, 6, 8 and 12 in Study A3921119 and at Week 2, 4, 6, 8, 12 and 16 in Study A3921120. Cav was used as the exposure metric for these E-R evaluations in AS; the use of Cav is supported by prior knowledge from the RA program, which established Cav as the most relevant tofacitinib exposure metric for efficacy (PMAR-EQDD-A392a-sNDA-830). Estimates of Cav for this analysis were obtained from a population PK analysis using PK samples from the AS patients in A3921119 and A3921120 (PMAR-EQDD-A392k-sNDA-1064).

Plots of model-predicted ASAS20 and ASAS40 response rates compared to observed response rates for placebo and IR 5 mg BID, in adult AS patients who are bDMARD-naive, are shown in Figure 1 and Figure 2, respectively.

Figure 1. Longitudinal Model-Predicted ASAS20 Responses in bDMARD-naive AS Patients Pooled Across A3921119 and A3921120

<!-- image -->

<div style=\"page-break-after: always\"></div>

Black solid squares correspond to observed ASAS20 response rates. Blue line and shaded area represent median and 95% CI of estimated response rates, respectively. Source: AS IR Module 5.3.3.5 PMAR-EQDD-A392k-sNDA-1065, Figure 6.

Figure 2. Longitudinal Model-Predicted ASAS40 Responses in bDMARD-naive AS Patients Pooled Across A3921119 and A3921120

<!-- image -->

Black solid squares correspond to observed ASAS40 response rates. Blue line and shaded area represent median and 95% CI of estimated response rates, respectively.

Source: AS IR Module 5.3.3.5 PMAR-EQDD-A392k-sNDA-1065, Figure 6.

Following an early onset of efficacy by Week 2, the drug effect continues to increase up to Week 8. The estimate  of  the  time  of  onset  parameter  (half-life  of  drug  effect  for  efficacy  responses)  from  the longitudinal model is 1.18 weeks, demonstrating a delay or time lag in attaining PD (clinical response) steady-state relative to PK. Placebo-corrected estimates of ASAS20 response rates after tofacitinib IR 5 mg BID were 18%, 28%, 31% and 32%, at Week 2, 4, 6 and 8, respectively, in AS patients who were bDMARD-naive, indicating that  efficacy  in  these  patients  continued  to  increase  beyond  Week  4  and approached steady-state (plateau) after Week 8. These results, which are consistent with observed ASAS20 response rates demonstrate that the delay in the attainment of efficacy (PD) steady-state occurs over a substantially longer time period (in weeks) compared to the attainment of PK steady-state of tofacitinib (in 24 -48 hours).

These data are consistent with the estimated onset half-life for clinical responses in RA and in PsA. The similar delay in attainment of PD steady-state as in RA and in PsA, suggests that within day fluctuations in PK profile of tofacitinib are unlikely to confer differential effectiveness in AS. The longitudinal E-R relationship in AS supports the conclusion that Cav is the relevant parameter for efficacy and that the 29% lower Cmin for the PR formulation is not relevant to efficacy in AS.

- The Cav-based E-R model adequately characterised the relationship between tofacitinib exposure and clinical efficacy in adult patients with active AS (the use of Cav is supported by prior knowledge from the  RA  program,  which  established  Cav  as  the  most  relevant  exposure  metric  for  efficacy).  Modelpredicted estimates of ASAS20 and ASAS40 were 67% and 44%, respectively after tofacitinib 5 mg BID in bDMARD-naive AS patients at Week 16. The predicted placebo-corrected estimates were 32% and 28%, respectively

<div style=\"page-break-after: always\"></div>

The predictive abilities of different tofacitinib exposure metrics were previously evaluated using data from  RA  patients.  These  evaluations  identified  Cav  as  the  most  relevant  PK  parameter  in  the characterisation of E-R relationships of clinical response despite the high correlation among Cav, Cmin and Cmax. Furthermore, it was seen that Cmin did not provide additive predictive value over and above that of Cav (PMAR-EQDD-A392a-sNDA-830).

Based on this prior knowledge from the RA program, a longitudinal ordered categorical E-R model was used  to  characterise  the  relationship  between  ASAS20  and  ASAS40  responses  in  AS  patients  and tofacitinib exposures, using Cav estimates as the predictor variable (ASAS20 illustrated in Figure 3). This analysis showed that model-predicted ASAS20 and ASAS40 response rates in bDMARD-naive AS patients at Week 16 after tofacitinib 5 mg BID were 67% and 44%, respectively. Placebo-corrected estimates of ASAS20 and ASAS40 were 32% and 28%, respectively.

Figure 3 . Exposure-Response Relationship Using ASAS20 Responders at Week 12 in bDMARD-Naive AS Patients Pooled Across A3921119 and A3921120

<!-- image -->

Blue line and shaded area are median and 95% CI of model-predicted ASAS20 response rates. Black squares are observed response rates at mean Cav values of each dose group. Simulations from final E-R model depicted at Week 12 as observed data across all dose groups were only available at this visit (unlike at Week 16).

Source: AS IR Module 5.3.5.3 PMAR-EQDD-A392k-sNDA-1065, Figure 7.

E-R models for ASAS20 and ASAS40 responses using Cav, Cmin or Cmax as the tofacitinib exposure metric were compared based on model diagnostics such as the OFV and AIC. Table below summarises the model evaluation for the different E-R models fitted.

Table 3. Comparison of E-R Models for ASAS20 and ASAS40 Response Rates

|   Run Number | Exposure Metric in E-R Model   |     OFV |     AIC |
|--------------|--------------------------------|---------|---------|
|            4 | C av                           | 3054.66 | 3072.66 |
|            9 | C max                          | 3054.16 | 3072.16 |
|           10 | C min                          | 3055.28 | 3073.28 |

Source: AS IR Module 5.3.5.3 PMAR-EQDD-A392k-sNDA-1065, Table 9

<div style=\"page-break-after: always\"></div>

Comparison of models with Cav, Cmin or Cmax as the predictor (univariate analysis) did not show differences in model diagnostics (ΔOFV or ΔAIC were less than 3.84, the critical chi squared value) that would lead to the conclusion of any one parameter (or exposure metric) as being more relevant than another to clinical efficacy. This was not unexpected since these PK parameters are highly correlated, particularly Cavg and Cmin (correlation coefficient = 0.85, PMAR-EQDD-A392k-sNDA-1065), indicating that the exposure measures contain very similar information.

Although this comparative assessment did not show differences in model diagnostics that would identify any one exposure parameter (Cav, Cmin or Cmax) as more relevant than another for clinical efficacy, the  results  suggest  that  a  measure  of  overall  exposure  (such  as  Cav)  can  adequately  describe  the observed efficacy responses, and metrics such as, Cmin and Cmax (plasma concentrations at discrete time points) do not provide greater predictive value compared to Cav. This is consistent with the indirect mechanism of action of tofacitinib as well as the demonstrated lag between the times to attain steadystate clinical response (PD) versus PK.

The Exposure-Response Evaluation of Tofacitinib for Efficacy (ASAS20/40) in Patients with Ankylosing Spondylitis (PMAR-EQDD-A392k-sNDA-1065) has been submitted by the MAH during the variation II/35 (eCTD  0113)  in  addition  to  efficacy  data  from  studies  A3921119  and  A3921120,  to  describe  the relationship  between  tofacitinib  exposure  and  clinical  efficacy  in  patients  with  active  AS  after  the administration of placebo or tofacitinib doses of 2 mg, 5 mg or 10 mg BID up to Week 16.

For completeness of assessment, a summary of the aforementioned report is reported below.

The primary objectives in PMAR-EQDD-A392k-sNDA-1065 are:

· To characterize the relationship between tofacitinib exposure and ASAS response levels of 20% and 40% (ASAS20 and ASAS40, respectively) over time, in subjects with active AS using a longitudinal exposure response model.

· To compare predic ted PK measures, including of steady state Cavg, Cmin and Cmax, in an E-R analysis of ASAS20 and ASAS40 responses in subjects with active AS.

The secondary objectives are:

·  Investigate  the  effects  of  specified  covariates  (prior  biologic  therapy)  on the  E-R  relationship  for ASAS20 and ASAS40

A dose-response analysis (with a Bayesian Emax model) was conducted, using ASAS20 responder rates at Week 12 from the Phase 2 dose-ranging study, Study A3921119. This study had evaluated placebo and 3 tofacitinib doses (2 mg, 5 mg or 10 mg BID) for 12 weeks in bDMARD naïve patients with active AS. Placebo-corrected ASAS20 responder rates, along with 95%, 60% and 50% credible intervals were estimated using this Bayesian model.

This primary endpoint analysis using an Emax model, estimated that ASAS20 response rates were higher than placebo for all tofacitinib dose groups. However, although the tofacitinib 2 mg BID and tofacitinib 5  mg  BID  treatment  groups  showed  an  estimated  difference  from  placebo  of  15.8%  and  22.9%, respectively, they both did not meet the pre-specified statistical decision rules for the primary endpoint of the ASAS20 response rate at Week 12. Only the tofacitinib 10 mg BID treatment group met prespecified rules for the primary endpoint of the ASAS20 response rate at Week 12 with an estimated response  rate  of  67.4%,  an  estimated  difference  from  placebo  of  27.3%,  a  20.3%  difference  from placebo for the lower bound of the 2-sided 60% credible interval (ie, 1-sided 80% lower bound), and a 33.0% difference for the upper bound of the 2-sided 50% credible interval (ie, 1-sided 75% upper bound).

<div style=\"page-break-after: always\"></div>

The population  E-R  model  was  carried  out  using  the  nonlinear  mixed  effects  modeling  approach  as implemented in the software package NONMEMR version 7.4.1 (ICON Development Solutions, Hanover, MD). Perl-speaks-NONMEM (PsN), version 4.8.0 was used as supporting software for the execution of NONMEM.

## METHODS

The  analysis  was  conducted  based  on  the  following  strategy:  Base  Structural  Model  Development; Inclusion of Covariates; Assessment of Model Adequacy (Goodness of Fit); Assessment of Final Model Predictive Performance.

Base Model Description. The ASAS20 and ASAS40 responses were modelled simultaneously as an ordered categorical variable Y(t) taking on possible responses with Y = 2 if achieving ASAS40, Y = 1 if achieving ASAS20 but not ASAS40 and Y = 0, if not achieving ASAS20 , at time t. Hence the probability of achieving Y = k, with k = 1 or 2 to a predictor M(X;b) can be modelled using logistic regressions, such as:

<!-- formula-not-decoded -->

where α1 &gt; α2 represents the intercepts of each ASAS cutpoint, X a matrix of covariates, β a vector of regression coefficients, and h -1  the inverse link function that restricts the probability between 0 and 1. In a logistic regression, this parameteriza tion where M(X;β) is the same for all k corresponding to the proportional odds assumption.

Note that prob[Y(t) ≥ 0] = 1, so that in the model it is only necessary to estimate the cumulative probability for the score 1 and 2. The probability for each individual score can thereafter be calculated from the estimated cumulative probability using following equations.

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

For a logistic regression, the link function and its inverse function can be defined such as:

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

For the E-R modeling, a general nonlinear mixed-effects model was constructed based on the combined ASAS20 and ASAS40 response:

<!-- formula-not-decoded -->

<div style=\"page-break-after: always\"></div>

Where η is the inter -individual variance (IIV) which is assumed to be normally distributed with mean 0 and variance 1, fdrug(t) the drug effect function, and fplacebo(t) the placebo effect function. For the longitudinal analysis, the following exponential equation was used to investigate the time course and onset of drug effect and placebo effect:

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

where Deffect and Peffect are the drug effect and placebo effect, respectively; DThalf and PThalf are the half-life of drug effect and placebo effect respectively; t stands for time with unit of week.

Drug effect was evaluated using individual Cavg values as the exposure metric, and investigated with linear, Emax, or exponential models (Equation 9).

<!-- formula-not-decoded -->

where Dslp is the slope for the exposure-response relationship with Cavg. Emax is the maximum drug effect. EC50 is the concentration to reach 50% of Emax. K is shape parameter.

Inclusion of Covariates. The primary covariate of interest in this analysis was previous bDMARD use. Approximately 20% of subjects in Study A3921120 were stratified to be biologic-experienced (either TNF-inadequate responders or bDMARD-experienced). A covariate effect for previous bDMARD use was evaluated. This effect was assessed on the most appropriate model parameter (i.e., Peffect of the placebo effect, or Deffect of the drug effect) or function.

## RESULTS

A total of 466 patients were included in the longitudinal analysis.

Table 4. Number of subjects by treatment group

| Dose      |   A3921119 |   A3921120 |   Total |
|-----------|------------|------------|---------|
| Placebo   |         51 |        136 |     187 |
| 2 mg BID  |         50 |          0 |      50 |
| 5 mg BID  |         49 |        132 |     181 |
| 10 mg BID |         48 |          0 |      48 |

Table below summarizes prior bDMARD experience for the patients in this analysis dataset.

<div style=\"page-break-after: always\"></div>

Table 5. Summary of prior bDMARD Experience

| PriorbDMARD   | A3921119   | A3921120    | Total       |
|---------------|------------|-------------|-------------|
| Naive         | 198 (100%) | 207 (77.2%) | 405 (86.9%) |
| Experienced   | 0 (0%)     | 61 (22.8%)  | 61 (13.1%)  |

Repository artifact ID FI-4370388. Line 1 substituted.

bDMARD=biologic disease-modifying antirheumatic drug

Individual exposure metrics from a post processing step based on the final tofacitinib population PK modeling were used. The distribution of Cmax, Cmin and Cavg grouping by treatment groups is shown in Figure 4 and summary statistics are listed in Table 6.

Figure 4. Tofacitinib exposure metrics by study and dose

<!-- image -->

Repository artifact ID FI-4118742.

Cmax= maximum concentration; Cmin= minimum concentration; Cavg=average concentration; BID=twice daily

<div style=\"page-break-after: always\"></div>

Table 6. Summary of exposure metrics

| Variable     | Study   | Treatment   |   Mean |   Median |   Min |   Max |
|--------------|---------|-------------|--------|----------|-------|-------|
| Cmin (ng/mL) | 1119    | 2 mg BID    |    1.4 |      1.3 |   0.4 |   3.2 |
|              |         | 5 mg BID    |    3.5 |      3.2 |   0.8 |   8.2 |
|              |         | 10 mg BID   |    7   |      6.5 |   1.3 |  22.4 |
|              | 1120    | 5 mg BID    |    4   |      3.6 |   0.9 |  11.4 |
| Cmax (ng/mL) | 1119    | 2 mg BID    |   14.5 |     14.1 |   7.8 |  24.3 |
|              |         | 5 mg BID    |   35.7 |     37.1 |  17.2 |  49.3 |
|              |         | 10 mg BID   |   75.6 |     76.6 |  32.5 | 119.7 |
|              | 1120    | 5 mg BID    |   38.7 |     40   |  10   |  64   |
| Cavg (ng/mL) | 1119    | 2 mg BID    |    6.2 |      6   |   3.1 |   9.5 |
|              |         | 5 mg BID    |   15.3 |     15   |   8.4 |  20.7 |
|              |         | 10 mg BID   |   31.9 |     32.2 |  16.8 |  62.8 |
|              | 1120    | 5 mg BID    |   16.7 |     16.3 |   5.4 |  33.1 |

Repository artifact ID FI-4118746.

Cavg=average concentration, Cmax=maximum concentration, Cmin=minimum concentration, BID=twice daily

A longitudinal ordered categorical model with exponential time-dependent onsets of placebo and drug effect  was  used  to  evaluate  the  relationship  between  tofacitinib  exposure  and  ASAS20/40.  Linear, exponential and Emax model forms using Cavg, an exposure metric that has been previously established as relevant for the efficacy of tofacitinib in diseases like RA and PsA, were evaluated to characterize the drug effect component. A summary of model evaluation metrics for the key runs are provided in Table 7.

Table 7. List of key model runs

| Run   | ImproveID   | Model Description                                       |     OFV | Comments    |
|-------|-------------|---------------------------------------------------------|---------|-------------|
|       | ST-4099121  | Emax/EC50 model with Cavg                               | 3073.95 | Basemodel   |
| 2     | ST-4148540  | Linear model with Cavg                                  | 3111.64 |             |
| 3     | ST-4589958  | Exponential model with Cavg                             | 3073.57 |             |
| 4     | ST-4245150  | Runl + prior bDMARDs experience as covariate on Peffect | 3054.66 | Final model |
| 5     | ST-4245170  | Run4+Study effect onbaseline                            | 3051.99 |             |
| 6     | ST-4411916  | Run4 + Study effect on Peffect                          | 3054.66 |             |
| 7     | ST-4411960  | Run 1 with the same Drhalf and PThalf                   | 3077.24 |             |
| 8     | ST-4157085  | Emax/ED50modelwithdose                                  | 3073.74 |             |

Source:Improve analysis tree: AT-2109636

After careful evaluation of the various structural models, including a model that used tofacitinb BID dose, a  model  with  exponential  time-dependent  onsets  of  placebo  and  drug  effect,  and  the  drug  effect component described by an Emax model form (Run 1) was selected to describe the relationship between tofacitinib exposure and efficacy in AS.

Parameter estimates of the base model (Run 1) are presented in Table 8.

<div style=\"page-break-after: always\"></div>

Table 8. Parameter estimates of the base model

| Parameter     | Comment                                               |   Estimate |   RSE (%) | Bootstrap 90% CI   |
|---------------|-------------------------------------------------------|------------|-----------|--------------------|
| α1            | logit(prob[Y(t) ≥ 1]) without drug or placebo effect  |     -5     |     16.5  | (-6.52 to -3.99)   |
| α2            | logit(prob[Y(t) ≥ 1]) - logit(prob[Y(t) ≥2])          |     -2.06  |      5.88 | (-2.28 to -1.87)   |
| DThalf (week) | Half-life of drug effect                              |      1.16  |     29    | (0.735 to 2.02)    |
| Emax          | Maximum drug effect                                   |      3.13  |     40.5  | (2.63 to 4.48)     |
| EC50 (ng/mL)  | Concentration at which half of Emax was reached       |      0.831 |    604    | (0.2 to 6.24)      |
| PThalf (week) | Half-life of placebo effect                           |      2.55  |     37.7  | (1.62 to 4.36)     |
| Peffect       | Maximum placebo effect                                |      3.31  |     22.7  | (2.45 to 4.64)     |
| IIV           | Inter-individual variability of logit(prob[Y(t) ≥ 1]) |      8.8   |     13.3  | (7.09 to 11.1)     |

Repository artifact IDFI-4319783.

Bootstrap90%CI wasbased on 645 successful runs out of 1000.

RSE:relativestandarderror,Cl:confidenceinterval.

Inter Individual Variability (IIV) was applied to the logit value of cumulative probability (h -1 prob[Y(t) ≥ k]). The standard errors for the parameter estimates were small (30%), except for estimate of EC50 (RSE = 604%). h-shrinkage was 21.5%. There was absence of extreme pairwise correlations (r&gt;0.95) of  the  parameters  or  high  condition  number  of  the  correlation  matrix  of  the  parameter  estimates (k&gt;1000).  1000  non-parametric  bootstrap  were  performed  to  generate  the  90%CI  of  parameter estimates using the base model. Of these, 29 runs with miminisation terminated and 326 runs with estimates near a boundary (total 355) were excluded when calculating the bootstrap results.

Diagnostic plots for the base model are presented in Figure 5.

Figure 5. Diagnostic plots of the base model

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

As shown in the ETA (η) histograms and quantile -quantile plots, there is lack of normality in the η distribution. The sharp peak on the lower end of the distribution represents the inflated η values from non-responders (data not shown). T he η values estimated for these patients were consistently low. However,  this  lack  of  normality  in  distribution  did  not  impact  the  goodness  of  fit  evaluated  using simulation-based diagnostic plots, which are the primary diagnostic plots.

## Final Model Results

Prior bDMARD experience (PMED) and study effect (PROT) were tested on baseline (h -1 prob[Y(t) ≥ 1]), placebo effect (Peffect ), or drug effect (Deffect ) in order to evaluate their effect on ASAS20/40 response rates. PMED has 2 levels including 0 and 1, which represents bDMARD naive (0) or experienced (1). PMED was identified as significant covariate on Peffect (Run 4). Patients with prior bDMARD treatment

<div style=\"page-break-after: always\"></div>

experience showed a lower response to placebo in Study A3921120. However, study effect as a covariate did not provide a better fitting (Run 5 and 6), therefore, it was not included in the final model. Run 4 was considered the final model.

The parameter estimates for the final model are presented in Table 9.

Table 9. Parameter estimates of the final model run (Run 4)

| Parameter         | Comment                                               |   Estimate |   RSE (%) | Bootstrap 90% CI   |
|-------------------|-------------------------------------------------------|------------|-----------|--------------------|
| α1                | logit(prob[Y(t) ≥ 1]) without drug or placebo effect  |      -4.93 |     14.9  | (-6.3 to -3.96)    |
| α2                | logit(prob[Y(t) ≥ 1]) - logit(prob[Y(t) ≥ 2])         |      -2.07 |      5.73 | (-2.3 to -1.9)     |
| DThalf (week)     | Half-life of drug effect                              |       1.18 |     30.5  | (0.742 to 2.14)    |
| Emax              | Maximum drug effect                                   |       3.11 |     17.1  | (2.59 to 4.53)     |
| EC50 (ng/mL)      | Concentration at which half of Emax was reached       |       1.24 |    135    | (0.181 to 6.75)    |
| PThalf (week)     | Half-life of placebo effect                           |       2.55 |     26.4  | (1.63 to 4.06)     |
| Peffect           | Placebo effect                                        |       3.6  |     18.7  | (2.64 to 4.79)     |
| PMED=1 on Peffect | Coefficient of PMED=1 on placebo effect               |      -2.18 |     26.1  | (-3.16 to -1.24)   |
| IIV               | Inter-individual variability of logit(prob[Y(t) ≥ 1]) |       8.61 |     12.4  | (7.02 to 10.5)     |

Repository artifact ID FI-4312649.

Bootstrap 90% CI was based on 728 successful runs out of 1000.

RSE: relative standard error, CI: confidence interval, PMED: prior bDMARD experience

The standard errors for the parameter estimates were small (30%), except for the EC50 estimate with RSE of 135%. h-shrinkage was 21.6%. There was absence of extreme pairwise correlations (r&gt;0.95) of the parameters or high condition number of the correlation matrix of the parameter estimates (k&gt;1000). Diagnostic plots for goodness of fit are presented in the figure below:

Figure 6. Diagnostic plots of the final model

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

As shown in the parameter estimates from both the base and final models, there is a high degree of uncertainty on the EC50 estimate (high RSE values), most likely due to the lack of data at the lower end of the concentration range (Figure 7). 1000 non-parametric bootstrap were performed to generate the 90%CI  of  parameter  estimates  using  the  final  model.  Of  these,  27  runs  for  which  miminisation terminated,  and  245  runs  with  estimates  near  a  boundary  (total  272  runs)  were  excluded  when calculating the bootstrap results. This may be due to the limited information in the data to precisely characterize the EC50. Placebo treatment reached half of the maximum effect in 2.55 weeks (90%CI [1.63, 4.06]). The half-life of drug onset was estimated to be 1.18 weeks for ASAS20/40 (90%CI [0.74, 2.14]).

<div style=\"page-break-after: always\"></div>

Figure 7. Overlay of EC50 Bootstrap 90% CI with Cavg distribution

<!-- image -->

Repository artifact ID FI-4370385.

Shaded area represents the bootstrap 90% CI of EC50

## Final Model Predictive Performance

VPC plots for the final model are presented in Figure 8 and Figure 9.

<div style=\"page-break-after: always\"></div>

Figure 8. Visual predictive check for ASAS20 and ASAS40 response rates stratified by dose

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 9. Visual predictive check for ASAS20 and ASAS40 response rates stratified by prior bDMARD experience

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Model-Predicted ASAS20 and ASAS40 Responses based on Simulation

The model-predicted ASAS20 and ASAS40 response rates based on simulation are listed in Table 10. Model-predicted ASAS20 response rates after tofacitinib 2 mg, 5 mg and 10 mg BID were 64%, 67% and 68%, respectively and ASAS40 response rates were 40%, 44%, and 45% respectively, in bDMARDnaive AS patients at Week 16.

Placebo-corrected estimates of ASAS20 and ASAS40 response rates at Week 16 were 32% and 28% after 5 mg BID in AS patients who were bDMARD-naive. In the bDMARD-experienced group, placebocorrected ASAS20 and ASAS40 response rates at Week 16, after 5 mg BID were estimated to be 27% and 16%, respectively.

<div style=\"page-break-after: always\"></div>

Table 10. Model-predicted ASAS20 and ASAS40 response rates at week 16 in bDMARD-naïve patients

| Endpoint   | Dose      | Response rate (95%CI)   | Placebo-correctedresponserate (95%CI)   |
|------------|-----------|-------------------------|-----------------------------------------|
| ASAS20     | Placebo   | 0.34 (0.28 - 0.42)      |                                         |
| ASAS20     | 2 mg BID  | 0.64 (0.56 - 0.7)       | 0.29 (0.2 - 0.38)                       |
| ASAS20     | 5 mg BID  | 0.67 (0.6 -0.74)        | 0.32 (0.24 - 0.41)                      |
| ASAS20     | 10 mg BID | 0.68 (0.62 - 0.75)      | 0.34 (0.25 - 0.43)                      |
| ASAS40     | Placebo   | 0.16 (0.11 - 0.21)      |                                         |
| ASAS40     | 2 mg BID  | 0.4 (0.33 - 0.46)       | 0.24 (0.15 - 0.32)                      |
| ASAS40     | 5 mg BID  | 0.44 (0.36 - 0.5)       | 0.28 (0.2 - 0.36)                       |
| ASAS40     | 10 mg BID | 0.45 (0.38 - 0.52)      | 0.29 (0.2 - 0.38)                       |

Repository artifact ID FI-4955677. Line 1 substituted.

Simulations  to  illustrate  the  exposure-response  relationship  were  also  performed,  and  plotted  with observed response rates at Week 12 (Figure 10, Figure 11). Model predictions of placebo-corrected estimates after 2 mg BID (ASAS20 of 29% and ASAS40 of 24%) in bDMARD-naive AS patients at Week 16 were slightly lower compared to 5 mg BID.

Figure 10. Exposure-Response relationship in bDMARD-naïve patients (Week 12)

## bDMARDnaiveASAS20

## bDMARDnaiveASAS40

<!-- image -->

Repository artifact ID FI-4320119.

bDMARD=biologic disease-modifying antirheumatic drug; Cavg=average concentration. The Cavg of the observation data points were the mean Cavg values for each dose group. Median predictions and CIs for ASAS20 and ASAS40 were based on 1000 simulations (at Cavg values ranging from 0 to 65 ng/ml) using the final model

<div style=\"page-break-after: always\"></div>

Figure  11.  Exposure-Response  relationship  in  bDMARD-naïve  patients  (Week  12,  PBOcorrected)

## bDMARDnaiveASAS20

<!-- image -->

Repository artifact ID FI-4955670.

bDMARD=biologic disease-modifying antirheumatic drug; Cavg=average concentration. The Cavg of the observation data points were the mean Cavg values for each dose group. Median predictions and CIs for ASAS20

and ASAS40 were based on 1000 simulations (at Cavg values ranging from 0 to 65 ng/ml) using the final model

## Comparison Between Tofacitinib Exposure Metrics

Table 11 summarizes the model evaluation for the different E-R models fitted using ASAS20 and ASAS40 response rates in AS patients. Models with Cavg, Cmin or Cmax as the predictor (univariate analysis) did not show differences in model diagnostics (OFV or AIC differences less than 3.84 units) that would support the conclusion of any one exposure parameter being more relevant to clinical efficacy compared to another. This was not unexpected since these PK parameters are highly correlated, particularly Cavg and  Cmin  (correlation  coefficient=0.85)  (Figure  12);  the  exposure  measures  contain  very  similar information.

Table 11. Runs to compare between tofacitinib exposure metrics

|   Run | Improve    | Model Description                     |     OFV |     AIC |
|-------|------------|---------------------------------------|---------|---------|
|     4 | ST-4245150 | Final model using  Cavg               | 3054.66 | 3072.66 |
|     9 | ST-4616071 | Final model applied to Cmax           | 3054.16 | 3072.16 |
|    10 | ST-4616082 | Final model structure applied to Cmin | 3055.28 | 3073.28 |

OFV= Objective Function Value; AIC= Akaike information criterion; Cmax= maximum concentration; Cmin=

## bDMARDnaiveASAS40

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 12. Frequency distribution and correlation between tofacitinib exposure metrics

<!-- image -->

Repository artifact ID FI-4370386.

Corr=correlation coefficient, CAVG=average concentration, CMAX=maximum concentration, CMIN=minimum concentration

## Bridging  Safety  Data  from  Tofacitinib  IR  Formulation  to  PR  Formulation  in  AS  Patients (applicant's summary)

The data and strategy that supported the bridging of safety from tofacitinib IR (5 mg BID) to PR (11 mg QD) using similarity in PK, and supportive E-R analyses of expected on-target (possibly mechanismbased) safety endpoints in patients with RA, that have also indicated that Cav(or AUC) was the relevant predictor  when  an  E-R  relationship  existed  was  previously  discussed  in  the  RA  PR  application (EMEA/H/C/004214/X/0012).

The overall similarity of PK parameters (equivalent AUC and Cmax and slightly lower Cmin at steadystate) between the 2 formulations in healthy volunteers, provides assurance that the safety profile of PR is likely to be similar of that of IR in patients with AS. Inter- and intra-subject variability was similar between tofacitinib IR and PR formulations for all PK parameters.

Negligible  accumulation  of  systemic  exposure  (AUC  accumulation  ratio  of  1.12)  was  seen  following repeated dosing of tofacitinib PR. Similar to IR, more than 95% of PR is eliminated within 24 hours following discontinuation of treatment.

In addition, the expected duration of steady state plasma concentrations above the in vitro, whole blood IC50 for JAK 1/3 inhibition (17 ng/mL) is approximately 12-13 hours for both formulations over a 24hour period. This suggests a similar level of target enzyme inhibition over the dosing interval. All these data suggest that the safety profile of the PR formulation in AS patients would be consistent with that of the IR formulation in AS.

<div style=\"page-break-after: always\"></div>

Population PK analysis of tofacitinib in patients with active AS indicated that tofacitinib exposure, as measured by the steady-state AUC (over 24 hours) after 5 mg BID, was similar (differences between geometric means within 25%) among AS, PsA and RA patients. Geometric means of Cmax were also comparable between these 3 patient populations (AS IR PMAR-EQDD-A392k-sNDA-1064, PsA IR PMAREQDD-A392j-sNDA-601, RA IR PMAR- 00178). Furthermore, the similarities between the safety profile of tofacitinib 5 mg IR BID in AS subjects and the safety profile of tofacitinib 5 mg IR BID in RA and PsA support the conclusion that the safety profile of the PR formulation in AS would also be consistent with the PR formulation in RA.

Finally, the observed safety data with the PR formulation in RA patients from 2 clinical studies (A3921215 and A3921192), the Corrona registry and post-marketing pharmacovigilance activities demonstrated a consistent  safety  profile  for  the  2  formulations,  adding  substantially  to  the  totality  of  evidence  that supports the bridging of safety from the IR to the PR formulation.

## 2.3.2. Discussion on clinical pharmacology

No new pharmacology data was submitted in the current variation. The bridging of efficacy and safety of the IR formulation to the PR formulation in AS is based on the bridging strategy used in the previously approved RA PR submission (EMEA/H/C/004214/X/0012).

Given that the efficacy of tofacitinib IR in AS has been demonstrated (II/35), the bridging of efficacy from tofacitinib IR to the PR formulation in AS, is supported by: 1) previously provided Phase 1 studies that have demonstrated similarity of PK parameters between PR 11 mg QD and IR 5 mg BID (equivalent AUC  and  Cmax,  and  slightly  lower  Cmin);  2)  Previously  provided  E-R  analyses  in  RA  that  have demonstrated that a metric of overall exposure (Cav or AUC) is the relevant PK parameter to predict efficacy  of  tofacitinib;  3)  Longitudinal  E-R  analyses  using  efficacy  data  for  the  IR  formulation  in  AS patients that have demonstrated that Cav is the exposure metric most closely associated with efficacy.

Regarding the first point of the bridging strategy, no concern on the available information has been raised.

Regarding  the  second  and  third  points,  the  comparison  of  models  with  Cav,  Cmin  or  Cmax  as  the predictor  (univariate  analysis)  did  not  show  differences  in  model  diagnostics,  therefore  it  cannot  be concluded that any one parameter (or exposure metric) as being more relevant than another to clinical efficacy. This conclusion is acknowledged by the MAH.

The MAH choose Cavg as PK parameter to predict efficacy in line with RA procedure also justifying by the indirect mechanism of action of tofacitinib indicated by the lag between the times to attain steadystate clinical response (PD) versus PK.

Therefore, Cavg has been used as exposure metric to select the model to describe the relationship between tofacitinib  exposure  and  efficacy  in  AS,  since  it  was  previously  established  as  relevant  for tofacitinib efficacy in RA.

To note during the assessment of variation II/35 (extension of indication in AS with IR tablets), in which the E/R report was submitted for the first time, the following weaknesses on the aforementioned analysis were highlighted. For the E/R base model the standard error was high, not only for the estimate of EC50 (RSE = 604%), but also for the estimate of Emax (RSE=40.5%); in the final model the standard error for the parameter estimates continues to be high for the EC50 estimate with RSE of 135%. The high degree of uncertainty on the EC50 estimate was imputed (most likely) to the lack of data at the lower end of the concentration range contributing to the limitations of an E-R analysis.

<div style=\"page-break-after: always\"></div>

In section Assessment of Model Adequacy (Goodness o f Fit) it is reported that 'ETA (h) histograms and quantile-quantile plots were used assessing the assumption of normality and the appropriateness of the selected  parameter  variability.'  How ever, in  both  models,  the  base  and  the  final  ones,  ETA  (η) histograms  and  quantilequantile  plots  showed  lack  of  normality  in  the  η  distribution.  The  MAH commented that this lack of normality in distribution did not impact the goodness of fit evaluated using simulation-based diagnostic plots, which are the primary diagnostic plots.

The  simulated  exposure-response  relationship  in  AS  appears  to  be  flat,  even  flatter  compared  to observed data. In all the exposure-response plots, the 10 mg Cavg values are lower than the 5 mg, and, for the ASAS40 values (placebo-corrected), also lower than the 2 mg. The CHMP expressed concern that the E/R relationship was not properly captured by the E/R model ( i.e. the 10 mg Cavg values being lower than the 5 mg, and, for the ASAS40 values also lower than the 2 mg) thus hampering its reliability.

In their response the MAH has provided a re-discussion of submitted data focusing on the demonstration of  E/R  model  reliability  in  AS.  Although  the  VPCs  performed  for  the  base  and  final  models  show concordance between observed and predicted data, the simulations to illustrate the exposure-response relationship plotted with observed response rates at Week 12 did not capture the unexpected lower observed response rate forASAS20 and ASAS40 using 10 mg IR BID that was expected to be higher than that observed for 5 mg BID. The MAH justified this unexpected behaviour as likely due to variability in the observed data and not as a measure of the reliability of the E-R model.

Probably,  concomitant  factors  could  have  contributed  to  this  outcome,  including  the  variability  in patient's response (in Study A3921119 the ASAS20 response rate at Week 12 for 5 mg is 63% analysed by Emax model and 80.7% by normal approximation method; in Study A3921120, ASAS20 response rate at Week 16 is 56.39%) and the limited data used to populate the model i.e. 2 mg (N=50) and 10 mg (N=48) as compared to  5 mg (N=181).

Although the above-mentioned reasons might be considered a plausible explanation of the observed outcome.

The E/R relationship per se is  still  considered  not  certain  enough (due to plausible hypothesis of an artefact) to waive the clinical study as foreseen in the EMA Guideline on modified-release formulation (EMA/CHMP/EWP/280/96 Rev1); however, the totality of data available show the following:

i) the demonstrated BE between PR (11 mgx1) and IR formulations (5 mgx2) in terms of AUC and Cmax with only a difference in average Cmin (29% lower) not considered clinically relevant and having the Cavg as the primary PK parameter;

- ii) the efficacy of PR formulation in RA and PsA;
- iii) the same PK metrics are considered important for efficacy and safety in AS as in PsA;

The relevance of Cavg as the parameter for efficacy in AS  was illustrated by the strong association between Cavg on one hand, and Cmin and Cmax on the other hand, in both PsA as well as in AS (r = 0.93 between Cavg and Cmin).

A comparison of models with Cavg, Cmin, and Cmax did not show great differences in model diagnostics in AS, and may support the acceptability of the Cmin and Ctrough levels in the treatment of AS.

iv) the similarities in disease between PsA and AS.

Finally, the absence of a clear exposure-response relationship was likely to be due to the smaller patient numbers in the 10 mg BID group (n = 48) compared to the 5 mg BID group (n = 181), as mentioned

<div style=\"page-break-after: always\"></div>

above. However, although the observed response rates did not show a straight ER relationship at week 12, these rates were all within the 95% CI of the predicted response rates of the ASA20 and ASAS40, which supports the adequacy of the ER model.

Considering all the above and taking into account that the safety profile is not expected to be different with the use of PR formulation as compared to IR formulation, the absence of a clear E/R relationship in the presented model is not foreseen to affect the efficacy and safety of the 11 mg QD PR tablet in AS.

## 2.3.3. Conclusions on clinical pharmacology

Considering the totality  of  available data,  and  the  fact  that  the  safety  profile  is  not  expected  to  be different  with the use of PR formulation as compared to IR formulation, the  absence of a clear E/R relationship in the presented model is not foreseen to affect the efficacy and safety of the 11 mg QD PR tablet in AS.

## 2.4. Clinical efficacy

This application supports the efficacy of tofacitinib PR tablets (11 mg QD) for the treatment of adult patients with active AS.

Clinical studies of the tofacitinib PR formulation have not been conducted in patients with active AS.

Tofacitinib (Xeljanz) IR formulation is currently approved in the EU for treatment of RA, PsA, and UC. The tofacitinib IR formulation was approved in the EU at a dose of 5 mg BID (IR film-coated tablets approved on 22 Mar 2017; RA MAA procedure number EMEA/H/C/004214/0000) as monotherapy or in combination with MTX in adult patients with moderate to severe active RA, who have had an inadequate response or intolerance to 1 or more DMARDs. This formulation is also approved in the EU at a dose of 5 mg BID, in combination with MTX, for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy (25 June 2018; procedure EMEA/H/C/004214/II/0006). Recently tofacitinib IR at a dose of 5  mg BID obtained approval in the following indication: 'Tofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy'.

The tofacitinib PR formulation, administered as 11 mg QD, for RA was approved by the EU Commission (16 Dec 2019, procedure EMEA/H/C/004214/X/0012).

The approval of the tofacitinib PR tablet (administered as 11 mg QD) for RA in the EU was based on ER modelling and totality of evidence demonstrating similarity of efficacy and safety between the 11 mg PR QD and 5 mg IR BID, including:

- E-R analysis of RA patient data with the IR formulation to identify relevant exposure metrics for efficacy and safety (including characterisation of delay in the dynamics of clinical response in RA compared to the time to reach steady-state plasma drug concentrations or when considering within day fluctuations drug concentrations), along with Phase 1 PK studies to demonstrate similarity of relevant exposure metrics between the IR and PR formulations,
- Supportive evidence of similar clinical efficacy and safety between the IR and PR formulations in patients with RA from the clinical RA Studies A3921215 and A3921192, the observational US Corrona RA registry studies (A3921359 efficacy and A3921205 safety), and a real-world claims database adherence study (A3921349).

Similarity of efficacy was established by demonstration of AUC (Cavg) as the relevant PK parameter for efficacy in RA patients, and equivalence of AUC between tofacitinib 11 mg PR formulation administered QD and the 5 mg IR formulation administered BID. Additional supportive evidence for similar efficacy

<div style=\"page-break-after: always\"></div>

was based on direct comparison of clinical efficacy between IR and PR in the Japan only clinical study A3921215, and global clinical study A3921192 (single-arm PR) where efficacy of the PR formulation was consistent with efficacy of the IR formulation in prior RA studies, the US Corrona RA registry effectiveness study (A3921359), and a real-world claims adherence and effectiveness study (A3921349). In addition, efficacy  of  the  PR  formulation  in  RA  clinical  studies  A3921215  and  A3921192  (single  arm  PR)  were demonstrated to be consistent with efficacy of the IR formulation in prior RA studies, based on cross trial comparisons and E-R contextualisation.

The bridging approach to demonstrate therapeutic similarity (efficacy) between tofacitinib IR (dosed at 5 mg BID) and PR (dosed at 11 mg QD) in RA patients is proposed to be extrapolated to a similar immune-mediated inflammatory disease AS, to support the claim of therapeutic similarity of 11 mg PR QD and 5 mg IR BID in AS patients, given that the efficacy of tofacitinib IR (dosed at 5 mg BID) in AS has been established, and given that E-R relationships established in RA and in AS patients support Cavg (or AUC) as the relevant parameter for efficacy.

The tofacitinib IR AS development programme was designed to evaluate the efficacy of tofacitinib IR (5 mg BID) for the treatment of patients with active AS. The IR clinical programme included:

- Study  A3921120 ,  a  pivotal  Phase  3,  randomised  double  blind,  placebo-controlled  that evaluated the efficacy and safety of tofacitinib in patients with active AS. The treatment duration was  48  weeks,  which  comprised  an  initial  placebo-controlled  treatment  period  of  16  weeks duration (primary efficacy analysis), followed by an open-label treatment period of 32 weeks duration.
- Study  A3921119 ,  a  dose-ranging,  Phase  2b,  randomised,  double-blind,  placebo-controlled efficacy and safety study designed to characterise the dose-response of tofacitinib (2, 5, and 10 mg IR BID) versus placebo in patients with active AS. The treatment duration was 12 weeks.

The assessment of these studies is reported below.

## 2.4.1. Dose response study

A3921119 This was a Phase 2, multicenter, randomised, double-blind, placebo-controlled dose ranging, parallel  group  efficacy  and  safety  study  designed  to  characterise  the  dose  response  of  tofacitinib  in patients with active AS who had experienced an inadequate response to NSAIDs and were naïve to previous bDMARDs. This was a proof-of-concept as well as a dose-ranging study that evaluated the efficacy and safety of tofacitinib doses of 2 mg, 5 mg, and 10 mg IR BID versus placebo (randomised in 1:1:1:1 ratio) over a 12-week treatment period in adult patients with active AS who had an inadequate response to NSAIDs but were bDMARD-naïve. Given the results of Study A3921119, as well as taking into consideration the recommended BID posology for tofacitinib in other rheumatologic diseases, 5 mg IR BID of tofacitinib was selected to be evaluated in Study A3921120.

For complete study information please see section 'Supportive study'.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study

## Study A3921120

## Methods

The design of the pivotal A3921120 Study is presented in the Figure 13 :

Figure 13. Pivotal Study A3921120 Schematic of Study Design

## Primary endpoint: Proportion of subjects achieving ASAS20at16weeks

<!-- image -->

The  study  design  includes  a  screening  period  of  approximately  30  days,  a  16-week  double-blind treatment period, a 32-week open-label treatment period and a 28-day follow-up period (duration of participation for eligible subjects was approximately 56 weeks).

The primary efficacy analysis was at 16 weeks (data cutoff 19DEC2019, data snapshot 29JAN2020) and maintenance follow-up to 48 weeks.

In support of the sought indication the MAH is providing confirmatory evidence from one pivotal study only. As per the POINTS TO CONSIDER ON APPLICATION WITH 1. META-ANALYSES; 2. ONE PIVOTAL STUDY, CPMP/EWP/2330/99, this study will have to be exceptionally compelling, and in the regulatory evaluation special attention will be paid to key aspects including the internal/external validity; Clinical relevance, the estimated size of treatment benefit must be large enough to be clinically valuable; the degree of statistical significance, statistical evidence considerably stronger-internal consistency. Similar effects demonstrated in different pre-specified sub-populations. All-important endpoints showing similar findings.

The proposed study design is randomised, double-blind, placebo-controlled, parallel group comparing tofacitinib  5mg  dosed  twice  daily  to  placebo  in  subjects  with  active  AS,  who  had  experienced  an inadequate response to NSAIDs (NSAID-IR) and were additionally either naïve to previous bDMARDs, or TNFì-IR or experienced to previous bDMARDs but without inadequate response (bDMARD Use [Non-IR]). As per the EMA guideline on the Clinical Investigation of Medicinal products for the treatment of Axial Spondyloarthritis (EMA/CPMP/EWP/4891/03 Rev.1, Corr 1*) the  design could be acceptable however since tofacitinib belongs to a new therapeutic class for the AS indication and the study includes biological naïve  patients  a  three-arm  trial  (including  an  accepted  active  comparator)  would  have  been recommended, particularly for assessing a relative B/R balance. The Applicant has performed a meta-

<div style=\"page-break-after: always\"></div>

analysis of approved treatments and also included the results of the tofacitinib trials (dose-finding and pivotal study) as supportive data.

The time point for the primary analysis (DB phase) is within the time period indicated by the above guideline; the maintenance period is in line with the guideline although a longer Open-Label (OL) period would  have  been  recommended  for  assessing  structural  changes.  Moreover,  evaluation  of  dose reduction/stop and/or increased dose interval for subjects obtaining resolution of inflammation could have been useful to guide prescribers for long term treatment to avoid unnecessary toxicity.

The  MAH  clarified  that  dose  reduction/changing  dose  interval  in  AS  patients  after  resolution  of inflammation  following  tofacitinib  treatment  has  not  been  evaluated  and  that  there  are  no  data supporting changing dose interval. The same apply for other tofacitinib indications such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). The MAH does not intend to seek therapeutic claims in this area and therefore any decision on modifying or stopping treatment should be at physician discretion. Moreover, the MAH has also specified that at present there is no plan to conduct a long-term extension study for tofacitinib in ankylosing spondylitis (AS) patients.

## Study participants

Key Inclusion criteria:

1. Adults' subjects with a diagnosis of AS based on the Modified New York Criteria for Ankylosing Spondylitis (1984).
2. The subject must have a radiograph of the SI joints (AP Pelvis) documenting diagnosis of AS. Previous radiographs (up to 2 years old) can be used if they are accepted by the central reader. Otherwise, a new radiograph will be obtained during the screening period.
3. Subject has active AS Screening and Baseline (Day 1) visits defined as:
- BASDAI score of ≥4; and
- Back pain score (BASDAI Question 2) of ≥4.
4. Subject has active disease despite nonsteroidal anti-inflammatory drug (NSAID) therapy or is intolerant to NSAIDs as defined by:

Subject must have had at least a total of 2 occurrences of an inadequate clinical response (minimum of 4 weeks trial) or intolerance to at least 2 different oral NSAIDs. An inadequate response to a previous NSAID or TNFi is defined as a lack of sufficient clinical response based on a clinical judgment or based on a related adverse event. Intolerance is defined as having discontinued NSAID treatment due to a related adverse event (e.g., allergic reaction, gastrointestinal symptoms or signs, hypertension, etc).

5. Subjects who are designated as TNFi-IR must have received at least 1, but not more than 2 approved TNFi that was administered in accordance with its labelling recommendations and was inadequately effective after the minimum treatment times listed below and/or not tolerated after one or more doses.
- At least 3 months of adalimumab treatment;
- At least 3 months of etanercept treatment;
- At least 4 infusions of infliximab;
- At least 3 injections of golimumab;

<div style=\"page-break-after: always\"></div>

- At least 3 months of certolizumab treatment.

Intolerance is defined as having experienced a treatment-related AE.  Subjects may be receiving the following csDMARDs at the time of the screening visit. These medications should be continued throughout the entire study and doses should remain unchanged. Any other Disease-Modifying Anti-Rheumatic Drugs (DMARDs) require discussion prior to enrolment with the sponsor for washout timeframe.

- Methotrexate (MTX): Maximum dose of 25 mg/week. Minimum duration of therapy 4 months and dose stable for 4 weeks prior to first dose of investigational product.
- Sulfasalazine (Azulfidine, Salazopyrin): Maximum dose of 3 gm/day. Minimum duration of therapy 2 months and dose stable for 4 weeks prior to first dose of investigational product.
6. Subjects who are already taking oral corticosteroids (not injectables) may participate in the study:
- Oral corticosteroids: Subjects who are already receiving oral corticosteroids must be on a stable dose of ≤10 mg/day of predni sone or equivalent for 1 week prior to the first dose of investigational product.
- Injected (e.g., intraarticular, intramuscular, epidural or intravenous) corticosteroids must be discontinued 4 weeks prior to the first dose of investigational product.
- Topical and intra-rectal corticosteroids will be allowed during the study.
7. Subjects who are receiving any investigational or marketed treatment for AS, arthritis or back pain not mentioned elsewhere must have that treatment discontinued for 4 weeks or 5 halflives, whichever is longer.
8. Subjects receiving non-prohibited concomitant medications for any reason must be willing to stay on a stable regimen (doses and frequency) as defined in the protocol.
9. No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB) as defined by all of the following:
- A negative QuantiFERON-TB Gold (QFT G) In Tube test performed at or within 3 months prior to the Screening visit. Subjects with a history of Bacille Calmette Guérin (BCG) vaccination will be tested with the QFT G test.
- A chest radiograph taken at or within the 3 months prior to screening.
- No history of either untreated or inadequately treated latent or active TB infection. Women of childbearing potential must test negative for pregnancy prior to enrolment in this study.

Female subjects of non-childbearing potential only according to strict criteria.

## Key Exclusion criteria:

1. History of known or suspected complete ankylosis of the spine.
2. Subjects that have been exposed to or are currently receiving targeted synthetic DMARDS (including JAK inhibitors) or those currently on biological DMARDS (i.e., washout from any current bDMARD required per Section 5.8.1), thalidomide (including

<div style=\"page-break-after: always\"></div>

previous use) and other prohibited concomitant medications noted in Appendix 4 of the bioanalytical report.

3. History of allergies, intolerance or hypersensitivity to lactose or tofacitinib (CP690,550). This includes subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
4. Blood dyscrasias at screening or within 3 months prior to the first dose of investigational product including confirmed:
- Hemoglobin &lt;10 g/dL
- Absolute white blood cell count (WBC) &lt;3.0 x 10 9 /L (&lt;3000 mm 3 )
- Absolute neutrophil count (ANC) &lt;1.5 x 10 9 /L (&lt;1500 mm 3 )
- Absolute lymphocyte count &lt;1.0 x 10 9 /L (&lt;1000/mm 3 )
- Platelet count &lt;100 x 10 9 /L (&lt;100,000/mm 3 ).
5. Estimated Creatinine Clearance &lt;40 mL/min based on Cockcroft Gault equation at Screening visit.
6. Total bilirubin, AST or ALT more than 1.5 times the upper limit of normal (ULN) at screening visit.
7. History of any other autoimmune rheumatic disease.
8. History of an infected joint prosthesis at any time, with the prosthesis still in situ.
9. History of any lymphoproliferative disorder, such as Epstein Barr Virus related lymphoproliferative disease (EBV-LPD), history of lymphoma, leukemia, or signs and symptoms suggestive of current lymphatic disease.
10. History of recurrent (more than one episode) herpes zoster or disseminated/multidermatomal (a single episode) herpes zoster or disseminated (a single episode) herpes simplex.
11. History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 3 months prior to the first dose of investigational product. History of infection requiring antimicrobial therapy within 2 weeks prior to the first dose of investigational product.
12. Any prior treatment with non-B cell specific lymphocyte depleting agents/therapies (e.g., alemtuzamab, efalizumab), alkylating agents (e.g., cyclophosphamide or chlorambucil), or total lymphoid irradiation.
13. Any subject who has been vaccinated with live or attenuated vaccines within the 6 weeks prior to the first dose of investigational product or is to be vaccinated with these vaccines at any time during treatment or within 6 weeks after last dose of investigational product.
14. A subject with any condition possibly affecting oral drug absorption, e.g., gastrectomy, clinically significant diabetic gastroenteropathy, or certain types of bariatric surgery such as gastric bypass. Procedures such as gastric banding, that simply divide the stomach into separate chambers, are NOT exclusionary.
15. A subject that is considered at risk for GI perforation by the investigator or Sponsor.

<div style=\"page-break-after: always\"></div>

16. Screening 12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities which may affect subject safety (e.g., pattern of acute myocardial infarction, acute ischemia or serious arrhythmia) or interpretation of study results (e.g., continuously paced ventricular rhythm or complete left bundle branch block).
17. A subject with a known immunodeficiency disorder or a first degree relative with a hereditary immunodeficiency.
18. A subject with a malignancy or with a history of malignancy, with the exception of adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
19. Significant trauma or surgery procedure within 1 month prior to first dose of study medication, or any planned elective surgery during the study period.
20. A subject known to be infected with human immunodeficiency virus (HIV), hepatitis B virus or hepatitis C virus or any chronic infection.

## Treatments

During the first  16-week treatment period, patients were randomised in a double-blind 1:1 ratio to tofacitinib 5 mg BID or matching placebo BID. At the Week 16 visit, all patients, including those who were randomised to placebo, received open label tofacitinib 5 mg BID for the remaining 32 weeks of the study period.

## Prior and Concomitant Treatments

Patients continued their stable background AS therapy, which included NSAIDs including selective COX2 inhibitors, MTX, sulfasalazine, and corticosteroids.

Methotrexate was allowed if it had been used for at least 4 months, on a stable dose ( ≤ 25mg/week) during the last 4 weeks. Sulfasalazine was allowed if used for at least 2 months, on a stable dose ( ≤ 3g/day) during the last 4 weeks. Patients who were already receiving oral corticosteroids must be on a stable dose of ≤ 10 mg/day of prednisone or equivalent for 1 week before baseline. Topical NSAIDs were allowed during the study.

Daily dosages of NSAIDs/COX-2 inhibitors, opioids, and paracetamol must be stable for 1 week prior to first study dose and must remain so during the study treatment period (Week 48) except if adjustment is needed to protect a subject's safety. The total daily dose of acetaminophen may not exceed 2.6 grams per day, and the total daily dose of opioid may not exceed the potency equivalent of 30 mg of orally administered morphine.

## Rescue medications

The maximum dose of acetaminophen/paracetamol was 2.6 g/day for no more than 10 consecutive days. The maximum dose of opioids was the maximum potency equivalent of 30 mg/day of orally -administered morphine (with or without acetaminophen/paracetamol) for no more than 10 consecutive days (Table 12). Subjects who were not on stable, background opioid therapy, any of single opioid agents (e.g., hydrocodone,  oxycodone  or  tramadol)  could  be  given  as  rescue  medication  (with  or  without acetaminophen/paracetamol)  for  no  more  than  10  consecutive  days.  Subjects  who  required  rescue medication for more than 10 consecutive days were discontinued from the investigational product. In addition, subjects were not dosed with rescue acetaminophen/paracetamol or opioids within 24 hours prior to a study visit.

<div style=\"page-break-after: always\"></div>

Table 12. Rescue therapy for Study A3921119 and A3921120

| Study    | Rescue therapy                                                                                                                                                                                          |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A3921119 | Increases of acetaminophen/paracetamol and opioids were allowed as rescue medication for no more than 10 consecutive days.                                                                              |
|          | Acetaminophen/paracetamol were added or increased to a maximum of 2.6 gm/day.                                                                                                                           |
|          | Opioids were added or increased to a maximum potency equivalent of 30 mg of orally-administered morphine.                                                                                               |
|          | Subjects who required rescue for more than 10 consecutive days were discontinued from the study.                                                                                                        |
|          | There was no limit to the duration of nonconsecutive use of rescue medications.                                                                                                                         |
|          | Subjects were not dosed with rescue medication during the 24 hours prior to a study visit.                                                                                                              |
|          | Baseline stable use acetaminophen/paracetamol or opioids were not discontinued in advance of study visits.                                                                                              |
|          | Subjects were not dosed with rescue acetaminophen/paracetamol or opioids within 24 hours prior to a study visit.                                                                                        |
|          | Baseline stable acetaminophen/paracetamol or opioids was not discontinued in advance of study visits.                                                                                                   |
| A3921120 | Increases of acetaminophen/paracetamol and opioids were allowed as rescue medication for no more than 10 consecutive days.                                                                              |
|          | Acetaminophen/paracetamol was added or increased to a maximum of 2.6 gm/day.                                                                                                                            |
|          | Combination products such as over-the-counter 'cold remedies' or pain medications were assessed for acetaminophen/paracetamol content so that the total dose will not exceed 2.6 gm/day.                |
|          | Opioids were added or increased to a maximum potency equivalent of 30 mg of orally-administered morphine.                                                                                               |
|          | Subjects who required rescue for more than 10 consecutive days were discontinued from the investigational product and designated as discontinued from the investigational product for lack of efficacy. |
|          | There was no limit to the duration of nonconsecutive use of rescue medications.                                                                                                                         |
|          | Subjects were not dosed with rescue medication during the 24 hours prior to a study visit.                                                                                                              |
|          | In the judgement of the investigator, if rescue therapy had any effect on efficacy data collected during a study visit, this constituted a protocol deviation.                                          |
|          | Baseline stable use of acetaminophen/paracetamol or opioids was not discontinued in advance of study visits.                                                                                            |

Source: S0113 Module 5.3.5.4 A3921119 Protocol Amendment 1 Section 5.6 and Appendix 6; S0113 Module 5.3.5.1 A3921120 Protocol Amendment 3 Section 5.8.3 and Appendix 6

## Treatment compliance

At the study visits, sufficient investigational product was dispensed to complete dosing until the next scheduled visit and all study medication had to be returned at each visit. Compliance was assessed by pill  count  at  each  visit.  If  compliance  was  &lt;80%  the  patient  was  offered  counselling  to  improve compliance. If a patient was less than 80% compliant as assessed at two consecutive visits, the patient was withdrawn from investigational treatment.

## Discontinuation Criteria from the Investigational Product :

- serious or significant opportunistic infections, other serious or severe AEs
- defined alterations of neutrophils, lymphocytes, Hb, PLT, AST/ALT +/- hepatic injury, creatinine, CK,
- pregnancy,
- rescue medication &gt;10 consecutive days, interruption of IMP for more than 5 consecutive days (DB period) or 28 consecutive days (OL period) or &lt;80% compliance

## Objectives

Part I, double-blind, placebo-controlled (0-16 weeks): to evaluate the efficacy and safety of tofacitinib compared with placebo (superiority).

<div style=\"page-break-after: always\"></div>

Part II,  open label, tofacitinib  5mg (16-48 weeks): to evaluate the efficacy and  safety of tofacitinib through up to 48 weeks of treatment in subjects who have completed Part I.

## Outcomes/endpoints

Improvement criteria based upon ASAS response have been developed for clinical trials in AS which include the ASAS20, ASAS40, ASAS 5/6 assessments and partial remission. 1,2  These composite scores are derived from several of the PRO measures or disease activity assessments. The composite score was calculated by the Sponsor.

A summary of the efficacy endpoints evaluated in Study A3921120 are presented Table 13.

## Table 13. Summary of the efficacy endpoints

<!-- image -->

| Table l.        | Study Objeetives and Endpoints                                                                                                                                                                                                                  | Study Objeetives and Endpoints                                                                                                                                                                                                                              |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Type            | Objertive                                                                                                                                                                                                                                       | Endpoint                                                                                                                                                                                                                                                    |
| Primary         | Primary                                                                                                                                                                                                                                         | Primary                                                                                                                                                                                                                                                     |
| Efficacy        | To compare the efficacy of tofacitinib5mgBDversus placebo on the ASAS20' response rate at Week 16 in subjects with active AS that have had an inadequate response to previous treabment.                                                        | ASAS20 response* at Week 16.                                                                                                                                                                                                                                |
| Key Secondary   | Key Secondary                                                                                                                                                                                                                                   | Key Secondary                                                                                                                                                                                                                                               |
| Efficacy        | To compare the efficacy of tofacitimib 5 mgBID versus placebo on the ASAS40² response rate at Week 16 in subjects with active AS that have had an inadequate response to previous treabment.                                                    | ASAS40 response* at Week 16.                                                                                                                                                                                                                                |
| Other Secondary | Other Secondary                                                                                                                                                                                                                                 | Other Secondary                                                                                                                                                                                                                                             |
| Safety          | To compare the safety and tolerability of tofacitimib 5 mg BID versus placebo insubjecis with active AS that have had an inadequate response to previous treatment.                                                                             | Incidence and severity of AEs. Clinical laboratory tests, vital sigus, physical examination and 12-lead ECG parameters.                                                                                                                                     |
| Efficacy/HRQoL  | To compare the efficacy (including health-related quality of life, fimction, pain, and fatigue) of tofacitinib 5 mgBID versus placebo at all time points in subjects with active AS that have had an inadequate response to previous treatment. | ASAS20'response*at all other time points. ASAS40²response* at all other time points. Change from baseline in ASDAS(CRP)* at all time points. Change from baseline in hsCRp* at all time points. Change fom baseline in ASQoL* at all time points collected. |

<div style=\"page-break-after: always\"></div>

| Table l.   | Study Objectives and Endpoints   | Study Objectives and Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Type       | Objective                        | Endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |                                  | Change from baseline in SF-36v2* at all time points collected. Change from baseline in BASMI* including the 5 components (lateral spine flexion, tragus-to-wall distance, lumbar flexion, maximal intemmalleolar distance and cervical rotation) at all time points. Change from baseline in FACIT-F (3 endpoints: total score*, experience domain and impact domain scores) at all time points. Change from baseline in PGA** at all time points collected. Change from baseline in Patient's Assessment of Spinal Pain (Total Back Pain**, Noctumal Spinal Pain) at all time points collected. Change from baseline in BASFI** at all time points. Change from baseline in inflammation** (mean of the answers to questions 5 and 6 of the BASDAI) at all time points collected. ASAS 5/6 response at all time points. ASAS partial remission criteria at all time points. Change from baseline in BASDAI at all time points. |

<div style=\"page-break-after: always\"></div>

| Table l. Study Objectives and Endpoints   | Table l. Study Objectives and Endpoints                                                   | Table l. Study Objectives and Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Type                                      | Objective                                                                                 | Endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                           |                                                                                           | BASDAI50 response at all time points. ASDAS clinically important improvement, ASDAS major improvement and ASDAS inactive disease at all time points. Change from baseline in MASES at all time points collected. Change from baseline in extra-articular Imvolvement (Specific Medical History and peripheral articular involvement [as assessed by change from baseline in swollen joint coumt]) at all time points collected. Change from baseline in spinal mobility at all time points collected. Change from baseline in EQ-5D-3L and EQ-VAS, at all time points collected. Change from baseline in WPAI Questionnaire: Spondyloarthritis |
| Tertiary/Exploratory                      | Tertiary/Exploratory                                                                      | Tertiary/Exploratory                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| PK                                        | To descnibe thePKof tofacitimib in subjects with active AS.                               | Oral clearance (CL/F) and other PK parameters calculated from plasma tofacitinib concentrations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Safety                                    | To evaluate the effect of tofacitinib 5 mg BID on lymphocyte subsets using FACS analysis. | FACS analysis of lymphocyte subsets.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<!-- image -->

| Table l. Study Objectives and Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Table l. Study Objectives and Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Table l. Study Objectives and Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Objective                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Medical Resowrce Utilization                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | To measure the effect of tofacitinib5mgBIDonhealthcare resouwrce utilization at all collected time points.                                                                                                                                                                                                                                                                                                                                                                                                               | AS-HCRU at all time points collected.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| ASAS20improvementis definedas 220%and 21 unit in at least3 domains ona scale of 0-10 and no uemop aujuenai aq u lum Iz pue 90tz jo 2ujuasiom *ASAS40 improvement criteria are classified as 240%% and 22 units in at least 3 domains on a scale of 0-10 and no worsening at all in the remaining domain. *Global Type I error-controlled efficacy endpoints at Week 16 were tested in the following sequence: ASAS20. ASAS40. change from baseline in ASDAS(CRP). change from baseline in hsCRP, change from baseline in | ASAS20improvementis definedas 220%and 21 unit in at least3 domains ona scale of 0-10 and no uemop aujuenai aq u lum Iz pue 90tz jo 2ujuasiom *ASAS40 improvement criteria are classified as 240%% and 22 units in at least 3 domains on a scale of 0-10 and no worsening at all in the remaining domain. *Global Type I error-controlled efficacy endpoints at Week 16 were tested in the following sequence: ASAS20. ASAS40. change from baseline in ASDAS(CRP). change from baseline in hsCRP, change from baseline in | ASAS20improvementis definedas 220%and 21 unit in at least3 domains ona scale of 0-10 and no uemop aujuenai aq u lum Iz pue 90tz jo 2ujuasiom *ASAS40 improvement criteria are classified as 240%% and 22 units in at least 3 domains on a scale of 0-10 and no worsening at all in the remaining domain. *Global Type I error-controlled efficacy endpoints at Week 16 were tested in the following sequence: ASAS20. ASAS40. change from baseline in ASDAS(CRP). change from baseline in hsCRP, change from baseline in |

<div style=\"page-break-after: always\"></div>

The Table 14 summarises the description of the endpoints and the time points of the assessment.

Table 14. Summary and Description of all Efficacy Measures

| Assessment                                                                                                       | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Measurement Timepoint(s)                                                                                         |
|------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Endpoint A3921120                                                                                                | Endpoint A3921120                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Endpoint A3921120                                                                                                |
| Primary efficacy endpoint (subject to hierarchical testing procedure for global Type I error-control at Week 16) | Primary efficacy endpoint (subject to hierarchical testing procedure for global Type I error-control at Week 16)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Primary efficacy endpoint (subject to hierarchical testing procedure for global Type I error-control at Week 16) |
| ASAS20 Response                                                                                                  | ASAS20 assesses 4 domains: the Patient Global Assessment of Disease, Spinal Pain (total back pain), Function (BASFI) and Inflammation (average of questions 5 and 6 of BASDAI). ASAS20 response is defined as an improvement from Baseline ≥20% and ≥1 unit in at least 3 domains on a scale of 0 to 10 and no worsening of ≥20% and ≥1 unit in the remaining domain.                                                                                                                                                                                                           | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48 At Week 16 was the Primary Efficacy Endpoint                        |
| Key secondary efficacy endpoint (subject to hierarchical testing procedure for global Type I error-control at    | Key secondary efficacy endpoint (subject to hierarchical testing procedure for global Type I error-control at                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Key secondary efficacy endpoint (subject to hierarchical testing procedure for global Type I error-control at    |
| ASAS40 Response                                                                                                  | ASAS40 assesses the 4 domains as specified above. ASAS40 response is defined as an improvement from Baseline ≥40% and ≥2 units in at least 3 domains on a scale of 0 to 10 and no worsening at all in the remaining domain                                                                                                                                                                                                                                                                                                                                                      | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48 At Week 16 was the Key Secondary Efficacy Endpoint                  |
| Secondary efficacy endpoints (subject to hierarchical testing procedure for global Type I error-control at Week  | Secondary efficacy endpoints (subject to hierarchical testing procedure for global Type I error-control at Week                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Secondary efficacy endpoints (subject to hierarchical testing procedure for global Type I error-control at Week  |
|  ASDAS(CRP) a                                                                                                   | The ASDAS(CRP) endpoint is derived from several patient-reported outcomes (Back Pain, Duration of Morning Stiffness, Patient Global Assessment, and Peripheral Pain/Swelling) and hsCRP and was calculated by the Sponsor. The following formula was used to calculate the ASDAS(CRP): ASDAS(CRP) = 0.121 × Back Pain + 0.058 × Duration of Morning Stiffness + 0.110 × Patient Global + 0.073 × Peripheral Pain/Swelling + 0.579×Ln (hsCRP mg/L+1)                                                                                                                             | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                     |
|  hsCRP                                                                                                          | Blood samples were analysed by a central laboratory.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                     |
|  ASQoL                                                                                                          | The ASQoL is an 18-item patient-completed questionnaire assessing the amount of restriction the patient is experiencing in daily activities, level of pain and fatigue, and the impact on the patient's emotional state. Each item is scored as 0 (no impact) or 1 (yes - impact). A total score was calculated by summing the items. The total score ranges from 0 to 18, with higher values indicating more impaired health-related quality of life.                                                                                                                          | Weeks 16 and 48                                                                                                  |
|  SF-36v2                                                                                                        | The SF-36 (Acute) is a 36-item patient-completed generic health status measure. It measures 8 general health domains (norm-based scores were used in analysis): physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. These domains are also summarised as physical and mental component summary scores (PCS and MCS, respectively). Higher scores indicate better health outcomes. PCS was a Type I error- controlled endpoint. | Weeks 16 and 48                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Assessment Endpoint                                                                                         | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Measurement Timepoint(s) A3921120                                                                           |
|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
|  BASMI Score - Linear Method                                                                               | The BASMI was used to assess the axial status and mobility (cervical, dorsal and lumbar spine, hips and pelvic soft tissue). Five clinical measures comprise this scale and in this clinical study the linear function method was used. The combined index score was calculated by the Sponsor using the individual scores from the following measures: lateral spinal flexion, tragus to wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, and cervical rotation.                                             | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
|  FACIT-F                                                                                                   | The FACIT - Fatigue Scale is a patient completed questionnaire consisting of 13 items that assess fatigue. Instrument scoring yields a range from 0 to 52 for the total score, with higher scores representing better patient status (less fatigue). FACIT-F is also summarised as FACIT-F experience domain score (range 0-20) and FACIT-F impact domain (range 0-32) score. FACIT-F Total score was a Type I error-controlled endpoint.                                                                                                       | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
| Secondary efficacy endpoints (subject to hierarchical testing procedure for Type I error-control within the | Secondary efficacy endpoints (subject to hierarchical testing procedure for Type I error-control within the                                                                                                                                                                                                                                                                                                                                                                                                                                     | Secondary efficacy endpoints (subject to hierarchical testing procedure for Type I error-control within the |
|  PGA                                                                                                       | Patients assessed their overall disease activity over the last week using a NRS between 0 (Not Active) and 10 (Very Active) to the question, 'How active was your spondylitis on average during the last week?' PGA is 1 of the 4 ASAS20/ASAS40 components and the results of this assessment were used to calculate the ASAS improvement criteria.                                                                                                                                                                                             | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
|  Spinal pain                                                                                               | Two NRS scales were used to assess the patient's spinal pain: level of nocturnal pain and total back pain on average during the last week. For each of these scales, patients marked their level of pain on a 0 to 10 NRS anchored by 0 for 'No Pain' to 10 'Most Severe Pain.' Results of total back pain were used to calculate the ASAS improvement criteria. The total back pain was a Type I error-controlled endpoint.                                                                                                                    | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
|  Inflammation (morning stiffness)                                                                          | Inflammation is 1 of the 4 ASAS20/ASAS40 components, which is the average of the answers to questions 5 &6of BASDAI.                                                                                                                                                                                                                                                                                                                                                                                                                            | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
|  BASFI                                                                                                     | The BASFI is a set of 10 questions designed to determine the degree of functional limitation in those with AS. The first 8 questions consider activities related to functional anatomy. The final 2 questions assess the patients' ability to cope with everyday life. A 0-10 NRS is used to answer the questions with 0 being 'Easy' and 10 being 'Impossible.' BASFI is the average of these 10 scores and it ranges from 0 to 10, with higher scores indicating greater functional limitation. BASFI is 1 of the 4 ASAS20/ASAS40 components. | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
| Secondary efficacy endpoints (not controlled for Type I error)                                              | Secondary efficacy endpoints (not controlled for Type I error)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Secondary efficacy endpoints (not controlled for Type I error)                                              |
| ASAS 5/6 response                                                                                           | ASAS 5/6 assesses 6 domains: the domains as noted in the ASAS20 and ASAS40, hsCRP and Spinal mobility, specifically lateral spinal flexion (from the BASMI). Response is defined as improvement ≥20% in at least 5 domains                                                                                                                                                                                                                                                                                                                      | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |
| ASAS partial remission                                                                                      | ASAS partial remission is based on the same 4 ASAS domains noted above. Partial remission is defined as a response if a score of 2 or less (on a scale of 0 to 10) for each of the 4 domains                                                                                                                                                                                                                                                                                                                                                    | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48                                                                |

<div style=\"page-break-after: always\"></div>

| Assessment Endpoint                                                              | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Measurement Timepoint(s) A3921120            |
|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
|  Spinal mobility (Chest expansion)                                              | The chest expansion (cm) was measured as the difference between maximal inspiration and expiration. Two attempts were performed and the better (ie, larger) of the 2 attempts was utilised for data analysis.                                                                                                                                                                                                                                                                                                     | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48 |
|  BASDAI                                                                         | The BASDAI is a validated patient-completed questionnaire that consists of 6 questions pertaining to the 5 major symptoms of AS: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a NRS from 0 (none) to 10 (very severe). The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5.                      | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48 |
| ASDAS Clinically Important Improvement, Major Improvement and Inactive Disease a | The ASDAS Clinically Important Improvement, Major Improvement and Inactive Disease were calculated from the ASDAS(CRP) data. Clinically important improvement and major improvement were defined as a decrease from Baseline in ASDAS(CRP) ≥1.1 units and ≥2.0 units, respectively. Inactive disease was defined as ASDAS(CRP) <1.3 unit.                                                                                                                                                                         | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48 |
|  MASES                                                                          | Enthesitis was evaluated by the qualified blinded assessor using the MASES. Thirteen sites (right and left) were assessed for tenderness: costochondral 1 (right and left), costochondral 7 (right and left), spina iliaca anterior superior (right and left), crista iliaca (right and left), spina iliaca posterior (right and left), processus spinosus at L5 and Achilles tendon proximal insertion (right and left). Scoring at each site will be 0 for no tenderness or 1 for tenderness.                   | At Weeks 4, 8, 12, 16, 24, 32, 40, and 48    |
|  Swollen Joint Count                                                            | Forty-four (44) joints were assessed for swelling and included the following: sternoclaviculars, acromioclaviculars, shoulders, elbows, wrists, metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), knees, ankles, and metatarsophalangeals (MTP I, II, III, IV, V).                                                                                                                                                                        | At Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48 |
|  EuroQoL EQ-5D- 3L and EQ-VAS                                                   | The EuroQol 3 Levels EQ-5D-3L Health State Profile is a patient completed instrument designed to assess impact on health-related quality of life in 5 domains: mobility, self- care, usual activities, pain/discomfort, and anxiety/depression with lower scores indicating better health outcomes. EQ-VAS (Your own health state today) records the patient's self-rated health, a score ranging from 0 to 100 mmis recorded, with higher scores representing                                                    | Weeks 16 and 48                              |
|  WPAI                                                                           | better health state today The WPAI: Spondyloarthritis is a 6-item patient- completed questionnaire that is specific for spondyloarthritis which yields 4 types of scores: percent work time missed due to health problem; percent impairment while working due to health problem; percent overall work impairment due to health problem; percent inactivity due to health problem. WPAI outcomes are expressed as impairment percentages with higher numbers indicating greater impairment and less productivity. | Weeks 16 and 48                              |

<div style=\"page-break-after: always\"></div>

a. Per the method published by Machado et al3, for hsCRP values &lt; 2 mg/L, it is set to 2 mg/L in the formula to derive ASDAS(CRP) and endpoints based on ASDAS(CRP).

## Sample size

The primary efficacy analysis is to compare the ASAS20 response rate at week 16 of the tofacitinib 5 mg BID and placebo via the normal approximation for the difference in binomial proportions. Assuming a placebo response rate of 40% for ASAS20 response at week 16, a sample size of 120 per arm will yield about 89% power to detect a difference of at least 20% between tofacitinib 5 mg BID and placebo at a two-sided significance level of 5%. In the Phase 2 proof of concept trial A3921119, ASAS20 response rates at week 12 were 63% and 40% for tofacitinib 5 mg BID and placebo, respectively.

Sample size calculation for pivotal phase III study A3921120 was based on the response rate found in phase  2  dose-ranging,  proof  of  concept  trial.  It  is  recognized  as  appropriate,  although  the  primary efficacy  endpoint  was  then  analysed  by  the  Cochran-Mantel-Haenszel  (CMH)  test  stratified  by  the randomisation strata (prior treatment history).

## Randomisation

By  use  of  an  automatic  Interactive  web-based  Response  system.  Subjects  were  randomised  at  the Baseline visit in a 1:1 ratio to one of the following two parallel blinded treatment sequences for a total of 16 weeks of treatment. Randomization was stratified by prior treatment history: (1) bDMARD-naive and (2) TNFi-IR or bDMARD use (non-IR) as shown in Table 15. The clinical trial was designed to reflect the proportion of bDMARD-naïve and TNFi-IR or bDMARD use (non-IR) of approximately 80%/20%.

Table 15 . Safety Analysis Set (Final Analysis)

| Stratum                                    | NumberofbDMARDswith InadequateResponse   | Tofacitinib 5 mgBID (N=133) m(%)   | Placebo-> Tofacitinib 5 mg BID (N=136) n (%)   | Total (N=269) n (%)   |
|--------------------------------------------|------------------------------------------|------------------------------------|------------------------------------------------|-----------------------|
| bDMARD-naive                               |                                          | 102 (76.7)                         | 105 (77.2)                                     | 207 (77.0)            |
| TNFi-IR or bDMARD Use (Non-IR)             |                                          | 31 (23.3)                          | 31 (22.8)                                      | 62 (23.0)             |
| TNFi-IR                                    | 1 TNFi-IR                                | 23 (79.3)                          | 20 (66.7)                                      | 43 (72.9)             |
|                                            | 2 TNFi-IR                                | 6 (20.7)                           | 10 (33.3)                                      | 16 (27.1)             |
| bDMARD Use (Non- 1 bDMARD Use (Non-IR) IR) |                                          | 2 (100.0)                          | 1 (100.0)                                      | 3 (100.0)             |

WHODDE v202003 coding dictionary applied.

Prior drug treatment was defined as a drug taken on or beforeDay -1.

Each subject was counted with the number of unique bDMARD-naive, TNFi-IR, or bDMARD Use (Non-IR) .

ie.If there was more than one record per drug for a subject,count as one medication.

The strata ofbDMARD-naive, TNFi-IR, and bDMARD Use (Non-IR) were derived from clinical database

Safety Analysis Set (SAFETY) - All subjects who were randomized and received at least one dose of the investigational product.

Numbers of inadequate responses were summarized as number (%) of subjects in each category.

PFIZER CONFIDENTIAL SDTM Creation:11SEP2020(02:55)Source Data: adcm Table Generation:26SEP2020 (21:12)

OutputFile:./cdisc/A3921120\\_SCD/adcm\\_s005\\_i\\_a

Table 14.1.4.4.4.2A is for Pfizer internal use.

<div style=\"page-break-after: always\"></div>

At the end of the 16 weeks double-blinded treatment period, all subjects were assigned to open-label tofacitinib 5 mg BID to Week 48. The investigators, subjects and sponsor study team remained blinded to the first 16 weeks of treatment assignment through the entire duration of the trial  until database release.

## Blinding (masking)

This study was subject-, investigator-, and sponsor-blinded. An IRT drug management system was used to dispense the bottles with medication at each visit from baseline to week 40, using unique container numbers. For the open-label treatment period, subjects, investigator and sponsor study team remained blinded to the double-blind treatment period study sequence. All subjects received tofacitinib 5 mg tablets supplied in containers labelled according to local regulatory requirements.

## Statistical methods

Analysis of efficacy parameters

Full Analysis Set: The full analysis set (FAS) included all randomized subjects who received at least one dose of the randomised investigational product (i.e., tofacitinib or placebo).

Per Protocol Analysis Set: The Per-Protocol (PP) analysis set excluded all subjects who had a protocol deviation The PP analysis set was used as a supportive analysis for the primary endpoint of ASAS20 and the key secondary endpoint of ASAS40.

There were 2 planned analyses: Week 16 Analysis (data cut-off 19DEC2019, data snapshot 29JAN2020) and Week 48 Analysis following the final database release.

The Week 16 Analysis included all placebo-controlled efficacy data through Week 16.  The Week 48 analysis  results,  which  contained  placebo-controlled  results  through  Week  16  as  well  as  open-label results post-Week 16, were secondary and supportive in nature.

All statistical tests were conducted on a 2 sided 5% significance level for comparing tofacitinib 5 mg BID to placebo. Type I error was controlled on a 2-sided 5%.

For  the  primary  endpoint  of  ASAS20  response  at  Week  16,  if  the  2-sided  p-value  was ≤ 5%,  the superiority of tofacitinib 5 mg BID to placebo was declared and the primary objective of the study was considered as being met.

## Estimands for ASAS20 and ASAS40 at Week 16

Only discontinuation of the investigational product was considered as an intercurrent event to define the estimands for this study. There are three estimands for the primary endpoint of ASAS20 at Week 16.

## Estimand 1:

The first estimand of ASAS20 at Week 16 is a composite estimand that accounts for both treatment adherence and response. A responder is defined as having a response without discontinuation of the investigational product prior to Week 16.

## Estimand 2:

The second estimand of ASAS20 at Week 16 is supportive to Estimand 1 and is a treatment policy estimand. It estimates the effect regardless of treatment adherence.

<div style=\"page-break-after: always\"></div>

## Estimand 3:

The third estimand of ASAS20 at Week 16 is supportive to Estimand 1 and is a hypothetical estimand. It estimates the treatment effect as if the intercurrent event of discontinuation of investigational product prior to Week 16 has not occurred.

The main difference between Estimand 1 and 3 is that Estimand 3 assumes the intercurrent event of discontinuation of investigational product prior to Week 16 has not occurred, while Estimand 1 considers the  response  after  discontinuation  of  investigational  product  as  non-response  via  the  composite strategy. Also, the population-level summary in Estimand 3 is an odds ratio instead of difference in response rates as in Estimand 1.

Similarly, the same three estimand are also applicable to ASAS40 at Week 16. Specifically, Estimand 1 for ASAS40 at Week 16 is called the Key Secondary Estimand, defined according to the key secondary objective. Estimand 1 was also used for other binary secondary endpoints.

## Estimands for Continuous Secondary Endpoints

Only discontinuation of the investigational product was considered as an intercurrent event to define the  estimands  for  this  study.  Estimand  4,  a  hypothetical  estimand  was  used  for  other  continuous secondary endpoints that estimates the treatment effect as if the intercurrent event of discontinuation of investigational product prior to Week 16 has not occurred

Estimand 5 was used only for the Type I error controlled continuous secondary endpoints as supportive analyses to Estimand 4 and is a treatment policy estimand.

Estimand  4:  The  difference  between  Estimand  5  and  4  is  that  Estimand  5  disregards  treatment adherence and includes the additional data collected after the intercurrent event of discontinuation of the investigational product prior to Week 16, ie, On-Study data are used.

Primary  analysis: For  the  primary  analysis  of  the  ASAS20  response  at  Week  16,  the  normal approximation for the difference in binomial proportions adjusting for the stratification factor (ie, prior treatment history: \"bDMARD naïve\" versus \"TNFi IR or bDMARD Use [Non-IR]\") at randomisation via the CMH approach was used to test the superiority of tofacitinib 5 mg BID to placebo and to generate a 95% CI for the difference on the FAS.

ASAS40 response at Week 16 was analysed using the same methods as those for the primary endpoint ASAS20 response, as well as other binary endpoints.

Continuous endpoints were analysed as change from baseline with a mixed model for repeated measures (MMRM).

When analysis included only a single post-baseline visit, these endpoints were analysed as change from baseline with an analysis of covariance (ANCOVA) model that included treatment group, stratification factor (i.e., prior treatment history), and baseline value.

For  both  MMRM  and  ANCOVA,  if  the  Baseline  was  missing  or  if  there  were  no  post-baseline measurements, the patient was excluded from the analysis. In the final analysis, all data up to Week 48 were included in the analyses using another MMRM.

A tipping point analysis for the primary endpoint of ASAS20 and the key secondary endpoint of ASAS40 was conducted to address impact of missing values on the conclusions and to assess the robustness of the data; it was based on multiple imputation.

## Analysis at week 48

At week 16 all subjects have been assigned to open-label tofacitinib until week 48. Both primary and secondary endpoints have been analysed by the same models used until week 16 but extending visits until week 48. As the primary endpoint (ASAS20), the key secondary endpoint (ASAS40), and the other Type I error controlled secondary endpoints were at week 16, there was no additional adjustment made for Type I error rate at the final analysis at week 48. The week 48 contains results for earlier visits and

<div style=\"page-break-after: always\"></div>

serves as sensitivity analysis only to ensure there were no major changes to the definitive results for the primary and key secondary endpoints obtained at week 16.

Table 16. Numerical Characteristics of Select Continuous Efficacy Endpoints

| Endpoint                                                                                                                                         | Unit                                                                                                                                                                | Theoretical Range of Values                        | Direction of Improvement from Baseline                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Patient Global Assessment of Disease                                                                                                             | None                                                                                                                                                                | 0-10                                               | Decrease from Baseline                                                                                                                                                                    |
| Patient Assessment of Spinal Pain (Total Back Pain, Nocturnal Spinal Pain)                                                                       | None                                                                                                                                                                | All: 0-10                                          | Decrease from Baseline                                                                                                                                                                    |
| BASFI                                                                                                                                            | None                                                                                                                                                                | 0-10                                               | Decrease from Baseline                                                                                                                                                                    |
| BASDAI                                                                                                                                           | None                                                                                                                                                                | 0-10                                               | Decrease from Baseline                                                                                                                                                                    |
| Inflammation Score (ie, Average of Q5 and Q6 of BASDAI)                                                                                          | None                                                                                                                                                                | 0-10                                               | Decrease from Baseline                                                                                                                                                                    |
| hsCRP                                                                                                                                            | mg/L                                                                                                                                                                | ≥0                                                 | Decrease from Baseline                                                                                                                                                                    |
| BASMI score and its 5 component scores (A, S) (A is the unmapped component score, S is the mapped component score [range 0-10] via linear method | BASMI, 5 components (S): None Lateral flexion, Tragus-to-wall distance, lumbar flexion, and intermalleolar distance (A): cm Cervical rotation angle (A): degree (°) | BASMI, 5 components (S): 0-10 5 components (A): ≥0 | BASMI, 5 components (S), Tragus-to-wall distance (A): Decrease from Baseline Lateral flexion, lumbar flexion, intermalleolar distance, and cervical rotation (A): Increase from Baseline. |
| Spinal Mobility - Chest Expansion                                                                                                                | cm                                                                                                                                                                  | ≥0                                                 | Increase from Baseline (ie, higher score represents more spinal mobility)                                                                                                                 |
| ASDAS CRP                                                                                                                                        | None                                                                                                                                                                | ≥0                                                 | Decrease from Baseline                                                                                                                                                                    |
| MASES                                                                                                                                            | None                                                                                                                                                                | 0-13                                               | Decrease from Baseline                                                                                                                                                                    |
| Swollen Joint Count (44)                                                                                                                         | None                                                                                                                                                                | 0-44                                               | Decrease from Baseline                                                                                                                                                                    |
| SF-36v2, 8 domain scale (ie, norm- based), PCS, and MCS scores                                                                                   | None                                                                                                                                                                | All: Real values (Mean=50, SD=10)                  | Increase from Baseline                                                                                                                                                                    |
| EQ-5D-3L, 5 dimension scores                                                                                                                     | None                                                                                                                                                                | All: 1, 2, 3                                       | Decrease from Baseline                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| EQ-VAS                                                   | mm   | 0-100                                                   | Increase from Baseline                                            |
|----------------------------------------------------------|------|---------------------------------------------------------|-------------------------------------------------------------------|
| EQ-5D-3L, Utility Score (UK)                             | None | -0.594 - 1                                              | Increase from Baseline                                            |
| FACIT-F (Total, Impact domain, Experience domain scores) | None | Total: 0-52 Impact domain: 0-32 Experience domain: 0-20 | Increase from Baseline (ie, higher score represents less fatigue) |
| ASQoL                                                    | None | 0-18                                                    | Decrease from Baseline                                            |
| WPAI 4 subscale scores                                   | %    | All: 0-100                                              | Decrease from Baseline                                            |
| AS-HCRU Self-Rating of Job Performance                   | None | 0-10                                                    | Decrease from Baseline                                            |

Abbreviations: % = percent; ASDASCRP = Ankylosing Spondylitis Disease Activity Score using C-Reactive Protein; AS-HCRU = Ankylosing Spondylitis - HealthCare Resource Utilization Questionnaire; ASQoL = Ankylosing Spondylitis Quality of Life; BASDAI = Bath Ankylosing Spondylitis Disease  Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; cm = centimeter; EQ-5D-3L = EuroQol Health State Profile - 5 Dimensions - 3 Levels; EQ-VAS = EuroQol Your own health state today-Visual Analog Scale; FACIT-F = Functional Assessment of Chronic Illness Therapy - Fatigue; hsCRP = high sensitivity C-Reactive Protein; MASES = Maastricht Ankylosing Spondylitis Enthesitis Score;

MCS = mental component summary; mg/L = milligrams per liter; PCS = physical component summary; SD = standard deviation; SF-36v2 = 36-Item Short Form Survey Version 2 Acute; UK = United Kingdom; WPAI = Work Productivity &amp; Activity Impairment.

For the Phase III study, all statistical tests were conducted at the 2-sided 5% significance level for comparing tofacitinib 5 mg BID to placebo. The family-wise Type I error rate has been controlled at the 2-sided 5% significance level using a step-down.

In Study A3921120, 5 estimands were defined for the efficacy endpoints. The discontinuation of the investigational product was considered as an intercurrent event for the respective definitions.  There were 3 estimands for the primary endpoint of ASAS20 response at Week 16 and the key secondary endpoint of ASAS40 response at Week 16. Estimand 1 included only on-drug data and was the main estimand;  Estimand  2  included  on-study  data;  Estimand  3  assumed  the  intercurrent  event  had  not occurred and included only on-drug data. Both Estimands 2 and 3 were supportive estimands. Two additional  estimands,  Estimand  4  (main)  and  Estimand  5  (supportive)  were  used  for  continuous secondary endpoints.

## Results

## Participant flow

Five  hundred  and  fifty-six  AS  patients  were  screened  globally.  A  total  of  270  eligible  patients  were randomised in a 1:1 ratio to 1 of the following 2 parallel treatment groups

- Tofacitinib 5 mg BID (n = 134)
- Placebo (n = 136)

<div style=\"page-break-after: always\"></div>

Of the 270 randomised patients, 1 patient was randomised to tofacitinib 5 mg BID in error by the site but did not receive study drug, thus was excluded from all analyses. There were 269 patients included in the FAS. Overall, 9 (3.3%) patients discontinued from the study drug; 4 (3.0%) from tofacitinib 5 mg BID and 5 (3.7%) in the placebo treatment group up to Week 16. Subject disposition Up to Week 16 and 48 is presented in Figures 14 and 15 respectively.

Figure 14. Subject Disposition Up to Week 16

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 15. Subject Disposition Up to Week 48

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 17 summarises patient disposition for Study A3921120 up to Week 16 and Week 48, respectively.

Table 17. Patient Disposition

|                                                      | Up to Week 16        | Up to Week 16   | Up to Week 48        | Up to Week 48                  |
|------------------------------------------------------|----------------------|-----------------|----------------------|--------------------------------|
|                                                      | Tofacitinib 5 mg BID | Placebo         | Tofacitinib 5 mg BID | Placebo- >Tofacitinib 5 mg BID |
| Randomised                                           | 134                  | 136             | 134                  | 136                            |
| Treated                                              | 133 (99.3)           | 136 (100.0)     | 133 (99.3)           | 136 (100.0)                    |
| Not treated                                          | 1 (0.7)              | 0               | 1 (0.7)              | 0                              |
| Discontinued                                         | 4 (3.0)              | 5 (3.7)         | 15 (11.3)            | 14 (10.3)                      |
| Discontinuations due to AE                           | 3 (2.3)              | 1 (0.7)         | 8 (6.0)              | 3 (2.2)                        |
| Discontinuations due to                              | 1 (0.8)              | 2 (1.5)         | 6 (4.5)              | 4 (2.9)                        |
| Insufficient Clinical Response Analysed for Efficacy |                      |                 |                      |                                |
| Per-protocol analysis set                            | 130 (97.7)           | 134 (98.5)      | -                    | -                              |
| Full analysis set                                    | 133 (100.0)          | 136 (100.0)     | 133 (100.0)          | 136 (100.0)                    |

Percentages for the 'Not treated' and 'Treated' rows are calculated using the number of patients assigned to treatment (randomised) as the denominator. Other percentages are calculated using the number of 'Treated' patients as the denominator.

Discontinuations due to AE and discontinuations due to insufficient clinical response refer to discontinuation of study drug and not discontinuation of study participation.

Based on the Week 48 Analysis data.

A total of 269 patients in the A3921120 were treated and included in the FAS and 133 received tofacitinib 5 mg BID as shown in Table 17.

Five hundred and fifty-six AS patients were screened and a total of 270 eligible patients were randomised (Tofacitinib 5 mg BID n = 134 and Placebo n = 136).

Patient's disposition was balanced across the study. The great majority completed the DIB 16 weeks phase (only 4 and 5 subjects discontinued study drug in the Tofa and PLB arm, respectively). A higher but similar number of subjects discontinued study drug up to 48 weeks: 15 in the Tofa-Tofa and 14 in the  PLB-Tofa  arm;  the  main  reasons  of  discontinuation  being  the  same  safety  and  lack  of  efficacy although a higher number is registered in the Tofa-Tofa (8 and 6, respectively) as compared to PLB-Tofa (3 and 4) group.

## Recruitment

Study  Centres:  A  total  of  57  sites  randomised  subjects  from  the  following  countries:  Australia  (3), Bulgaria (2), Canada (2), China (5), Czech Republic (3), France (1), Hungary (2), Republic of Korea (3), Poland (9), Russian Federation (6), Turkey (4), Ukraine (5), United States (12).

## Conduct of the study

## Amendments

Amendment 1, 06 September 2018 main changes:

1. Clarified the role of ASAS40 response at 16 weeks as a key secondary endpoint. Replaced ΔSF -36v2 Physical Functioning domain by ΔSF -36v2 PCS as a Type I error-controlled endpoint. Added ΔASQoL as an additional Type I error -controlled endpoint. Moved AS-HCRU from a secondary to tertiary endpoint.
2. Added Inflammation, Patients Assessment of Spinal Pain and PGA to the secondary endpoints. Clarified  the  BASMI  secondary  endpoint  includes  the  5  components.  Realigned  secondary endpoints to be consistent with the statistical testing (ie, Type I error control).

<div style=\"page-break-after: always\"></div>

3. Updated sections based upon FDA feedback for subject discontinuation of investigational product and withdrawal from study.
4. Inclusion criteria #7 updated the definition of inadequate response and clarified the definition of intolerance.
5. Updated inclusion criteria #9 (Subject must be on a stable dose of corticosteroids for 1 week prior to first dose of investigational product).
6. Updated exclusion criteria #5 to exclude targeted synthetic DMARDs (including tofacitinib) and subjects that have been previously exposed to conventional synthetic, targeted synthetic, or biological DMARDs

Amendment 2 10 April 2019 main changes:

1. Changed  to  not  exclude  subjects  with  prior  bDMARD  use  (non-IR)  based  on  the  available population to improve the recruitment in the study.
2. Moved the ASQol in sequence for global type 1 error control before the SF-36v2 PCS. Added the FACIT-F Total score to the global type I error control scheme.

Amendment 3 03 April 2020 main changes:

This global amendment incorporates venous thromboembolism (VTE) risk factor checks. Pfizer has determined that VTE is identified as an important identified risk/dose dependent adverse drug reaction for tofacitinib.

A summary of important protocol deviations is presented in Table 18:

- There was a similar proportion of subjects with protocol deviations in both treatment groups.
- The majority of the protocol deviations occurred in the category of procedures/tests and concomitant medications with the most common being efficacy assessment/procedure not performed at appropriate visits.

<div style=\"page-break-after: always\"></div>

Table 18. Summary of important Protocol Deviations -Randomised Subjects (Final Analysis)

|                                                                                                                                                                                                       | Tofacitinib 5mgBID (N=134)   | Placebo-> Tofacitinib s mgBID (N=136)   | Total (N=270)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|-----------------------------------------|-----------------|
| Category forProtocolDeviation Subcategory forProtocol Deviation                                                                                                                                       | n(%)                         | n(%)                                    | (6）u            |
| Number (%) of Subjects With Any Important Protocol Deviation                                                                                                                                          | 37 (27.6)                    | 32 (23.5)                               | 69 (25.6)       |
| CCMEDS                                                                                                                                                                                                | 10(7.5)                      | 12(8.8)                                 | 22 (8.1)        |
| Didnot remainon stable doseofpermitted Concomuitant                                                                                                                                                   | 4(3.0)                       | 7(5.1)                                  | 11(4.1)         |
| Medication as specifiedperProtocol Subject took moderate orpotent CYP3A4inhibitorsand/or moderateorpotentCY3A4inducerswithconcomitantuseofstudy                                                       | 0                            | 1(0.7)                                  | 1(0.4)          |
| drug>7days Tookprohibited ConcomitantMedication/Vaccine                                                                                                                                               | 6(4.5)                       | 5 (3.7)                                 | 11(4.1)         |
| INCLUSION/EXCLUSION                                                                                                                                                                                   | 6(4.5)                       | 4(2.9)                                  | 10 (3.7)        |
| Did not meet inclusion criterion-Subject has active AS screening andbaselinevisitsdefinedas-BASDAI score of>=4 andBackpain score>=4                                                                   | 3(2.2)                       | 1(0.7)                                  | 4(1.5)          |
| Did not meet inclusion criterion-Subject has discontinued any investigational or marketed therapy forAS,backpain,arthritis,for4 weeksor5half-lives                                                    | 0                            | 1(0.7)                                  | 1(0.4)          |
| Did not meet inclusion criterion- Subject has inadequate clinical responseof at least 2 NSAIDs (at least 4 weeks）or intolerance to at least 2 oral NSAIDs                                             | 2(1.5)                       | 2(1.5)                                  | 4(1.5)          |
| Did not meetinclusion criterion-subject takingmethotrexate or sulfasalazine should be taking it at appropriate dose and forminimum duration with a stable dose4weekspnior to first dose of study drug | 1(0.7)                       | 0                                       | 1(0.4)          |
| Did not meet inclusion criterion-subjects designated as TNFi-IR must have aninadequateresponseorintolerance of1ornot more than2                                                                       | 2(1.5)                       | 1(0.7)                                  | 3(1.1)          |
| TNFiagents Did not meet inclusion criterion- subjects taking injectable corticosteroiddiscontined4weeksprior to first dose                                                                            | 1(0.7)                       | 0                                       | 1(0.4)          |
| INVESTIGATIONALPRODUCT                                                                                                                                                                                | 3 (2.2)                      | 0                                       | 3(1.1)          |
| Dosing/Admunistration Error-Compliance withstudy drug less than S0% for2consecutive visitsaffer week16visit                                                                                           | 3(2.2)                       | 0                                       | 3(1.1)          |
| LAB                                                                                                                                                                                                   | 8(6.0)                       | 5(3.7)                                  | 13 (4.8)        |
| Specimen could not be analyzed                                                                                                                                                                        | 7(5.2)                       | 5(3.7)                                  | 12(4.4)         |
| Subject is a women of childbearing potential andpregnancy testing orFSH wasnotperformed ornegative testresultwasnot documented                                                                        | 1 (0.7)                      | 0                                       | 1(0.4)          |
| prior to dosing OTHER                                                                                                                                                                                 | 6(4.5)                       | 1(0.7)                                  | 7(2.6)          |
| Study personnel exposed to unblinded sensitive clinical data                                                                                                                                          | 6(4.5)                       | 1(0.7)                                  | 7(2.6)          |
| PROCEDURES/TESTS                                                                                                                                                                                      | 13 (9.7)                     | 21(15.4)                                | 34(12.6)        |
| Efficacy assessments/procedures not performed at appropriate                                                                                                                                          | 11 (8.2)                     | 16 (11.8)                               | 27(10.0)        |
| visits Patient reported outcome questionnariesnot performed at appropriate visits                                                                                                                     | 2(1.5)                       | 2(1.5)                                  | 4(1.5)          |
| Procedure notperformedby amedicallyqualifiedindividual or by incorrect personnel                                                                                                                      | 0                            | 1(0.7)                                  | 1(0.4)          |
| Procedure/Test not performed as specified in the protocol                                                                                                                                             | 0                            | 3(2.2)                                  | 3(1.1)          |
| RANDOMIZATION                                                                                                                                                                                         | 2(1.5)                       | 0                                       | 2(0.7)          |
| Randomized under wrong stratification (ie-TNFi naive vs TNFi- IR)                                                                                                                                     | 1(0.7)                       | 0                                       | 1(0.4)          |
| Subject wasrandomized inerror (received a randomization mumber however didn't qualify)                                                                                                                | 1(0.7)                       | 0                                       | 1(0.4)          |
| SAFETYREPORTING                                                                                                                                                                                       | 1(0.7)                       | 0                                       | 1(0.4)          |
| Matermal or Patermal exposure in utero wasnotreported orwas not reportedin therequired timeframespecifiedin theprotocol                                                                               | 1(0.7)                       | 0                                       | 1(0.4)          |

N:Number of randomized subjects,n (%):Number of subjects in each analysis category (Percentages were based on N) PFIZER CONFIDENTIALSDTM Creation:13SEP2020(09:08)Source Datr:dv Table Generation:26SEP2020(21:11) OutputFile:/edisc/A3921120 SCD/addvs001ia

Table14.1.5.1A isforPfizerinternal use.

<div style=\"page-break-after: always\"></div>

## Impact of COVID-19

In response to the COVID-19 pandemic, a PACL was approved on 30 March 2020 that outlined the administrative changes that were implemented to clarify study procedures during the pandemic.

The COVID-19 pandemic impact of protocol changes due to the deviations on the data quality, data analysis or conclusion was minimal as the majority of patients had completed study participation prior to start of the COVID-19 pandemic.

Amendments have been done basically to refine the endpoints and their hierarchy; another important point was the inclusion of bDMARD non-IR subjects. No impact on study results is foreseen.

## Baseline data

Table 19 presents baseline demographic characteristics for the tofacitinib 5 mg BID and placebo groups for Study A3921120.

Table 19. Demographics and Baseline Characteristics by Treatment Group - Safety Analysis Set (Final Analysis)

|                    | Tofacitinib 5 mg BID (N = 133)   | Placebo->Tofacitinib 5 mg BID (N = 136)   | Total (N=269)   |
|--------------------|----------------------------------|-------------------------------------------|-----------------|
| Age years, n (%) a |                                  |                                           |                 |
| 18-44              | 83 (62.4%)                       | 86 (63.2%)                                | 169 (62.8%)     |
| 45-64              | 44 (33.1%)                       | 50 (36.8%)                                | 94 (34.9%)      |
| 65-74              | 6 (4.5)                          | 0                                         | 6 (2.2%)        |
| 75-84              | 0                                | 0                                         | 0               |
| ≥85                | 0                                | 0                                         | 0               |
| N1                 | 133                              | 136                                       | 269             |
| Mean (SD)          | 42.2 (11.85%)                    | 40.0 (11.06%)                             | 41.1 (11.49%)   |
| Range              | 20, 70                           | 20, 62                                    | 20, 70          |
| Gender, n (%)      |                                  |                                           |                 |
| Male               | 116 (87.2%)                      | 108 (79.4%)                               | 224 (83.3%)     |
| Female             | 17 (12.8%)                       | 28 (20.6%)                                | 45 (16.7%)      |
| Race, n (%)        |                                  |                                           |                 |
| White              | 107 (80.5%)                      | 106 (77.9%)                               | 213 (79.2%)     |
| Asian              | 25 (18.8%)                       | 30 (22.1%)                                | 55 (20.4%)      |
| Not reported       | 1 (0.8%)                         | 0                                         | 1 (0.4%)        |

Ethnicity, n (%)

<div style=\"page-break-after: always\"></div>

|                             | Tofacitinib 5 mg BID (N = 133)   | Placebo->Tofacitinib 5 mg BID (N = 136)   | Total (N=269)   |
|-----------------------------|----------------------------------|-------------------------------------------|-----------------|
| Hispanic/Latino             | 2 (1.5%)                         | 2 (1.5%)                                  | 4 (1.5%)        |
| Not Hispanic/Latino         | 129 (97.0%)                      | 133 (97.8%)                               | 262 (97.4%)     |
| Not reported                | 2 (1.5%)                         | 1 (0.7%)                                  | 3 (1.1%)        |
| BMI (kg/m 2 )               |                                  |                                           |                 |
| N1                          | 132                              | 136                                       | 268             |
| Mean (SD)                   | 26.7 (5.6)                       | 26.3 (5.77)                               | 26.5 (5.70)     |
| Range                       | 16.0, 50.6                       | 15.9, 48.9                                | 15.9, 50.6      |
| Weight (kg),n (%)           |                                  |                                           |                 |
| <60                         | 18 (13.5%)                       | 16 (11.8%)                                | 34 (12.6%)      |
| >=60 to <=100               | 97 (72.9%)                       | 110 (80.9%)                               | 207 (77.0%)     |
| >100                        | 18 (13.5%)                       | 10 (7.4%)                                 | 28 (10.4%)      |
| Geographic Region b , n (%) |                                  |                                           |                 |
| United States/Canada        | 16 (12.0%)                       | 11 (8.1%)                                 | 27 (10.0%)      |
| European Union              | 51 (38.3%)                       | 55 (40.4%)                                | 106 (39.4%)     |
| Asia b                      | 23 (17.3%)                       | 30 (22.1%)                                | 53 (19.7%)      |
| ROW c                       | 43 (32.3%)                       | 40 (29.4%)                                | 83 (30.9%)      |
| Smoking Status, n (%)       |                                  |                                           |                 |
| Never smoked                | 75 (56.4%)                       | 72 (52.9%)                                | 147 (54.6%)     |
| Current smoker              | 34 (25.6%)                       | 45 (33.1%)                                | 79 (29.4%)      |
| Ex-smoker                   | 24 (18.0%)                       | 19 (14.0%)                                | 43 (16.0%)      |

a. Age at screening.

N = number of patients included in the safety analysis set

N1 = number of patients included in the analysis

The data for Study A3921120 was based on the Week 48 Analysis data

<div style=\"page-break-after: always\"></div>

Table 20. Baseline Disease Characteristics by Treatment Group- Safety Analysis Set (Final Analysis)

|                                                                          |                             | Tofacitinibs mgBID (N=133)   | Placebo> Tofacitinib5mg BID (N=136)   | Total (N=269)   |
|--------------------------------------------------------------------------|-----------------------------|------------------------------|---------------------------------------|-----------------|
| Parameter                                                                | Sunmary Statisties          |                              |                                       |                 |
| Prior TreatmentHistoryDerived from Clinical Database,n(%)                | bDMARD-aaive                | 102 (76.7%)                  | 105(77.2%)                            | 207(77.0%)      |
|                                                                          | TNFi-IRorbDMARD Use(Non-IR) | 31(23.3%)                    | 31 (22.8%)                            | 62(23.0%)       |
|                                                                          | TNFi-IR                     | 29 (21.8%)                   | 30(22.1%)                             | 59(21.9%)       |
|                                                                          | bDMARD Uue (Non IR)         | 2(1.5%)                      | 1(0.7%)                               | 3 (1.1%)        |
| Ankylosing Spondylitis DiseaseSymptom                                    |                             | 23 (17.3%)                   | 35(25.7%)                             | 58(21.6%)       |
| Duration (Years).n(%)                                                    |                             | 110 (82.7%)                  | 101(74.3%)                            | 211(78.4%)      |
|                                                                          | N1                          | 133                          | 136                                   | 269             |
|                                                                          | Mean                        | 14.2                         | 12.9                                  | 13.5            |
|                                                                          | Std.Dev.                    | 9.80                         | 9.47                                  | 9.64            |
|                                                                          | Median                      | 11.3                         | 10.3                                  | 10.7            |
|                                                                          | Range(min,max)              | (0.3,46.8)                   | (0.7,49.4)                            | (0.3,49.4)      |
| Anlylosing Spondylitis Duxation (Years)                                  | S                           | 63(47.4%)                    | 74 (54.4%)                            | 137(50.9%)      |
| Bince Diagnosis,n(%)                                                     |                             | 70 (52.69)                   | 62(45.6%)                             | 132(49.1%)      |
|                                                                          | N1                          | 133                          | 136                                   | 269             |
|                                                                          | Mean                        | 8.9                          | 6.8                                   | 7.8             |
|                                                                          | Std.Dev.                    | 9.06                         | 6.94                                  | S.11            |
|                                                                          | Median                      | 5.8                          | 4.8                                   | 4.9             |
|                                                                          | Range(min,max)              | (0.1, 42.8)                  | (0.1, 34.9)                           | (0.1.42.8)      |
| History ofUveitis, n (%)                                                 | Yes                         | 22(16.59)                    | 20 (14.7%)                            | 42 (15.6%)      |
|                                                                          | No                          | 94(70.7%)                    | 94(69.1%)                             | 188(69.9%)      |
|                                                                          | Masaing                     | 17(12.8%)                    | 22 (16.2%6)                           | 39(14.5%)       |
| Current Diagnosis ofUteitis for Subjects with History ofUteitis,n(%)     | Yes                         | 6(27.3%)                     | 5(25.0%)                              | 11(26.2%)       |
|                                                                          | No                          | 16(72.7%)                    | 15(75.0%)                             | 31(73.8%)       |
| History ofPsoriasis,n(%)                                                 | Yes                         | 5(3.8%)                      | 3(2.2%)                               | 8(3.0%)         |
|                                                                          | No                          | 95(71.4%)                    | 95(69.9%)                             | 190(70.6%)      |
|                                                                          | Missing                     | 33 (24.8%)                   | 38(27.9%)                             | 71(26.4%)       |
| Curent Dingnosis of Psoriasis for Subjects with History ofPsoriasis, (%) | Yes                         | 2(40.0%)                     | 2(66.7%)                              | 4(50.0%)        |
|                                                                          | No                          | 3(60.0%)                     | 1(33.3%)                              | 4(50.0%)        |
| History ofInfiammatoryBowel Disease (IBD）(%)                             | Yes                         | 1 (0.8%)                     | 2(1.5%)                               | 3 (1.1%)        |
|                                                                          | No                          | 95 (71.4%)                   | 94 (69.1%)                            | 189 (70.3%)     |

<div style=\"page-break-after: always\"></div>

|                                                                                                |                    | Tofacitinibs mgBID (N=133)   | Placebo> Tofacitinib5mg BID (N-136)   | Total (N=269)        |
|------------------------------------------------------------------------------------------------|--------------------|------------------------------|---------------------------------------|----------------------|
| Parameter                                                                                      | Sunmary Statisties |                              |                                       |                      |
|                                                                                                | Missing            | 37(27.8%)                    | 40(29.4%)                             | 77(28.6%)            |
| Cureat Diagnotis ofIBD forSubjects with Yes History ofIBD,n (%)                                |                    | 1(100.0%)                    | 1(50.0%)                              | 2(66.796)            |
|                                                                                                | No                 | 0                            | 1(50.0%)                              | 1(33.3%)             |
| History ofPeripberal Arthritis,n(%)                                                            | Yes                | 21 (15.8%)                   | 25(18.4%)                             | 46(17.1%)            |
|                                                                                                | No                 | 96(72.296)                   | 94(69.1%)                             | 190 (70.6%)          |
|                                                                                                | Minsing            | 16(12.0%)                    | 17 (12.5%)                            | 33 (12.3%)           |
| Current Diagmosis ofPeripheral Arthritis for Subjects withHistory ofPeripberal Arthritis,n (%) | Yes                | 18 (85.796)                  | 22 (88.0%)                            | 40(87.0%)            |
|                                                                                                | No                 | 3 (14.3%)                    | 3 (12.0%)                             | 6(13.0%)             |
| HLA.B27,n (%)                                                                                  | Negative           | 12 (9.0%)                    | 14(10.3%)                             | 26(9.7%)             |
|                                                                                                | Positive           | 117 (88.0%)                  | 118 (86.8%)                           | 235(87.4%)           |
|                                                                                                | Missing            | 4(3.0%)                      | 4(2.99)                               | 8(3.0%)              |
| BaselinehsCRP(mg/L),n(%)                                                                       | =2.87              | 23 (17.3%)                   | 20 (14.7%)                            | 43 (16.0%)           |
|                                                                                                | >2.87              | 110 (82.7%)                  | 116(85.3%)                            | 226(84.0%)           |
|                                                                                                | >5                 | 41(30.8%) 92(69.296)         | 33(24.3%) 103(75.7%)                  | 74(27.5%) 195(72.59) |
|                                                                                                | N1                 | 133                          | 136                                   | 269                  |
|                                                                                                | Mean               | 16.36                        | 18.02                                 | 17.20                |
|                                                                                                | Std.Dev.           |                              | 13.55                                 | 18.508               |
|                                                                                                |                    | 17.255                       | 19.685                                |                      |
|                                                                                                | Range(min,max)     | (0.23,87.10)                 | (0.20,173.00)                         | (0.20,173.00)        |
|                                                                                                |                    | 133                          | 136                                   | 269                  |
| Baseline PGA (NRS)                                                                             | N1 Mean            |                              | 7.0                                   | 6.9                  |
|                                                                                                |                    | 6.9 1.76                     | 1.66                                  | 1.71                 |
|                                                                                                | StdDev. Median     | 7.0                          | 7.0                                   | 7.0                  |
|                                                                                                | Range(min.max)     | (1,10)                       | (2,10)                                | (1.10)               |
| Baselne Patient Assessment of Pain-Total N1                                                    |                    | 133                          | 136                                   | 269                  |
| Back Pain (NRS)                                                                                |                    | 6.9                          | 6.9                                   | 6.9                  |
|                                                                                                | Mean Std.Dev.      | 1.52                         | 1.61                                  | 1.57                 |
|                                                                                                | Median             | 7.0                          | 7.0                                   | 7.0                  |
|                                                                                                | Range(min_max)     | (1,10)                       | (2.10)                                | (1.10)               |
| Baseline Patient Assessmeat ofPain-                                                            |                    | 133                          | 136                                   | 269                  |
| Nochurmal SpinalPain(NRS)                                                                      | IN                 |                              |                                       |                      |
|                                                                                                | Mean Std.Dev.      | 6.8 1.92                     | 6.8 1.86                              | 6.8 1.89             |
|                                                                                                | Median             | 7.0                          | 7.0                                   | 7.0                  |

<div style=\"page-break-after: always\"></div>

|                                                  |                                   | TofacitinibS mgBID (N=133)   | Placebo> Tofacitinib5mg BID (N-136)   | Total (N-269)   |
|--------------------------------------------------|-----------------------------------|------------------------------|---------------------------------------|-----------------|
| Parameter                                        | Summary Statisties                |                              |                                       |                 |
|                                                  | Range(min,max)                    | (0,10)                       | (1,10)                                | (0,10)          |
| Baseline BASFI                                   | N1                                | 133                          | 136                                   | 269             |
|                                                  | Mean                              | 5.8                          | 5.9                                   | 5.9             |
|                                                  | Sd.Dev.                           | 231                          | 2.07                                  | 2.19            |
|                                                  | Median                            | 6.3                          | 6.2                                   | 6.2             |
|                                                  | Range(min.max)                    | (0.0,10.0)                   | (0.3,9.6)                             | (0.0,10.0)      |
| BaselineBASDAI Score                             | IN                                | 133                          | 136                                   | 269             |
|                                                  | Mean                              | 6.4                          | 6.5                                   | 6.5             |
|                                                  | Std.Dev.                          | 1.48                         | 1.44                                  | 1.46            |
|                                                  | Median                            | 6.5                          | 6.7                                   | 6.5             |
|                                                  | Range(min,max)                    | (1.5,10.0)                   | (3.3,10.0)                            | (15.10.0)       |
| Baseline Inflammation                            | N1                                | 133                          | 136                                   | 269             |
|                                                  | Mean                              | 6.6                          | 8'9                                   | 6.7             |
|                                                  | Std.Dev,                          | 1.86                         | 1.91                                  | 1.88            |
|                                                  | Median                            | 6.5                          | 6.5                                   | 6.5             |
|                                                  | Range(min.max)                    | (0.0,10.0)                   | (1.5,10.0)                            | (0.0,10.0)      |
| Baseline BASM-Linear Method                      | IN                                | 133                          | 136                                   | 269             |
|                                                  | Mean                              | 4.5                          | 4.4                                   | 4.4             |
|                                                  | Std.Dev.                          | 1.73                         | 1.78                                  | 1.75            |
|                                                  | Median                            | 4.6                          | 4.5                                   | 4.6             |
|                                                  | Range(minmax)                     | (1.1.7.8)                    | (0.6,8.4)                             | (0.6,8.4)       |
| Baseline Spinal Mobility-Chest Expansicn N1 (cm) |                                   | 133                          | 136                                   | 269             |
|                                                  | Mean                              | 3.0                          | 3.3                                   | 3.2             |
|                                                  | Std.Dev,                          | 1.63                         | 1.55                                  | 1.59            |
|                                                  | Median                            | 25                           | 3.0                                   | 3.0             |
|                                                  | Range(min,max)                    | (0.1,9.0)                    | (0.0,7.3)                             | (0.0,9.0)       |
| BaelineASDAS（CRP).n(%)                           | <13[nactive dinease]              | 0                            | 0                                     | 0               |
|                                                  | 13t0Q.1ow disease activityl       | 2(1.5%)                      | D                                     | 2 (0.7%)        |
|                                                  | >2.1to<=3.5high disease activityl | 48 (36.19)                   | 40 (29.4%)                            | 88(32.75)       |
|                                                  | activity]                         | 83 (62.4%)                   | 96(70.6%)                             | 179 (66.5%)     |
|                                                  | IN                                | 133                          | 136                                   | 269             |
|                                                  | Mean                              | 3.8                          | 3.9                                   | 3.9             |
|                                                  | Std.Dev,                          | 0.82                         | 0.79                                  | 0.81            |
|                                                  | Median                            | 3.7                          | 3.9                                   | 3.9             |
|                                                  | Range(minmx)                      | (1.4,5.6)                    | (2.1,5.9)                             | (1.4,5.9)       |

<div style=\"page-break-after: always\"></div>

|                                                       |                    | Tofacitinib5 mgBID (N=133)   | Placebo> Tofacitinib5mg BID (N=136)   | Total (N=269)   |
|-------------------------------------------------------|--------------------|------------------------------|---------------------------------------|-----------------|
| Parameter                                             | Sunmary Statistics |                              |                                       |                 |
| BaselinePresence ofEnthesitis Based on MASES,=([]     | Yes                | 71(53.49)                    | (%965)18                              | 152(56.59)      |
|                                                       | No                 | 62(46.69)                    | 55（40.4%）                             | 117(43.5%)      |
| BaselineMASESforSubjectswith BaselineMASES>O          | IN                 | 71                           | S1                                    | 152             |
|                                                       | Mean               | 3.7                          | 3.6                                   | 3.7             |
|                                                       | Std.Dev.           | 2.49                         | 2.40                                  | 2.44            |
|                                                       | Median             | 3.0                          | 3.0                                   | 3.0             |
|                                                       | Range(min,max)     | (1,11)                       | (1,13)                                | (1,13)          |
| Baseline Presence ofSwollenJoints,n                   | Yes                | 33 (24.8%)                   | 38 (27.9%)                            | 71(26.4%)       |
| [ql(%)                                                | No                 | 100 (75.2%)                  | 98(72.1%6)                            | 198(73.6%)      |
| Baseline SJC（44) for Subjects with Baseline SJC(44)>0 | IN                 | 33                           | 38                                    | 71              |
|                                                       | Mean               | 3.4                          | 4.1                                   | 3.8             |
|                                                       | Std.Dew.           | 2.97                         | 5.22                                  | 4.31            |
|                                                       | Median             | 20                           | 2.0                                   | 2.0             |
|                                                       | Range(min,max)     | (1,11)                       | (1,24)                                | (1.24)          |
| BanelineSF-36v2PhvsicalCompooeat Summsry (PCS)Score   | NI                 | 133                          | 135                                   | 268             |
|                                                       | Mean               | 33.5                         | 33.1                                  | 33.3            |
|                                                       | Std.Dev,           | 7.25                         | 6.98                                  | 7.11            |
|                                                       | Median             | 33.6                         | 33.5                                  | 33.6            |
|                                                       | Range(min,max)     | (17.9,57.3)                  | (14.7,53.7)                           | (14.7,57.3)     |
| Baseline SF-36v2Mental Compoent                       | IN                 | 133                          | 135                                   | 268             |
| Stmmary(MCS) Score                                    | Mean               | 39.4                         | 39.8                                  | 39.6            |
|                                                       | Std.Dev,           | 11.09                        | 12.69                                 | 11.90           |
|                                                       | Median             | 38.1                         | 40.8                                  | 39.1            |
|                                                       | Range(min,max)     | (14.1,65.3)                  | (8.0.64.7)                            | (8.0.65.3)      |
| Baseline FACIT-F Total Score                          | IN                 | 133                          | 136                                   | 269             |
|                                                       | Mean               | 272                          | 27.4                                  | 27.3            |
|                                                       | Std.Dev.           | 10.71                        | 9.32                                  | 10.01           |
|                                                       | Median             | 27.0                         | 27.0                                  | 27.0            |
|                                                       | Range(min,mxx)     | (4,52)                       | (1,46)                                | (1,52)          |
| Baseline ASQoL Total Score                            |                    |                              |                                       | 269             |
|                                                       | NI Mean            | 133 11.6                     | 136 113                               | 11.5            |
|                                                       | SId.Dev,           | 4.67                         | 4.20                                  | 4.43            |
|                                                       | Median             | 12.0                         | 12.0                                  | 12.0            |
|                                                       | Range(minmax)      | (0,18)                       | (0,18)                                | (0,18)          |

Tofacitinib5 mgBID (N=133)

Placebo-&gt; Tofacitinib5mg BID (N=136)

Total (N=269)

Parameter

Suminary Statistics

N:Number of subjects included in the Safety Analysis Set;N1:Number of subjects included in the analysis;n(%): Number ofsubjects in each analysis category(Percentages were basedonN).Percentagesforcurrent symptomofUveitisPsoriasisIBDPeripheralAthritiswerebased onumberof subjectswithhistory ofUveitis,Psoriasis,IBD,Peripheral

Arthritis,respectively.ForhsCRPvalues&lt;2mg/L,itissetto2mg/Lin theformula toderiveASDAS(CRP). Inflammationbaselinewastheaverageofquestions5and6ofBASDAI.

Baselinewasdefined aslastnon-missingassessment onorbeforeday1 andprior tofirstdoseofinvestigationalproduct. [alYeswasdefinedforthosesubjectswithbaselineMaastrichtAnkylosingSpondylitisEnthesitisScore(MASES)&gt;O.

[b]YeswasdefinedforthosesubjectswithbaselineSwollenJointCount(44)&gt;0.

ForHLAB27,ifbaselineresultswerenotavailableresults afterbaselinewere alsoincludedin thesummary.

SafetyAnalysisSet(SAFETY)-Allsubjectswhowererandomizedandreceivedatleastonedoseoftheinvestigational

<div style=\"page-break-after: always\"></div>

## Prior Treatments

## NSAIDS

Most (99.6%) subjects received prior NSAIDs such as diclofenac, celecoxib and meloxicam and a minor rate  of  patients  received  corticosteroids  (16%),  the  most  of  which  were  oral  corticosteroids  (13%). However, it was noted that a higher number of subjects was treated with corticosteroids in tofacitinib 5 mg  (19.5%)  compared  to  placebo  group  (12.5%)  both  with  oral  and  intrarticular  administration, suggesting possible more severe manifestations. Moreover, this imbalance was mainly observed in highly treated patients (TNFi-IR and bDMARD use), in which a higher percentage of subjects in the tofacitinib 5 mg BID group (19.4%) compared to placebo (6.5%) had prior use of oral corticosteroids and this is expected  likely  due  to  a  more  difficult  to  treat  disease.  No  important  differences  were  reported  in previous csDMARDs use that was similar between tofacitinib and placebo group (57.1% vs 59.6%). The majority of patients were bDMARDs naïve (77%) with a similar distribution between the two groups. A minor number of patients (31 subjects in each arm, 23%) were bDMARDs experienced (bDMARDs use or TNFi-IR), 2 subjects were bDMARDs use non-IR.; 1 subject did not take NSAIDs due to prior medical history.

Table 21. Prior Drug Treatments by Medication Type (Corticosteroids, NSAIDs, DMARDs) and Treatment Group - Safety Analysis Set (Week 16 Analysis) (Data Cutoff 19Dec2019, Data Snapshot 29Jan2020)

| Medication Type   | Route/Subcategory   | Tofacitinib 5 mg BID (N=133) n (%)   | Placebo->Tofacitinib 5 mg BID (N=136) n (%)   | Total (N=269) n (%)   |
|-------------------|---------------------|--------------------------------------|-----------------------------------------------|-----------------------|
| Corticosteroids   | Overall             | 26 (19.5)                            | 17 (12.5)                                     | 43 (16.0)             |
|                   | Intra-articular     | 4 (3.0)                              | 0                                             | 4 (1.5)               |
|                   | Oral                | 19 (14.3)                            | 16 (11.8)                                     | 35 (13.0)             |
|                   | Topical             | 5 (3.8)                              | 2 (1.5)                                       | 7 (2.6)               |
|                   | Missing             | 0                                    | 2 (1.5)                                       | 2 (0.7)               |
| DMARD             | CS-DMARD            | 76 (57.1)                            | 81 (59.6)                                     | 157 (58.4)            |
|                   | B-DMARD             | 31 (23.3)                            | 31 (22.8)                                     | 62 (23.0)             |
|                   | TNFiB-DMARD         | 31 (23.3)                            | 31 (22.8)                                     | 62 (23.0)             |
| NSAID             | Overall             | 133 (100.0)                          | 135 (99.3)                                    | 268 (99.6)            |

|                 |                   | Tofacitinib 5 mg BID (N=133)   | Placebo ->Tofacitinib 5 mg BID (N=136)   | Total (N=269)   |
|-----------------|-------------------|--------------------------------|------------------------------------------|-----------------|
| Medication Iype | Route/Subcategory | n (%)                          | n (%)                                    | (%) uI          |

WHO DDE v201903 coding dictionary applied.

Prior drug treatment was defined as a drug taken on or before Day -1.

Safety Analysis Set (SAFETY) - All subjects who were randomized and received at least one dose of the investigational product.

PFIZER CONFIDENTIAL SDTM Creation: 31JAN2020 (23:27) Source Data: adcm Output File:

./umblind\\_1120/A3921120/adcm\\_s002\\_b\\_i Date of Generation: 17APR2020 (10:14)

Table 14.1.4.4.4.1 is for Pfizer internal use.

<div style=\"page-break-after: always\"></div>

Table 22. Prior Treatment History of Stratification Factor (bDMARD-naive, TNFi-IR or bDMARD Use (Non-IR)) by Treatment Group - Safety Analysis Set (Week 16 Analysis) (Data Cutoff 19Dec2019, Data Snapshot 29Jan2020)

| Stratum                                   | Number of Inadequate Responses            | BID (N=133) (%) uI   | Tofacitinib 5 mg Placebo -> Tofacitinib 5 mg BID (N=136) (%) uI   | Total (N=269) n (%)   |
|-------------------------------------------|-------------------------------------------|----------------------|-------------------------------------------------------------------|-----------------------|
| bDMARD-naive                              |                                           | 102 (76.7)           | 105 (77.2)                                                        | 207 (77.0)            |
| TNFi-IR or bDMARD Use (Non-IR)            |                                           | 31 (23.3)            | 31 (22.8)                                                         | 62 (23.0)             |
| TNFi-IR                                   | 1 TNFi-IR                                 | 23 (79.3)            | 20 (66.7)                                                         | 43 (72.9)             |
|                                           | 2 TNFi-IR                                 | 6 (20.7)             | 10 (33.3)                                                         | 16 (27.1)             |
| bDMARD Use (Non-IR) 1 bDMARD Use (Non-IR) | bDMARD Use (Non-IR) 1 bDMARD Use (Non-IR) | 2 (100.0)            | 1 (100.0)                                                         | 3 (100.0)             |

WHO DDE v201903 coding dictionary applied.

Prior drug treatment was defined as a drug taken on or before Day -1.

Each subject was counted with the number of unique bDMARD-naive, TNFi-IR, or bDMARD Use (Non-IR).

ie. if there was more than one record per drug for a subject, count as one medication.

The strata of bDMARD-naive, TNFi-IR, and bDMARD Use (Non-IR) were derived from clinical database.

Safety Analysis Set (SAFETY) - All subjects who were randomized and received at least one dose ofthe investigational product.

Numbers of inadequate responses were summarized as number (%) of subjects in each category.

PFIZER CONFIDENTIAL SDTM Creation: 31JAN2020 (22:27) Source Data: adcm Output File: /unblind\\_1120/A3921120/adcm\\_s005\\_iDate of Generation:25FEB2020 (08:47) Table 14.1.4.4.4.2 is for Pfizer internal use.

## Corticosteroid

Prior corticosteroid use for the bDMARD naïve strata was similar, 12.7% in the tofacitinib 5 mg BID group compared with 13.3% in the placebo group.

In the TNFi-IR and bDMARD (non-IR) strata, a higher percentage of subjects in the tofacitinib 5 mg BID group (19.4%) compared to placebo (6.5%) had prior use of oral corticosteroids.

## DMARDs

A similar proportion of subjects received prior DMARDs in both treatment groups. The most frequently received prior csDMARD (approximately 50% in each treatment group) was sulfasalazine (Table 23).

Table 23 shows the most frequently received prior csDMARD (approximately 50% in each treatment group) was sulfasalazine.

Table 23. Most frequently received prior csDMARD

<!-- image -->

|             |                                                 | Tofacitinib5mgBID (N=133)   | Placebo-> Tofacitinib5mgB (N=136)   | Total (N=260)   |
|-------------|-------------------------------------------------|-----------------------------|-------------------------------------|-----------------|
| Subcategory | Preferred Term                                  | (q6)n                       | (]                                  | n (%)           |
| CS-DMARD    | Number (%) of Subjects with Any PriorMedication | 76 ( 57.1)                  | 81 ( 59.6)                          | 157 ( 58.4)     |
|             | LEFLUNOMDE                                      | 3(2.3)                      | 4 (2.9)                             | 7 (2.6)         |
|             | METHOTREXATE                                    | 22 ( 16.5)                  | 20 ( 14.7)                          | 42 (15.6)       |
|             | METHOTREXATESODIUM                              | 2 (1.5)                     | 1 (0.7)                             | 3 (1.1)         |
|             | SULFASALAZINE                                   | 66 ( 49.6)                  | 69 ( 50.7)                          | 135 ( 50.2)     |

<div style=\"page-break-after: always\"></div>

## bDMARDs

The percentage of bDMARD naïve or TNFi-IR or bDMARD use (non-IR) subjects were similar between treatment groups. The most frequently received prior bDMARDs (approximately 10% in each treatment group) were etanercept and adalimumab (Table 24).

Table 24. Most frequently received prior bDMARDs

<!-- image -->

- All subjects had received bDMARDs included in the category of TNFi. There were 43 (72.9%) subjects with 1 prior TNFi-IR and 16 (27.1%) subjects 2 prior TNFi-IR
- The most frequently received prior bDMARDs (approximately 10% in each treatment group) were etanercept and adalimumab. The most common reason for discontinuation in the majority of bDMARDs was lack of efficacy.
- There were 2 subjects in the tofacitinib 5 mg BID treatment group and 1 subject in the placebo group  with  prior  use  of  1  bDMARD  (non-IR).  These  subjects  had  bDMARD  use  with  the discontinuation reason of other, not due to either AE or lack of efficacy.

## Concomitant Rescue Medications

- -The most common rescue medication in either treatment group Day 1 up to Week 16 and Day 1 up to Week 48 was paracetamol (2.2% and 2.6% of subjects, respectively)
- -The  most  common  NSAIDs  used  throughout  the  study  were  celecoxib  and  meloxicam, approximately 16% and 18% of all subjects, respectively
- -The most common concomitant corticosteroids taken at baseline (Day 1 only) and Day 1 up to Week 16 were methylprednisolone (3.7% of subjects for both) and prednisone (1.5% and 1.9% of subjects, respectively)
- -The most common concomitant corticosteroids taken Day 1 up to Week 48 were dexamethasone (2.2% of subjects), methylprednisolone (4.1% of subjects), and prednisone (1.9% of subjects)
- -The  most  common  concomitant  csDMARD  in  both  treatment  groups  (approximately  20%  of subjects) throughout the study was sulfasalazine

Concomitant  rescue  medications,  NSAIDs,  oral  corticosteroids,  intra-articular  corticosteroids,  and csDMARDs were taken by a similar proportion of subjects between treatment groups at baseline up to Week 48. A higher percentage of subjects with any csDMARDs was observed in placebo group than in tofacitinib  group  (33%  vs  22%)  probably  reflecting  a  higher  number  of  patients  with  a  history  of

<div style=\"page-break-after: always\"></div>

peripheral arthritis (18.4% vs 15.8%). The most common rescue medication in either treatment group Day  1  up  to  Week  16  and  Day  1  up  to  Week  48  was  paracetamol  (2.2%  and  2.6%  of  subjects, respectively).

Table  25.  Concomitant  Medications  (Rescue,  NSAIDs,  Oral  Corticosteroids,  Intra-Articular Corticosteroids, csDMARD, and Pain Management/Analgesics) by Treatment Group -Safety Analysis Set (Week 16 Analysis) Date Cutoff 19 Dec 2019) Data snapshot 29 Jan 2020

|                                                           | UptoWeek16                        | UptoWeek16   | UptoWeek16           | UptoWeek4S                 | UptoWeek4S                           | UptoWeek4S    |
|-----------------------------------------------------------|-----------------------------------|--------------|----------------------|----------------------------|--------------------------------------|---------------|
| MedicationType                                            | Tofacitinib5Placebo ngBID (N=133) |              | Total (N=130)(N=269) | Tofacitinibs mgBID (N=133) | Placebo-> Tofacitinib5 mgBID (N=130) | Total (N=269) |
|                                                           | n(%)                              | n(%)         | n(%)                 | (6）                        | n(%)                                 | n(%)          |
| Number (%)ofSubjects with AnyRescue Concomtant Medication | 3(2.3)                            | 5(3.7)       | 8(3.0)               | 5(3.8)                     | 5(3.7)                               | 10 (3.7)      |
| Number(%o)ofSubjects with Any ConcomitantNSAID            | 105 (78.9)                        | 109 (80.1)   | 214(79.6)            | 107(80.5)                  | 109 (80.1)                           | 216(80.3)     |

|                                                              | UptoWeek16                        | UptoWeek16   | UptoWeek16    | Up toWeek48                | Up toWeek48                          | Up toWeek48   |
|--------------------------------------------------------------|-----------------------------------|--------------|---------------|----------------------------|--------------------------------------|---------------|
| MedicationType                                               | Tofacitinib5Placebo mgBID (N=133) | (N=136)      | Total (N=269) | Tofacitinibs ngBID (N=133) | Placebo-> Tofacitinib5 mgBID (N=136) | Total (N=269) |
|                                                              | (%)                               | (%6）u        | n(%6)         | (%）u                       | (%6）u                                | (%）           |
| Number (%6)ofSubjects with AnyOral Corticosteroid            | 13(9.8)                           | 10(7.4)      | 23(8.6)       | 13 (9.8)                   | 10 (7.4)                             | 23(8.6)       |
| Number(%)of Subjects with Any Intra-Articular Corticosteroid | 1(0.8)                            | 0            | 1(0.4)        | 2(1.5)                     | 0                                    | 2(0.7)        |
| Number(%6)ofSubjects with AnycsDMARD                         | 29(21.8)                          | 45 (33.1)    | 74(27.5)      | 29 (21.8)                  | 45 (33.1)                            | 74(27.5)      |
| Number(%)ofSubjects with Any Pain Management/Analgesics      | 16(12.0)                          | 19 (14.0)    | 35(13.0)      | 22(16.5)                   | 20 (14.7)                            | 42(15.6)      |

Subjectswereonlycountedoncepertreatmentforeachrow

SafetyAnalysisSet(SAFETY)-All subjectswho wererandomized andreceived atleast one dose ofthe investigational product.

PFIZERCONFIDENTIALSDTMCreation:31JAN2020(22:27)SourceData:adcmOutputFile:

unblind1120/A3921120/adcm\\_s001\\_biDateofGeneration:19FEB2020（12:55)

Table14.4.2.7.11isforPfizerintemaluse

## Numbers analysed

Full Analysis Set: subjects 133 in the Tofa and 136 in the PLB arm.

Per Protocol Analysis Set: which excluded 3 subjects in the tofacitinib 5 mg BID group and 2 subjects in the placebo group from the FAS.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary Endpoint Result -ASAS20 Response Rate at Week 16

The study met the primary endpoint, tofacitinib 5 mg BID demonstrated superiority over placebo in ASAS20 response at Week 16 (p &lt;0.0001) (as shown in Table 26). ASAS20 response was a global Type I error-controlled endpoint.

Table 26. ASAS20 Response Rate at week 16, Treatment Comparison -Estimand 1, FAS, OnDrug Date, MR=NR- Primary Anslysis (Week 16 Analysis)

Table14.2.1.2.1.3isforPfizerimtermal use

<!-- image -->

The results from pre-specified supportive analyses for ASAS20 response at Week 16 i.e. tipping analysis for different scenarios of missing responses in both arms were consistent with the primary analysis.

A summary of subjects was produced based on on-drug data for those who completed the Week 16 visit by their ASAS20 response status at Week 16 and those who discontinued from the investigational product prior to the Week 16 visit by their reason of discontinuation (estimand 1) are provided below (Table 27). The summary for the on-study data (Estimand 2 as shown in Table 27) was consistent with the on-drug data.

<div style=\"page-break-after: always\"></div>

Table 27. ASAS20 Response Rate at week 16, Treatment Comparison -Estimand 2

| Status - n (%)                                                                           | Tofacitinib5mgBID (N=133) n (%)   | Placebo (N=136) n (%)   |
|------------------------------------------------------------------------------------------|-----------------------------------|-------------------------|
| ASAS20 Responders                                                                        | 75 (56.39)                        | 40 (29.41)              |
| ASAS20Non-Responders                                                                     | 58 (43.61)                        | 96 (70.59)              |
| ASAS20Non-RespondersWhoCompletedtheWeek16Visitwith                                       | 54 (40.60)                        | 91 (66.91)              |
| ObservedOn-DrugData ASAS20Non-RespondersWhoCompletedtheWeek16VisitwithMissing            | 0                                 | 0                       |
| On-DrugData ASAS20Non-RespondersWhoDiscontinuedInvestigationalProductPrior toWeek16Visit | 4 (3.01)                          | 5(3.68)                 |
| ReasonsforDiscontinuationofInvestigationalProduct Adverse Event                          | 3 (2.26)                          | 1 (0.74)                |
| Lack of Efficacy                                                                         | 1 (0.75)                          | 1(0.74)                 |
| Lost to Follow-Up                                                                        | 0                                 | 1 (0.74)                |
| PhysicianDecision                                                                        | 0                                 | 1 (0.74)                |
| Withdrawal by Subject                                                                    | 0                                 | 1(0.74)                 |

N: Number of subjects in FAS. n (%): Number of subjects in each analysis category (Percentages were based on N). MR=NR:Missing response as non-response.

FullAnalysisSet(FAS)-All subjectswhowererandomized tothestudy andreceived atleast one dose of therandomized investigationalproduct.

ASAS20responsewasdefined as&gt;=20%and&gt;=1unitimprovement in atleast 3domainsonascaleof0-10andno worsening of&gt;=20%and&gt;=1 unit in theremaining domain.

PFIZERCONFIDENTIALSDTMCreation:31JAN2020(23:20)SourceData:adasOutputFile:

/unblind1120/A3921120/adass001DateofGeneration:16APR2020(22:48)

Table 14.2.1.1.1 isforPfizer internaluse.

## Subgroup Analysis for the Primary Endpoint

Subgroup comparisons for ASAS20 response at Week 16 were made on the FAS with missing values handled by MR=NR using the on-drug data corresponding to Estimand 1. Subgroup comparisons were not Type I error-controlled.

The efficacy of tofacitinib 5 mg BID versus placebo for ASAS20 responses at Week 16 was consistent across different subgroups examined with the exception of some which were smaller in size (Figure 16).

- For the subgroup of prior treatment history (bDMARD naïve and TNFi-IR or bDMARD use [NonIR]), ASAS20 response rate of tofacitinib 5 mg BID was greater than that of placebo at Week 16 in both categories (Figure 16).
- The efficacy  of  tofacitinib  5  mg  BID  versus  placebo  for  ASAS20  responses  at  Week  16  was consistent for the subgroup of baseline AS disease activity defined by the categorization of baseline ASDAS(CRP) derived using hsCRP 2 mg/L as minimum for values of hsCRP less than 2 mg/L.

<div style=\"page-break-after: always\"></div>

Figure 16. Forest Plot of Subgroup Analysis of ASAS20 Response Rate at Week 16 (Estimand 1, FAS, On-Drug Data, MR=NR)

<!-- image -->

Ful1 Analyais Det (FAs）-All subjeots ho were randonised to the study and reoeived at least one dose of the randonized investigatiomal produot.

[a] oral appronimation adjusting for the stratitication factor (prior treataent hiatory: bcaD-naive ys TFi-IR or hoARD Use [Non-IR) derived from clinioal database via Co approach vaswsedfos each category ofasibgroup variable.【b] Normalapptonimation vas used for each category ofasabgroup variable. AAs20ronse was defined as=204and&gt;=unit inprovement inatLeastJdomains onascaleof0-i0 andnoworsening of&gt;0and&gt;=lmit in thereaining doain. Atasubgroup categony.xben one of the tvo treatment groups in conparison had 0subeot.no formal oouarion vas made.Mhen reaponse rate of Oor Loot vas obterved sn both treatent groupa in oparisn and in both strata,no foal onparison vas perfoedTse inludedOther'for Raoe,e65 years′for Age at Baeline.&gt;o0 kg/n2'ndtissingfo Baseline Sit,Tnaetive Disease'andLow Disease Aetavity'for Baseline As Disease Aetivity.

PF12COF1DENASDH Creation:31JAN2020（23:20)Soure Data:adasOuttF4le:/u1inA\\_1120/A3921120/adas\\_002DateofGenatom:01APR2020 （08:38）

<div style=\"page-break-after: always\"></div>

Table 28. Protocol A3921120 CMH Normal Approximation to ASAS20 Response Rate at Week 16 by Subgroup, Treatment Comparison - Estimand 1, FAS, On-Drug Data, MR=NRSubgroup Analysis (Week 16 Analysis) (Data Cutoff 19Dec2019, Data Snapshot 29Jan2020)

<!-- image -->

|                |                                               |                              |     |     |    |                   |       | Treatment Comparison [a]   | Treatment Comparison [a]   | Treatment Comparison [a]   | Treatment Comparison [a]   |
|----------------|-----------------------------------------------|------------------------------|-----|-----|----|-------------------|-------|----------------------------|----------------------------|----------------------------|----------------------------|
| Subgroup       | Category                                      | Visit Treatment              | N   | N1  |    | Response Rate (%) | SE    | Diff                       | SE                         | 10 %56 (Lower, Upper)      |                            |
|                | High disease activity (2.1<=ASDAS (CRP)<=3.5) | Week 16 Tofacitinib 5 mg BID | 48  | 45  | 23 | 47.92             | 7.21  | 12.61                      | 9.97                       | (-6.94,32.16)              |                            |
|                |                                               | Placebo                      | 41  | 41  | 15 | 36.59             | 7.52  |                            |                            |                            |                            |
|                | Very high disease activity (ASDAS (CRP)>3.5)  | Week 16Tofacitinib5mg BID    | 82  | 81  | 51 | 62.20             | 5.35  | 35.43                      |                            | 6.91( 21.88,48.98)         |                            |
|                |                                               | Placebo                      | 94  | 89  | 25 | 26.60             | 4.56  |                            |                            |                            |                            |
| Baseline hsCRP | <=2.87 mg/L                                   | Week 16 Tofacitinib 5 mg BID | 23  | 22  | 11 | 47.83             | 10.42 | 17.02                      | 14.04                      | （-10.49, 44.54)            |                            |
|                |                                               | Placebo                      | 20  | 20  | 6  | 30.00             | 10.25 |                            |                            |                            |                            |
|                | >2.87 mg/L                                    | Week 16Tofacitinib 5 mg BID  | 110 | 107 | 64 | 58.18             | 4.70  | 28.95                      | 6.17                       | (16.86,41.05)              |                            |
|                |                                               | Placebo                      | 116 | 111 | 34 | 29.31             | 4.23  |                            |                            |                            |                            |

Key Secondary Endpoint Result -ASAS40 Response Rate at Week 16

The study met the key secondary endpoint, tofacitinib 5 mg BID demonstrated superiority over placebo in ASAS40 response at Week 16 (p &lt;0.0001) (Table 29). ASAS40 response was a global Type I errorcontrolled endpoint.

|         |                            |          |                         |      | TreatmentComparison[a]   | TreatmentComparison[a]   | TreatmentComparison[a]   |
|---------|----------------------------|----------|-------------------------|------|--------------------------|--------------------------|--------------------------|
| Visit   | Treatment                  |          | NN1 n Response Rate (%) | Diff | SE                       | 95%CI (Lower,Upper)      | p-Value                  |
| Week 16 | Tofacitinib5mg13312954 BID |          | 40.60                   |      | 28.175.06                | (18.26,38.09)            | <.0001                   |
|         | Placebo                    | 13613117 | 12.50                   |      |                          |                          |                          |

Table 29. ASAS40 Response Rate at Week 16

<!-- image -->

Results from all the pre-specified supportive analyses for ASAS40 response at Week 16 (Table 30) were consistent with the key secondary analysis.

A summary of subjects was produced based on on-drug data for those who completed the Week 16 visit by their ASAS40 response status at Week 16 and those who discontinued from the investigational product

<div style=\"page-break-after: always\"></div>

prior to the Week 16 visit by their reason of discontinuation (Table 30). The summary for the on-study data (Estimand 2) was consistent with the on-drug data.

Table 30. ASAS40 Response at Week 16 and Reasons for Study Drug Discontinuation prior to Week 16 -Estimand 1

| Status - n (%)                                                                           | Tofacitinib 5 mg BID (N=133) n (%)   | Placebo (N=136) n (%)   |
|------------------------------------------------------------------------------------------|--------------------------------------|-------------------------|
| ASAS40Responders                                                                         | 54 (40.60)                           | 17 (12.50)              |
| ASAS40Non-Responders                                                                     | 79 (59.40)                           | 119 (87.50)             |
| ASAS40 Non-Responders Who Completed the Week 16 Visit with                               | 75 (56.39)                           | 114 (83.82)             |
| Observed On-Drug Data ASAS40 Non-Responders Who Completed the Week 16 Visit with Missing | 0                                    | 0                       |
| ASAS40Non-RespondersWhoDiscontinuedInvestigationalProductPrior to Week 16 Visit          | 4 (3.01)                             | 5 (3.68)                |
| Reasons for Discontinuation of Investigational Product                                   |                                      |                         |
| AdverseEvent                                                                             | 3 (2.26)                             | 1 (0.74)                |
| Lack of Efficacy                                                                         | 1 (0.75)                             | 1(0.74)                 |
| Lost to Follow-Up                                                                        | 0                                    | 1 (0.74)                |
| Physician Decision                                                                       | 0                                    | 1 (0.74)                |
| Withdrawal by Subject                                                                    | 0                                    | 1 (0.74)                |

N: Number of subjects in FAS. n (%): Number of subjects in each analysis category (Percentages were based on N). MR=NR: Missing response as non-response.

ASAS40 response was defined as &gt;=40% and &gt;=2 units improvement in at least 3 domains on a scale of 0-10 and no worsening at all in the remaining domain.

Full Analysis Set (FAS) - All subjects who were randomized to the study and received at least one dose of the randomized investigationalproduct.

PFIZER CONFIDENTIAL SDTM Creation: 31JAN2020 (23:20) Source Data: adas Output File:

./unblind 1120/A3921120/adas s001 3 Date of Generation: 16APR2020 (22:57)

Table 14.2.2.1.1 is for Pfizer internal use.

## Subgroup Analyses for the Key Secondary Endpoint

Subgroup comparisons for ASAS40 response at Week 16 were made on the FAS with missing values handled  by  MR=NR  using  the  on-drug  data  corresponding  to  Estimand  1  (Figure  17).  Subgroup comparisons were not Type Ierror-controlled.

- The efficacy  of  tofacitinib  5  mg  BID  versus  placebo  for  ASAS40  responses  at  Week  16  was consistent across different subgroups examined except for baseline weight in the category of &gt;100 kg, likely due to small sample size. The ASAS40 response rates for tofacitinib 5 mg BID were greater compared to placebo for the subgroups except for baseline weight in the category of &gt;100 kg.
- For the subgroup of prior treatment history (bDMARD naïve and TNFi-IR or bDMARD use [NonIR]), ASAS40 response rate of tofacitinib 5 mg BID was greater than that of placebo at Week 16 in both categories.
- The efficacy  of  tofacitinib  5  mg  BID  versus  placebo  for  ASAS40  responses  at  Week  16  was consistent  for  the  subgroup  of  baseline  AS  disease  activity  defined  by  the  categorization  of baseline ASDAS(CRP) derived using hsCRP 2 mg/L as minimum for values of hsCRP less than 2 mg/L.

<div style=\"page-break-after: always\"></div>

Figure 17 . Forest Plot of Subgroup Analysis of ASAS40 Response Rate at Week 16 (Estimand 1, FAS, On-Drug Data, MR=NR)

<!-- image -->

Full Analyaie Set （FAs)-All sabjecto who were randomized to the atudy and received atleant one dose of the Tandomied iaveatigaticnal prodoct.

[a]Nornal approxcimation adjusting for the stratification factor (prlor treatnent hiatory:bDMA-naive va mFi-IR or bcmuD tse [Non-In]) derived from clinical database via CMH approach vas uped foreach category ofasubgroup variable.[b] Normalapproximation wan used for eachcategory ofasabgroup variable.

AsAs40 reaponse was defised as&gt;=4o% and&gt;=2umits iaprovement sn at least 3 donains onascale of0-i0 andno worsening at all1n the remaining domain.

At4oubgroup category,when ose of the tuo treataent groups in couparioon had 0 subject,no formal conpariaon was mede.hen reopons rate of ox or 1oox as observed in both troataent groups in comparison and in both strata.no formal coaparison was pertorned.These includedOther'for Race,&gt;=65yearsfor Age at Baseline.&gt;4o kg/m**2andKissingfor

Baneline Bxt.Tnactive Disoase'andLou Disease Activity'for Baseline As Disease Activity.

PFI2ERCONFIDENTIALSDTN Creation:31JAN2020(23:20)SouroeData1adasOutput File1./wnb11nd1120/A3921120/adas\\_f002\\_2DateofGeneration:01APR2020(08:41)

## Secondary Endpoints Results

Table  31  presents  the  results  of  primary  endpoints  and  selected  secondary  endpoints  of  the  study. Primary and key secondary endpoints are reported above in the AR.

Secondary efficacy endpoints supported the primary findings:

- Tofacitinib 5 mg BID demonstrated superiority to placebo in signs and symptoms as well as health-related outcomes, based on the mean changes from baseline in ASDAS(CRP), hsCRP, ASQoL, SF36v2 PCS, BASMI Score (Linear Method), and FACIT-F Total Score at Week 16.
- Tofacitinib 5 mg BID demonstrated superiority to placebo in mean change from baseline in each of the 4 ASAS components: PGA, Total Back Pain, BASFI (physical function), and Inflammation at Week 16 (all p&lt;0.0001; Table 31).
- Tofacitinib 5 mg BID also demonstrated superiority to placebo at all timepoints through Week16 for ASAS20 response rates. In addition, tofacitinib 5 mg BID demonstrated superiority to placebo at all timepoints through Week 16 except Week 2 for ASAS40 response rates (Figure 16).
- For most of the secondary efficacy endpoints not controlled for Type I error, including SF-36v2 Physical Functioning, Role-Physical, Bodily Pain, General Health, and Social Functioning domains, the tofacitinib 5 mg BID group showed greater numerical increases over placebo at Week 16 (Table 31).

<div style=\"page-break-after: always\"></div>

· Tofacitinib 5 mg BID demonstrated sustained efficacy in ASAS20 and ASAS40 response rates and other secondary endpoints (ASDAS(CRP), hsCRP, ASQoL, SF-36v2 [PCS, Physical Functioning, RolePhysical, Bodily Pain, General Health, and Social Functioning domains], BASMI Score (Linear Method), FACIT-F Total Score, PGA, total back pain, BASFI, and inflammation) over time up to Week 48.

Table 31. Selected Efficacy Endpoints at Week 16 and Week 48 (FAS, On-Drug Data) -Study A3921120

|                                                                                                                                   | Week 16                                                                                                                           | Week 16                                                                                                                           | Week 16                                                                                                                           | Week 48                                                                                                                           | Week 48                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                   | Tofacitinib 5 mg BID (N =133)                                                                                                     | Placebo (N =136)                                                                                                                  | Difference From Placebo                                                                                                           | Tofacitinib 5 mg BID (N =133)                                                                                                     | Placebo->Tofacitinib 5 mgBID (N =136)                                                                                             |
| Primary efficacy endpoint (subject tohierarchical testing procedurefor global Type I error-control)                               | Primary efficacy endpoint (subject tohierarchical testing procedurefor global Type I error-control)                               | Primary efficacy endpoint (subject tohierarchical testing procedurefor global Type I error-control)                               | Primary efficacy endpoint (subject tohierarchical testing procedurefor global Type I error-control)                               | Primary efficacy endpoint (subject tohierarchical testing procedurefor global Type I error-control)                               | Primary efficacy endpoint (subject tohierarchical testing procedurefor global Type I error-control)                               |
| ASAS20 response, n (%)                                                                                                            | 75 (56.39)                                                                                                                        | 40 (29.41)                                                                                                                        | 27.08***                                                                                                                          | 87 (65.41)                                                                                                                        | 82 (60.29)                                                                                                                        |
| [N1] or [95% C1]                                                                                                                  | [129]                                                                                                                             | [131]                                                                                                                             | [15.89,38.28]                                                                                                                     | [112]                                                                                                                             | [112]                                                                                                                             |
| Key secondary efficacy endpoint (subject tohierarchical testing procedure for global Type I error-control)                        | Key secondary efficacy endpoint (subject tohierarchical testing procedure for global Type I error-control)                        | Key secondary efficacy endpoint (subject tohierarchical testing procedure for global Type I error-control)                        | Key secondary efficacy endpoint (subject tohierarchical testing procedure for global Type I error-control)                        | Key secondary efficacy endpoint (subject tohierarchical testing procedure for global Type I error-control)                        | Key secondary efficacy endpoint (subject tohierarchical testing procedure for global Type I error-control)                        |
| ASAS40 response, n (%)                                                                                                            | 54 (40.60)                                                                                                                        | 17 (12.50)                                                                                                                        | 28.17***                                                                                                                          | 67 (50.38)                                                                                                                        | 61 (44.85)                                                                                                                        |
| [N1] or [95% C1]a                                                                                                                 | [129]                                                                                                                             | [131]                                                                                                                             | [18.26,38.09]                                                                                                                     | [112]                                                                                                                             | [112]                                                                                                                             |
| Secondaryeficacy endpoints (subject tohierarchical testingprocedureforglobal TypeI error-control)                                 | Secondaryeficacy endpoints (subject tohierarchical testingprocedureforglobal TypeI error-control)                                 | Secondaryeficacy endpoints (subject tohierarchical testingprocedureforglobal TypeI error-control)                                 | Secondaryeficacy endpoints (subject tohierarchical testingprocedureforglobal TypeI error-control)                                 | Secondaryeficacy endpoints (subject tohierarchical testingprocedureforglobal TypeI error-control)                                 | Secondaryeficacy endpoints (subject tohierarchical testingprocedureforglobal TypeI error-control)                                 |
| △ASDAS(CRP), LSM (SE)                                                                                                             | -1.36 (0.073)                                                                                                                     | -0.39 (0.073)                                                                                                                     | -0.98***                                                                                                                          | -1.70 (0.087)                                                                                                                     | -1.50 (0.086)                                                                                                                     |
| [N1] or [95% C1] b                                                                                                                | [129]                                                                                                                             | [131]                                                                                                                             | [-1.16, -0.79]                                                                                                                    | [100]                                                                                                                             | [103]                                                                                                                             |
| △hsCRP (mg/dL), LSM (SE)                                                                                                          | -1.05 (0.096)                                                                                                                     | -0.09 (0.096)                                                                                                                     | -0.96***                                                                                                                          | -1.17 (0.081)                                                                                                                     | -1.11 (0.080)                                                                                                                     |
| [N1] or [95% C1] b                                                                                                                | [129]                                                                                                                             | [131]                                                                                                                             | [-1.20, -0.72]                                                                                                                    | [100]                                                                                                                             | [103]                                                                                                                             |
| △ASQoL, LSM (SE)                                                                                                                  | -4.03 (0.404)                                                                                                                     | -2.01 (0.405)                                                                                                                     | -2.02**                                                                                                                           | -5.97 (0.454)                                                                                                                     | -4.70 (0.451)                                                                                                                     |
| [N1] or [95% CI]“                                                                                                                 | [129]                                                                                                                             | [130]                                                                                                                             | [-3.03, -1.01]                                                                                                                    | [112]                                                                                                                             | [112]                                                                                                                             |
| △SF-36v2 PCS, LSM (SE)                                                                                                            | 6.69 (0.588)                                                                                                                      | 3.14 (0.590)                                                                                                                      | 3.55***                                                                                                                           | 8.81 (0.720)                                                                                                                      | 7.39 (0.714)                                                                                                                      |
| [N1] or[95%CI]                                                                                                                    | [129]                                                                                                                             | [130]                                                                                                                             | [2.09, 5.02]                                                                                                                      | [112]                                                                                                                             | [111]                                                                                                                             |
| △BASMI Score (Linear Method), LSM (SE)                                                                                            | -0.63 (0.060)                                                                                                                     | -0.11 (0.060)                                                                                                                     | -0.52***                                                                                                                          | -0.69 (0.074)                                                                                                                     | -0.54 (0.073)                                                                                                                     |
| [N1] or [95% C】] b                                                                                                                | [129]                                                                                                                             | [131]                                                                                                                             | [-0.67, -0.37]                                                                                                                    | [100]                                                                                                                             | [103]                                                                                                                             |
| △FACIT-F Total score,LSM (SE)                                                                                                     | 6.54 (0.795)                                                                                                                      | 3.12 (0.794)                                                                                                                      | 3.43**                                                                                                                            | 9.54 (0.897)                                                                                                                      | 7.35 (0.891)                                                                                                                      |
| [N1] or [95% C1] b                                                                                                                | [129]                                                                                                                             | [131]                                                                                                                             | [1.44, 5.42]                                                                                                                      | [112]                                                                                                                             | [111]                                                                                                                             |
| Secondary efficacy endpoints (subject to hierarchical testingprocedur'eforType I error-control within thefamily of ASASresponses) | Secondary efficacy endpoints (subject to hierarchical testingprocedur'eforType I error-control within thefamily of ASASresponses) | Secondary efficacy endpoints (subject to hierarchical testingprocedur'eforType I error-control within thefamily of ASASresponses) | Secondary efficacy endpoints (subject to hierarchical testingprocedur'eforType I error-control within thefamily of ASASresponses) | Secondary efficacy endpoints (subject to hierarchical testingprocedur'eforType I error-control within thefamily of ASASresponses) | Secondary efficacy endpoints (subject to hierarchical testingprocedur'eforType I error-control within thefamily of ASASresponses) |
| △PGA, LSM (SE)                                                                                                                    | -2.47 (0.204)                                                                                                                     | -0.91 (0.204)                                                                                                                     | -1.56***                                                                                                                          | -3.47 (0.225)                                                                                                                     | -2.94 (0.223)                                                                                                                     |
| [N1] or [95% C1] b                                                                                                                | [129]                                                                                                                             | [131]                                                                                                                             | [-2.07, -1.05]                                                                                                                    | [112]                                                                                                                             | [112]                                                                                                                             |
| △Total back Pain, LSM (SE)                                                                                                        | -2.57 (0.191)                                                                                                                     | -0.96 (0.191)                                                                                                                     | -1.62***                                                                                                                          | -3.57 (0.220)                                                                                                                     | -2.87 (0.218)                                                                                                                     |
| [N1] or [95% C1] b                                                                                                                | [129]                                                                                                                             | [131]                                                                                                                             | [-2.10, -1.14]                                                                                                                    | [113]                                                                                                                             | [112]                                                                                                                             |
| △BASFI, LSM (SE)                                                                                                                  | -2.05 (0.170)                                                                                                                     | -0.82 (0.169)                                                                                                                     | -1.23***                                                                                                                          | -2.61 (0.196)                                                                                                                     | -2.32 (0.195)                                                                                                                     |
| [N1] or [95% C1] b                                                                                                                | [129]                                                                                                                             | [131]                                                                                                                             | [-1.66, -0.80]                                                                                                                    | [113]                                                                                                                             | [113]                                                                                                                             |
| △Inflammation, LSM (SE)                                                                                                           | -2.69 (0.185)                                                                                                                     | -0.97 (0.185)                                                                                                                     | -1.72***                                                                                                                          | -3.46 (0.214)                                                                                                                     | -2.90 (0.213)                                                                                                                     |
| [N1] or [95% C1] b                                                                                                                | [129]                                                                                                                             | [131]                                                                                                                             | [2.18, -1.25]                                                                                                                     | [113]                                                                                                                             | [113]                                                                                                                             |

|                                                                                                                                                   | Week 16                                                                                                                                           | Week 16                                                                                                                                           | Week 16                                                                                                                                           | Week48                                                                                                                                            | Week48                                                                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                   | Tofacitinib 5 mg BID (IN =133)                                                                                                                    | Placebo (N =136)                                                                                                                                  | Difference From Placebo                                                                                                                           | Tofacitinib 5 mg BID (N =133)                                                                                                                     | Placebo->Tofacitinib 5 mg BID (N =136)                                                                                                            |
| ASAS20 Response Rate Time Points (subject to hierarchical testing procedure for Type I error-control within the ASAS20 response rate time course) | ASAS20 Response Rate Time Points (subject to hierarchical testing procedure for Type I error-control within the ASAS20 response rate time course) | ASAS20 Response Rate Time Points (subject to hierarchical testing procedure for Type I error-control within the ASAS20 response rate time course) | ASAS20 Response Rate Time Points (subject to hierarchical testing procedure for Type I error-control within the ASAS20 response rate time course) | ASAS20 Response Rate Time Points (subject to hierarchical testing procedure for Type I error-control within the ASAS20 response rate time course) | ASAS20 Response Rate Time Points (subject to hierarchical testing procedure for Type I error-control within the ASAS20 response rate time course) |
| Week 12,n (%) [N1] or[95% C】]                                                                                                                     | 85 (63.91) [132]                                                                                                                                  | 40 (29.41) [132]                                                                                                                                  | 34.61*** [23.63, 45.58]                                                                                                                           | NA                                                                                                                                                | NA                                                                                                                                                |
| Week 8, n (%) [N1] or [95% CI]                                                                                                                    | 76 (57.14) [132]                                                                                                                                  | 34 (25.00) [133]                                                                                                                                  | 32.24*** [21.32, 43.17]                                                                                                                           | NA                                                                                                                                                | NA                                                                                                                                                |
| Week 4, n (%) [N1] or[95% CI]                                                                                                                     | 68 (51.13) [132]                                                                                                                                  | 27 (19.85) [132]                                                                                                                                  | 31.35*** [20.64, 42.06]                                                                                                                           | NA                                                                                                                                                | NA                                                                                                                                                |
| Week 2, n (%) [N1] or [95% C1]                                                                                                                    | 38 (28.57) [132]                                                                                                                                  | 14 (10.29) [133]                                                                                                                                  | 18.28** [9.06, 27.50]                                                                                                                             | NA                                                                                                                                                | NA                                                                                                                                                |
| ASAS40ResponseRatesTimePoints(subject tohierarchical testingprocedureforTypeIerror-control within theASAS40responserate time cou'se)              | ASAS40ResponseRatesTimePoints(subject tohierarchical testingprocedureforTypeIerror-control within theASAS40responserate time cou'se)              | ASAS40ResponseRatesTimePoints(subject tohierarchical testingprocedureforTypeIerror-control within theASAS40responserate time cou'se)              | ASAS40ResponseRatesTimePoints(subject tohierarchical testingprocedureforTypeIerror-control within theASAS40responserate time cou'se)              | ASAS40ResponseRatesTimePoints(subject tohierarchical testingprocedureforTypeIerror-control within theASAS40responserate time cou'se)              | ASAS40ResponseRatesTimePoints(subject tohierarchical testingprocedureforTypeIerror-control within theASAS40responserate time cou'se)              |
| Week 12, n (%) [N1] or [95% CI]                                                                                                                   | 57 (42.86) [132]                                                                                                                                  | 16 (11.76) [132]                                                                                                                                  | 31.18*** [21.34, 41.02]                                                                                                                           | NA                                                                                                                                                | NA                                                                                                                                                |
| Week 8, n (%) [N1] or[95% CI]                                                                                                                     | 46 (34.59) [132]                                                                                                                                  | 8 (5.88) [133]                                                                                                                                    | 28.56*** [19.66, 37.47]                                                                                                                           | NA                                                                                                                                                | NA                                                                                                                                                |
| Week 4, n (%) [N1] or [95% C】]                                                                                                                    | 36 (27.07) [132]                                                                                                                                  | 5 (3.68) [132]                                                                                                                                    | 23.43*** [15.30, 31.56]                                                                                                                           | NA                                                                                                                                                | NA                                                                                                                                                |
| Week 2, n (%) [N1] or [95% C1]                                                                                                                    | 14 (10.53) [132]                                                                                                                                  | 6 (4.41) [133]                                                                                                                                    | 6.12 [-0.13, 12.37]                                                                                                                               | NA                                                                                                                                                | NA                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                               | Week 16                                                                                 | Week 16                                                                                                  | Week 16                                                                                                                           | Week 48                                                                                                                  | Week 48                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                               | Tofacitinib 5 mg BID (N = 133)                                                          | Placebo (N =136)                                                                                         | Difference From Placebo                                                                                                           | Tofacitinib 5 mg BID (N =133)                                                                                            | Placebo->Tofacitinib 5 mgBID (N =136)                                                                                       |
| Secondary efficacy endpoints (not controlledfor Type I error)                                                                                                                                                                                                                 | Secondary efficacy endpoints (not controlledfor Type I error)                           | Secondary efficacy endpoints (not controlledfor Type I error)                                            | Secondary efficacy endpoints (not controlledfor Type I error)                                                                     | Secondary efficacy endpoints (not controlledfor Type I error)                                                            | Secondary efficacy endpoints (not controlledfor Type I error)                                                               |
| ASAS 5/6, n (%) [N1] or [95% C】] ASAS Partial Remission, n (%) [N1] or[95%CI] Spinal mobility (Chest expansion), LSM (SE) [N1] or [95% C1] b △BASDAI, LSM (SE) [N1] or [95% C1] 6 ASDAS Clinically Important Improvement, n (%) [N1] or[95%CI] ASDAS Major Improvement, n (%) | 58 (43.61) [129] 20 (15.04) [129] 0.59 (0.128)                                          | [131] 4 (2.94) [131] 0.38 (0.127) [131] [131] [131] 6 (4.65) [124] 0 (0.00) [131] [76] [36] 3.29 (0.665) | 36.34*** [27.05, 45.63] 12.05** [5.29, 18.80] 0.21 [-0.11, 0.53] -1.44*** 42.30*** 25.28*** 6.69* [2.05, 11.33] -0.53 -0.57 2.22* | [100] 31 (23.31) [112] 0.50 (0.127) [100] [113] 77 (58.33) [100] 41 (33.33) [94] 20 (15.04) [100] [60] [23] 7.80 (0.775) | 61 (44.85) [103] 24 (17.65) [112] 0.47 (0.125) [103] -2.80 (0.197) [113] 72 (52.94) [103] 37 (28.68) [100] 18 (13.24) [103] |
|                                                                                                                                                                                                                                                                               |                                                                                         | 10 (7.35)                                                                                                |                                                                                                                                   | 58 (43.61)                                                                                                               |                                                                                                                             |
| Physical Functioning                                                                                                                                                                                                                                                          | [129] -2.55 (0.175) [129] 81 (61.36) [128] 37 (30.08) [119] 9 (6.77) [129] 5.52 (0.665) | -1.11 (0.174)                                                                                            | [-1.88, -1.00] [31.73, 52.88]                                                                                                     | -3.30 (0.199)                                                                                                            |                                                                                                                             |
| [N1] or [95% C1]  ASDAS Inactive Disease, n (%) [N1] or [95% C1] △MASES, LSM (SE)                                                                                                                                                                                             |                                                                                         | 26 (19.12)                                                                                               |                                                                                                                                   |                                                                                                                          |                                                                                                                             |
|                                                                                                                                                                                                                                                                               |                                                                                         |                                                                                                          | [16.47, 34.10]                                                                                                                    |                                                                                                                          |                                                                                                                             |
|                                                                                                                                                                                                                                                                               |                                                                                         |                                                                                                          | [-1.22, 0.16]                                                                                                                     | -2.87 (0.225)                                                                                                            |                                                                                                                             |
|                                                                                                                                                                                                                                                                               | -1.94 (0.288)                                                                           | -1.41 (0.272)                                                                                            |                                                                                                                                   |                                                                                                                          |                                                                                                                             |
| [N1] or [95% C1] b                                                                                                                                                                                                                                                            | [70]                                                                                    | -2.79 (0.465)                                                                                            | [-1.78, 0.65]                                                                                                                     | -3.31 (0.176)                                                                                                            | [6s] -3.82 (0.174)                                                                                                          |
|                                                                                                                                                                                                                                                                               |                                                                                         |                                                                                                          |                                                                                                                                   |                                                                                                                          | -2.56 (0.222)                                                                                                               |
| △Swollen Joint Count, LSM (SE) [N1] or [95% C】] b                                                                                                                                                                                                                             | -3.35 (0.475) [33]                                                                      |                                                                                                          |                                                                                                                                   |                                                                                                                          |                                                                                                                             |
| △SF-36v2, LSM (SE) [N1] or [95% C1]“                                                                                                                                                                                                                                          |                                                                                         |                                                                                                          |                                                                                                                                   |                                                                                                                          | [27]                                                                                                                        |
| Role Physical                                                                                                                                                                                                                                                                 | [129] 6.13 (0.744) [129] 7.93 (0.710)                                                   | [130] 3.13 (0.745) [130] 3.47 (0.713) [130]                                                              | [0.56, 3.88] 3.00* [1.15, 4.85] 4.46*** [2.69, 6.23] 3.24***                                                                      | [112] 8.66 (0.870) [112]                                                                                                 | 6.94 (0.766) [111] 7.29 (0.862) [111]                                                                                       |
| Bodily Pain                                                                                                                                                                                                                                                                   | [129]                                                                                   |                                                                                                          |                                                                                                                                   | 11.67 (0.920) [112]                                                                                                      | [111]                                                                                                                       |
|                                                                                                                                                                                                                                                                               |                                                                                         |                                                                                                          |                                                                                                                                   | 6.31 (0.777)                                                                                                             | 5.10 (0.770)                                                                                                                |
|                                                                                                                                                                                                                                                                               | 5.00 (0.617)                                                                            | 1.76 (0.618)                                                                                             |                                                                                                                                   |                                                                                                                          | 9.55 (0.912)                                                                                                                |
| General Health                                                                                                                                                                                                                                                                |                                                                                         |                                                                                                          |                                                                                                                                   |                                                                                                                          |                                                                                                                             |
|                                                                                                                                                                                                                                                                               |                                                                                         |                                                                                                          |                                                                                                                                   |                                                                                                                          | [111]                                                                                                                       |
|                                                                                                                                                                                                                                                                               | [129]                                                                                   | [130]                                                                                                    | [1.70, 4.78]                                                                                                                      | [112]                                                                                                                    |                                                                                                                             |

|                                                        | Week 16                       | Week 16             | Week 16                   | Week 48                       | Week 48                                 |
|--------------------------------------------------------|-------------------------------|---------------------|---------------------------|-------------------------------|-----------------------------------------|
|                                                        | Tofacitinib 5 mg BID (N =133) | Placebo (N =136)    | Difference From Placebo   | Tofacitinib 5 mg BID (N =133) | Placebo ->Tofacitinib 5 mgBID (N = 136) |
| Vitality                                               | 5.34 (0.864) [129]            | 3.56 (0.869) [130]  | 1.78 [-0.38, 3.94]        | 9.83 (0.997) [112]            | 9.28 (0.992) [111]                      |
| Social Functioning                                     | 5.45 (0.835) [129]            | 2.49 (0.837) [130]  | 2.96* [0.88, 5.05]        | 8.16 (0.923) [112]            | 6.77 (0.915) [111]                      |
| Role-Emotional                                         | 4.13 (1.020) [129]            | 2.05 (1.017) [130]  | 2.08 [-0.46, 4.61]        | 7.17 (1.004) [112]            | 6.32 (0.989) [111]                      |
| Mental Health                                          | 3.57 (0.886) [129]            | 2.49 (0.888) [130]  | 1.08 [-1.13, 3.29]        | 7.10 (0.960) [112]            | 6.45 (0.954) [111]                      |
| Mental Component Summary                               | 3.45 (0.914) [129]            | 2.13 (0.915) [130]  | 1.33 [-0.95, 3.61]        | 7.07 (0.926) [112]            | 6.35 (0.920) [111]                      |
| △EQ-VAS (mm), LSM (SE) [N1] or [95% C1]                | 13.00 (1.840) [128]           | 2.89 (1.840) [130]  | 10.11*** [5.52, 14.70]    | 20.64 (1.879) [112]           | 18.00 (1.862) [111]                     |
| △EuroQoL EQ-5D-3L,LSM (SE) [N1]\"                       |                               |                     |                           |                               |                                         |
| Mobility                                               | -0.23 (0.044) [129]           | -0.06 (0.044) [131] | -0.17* [-0.28, -0.06]     | -0.32 (0.051) [112]           | -0.26 (0.050) [112]                     |
| Self-care                                              | -0.21 (0.043) [129]           | -0.20 (0.043) [131] | -0.01 [-0.11, 0.10]       | -0.33 (0.048) [112]           | -0.33 (0.047) [112]                     |
| Usual activities                                       | -0.18 (0.046) [129]           | -0.09 (0.046) [131] | -0.09 [-0.20, 0.03]       | -0.32 (0.053) [112]           | -0.34 (0.053) [112]                     |
| Pain/discomfort                                        | -0.30 (0.036) [129]           | -0.12 (0.036) [131] | -0.18*** [-0.27, -0.09]   | -0.37 (0.047) [112]           | -0.36 (0.047) [112]                     |
| Anxiety/depression                                     | -0.11 (0.048) [129]           | -0.10 (0.048) [131] | -0.01 [-0.13, 0.11]       | -0.17 (0.054) [112]           | -0.21 (0.053) [112]                     |
| WPAI, LSM (SE) [N1] or[95%CI]                          |                               |                     |                           |                               |                                         |
| Percentwork timemisseddue tohealth problem             | -3.65 (2.659) [74]            | 0.88 (2.622) [81]   | -4.53 [-11.15,2.09]       | -8.10 (2.136) [61]            | -5.79 (2.047) [70]                      |
| Percent impairment while working due to health problem | -19.83 (2.274) [71]           | -6.94 (2.303) [77]  | -12.89*** [-18.59, -7.19] | -25.35 (2.769) [58]           | -23.00 (2.656) [70]                     |
| Percent overall work impairment due to health          | -21.49 (2.508)                | -7.64 (2.559)       | -13.85***                 | -27.63 (3.005)                | -23.22 (2.890)                          |
| problem                                                | [71]                          | [76]                | [-20.18, -7.52]           | [58]                          | [69]                                    |

<div style=\"page-break-after: always\"></div>

|                                      | Week16                        | Week16           | Week16                  | Week48                         | Week48                                |
|--------------------------------------|-------------------------------|------------------|-------------------------|--------------------------------|---------------------------------------|
|                                      | Tofacitinib 5 mgBID (N = 133) | Placebo (N =136) | Difference From Placebo | Tofacitinib 5 mg BID (N = 133) | Placebo->Tofacitinib 5 mgBID (N =136) |
| Percentactivityimpairmentduetohealth | -19.03 (1.969)                | -5.63 (1.968)    | -13.40***               | -27.37 (2.339)                 | -19.77 (2.310)                        |
| problem                              | [129]                         | [131]            | [-18.30, -8.50]         | [112]                          | [112]                                 |

c. ANCOVA model that included fixed effects of treatment group, stratification factor derived from clinical database, and baseline value, was fited using data at Week 16 for the 2 treatments: tofacitinib 5 mg BID and placebo for Week 16 Analysis only. Missing value was not imputed. Results at Week 16 were from this ANCOVA model. Results at Week48werefromanotherMMRMmodelfittedusing data up toWeek48for the 2 treatments:tofacitinib5mgBIDand placebo-&gt;tofacitinib5mgBID(Week48Final Analysis).

b. MMRM included fixed effect of treatment group, visit, and treatment-group by visit interaction, stratification factor derived from clinical database, stratification-factor by visitinteraction,baselinevalue,andbaseline-valuebyvisitinteraction;anunstructuredcovariancematrixwasused.Missingvaluewasnotimputed.ResultsatWeek16were from 1 MMRM model fitted using data up to Week 16 for the 2 treatments: tofacitinib 5 mg BID and placebo (Week 16 Analysis). Results at Week 48 were from another MMRM modelfited using data up toWeek48for the 2 treatments:tofacitinib5mgBIDand placebo-&gt;tofacitinib5mg BID (Week 48Final Analysis).

Results at Week 16 were based on the Week 16 Analysis data: data cutoff 19DEC2019, data snapshot 29JAN2020. Results at Week 48 were based on Week 48 Final Analysis.

Source: Module 5.3.5.1 A3921120 Week 16 Amended Study Report Tab1e 14.2.1.2.1.1; Table 14.2.2.2.1.1; Table 394a.14.2.6.1.3; Table 14.2.7.1.3; Table 14.2.12.1.3; Table 14.2.11.1.3;Table 14.2.12.1.3.1;Table 14.2.10.1.3;Table 14.2.3.1.3;Table 14.2.4.2;Table14.2.5.2;Table 14.2.19.3;Table 14.2.8.3.1;Table 14.2.3.1.3;Table 394a.14.2.6.3.2; 394a.Table 14.2.6.4.2; Table 394a.14.2.6.5.2;Table 14.2.17.4; Tab1e 14.2.18.4;Table 14.2.12.1.6; Table 14.2.13.1.3;Table 14.2.14.1.3.Module 5.3.5.1 A3921120Week 48Study ReportTab1e 14.2.1.2.1.1A;Table 14.2.2.2.1.1A;Table 14.2.6.1.3A;Table 14.2.7.1.3A;Table14.2.11.1.3A;Table 14.2.12.1.3A;Table 14.2.6.5.2A;Table 14.2.17.4A;Table 14.2.18.4A;Table 14.2.13.1.3A;Table14.2.14.1.3A.

The efficacy for the ASAS20 and ASAS40 response rates were increased at Week 24 (first post-placebo assessment) for tofacitinib 5 mg BID in patients who started placebo and advanced to tofacitinib at Week 16 (Figure 18 and Figure 19). This was maintained over time up to Week 48 in these patients (Figure 18 and Figure 19).

Figure 18. Line Graph of ASAS20 Response Rate (± SE) by Visit up to Week 48 - Estimand 1, FAS, On-Drug Data, MR=NR, Study A3921120

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 19. Line Graph of ASAS40 Response Rate (± SE) by Visit up to Week 48 - Estimand 1, FAS, On-Drug Data, MR=NR, Study A3921120

<!-- image -->

## Ankylosing Spondylitis Disease Activity Score using C-Reactive Protein Change from Baseline

Change from baseline in ASDAS(CRP) at Week 16 was a global Type I error-controlled endpoint.

-  The  LS  mean  change  from  baseline  in  ASDAS(CRP)  showed  a  statistically  significant  decrease  for tofacitinib  5  mg  BID  compared  to  placebo  at  Week  16  (p  &lt;0.0001)  based  on  the  MMRM  analysis (Estimand 4).
- The LS means decrease from baseline in ASDAS(CRP) for tofacitinib 5 mg BID were greater than those of placebo at all other time points (2-sided 95% CI excluded 0).
-  Results  of  the  supportive  analysis  (MMRM,  Estimand  5,  FAS,  on-study  data,  no  imputation)  were consistent with the on-drug data.
- Results were consistent for ASDAS(CRP) derived using hsCRP 2 mg/L as minimum for values of hsCRP less than 2 mg/L.

## High Sensitivity C-Reactive Protein (hsCRP) Change from Baseline

Change from baseline in hsCRP at Week 16 was a global Type I error-controlled endpoint.

- The LS mean change from baseline in hsCRP showed statistically significant decreases for tofacitinib 5 mg BID compared to placebo at Week 16 (p &lt;0.0001) based on the MMRM analysis (Estimand 4).
- The LS means decrease from baseline in hsCRP for tofacitinib 5 mg BID were greater than those of placebo at all other time points (2-sided 95% CI excluded 0).
-  Results  of  the  supportive  analysis  (MMRM,  Estimand  5,  FAS,  on-study  data,  no  imputation)  were consistent with the on-drug data.

Many secondary endpoints (21, 1 key) controlled for multiplicity (step-down testing procedure with a fixed alpha level for each comparison at the 2-sided 5%) were selected by the MAH.

<div style=\"page-break-after: always\"></div>

## Key secondary endpoint

Ankylosing Spondylitis Disease Activity Score (ASDAS)(CRP):  The ASDAS is a composite index that combines the following 5 disease activity variables:  spinal pain (BASDAI Question 2 NRS score 0 -10), peripheral joint pain/swelling (BASDAI Question 3 NRS score 0 -10),  duration  of  morning  stiffness (BASDAI Question 6 NRS score 0 -10), PtGA, and high-sensitivity C-reactive protein (hsCRP).  Higher scores indicate more active disease.

ASDAS  (CRP)  the  LS  mean  change  from  baseline  in  ASDAS(CRP)  showed  a  statistically  significant decrease for tofacitinib 5 mg BID compared to placebo at Week 16 (-1.36 in the tofa arm and -0.39 in the  PLB  arm  at  week  16,  delta  of  -0.98,  p  &lt;0.0001,  FAS  on  drug  data  estimand  4),  the  achieved difference was clinically relevant. Consistent results were shown by the supportive analysis (MMRM, Estimand 5, FAS, on-study data, no imputation) were consistent with the on-drug data.

At week 48 improvement of ASDAS(CRP) from baseline is still seen in both arms similarly -1.70 and 1.50 for the TOFA-TOFA and PLB-TOFA, respectively.

## Secondary endpoints type I controlled:

In  the  hierarchical  order  as  second  endpoint  the  MAH  selected  the  Change  from  baseline  of  an inflammatory marker i.e., hsCRP at Week 16 showing statistically significant decreases for tofacitinib 5 mg BID compared to placebo at Week 16 (-1.05 versus -0.09, p &lt;0.0001) based on the MMRM analysis (Estimand 4). Importantly this endpoint is not considered key for demonstration of tofacitinib clinical benefit but only regarded as supportive for effect on inflammation since no data support this biomarker as useful surrogate to assess efficacy in axial SpA.

## Secondary endpoints but not controlled for type I error:

-ASDAS clinically important improvement (61.3 versus 19.1 delta 42.3), ASDAS major improvement (30 versus 4.6 delta 25.3) ASDAS inactive disease (6.7 versus 0 delta 6.7) at week 16 overall showing a greater response in the Tofa arm which is maintained at week 48 and with an effect size of clinical significance for endpoint measuring improvement. Low disease activity or partial remission endpoints: ASDAS inactive disease (6.7 versus 0 delta 6.7, p 0 ˂ 0.05) at week 16 and ASAS partial remission (a value of =2 (on a 0 to 10 scale) present in each domain, 15 versus 3, p 0 ˂ 0.001) showing very/limited effect size.

-ASAS 5/6 results  are  consistent  with  those  of  the  primary  and  key  secondary  endpoint  showing  a statistical and clinical relevant improvement (44% responders, delta of 36 at week 16 and maintained at week 48).

As measure of improvement of enthesitis the MAH had included the change in MASES index (total score ranging 0 -13) at week 16 as not controlled secondary endpoint showing an improvement of -2 versus -1.41, delta of -0.53 slightly increasing at week 48.

Other  measures  of  symptoms  and  physical  function  recommended  which  has  been  included  within secondary endpoints not controlled for multiplicity is the change of BASDAI at week 16 (showing an improvement of -2.55 at week 16 delta of -1.44), however i) this is a widely used measure of disease activity and its changes with treatment should be assessed as secondary endpoint; ii) the percentage of patients with clinical response as measured by an improvement of at least a 50% from the baseline score in BASDAI is considered useful to judge the clinical benefit of a treatment and was not included by the MAH.

## Ancillary analyses

## Combination With csDMARDs Versus Monotherapy

In Study A3921120, the efficacy of tofacitinib 5 mg BID versus placebo for ASAS20 response rate at Week 16 was consistent between patients who were receiving tofacitinib 5 mg BID as monotherapy and

<div style=\"page-break-after: always\"></div>

those receiving tofacitinib 5 mg BID with concomitant csDMARDs However, the magnitude of the ASAS20 response rate was greater with concomitant csDMARD use. The efficacy of tofacitinib 5 mg BID versus placebo for ASAS40 response rate at Week 16 was consistent between patients who were receiving tofacitinib  5  mg  BID  as  monotherapy  and  those  receiving  tofacitinib  5  mg  BID  with  concomitant csDMARDs and again the magnitude of the response rate was greater with Day 1 concomitant csDMARD use (Table 32).

Table 32. CMH Normal Approximation to ASAS20 Response Rate at Week 16 by Subgroup, Treatment Comparison - Estimand 1, FAS, On-Drug Data, MR=NR -Subgroup Analysis (Week 16 Analysis)

-

<!-- image -->

Table 33. CMH Normal Approximation to ASAS40 Response Rate at Week 16 by Subgroup, Treatment Comparison - Estimand 1, FAS, On-Drug Data, MR=NR- Subgroup Analysis (Week 16 Analysis)

<!-- image -->

The ASAS20 and ASAS40 respones are higher in tofacitinib 5 mg BID compared to placebo group both in patients with concomitant csDMARDs use that in those with not (as shown in Tables 32 and 33). It is noted that the magnitude of the effect of tofacitnib is slightly greater when using concomitant csDMARDs compared  to  monotherapy  (diff.  of  30.88  vs  26.76  for  ASAS20  and  31.41  vs  27.56  for  ASAS  40 response), even though the number of patients with concomitant csDMARDs treatment (tofa: 29, PLB: 44) is limited compared to that of patients in monotherapy (tofa: 104, PLB: 92).

## Efficacy in the Pivotal Study A3921120 Beyond Week 16

The efficacy of the tofacitinib IR for AS is based on the Week 16 data analysis and supplemented by the Week 48 data analysis from Study A3921120. As previously described, all patients in this study received active treatment of tofacitinib 5 mg BID after Week 16. Therefore, no placebo data are available after this time point.

The efficacy of tofacitinib 5 mg BID as measured by ASAS20 and ASAS40 responses are shown over the full 48-week treatment period in the study (Figure 5 and Figure 6 above). The ASAS20 and ASAS40 response rates were sustained for tofacitinib 5 mg BID after Week 16 to the end of the study (Week 48).

<div style=\"page-break-after: always\"></div>

In addition, as measured by type-I error-controlled secondary endpoints (ASDAS(CRP), hsCRP, ASQoL, SF-36v2 PCS, BASMI Score (Linear Method), FACIT-F Total Score, PGA, total back pain, BASFI, and inflammation) efficacy was sustained or improved for tofacitinib 5 mg BID after Week 16 to the end of the study.

## Summary of main study

Table 34 summarises the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment.

Table 34. Summary of Efficacy

| Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING   | Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING   | Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING   | Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                     | A3921120                                                                                                                                             | A3921120                                                                                                                                             | A3921120                                                                                                                                                                                 |
| Design                                                                                                                                               | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study                                                                                      | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study                                                                                      | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study                                                                                                                          |
| Design                                                                                                                                               | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                       | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                       | 16 weeks not applicable 32 weeks                                                                                                                                                         |
| Hypothesis                                                                                                                                           | Superiority to placebo                                                                                                                               | Superiority to placebo                                                                                                                               | Superiority to placebo                                                                                                                                                                   |
| Treatments groups                                                                                                                                    | tofacitinib 5 mg                                                                                                                                     | tofacitinib 5 mg                                                                                                                                     | tofacitinib 5 mg po BID, N=134                                                                                                                                                           |
| Treatments groups                                                                                                                                    | Placebo                                                                                                                                              | Placebo                                                                                                                                              | Placebo po BID, N=136                                                                                                                                                                    |
| Endpoints and definitions                                                                                                                            | Primary endpoint                                                                                                                                     | ASAS20 response at week 16                                                                                                                           | Improvement of ≥ 20% and ≥ 1 unit on a scale of 0 to 10 in at least three of the four ASAS scale main domains and no worsening of ≥ 20% and ≥ 1 unit in the remaining domain, at week 16 |
| Endpoints and definitions                                                                                                                            | Secondary endpoint                                                                                                                                   | ASAS40 response at week 16                                                                                                                           | Improvement of ≥ 40% and ≥ 2 units on a scale of 0 to 10 in at least three of the four ASAS scale main domains and no worsening at all in the remaining domain, at week 16               |
| Endpoints and definitions                                                                                                                            | Secondary endpoint                                                                                                                                   | Change from baseline in ASDAS-CRP at week 16                                                                                                         | Change from baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) based on CRP at week 16                                                                                    |
| Endpoints and definitions                                                                                                                            | Secondary endpoint                                                                                                                                   | Change from baseline in hsCRP at week 16                                                                                                             | Change from baseline in high-sensitivity C- Reactive protein at week 16                                                                                                                  |
| Endpoints and definitions                                                                                                                            | Secondary endpoint                                                                                                                                   | Change from baseline in ASQoL at week 16                                                                                                             | Change from baseline in ankylosing spondylitis quality of life (ASQoL) at week 16                                                                                                        |
| Endpoints and definitions                                                                                                                            | Secondary endpoint                                                                                                                                   | Change from baseline in SF-36v2 PCS at week 16                                                                                                       | Change from baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Component Summary (PCS) score at week 16                                                                |

<div style=\"page-break-after: always\"></div>

|                                                 | Secondary endpoint                                                               | Change from baseline in BASMIlin at week 16                                      | Change from baseline in linear Bath Ankylosing Spondylitis Metrology Index - linear method (BASMIlin) at week 16   | Change from baseline in linear Bath Ankylosing Spondylitis Metrology Index - linear method (BASMIlin) at week 16   |
|-------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
|                                                 | Secondary endpoint                                                               | Change from baseline in FACIT-F at week 16                                       | Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale at week 16        | Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale at week 16        |
| Database lock                                   | Data cutoff 19 Dec 2019; data snapshot 29 Jan 2020                               | Data cutoff 19 Dec 2019; data snapshot 29 Jan 2020                               | Data cutoff 19 Dec 2019; data snapshot 29 Jan 2020                                                                 | Data cutoff 19 Dec 2019; data snapshot 29 Jan 2020                                                                 |
| Results and Analysis                            | Results and Analysis                                                             | Results and Analysis                                                             | Results and Analysis                                                                                               | Results and Analysis                                                                                               |
| Analysis description                            | Primary Analysis                                                                 | Primary Analysis                                                                 | Primary Analysis                                                                                                   | Primary Analysis                                                                                                   |
| Analysis population and time point description  | Full Analysis set (randomised, received at least one dose of study drug) Week 16 | Full Analysis set (randomised, received at least one dose of study drug) Week 16 | Full Analysis set (randomised, received at least one dose of study drug) Week 16                                   | Full Analysis set (randomised, received at least one dose of study drug) Week 16                                   |
| Descriptive statistics and estimate variability | Treatment group tofacitinib                                                      | Treatment group tofacitinib                                                      | BID 5 mg                                                                                                           | Placebo                                                                                                            |
| Descriptive statistics and estimate variability | Number of subjects 133                                                           | Number of subjects 133                                                           |                                                                                                                    | 136                                                                                                                |
| Descriptive statistics and estimate variability | ASAS20 response% 56.39%                                                          | ASAS20 response% 56.39%                                                          |                                                                                                                    | 29.41%                                                                                                             |
| Descriptive statistics and estimate variability | Number of subjects                                                               | Number of subjects                                                               | 129                                                                                                                | 131                                                                                                                |
| Descriptive statistics and estimate variability | ASAS40 response%                                                                 | ASAS40 response%                                                                 | 40.60%                                                                                                             | 12.50%                                                                                                             |
| Descriptive statistics and estimate variability | Number of subjects                                                               | Number of subjects                                                               | 129                                                                                                                | 131                                                                                                                |
| Descriptive statistics and estimate variability | Change from baseline in ASDAS-CRP -1.36                                          | Change from baseline in ASDAS-CRP -1.36                                          |                                                                                                                    | -0.39                                                                                                              |
| Descriptive statistics and estimate variability | Number of subjects 129                                                           | Number of subjects 129                                                           |                                                                                                                    | 131                                                                                                                |
| Descriptive statistics and estimate variability | Change from baseline in hsCRP -1.05                                              | Change from baseline in hsCRP -1.05                                              |                                                                                                                    | -0.09                                                                                                              |
| Descriptive statistics and estimate variability | Number of subjects 129                                                           | Number of subjects 129                                                           |                                                                                                                    | 131                                                                                                                |
| Descriptive statistics and estimate variability | Change from baseline in ASQoL units -4.03                                        | Change from baseline in ASQoL units -4.03                                        |                                                                                                                    | -2.01                                                                                                              |
| Descriptive statistics and estimate variability | Number of subjects 129                                                           | Number of subjects 129                                                           |                                                                                                                    | 130                                                                                                                |
| Descriptive statistics and estimate variability | Change from baseline in SF-36v2 PCS 6.69                                         | Change from baseline in SF-36v2 PCS 6.69                                         |                                                                                                                    | 3.14                                                                                                               |
| Descriptive statistics and estimate variability | Number of subjects 129                                                           | Number of subjects 129                                                           |                                                                                                                    | 130                                                                                                                |
| Descriptive statistics and estimate variability | Change from baseline in BASMIlin units -0.63                                     | Change from baseline in BASMIlin units -0.63                                     |                                                                                                                    | -0.11                                                                                                              |
| Descriptive statistics and estimate variability | Number of subjects 129                                                           | Number of subjects 129                                                           |                                                                                                                    | 131                                                                                                                |
| Descriptive statistics and estimate variability | Change from baseline in FACIT-F 6.54                                             | Change from baseline in FACIT-F 6.54                                             |                                                                                                                    | 3.12                                                                                                               |
| Descriptive statistics and estimate variability | Number of subjects 129                                                           | Number of subjects 129                                                           |                                                                                                                    | 131                                                                                                                |
| Effect estimates per comparison                 | Primary endpoint ASAS20 response                                                 | Primary endpoint ASAS20 response                                                 | Comparison groups                                                                                                  | tofacitinib BID 5 mg vs Placebo                                                                                    |
| Effect estimates per comparison                 | %                                                                                | %                                                                                | difference in response rate                                                                                        | 27.08                                                                                                              |
| Effect estimates per comparison                 |                                                                                  |                                                                                  | 95% CI                                                                                                             | 15.89, 38.28                                                                                                       |
| Effect estimates per comparison                 |                                                                                  |                                                                                  | P-value                                                                                                            | <0.0001                                                                                                            |
| Effect estimates per comparison                 | Secondary endpoint ASAS40 response                                               | Secondary endpoint ASAS40 response                                               | Comparison groups                                                                                                  | tofacitinib BID 5 mg vs Placebo                                                                                    |
| Effect estimates per comparison                 | %                                                                                | %                                                                                | difference in response                                                                                             | 28.17                                                                                                              |
| Effect estimates per comparison                 | rate 95%                                                                         | rate 95%                                                                         | CI                                                                                                                 | 18.26, 38.09                                                                                                       |
| Effect estimates per comparison                 | P-value                                                                          | P-value                                                                          |                                                                                                                    | <0.0001                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Secondary endpoint Change from baseline in ASDAS-CRP      | Comparison groups   | tofacitinib Placebo   | BID          | 5 mg         | vs           |
|-----------------------------------------------------------|---------------------|-----------------------|--------------|--------------|--------------|
| Secondary endpoint Change from baseline in ASDAS-CRP      | LS Mean Diff        | -0.98                 | -0.98        | -0.98        | -0.98        |
| Secondary endpoint Change from baseline in ASDAS-CRP      | 95% CI              | -1.16, -0.79          | -1.16, -0.79 | -1.16, -0.79 | -1.16, -0.79 |
| Secondary endpoint Change from baseline in ASDAS-CRP      | P-value             | <0.0001               | <0.0001      | <0.0001      | <0.0001      |
| Secondary endpoint Change from baseline in hsCRP          | Comparison groups   | tofacitinib Placebo   | BID          | 5 mg         | vs           |
| Secondary endpoint Change from baseline in hsCRP          | LS Mean Diff        | -0.96                 | -0.96        | -0.96        | -0.96        |
| Secondary endpoint Change from baseline in hsCRP          | 95% CI              | -1.20, -0.72          | -1.20, -0.72 | -1.20, -0.72 | -1.20, -0.72 |
| Secondary endpoint Change from baseline in hsCRP          | P-value             | <0.0001               | <0.0001      | <0.0001      | <0.0001      |
| Secondary endpoint Change from baseline in ASQoL          | Comparison groups   | tofacitinib Placebo   | BID          | 5 mg         | vs           |
| Secondary endpoint Change from baseline in ASQoL          | LS Mean Diff        | -2.02                 | -2.02        | -2.02        | -2.02        |
| Secondary endpoint Change from baseline in ASQoL          | 95% CI              | -3.03, -1.01          | -3.03, -1.01 | -3.03, -1.01 | -3.03, -1.01 |
| Secondary endpoint Change from baseline in ASQoL          | P-value             | <0.001                | <0.001       | <0.001       | <0.001       |
| Secondary endpoint Change from baseline in SF-36v2 PCS    | Comparison groups   | tofacitinib Placebo   | BID          | 5 mg         | vs           |
| Secondary endpoint Change from baseline in SF-36v2 PCS    | LS Mean Diff        | 3.55                  | 3.55         | 3.55         | 3.55         |
| Secondary endpoint Change from baseline in SF-36v2 PCS    | 95% CI              | 2.09, 5.02            | 2.09, 5.02   | 2.09, 5.02   | 2.09, 5.02   |
| Secondary endpoint Change from baseline in SF-36v2 PCS    | P-value             | <0.0001               | <0.0001      | <0.0001      | <0.0001      |
| Secondary endpoint Change from baseline in BASMIlin units | Comparison groups   | tofacitinib Placebo   | BID          | 5 mg         | vs           |
| Secondary endpoint Change from baseline in BASMIlin units | LS Mean Diff        | -0.52                 | -0.52        | -0.52        | -0.52        |
| Secondary endpoint Change from baseline in BASMIlin units | 95% CI              | -0.67, -0.37          | -0.67, -0.37 | -0.67, -0.37 | -0.67, -0.37 |
| Secondary endpoint Change from baseline in BASMIlin units | P-value             | <0.0001               | <0.0001      | <0.0001      | <0.0001      |
| Secondary endpoint Change from baseline in FACIT-F        | Comparison groups   | tofacitinib Placebo   | BID          | 5 mg         | vs           |
| Secondary endpoint Change from baseline in FACIT-F        | LS Mean Diff        | 3.43                  | 3.43         | 3.43         | 3.43         |
| Secondary endpoint Change from baseline in FACIT-F        | 95% CI              | 1.44, 5.42            | 1.44, 5.42   | 1.44, 5.42   | 1.44, 5.42   |
| Secondary endpoint Change from baseline in FACIT-F        | P-value             | <0.001                | <0.001       | <0.001       | <0.001       |

## Analysis performed across trials (pooled analyses and meta-analysis)

The Applicant has submitted a report concerning a systematic review and meta-analysis of placebocontrolled trials of EMA-approved biological DMARDs, including ASAS20/40 at week 12-16, in patients with AS with or without previous experience with biological DMARDs.

Placebo-controlled RCTs of biological DMARDs approved for AS by the EMA were included if they reported ASAS20 or ASAS40 at 12-16 weeks and included patients with prior nonsteroidal anti-inflammatory drug (NSAID) failure. Only multicenter studies were included and studies conducted in single countries were excluded. The initial search was conducted up to August 2019 and was recently refreshed up to August 2020. The studies concerning tofacitinib were studies A3921119 and A3921120 discussed in this report.

ASAS20 and ASAS40 response rates were extracted from the study reports, and from the AS subgroup in trials conducted in the SpA population. The mean differences and 95% confidence intervals (CI) for ASAS20 and ASAS40 responses between intervention arms and placebo were calculated, using ITT data. The results were depicted using forest plots, for all trials separately.

According to the results, ASAS20 and ASAS40 responses (Figure 20) for tofacitinib 5 mg BID across Studies A3921119 and A3921120, were similar compared with adalimumab, certolizumab, etanercept, golimumab, infliximab, ixekizumab and secukinumab. The treatment effects on ASAS40 were 26% and

<div style=\"page-break-after: always\"></div>

28% in the two tofacitinib trials (Figure 20), while the majority of treatment effects of the other biological DMARDs  ranged  from  17%  (adalimumab,  COAST  V)  to  37%  (infliximab,  ASSERT).  One  of  the secukinumab trials with a loading and a non-loading treatment arm versus placebo, had lower treatment effects (MEASURE 4).

Figure 20. ASAS40 Responses in placebo-controlled clinical trials: tofacitinib and approved AS therapies

<!-- image -->

| Drug                    | Drug-Placebo ASAS40   | Difference, % (95% CI)   |   Drug % |   Placebo % |   anua N |   Placebo N | Time Point   | Trial                |
|-------------------------|-----------------------|--------------------------|----------|-------------|----------|-------------|--------------|----------------------|
| Tofacitinib5 mg         |                       | 26.5 (9.2, 43.9)         |     46.2 |        19.6 |       52 |          51 | 12 weeks     | A3921119             |
| Tofacitinib5mg          |                       | 28.1 (18.1, 38.1)        |     40.6 |        12.5 |      133 |         136 | 16 weeks     | A3921120             |
| Adalimumab 40 mg        |                       | 26.8 (17.6, 36.0)        |     39.9 |        13.1 |      208 |         107 | 12 weeks     | ATLAS                |
| Adalimumab40mg          |                       | 17.2 (4.4, 30.0)         |     35.6 |        18.4 |       90 |          87 | 16 weeks     | COAST-V              |
| Certolizumab 200 mg     |                       | 20.7 (5.0, 36.4)         |     40   |        19.3 |       65 |          57 | 12 weeks     | RAPID-axSpAa         |
| Certolizumab400mg       |                       | 30.7 (14.1, 47.3)        |     50   |        19.3 |       56 |          57 | 12 weeks     | RAPID-axSpAa         |
| Etanercept50mgQW        |                       | 27.2 (18.8, 35.5)        |     59.8 |        32.6 |      378 |         187 | 16 weeks     | ASCENDb              |
| Etanercept50mgQW        |                       | 36.5 (22.8, 50.2)        |     58.1 |        21.6 |      155 |          51 | 12weeks      | Etanercept Study 314 |
| Etanercept25mgBIW       |                       | 31.8 (17.9, 45.6)        |     53.3 |        21.6 |      150 |          51 | 12 weeks     | EtanerceptStudy314   |
| Golimumab50 mg QW       |                       | 29.5 (18.0, 41.1)        |     44.9 |        15.4 |      138 |          78 | 14 weeks     | GO-RAISE             |
| Golimumab 50 mg QW      |                       | 30.0 (17.9, 42.1)        |     50   |        20   |      108 |         105 | 16 weeks     | Bao 2014             |
| Infliximab5mg/kg        |                       | 36.9 (26.8, 47.1)        |     49.8 |        12.8 |      201 |          78 | 12 weeks     | ASSERT               |
| Ixekizumab80mgQ4W       |                       | 29.8 (16.2, 43.3)        |     48.1 |        18.4 |       81 |          87 | 16 weeks     | COAST-V              |
| Secukinumab 150 mg (NL) |                       | 25.3 (12.1, 38.5)        |     36.1 |        10.8 |       72 |          74 | 16weeks      | MEASURE 2            |
| Secukinumab 150 mg (L)  |                       | 10.6 (-1.5, 22.6)        |     38.8 |        28.2 |      116 |         117 | 16 weeks     | MEASURE 4            |
| Secukinumab 150 mg (NL) |                       | 7.7(-4.2, 19.6)          |     35.9 |        28.2 |      117 |         117 | 16 weeks     | MEASURE4             |

Key: L = loading dose; NL = no loading dose.

a. Results from the RAPID-axSpA study were taken from the subgroup of patients with AS. The full analysis set included both patients with AS and non-radiographic axial spondyloarthritis.

b. The sulfasalazine arm of the ASCEND study was treated as placebo in this analysis.

c. The COAST-V study included ixekizumab 80 mg Q2W and Q4W. Results from ixekizumab Q4W are shown here.

Source: Module 5.3.5.3 Contextualization of Efficacy Endpoints for Tofacitinib Versus Currently Approved Treatments for AS Figure 3.

## Clinical studies in special populations

No data are available on special populations. No specific data on elderly are reported for axSA subjects. In the SmPC dose adjustments are included for renal and hepatic impairment based on initial submission.

## Supportive studies

## A3921119

This  was  Phase  2,  multicentre,  randomised,  double-blind,  placebo-controlled  dose-ranging,  parallel group efficacy and safety study designed to characterise the dose-response of tofacitinib in patients with active AS who had experienced an inadequate response to NSAIDs and were naïve to previous bDMARDs (Figure 21) for design schematic.

<div style=\"page-break-after: always\"></div>

Figure 21.  Study A3921119 Schematic of Study Design

<!-- image -->

## Methods

## Study participants

The clinical programme was designed to evaluate the efficacy of tofacitinib in adult patients with active AS who had experienced an inadequate clinical response or were intolerant to NSAID therapy. A diagnosis of AS was based on the Modified New York Criteria for AS (1984). Active disease was also defined as: BASDAI score of ≥ 4 and back pain score (BASDAI Question 2) of ≥ 4 despite treatment with NSAIDs at both screening and baseline. Patients met the definition of NSAID-IR if they had either an inadequate clinical response, intolerance to at least 2 different oral NSAIDs, or ongoing NSAID treatment but with active AS.

Patients continued their stable background AS therapy, which included NSAIDs including selective COX2 inhibitors, MTX, sulfasalazine, and corticosteroids ( ≤ 10 mg/day of prednisone or equivalent). In Study A3921119, background therapies were to be stable for 4 weeks except NSAIDs (1 week) prior to the first dose of investigational product.

Selected key enrolment criteria for Study A3921119 are the same of the pivotal phase study with the exception of exclusion of subjects exposed to bDMARDs.

## Treatments

A twice daily dosing regimen (3 doses of tofacitinib 2 mg, 5 mg, 10 mg, or placebo) was evaluated in the  dose-ranging  Phase  2  Study  A3921119.  During  the  12-week  treatment  period,  patients  were randomised  in  a  1:1:1:1  ratio  to  receive  1  of  the  4  blinded  treatments.  The  assignment  occurred according  to  a  randomisation  schedule  and  to  which  the  patient,  site  personnel,  and  the  Sponsor's personnel directly involved in the study conduct were blinded through the entire duration of the study.

The duration of participation for eligible patients was approximately 150 days. This included a screening period of approximately 28 days, a 12-week double-blind treatment period, and a 28-day follow-up period.

Of 445 subjects screened for entry into the study, 208 subjects were randomized in a 1:1:1:1 ratio to double-blind treatment; 52 subjects to each treatment group (tofacitinib 2 mg BID, tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo).

The efficacy of Tofacitinib 5 mg BID dose was supported by the outcomes of the Phase 2 dose-ranging Study  A3921119.  The  study  design  is  considered  appropriate  and  in  line  with  the  EMA  guideline (EMA/CPMP/EWP/4891/03 Rev.1, Corr 1*) recommendation for placebo controlled parallel group studies. Similar eligibility criteria were applied across the two key studies. Inclusion and exclusion criteria are orET

<div style=\"page-break-after: always\"></div>

overall  appropriate  reflecting  subjects  with  AS  who  have  responded  inadequately  to  conventional therapy. However, differently to Study A3921120, only patients naïve to previous bDMARDs were allowed to be included in Study A3921119, excluding patients bDMARDs experienced. Therefore, the phase 2 study could be of support of tofacitinib treatment only in a bDMARD naïve patient population. The activity of disease required for entry into this study was defined as for the pivotal on: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of ≥4 and back pain score (BASDAI Question 2) of ≥4 despite treatment with NSAIDs (or intolerance to NSAIDs). Regarding the different doses, the MAH states that similar to the RA and psoriasis Phase 2 studies, where inclusion of doses &lt;5 mg BID provided lower efficacy thereby allowing a complete characterization of the dose-response curve, a 2 mg BID dose was included in the study.

## Objectives

1. To compare the efficacy of tofacitinib, in doses of 2 mg twice daily (BID), 5 mg BID, 10 mg BID versus placebo on the ASAS20 response rate at Week 12 in subjects with active AS that had an inadequate response to previous treatment.

2. To estimate the placebo-corrected dose-response for the ASAS20 at Week 12 in subjects with active AS that had an inadequate response to previous treatment.

3. To compare the safety of tofacitinib at all doses versus placebo in all study subjects.

## Outcomes/endpoints

The primary efficacy endpoint was ASAS20 response rate at 12 weeks of treatment.

The secondary efficacy endpoints were:

- A validated endpoint such as Spondyloarthritis Research Consortium of Canada (SPARCC) MRI index of  disease  activity  score  and/or  modified  Berlin  Ankylosing  Spondylitis  Spine  Magnetic Resonance Imaging (ASspiMRI) Activity Score of the SI joints and spine at Week 12.
- ASAS20 response at all other time points (2,4 and 8 weeks).
- ASAS40 response at all time points (2,4,8 and 12 weeks).
- ASAS 5/6 response at all time points (2,4,8 and 12 weeks).
- ASAS partial remission criteria at all time points (2,4,8 and 12 weeks).
- Ankylosing Spondylitis Disease Activity Score (ASDAS) using C-Reactive Protein (ASDASCRP) at all time points (2,4,8 and 12 weeks).
- ASDAS  clinically  important  improvement,  ASDAS  major  improvement  and  ASDAS  inactive disease at all time points (2,4,8 and 12 weeks).
- BASDAI at all time points (2,4,8 and 12 weeks).
- 50% improvement from Baseline in the BASDAI (BASDAI50) response at all time points (2,4,8 and 12 weeks).
- BASFI at all time points (2,4,8 and 12 weeks).
- BASMI at all time points (2,4,8 and 12 weeks).
- Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at all time points collected (4,8 and 12 weeks)

<div style=\"page-break-after: always\"></div>

- Extra-articular involvement (specific medical history and peripheral articular involvement [as assessed by swollen joint count]) at all time points collected (2,4,8 and 12 weeks).

Other evaluations included QoL endpoints: Ankylosing Spondylitis Quality of Life (ASQoL), Short-Form36 Health Survey (SF-36) Version 2, EuroQol Health State Profile -5  Domains (EQ-5D), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Work Productivity and Activity Impairment (WPAI) Questionnaire: Spondyloarthritis, AS HealthCare Resource Utilization Questionnaire (AS-HCRU).

The efficacy of tofacitinib in active AS in phase 2 Study was evaluated using a core set of validated measures similar to those used in the pivotal Study and this is agreed. However, the primary endpoint (ASAS20) was assessed at week 12 instead of at week 16 as in Study A3921120 not allowing for a pooling of efficacy results. As reported in the above comment for Study A3921120, ASAS 20 is not the preferred primary endpoint according to EMA guideline (EMA/CPMP/EWP/4891/03 Rev.1, Corr 1*) that recommends to use the more stringent endpoint ASAS40 as primary. However, due to the reasons explained above and considering this as a supportive study, ASAS20 is deemed an acceptable endpoint. Moreover, ASAS40 response is one of the secondary end-point together with other validated endpoints such as ASAS 5/6, ASAS partial remission, ASDAS (CRP), BASDAI improvement, BASDAI 50. It is also noted that a radiological endpoint is also included (SPARCC) and this is agreed according to EMA GL.

Eligible subjects were randomized in a 1:1:1:1 ratio to one of the 4 blinded treatments (tofacitinib 2 mg BID, tofacitinib 5 mg BID, tofacitinib 10 mg BID, or placebo BID as shown in Table 35). Tofacitinib was provided as 1 mg or 5 mg tablets with corresponding matching placebo. A total of 8 tablets per day encompassed the total daily dose taken by the subject:

Table 35. Treatment Allocation

| Sequence   | TreatmentDescription                                                                                  |   Planned Numberof Randomized Subjects |
|------------|-------------------------------------------------------------------------------------------------------|----------------------------------------|
| I          | Tefacitinib2mgBID TwoImgtabletsandheo5mgmatchingplacebo tabletsinAMandPM                              |                                     50 |
|            | Tofacitinib SmgBID OueSmgtablet,one5mgmatchingplacebotablet andnwoImgmatchingplacebotabletsinAMand PM |                                     50 |
|            | TofacitinibIomgBID Two5mgtabletsandhro1mgmatchingplacebo abletsnAMandPM                               |                                     50 |
|            | PlaceboBID TwoImgmatckingplacebo tablets andnwo5mg matchingplacebo tobletsinAMandPM                   |                                     50 |

Source:FinalProtocolAendmentI.SectionI6.I.1

Abbreviations:AM-ante menidiem,BID-rwice daily.PMI-post menidiem

## Selection of Doses in the Study

The 5 and 10 mg BID doses were demonstrated to be efficacious in RA subjects and in subjects with psoriasis.  Since  10  mg  BID  provided  increased  efficacy  over  5  mg  BID  in  RA  and  psoriasis  while maintaining an acceptable safety profile, and doses &gt;10 mg BID did not provide substantially improved efficacy,  10  mg  BID  was  selected  as  the  highest  dose  for  the  current  study.  Similar  to  the  RA  and psoriasis Phase 2 studies, where inclusion of doses &lt;5 mg BID provided lower efficacy thereby allowing a complete characterization of the dose-response curve, a 2 mg BID dose was included in the study.

## Rescue medications:

The maximum dose of acetaminophen/paracetamol was 2.6 g/day for no more than 10 consecutive days. The maximum dose of opioids was the maximum potency equivalent of 30 mg/day of orally -administered morphine.

## Sample size

<div style=\"page-break-after: always\"></div>

Sample  size  was  assessed  using  clinical  trial  simulations  in  which  a  dose-response  model  (the  3parameter maximal effect [Emax] model) determined the true percentage of ASAS20 responders at week 12. Simulations under several plausible truths were conducted assuming 50 subjects per treatment group to evaluate the operational characteristics of this same model when used for the analysis. If the true placebo-corrected ASAS20 response in the range of 1 to 10 mg BID was between 20 to 40%, then it was projected based on simulations that the estimated placebo-corrected effect for that dose ±10%, would capture the true placebo-corrected response at least 83% of the time. Under the same assumption about the true effect, it was projected that the estimated placebo-controlled effect ±5% would capture the true value at least approximately 50% of the time.

Emax model to the primary endpoint was used for the dose -response study A3921119. It is recognised to find the optimal dose and investigate the relationship between dose and efficacy relative to control.

## Randomisation

A total of 208 patients were randomised in a 1:1:1:1 ratio to receive tofacitinib 2 mg BID, tofacitinib 5 mg BID, tofacitinib 10 mg BID, or placebo.

## Blinding (masking)

The Study was conducted in a double-blind, placebo-controlled manner. The randomization scheme is considered adequate.

## Statistical methods:

A 3-parameter Emax model to estimate the ASAS20 dose-response at Week 12, the primary efficacy endpoint,  with  missing  response  considered  as  non-response.  As  a  supportive  analysis,  the  normal approximation for estimating the difference in binomial proportions was used to compare each of the dose groups of tofacitinib to placebo at Week 12 with missing response considered as non-response. All analyses of the efficacy endpoints were based on the FAS. Evaluation of secondary efficacy endpoints was either by:

The  normal  approximation  for  the  difference  in  binomial  proportions  (both  testing  and  confidence interval) was applied to the following endpoints:

- ASAS20 response at all other time points.
- ASAS40 response at all time points.
- ASAS 5/6 response at all time points.
- ASAS partial remission criteria at all time points.
- ASDAS  clinically  important  improvement,  ASDAS  major  improvement  and  ASDAS  inactive disease at all time points.
- BASDAI50 response at all time points.

Missing values due to dropout were set to non-responsive and mixed LOCF was used for missing data that may have existed in components of the above endpoints.

A repeated measures model was used to analyze change from Baseline for the endpoints listed below. The marginal repeated measure model included fixed effects of treatment group, visit, and treatmentgroup by visit interaction, and Baseline value. An unstructured variance covariance matrix was used. Pairwise  comparisons of each tofacitinib  dose to  placebo  (providing  both  2-sided  p-values  and 95% confidence interval) at each post-Baseline time point was generated from contrast statements using this model.

<div style=\"page-break-after: always\"></div>

- ASDASCRP at all time points.
- BASDAI at all time points.
- BASFI at all time points.
- BASMI (linear method) at all time points.
- MASES at all time points collected.
- Extra-articular involvement (specific medical history and peripheral articular involvement [as assessed by swollen joint count]) at all time points collected.
- Spinal mobility at all time points collected
- Total score on the FACIT-F at all time points.

An analysis of covariance (ANCOVA) model was used to analyze change from Baseline for the endpoints listed below. The ANCOVA model included a fixed effect for treatment group and Baseline value as a covariate. Pairwise comparisons of each tofacitinib dose to placebo (providing both 2-sided p-values and 95% confidence interval) were generated from contrast statements using this model.

- Total score on the ASQoL at Week 12.
- Summary components and domains of the SF-36 Version 2, Acute at Week 12.
- Domains and utility index from the EQ-5D at Week 12.
- WPAI Questionnaire: spondyloarthritis at Week 12.
- A validated endpoint such as SPARCC MRI index of disease activity score and/or modified Berlin ASspiMRI Activity Score of the SI joints and spine at Week 12.

The Early Termination visit value was used as the Week 12 value if the Week 12 value for a subject was missing.

The use of the Emax model as primary analysis to estimate the ASAS20 dose-response at Week 12, and the use of the normal approximation as supportive analysis for estimating the difference in binomial proportions to compare each of the dose groups of tofacitinib to placebo at Week 12 are acknowledged.

## Participant flow

The duration of participation for eligible patients was approximately 150 days. This included a screening period of approximately 28 days, a 12-week double-blind treatment period, and a 28-day follow-up period. Table 36 summaries patient dispositions for Studies A3921119 up to week 12.

Of 445 subjects screened for entry into the study, 208 subjects were randomized in a 1:1:1:1 ratio to double-blind treatment; 52 subjects to each treatment group (tofacitinib 2 mg BID, tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo).

Table 36. Patient Disposition - Studies A3921119 (up to Week 12)

|                | Number (%) of Patients   | Number (%) of Patients   |                       |           |
|----------------|--------------------------|--------------------------|-----------------------|-----------|
|                | Tofacitinib 2 mg BID     | Tofacitinib 5 mg BID     | Tofacitinib 10 mg BID | Placebo   |
| Study A3921119 |                          |                          |                       |           |
| Randomised     | 52                       | 52                       | 52                    | 52        |
| Treated        | 52                       | 52                       | 52                    | 51        |
| Completed      | 51 (98.1)                | 51 (98.1)                | 47 (90.4)             | 47 (90.4) |

<div style=\"page-break-after: always\"></div>

Table 36. Patient Disposition - Studies A3921119 (up to Week 12)

|                                                         | Number (%) of Patients   | Number (%) of Patients   |                       |           |
|---------------------------------------------------------|--------------------------|--------------------------|-----------------------|-----------|
|                                                         | Tofacitinib 2 mg BID     | Tofacitinib 5 mg BID     | Tofacitinib 10 mg BID | Placebo   |
| Discontinued                                            | 1 (1.9)                  | 1 (1.9)                  | 5 (9.6)               | 4 (7.7)   |
| Discontinuations due to treatment related Adverse Event | 0                        | 1 (1.9)                  | 1 (1.9)               | 2 (3.9)   |
| Analysed for Efficacy Per-protocol analysis             | 49 (94.2)                | 49 (94.2)                | 50 (96.2)             | 49 (94.2) |
| set                                                     | 52 (100.0)               | 52 (100.0)               | 52 (100.0)            | 51 (98.1) |

Percentages for the 'Not treated' and 'Treated' rows are calculated using the number of patients assigned to treatment (randomised) as the denominator. Other percentages are calculated using the number of 'Treated' patients as the denominator.

Of the 208 randomised patients, 1 patient was randomised to placebo but did not receive study drug thus was excluded from analyses. There were 207 patients included in the FAS; all 207 patients in the FAS were analysed for AEs and 205 patients were analysed for laboratory data. Overall, 196 patients completed the study; approximately 98% of patients in the lower dose treatment groups (tofacitinib 2 mg and 5 mg BID) compared to approximately 90% in the tofacitinib 10 mg BID and placebo treatment groups.

## Recruitment

Study A3921119

Study initiation date: 17 April 2013

Completion date: 18 March 2015

Conduct of the study: One amendment to the study A3921119 protocol was planned; the implemented changes seem do not impact study results, and no significant concern has been identified.

## Baseline data

Patient baseline demographics and disease characteristics were similar across all treatment groups. The overall mean age was 41.6 years. The majority (82.7%) of patients in the study were White and 3.8% of patients were of Hispanic/Latino ethnicity. Patients were from the EU (61.8%), Asia (18.8%), North America  (13.5%),  and  the  ROW  (5.8%).  Patients  were  balanced  across  treatment  groups  in  their corticosteroid (3.8% to 17.3%) and DMARD (34.6% to 55.8%) use at baseline. The mean (median) duration since diagnosis of AS for the 5 mg BID treatment group was 6.3 (3.5 [range: 0.0-24.4]) years and was similar across treatment groups.

## Medical history

<div style=\"page-break-after: always\"></div>

Table 37. Medical History Related to Primary Diagnosis -Safety Analysis Set

|                                                                | Tofacitinib2mgBID   | Tofacitinib2mgBID   | Tofacitinib2mgBID   | Tofacitinib5mgBID   | Tofacitinib5mgBID   | Tofacitinib5mgBID   |
|----------------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Numberofsubjects Nosignificanthistoryrelatedtoprimarydiagnosis | Yes                 | 52 32 No            | Unknown n (%)       | Yes n (%)           | 52 34 No n (%)      | Unknown n (%)       |
| Eye disorders                                                  | n (%) 13 (25.0)     | n (%) 12 (23.1)     | 0                   | 12 (23.1)           | 14 (26.9)           | 0                   |
| Uveitis                                                        | 13 (25.0)           | 12 (23.1)           | 0                   | 12 (23.1)           | 14 (26.9)           | 0                   |
| Gastrointestinaldisorders                                      | 0                   | 25 (48.1)           | 0                   | 3 (5.8)             | 23 (44.2)           | 0                   |
| Inflammatoryboweldisease                                       | 0                   | 25 (48.1)           | 0                   | 3 (5.8)             | 23 (44.2)           | 0                   |
| Skin and subcutaneous tissue disorders                         | 1 (1.9)             | 24 (46.2)           | 0                   | 2 (3.8)             | 24 (46.2)           | 0                   |
| Psoriasis                                                      | 1 (1.9)             | 24 (46.2)           | 0                   | 2 (3.8)             | 24 (46.2)           | 0                   |
| Uncoded                                                        | 11 (21.2)           | 14 (26.9)           | 0                   | 6 (11.5)            | 20 (38.5)           | 0                   |
| Peripheral articularinvolvement                                | 11 (21.2)           | 14 (26.9)           | 0                   | 6 (11.5)            | 20 (38.5)           | 0                   |
|                                                                | Tofacitinib10mgBID  | Tofacitinib10mgBID  | Tofacitinib10mgBID  | Placebo             | Placebo             | Placebo             |
| Number ofsubjects                                              |                     | 52                  | Unknown             |                     | 51 36               | Unknown n (%)       |
| Nosignificanthistoryrelatedtoprimarydiagnosis                  | Yes                 | 36 No               |                     | Yes                 | No n (%)            |                     |
| Eye disorders                                                  | n (%) 6 (11.5)      | n (%) 14 (26.9)     | n (%) 0             | n (%) 7 (13.7)      | 14 (27.5)           | 0                   |
| Uveitis                                                        | 6 (11.5)            | 14 (26.9)           | 0                   | 7 (13.7)            | 14 (27.5)           | 0                   |
| Gastrointestinal disorders                                     | 0                   | 20 (38.5)           | 0                   | 1 (2.0)             | 20 (39.2)           | 0                   |
| Inflammatorybowel disease                                      | 0                   | 20 (38.5)           | 0                   | 1 (2.0)             | 20 (39.2)           | 0                   |
| Skin and subcutaneous tissue disorders                         | 1 (1.9)             | 19 (36.5)           | 0                   | 2 (3.9)             | 19 (37.3)           | 0                   |
| Psoriasis                                                      | 1 (1.9)             | 19 (36.5)           | 0                   | 2 (3.9)             | 19 (37.3)           | 0                   |
| Uncoded                                                        | 9 (17.3)            | 10 (19.2)           | 1 (1.9)             | 6 (11.8)            | 15 (29.4)           | 0                   |
| Peripheral articular involvement                               | 9 (17.3)            | 10 (19.2)           | 1 (1.9)             | 6 (11.8)            | 15 (29.4)           | 0                   |

Source: Table 14.1.3.2

Subjects are counted only oncefor specific disease/syndromein the table body.

MedDRA (v18.0) coding dictionary applied.

Abbreviations: BID = twice daily, MedDRA = Medical Dictionary for Regulatory Activities, n = number of subjects with data.

Few patients (7 treated and 4 placebo) discontinued the Study A3921119, of which the majority in tofacitinib 10 mg BID arm, and 94-96% of subjects were included in the Per-protocol analysis set.

Overall, demographic characteristics were quite balanced across groups and similar to those of phase 3 study.  The  majority  of  subjects  in  all  treatment  groups  were  white  males  HLA-B27  positive;  the proportion of subjects positive for HLA-B27 was greatest in the tofacitinib 10 mg BID treatment group. The baseline disease characteristics were compatible with the diagnosis of active AS disease indicated by a median value of 6.2 in tofa 5 mg BID and 6.6 in placebo group for BASDAI and of 3.7 and 3.5, respectively in ASDAS (CRP). A slightly higher median baseline hsPCR value was observed in tofa 5 mg BID group (8.74) compared to placebo group (6.91). A higher number of patients in tofa 5 mg BID group compared to placebo group had a history of IBD, psoriasis and peripheral articular involvement.

## Results

Results of the primary and secondary efficacy endpoints at Week 12 were as follows:

· The primary analysis of the ASAS20 response rate at Week 12 was conducted on the FAS using an Emax model with MR=NR (as shown in Table 38). The estimated response rates were 40.1% for placebo and 56.0%, 63.0%, 67.4% for tofacitinib 2, 5, and 10 mg BID, respectively, demonstrating that the response rates for tofacitinib were higher than for placebo.

<div style=\"page-break-after: always\"></div>

Table 38 . Analysis of ASAS20 Response Rate at Week 12 Using Emax Model, Comparison to Placebo -Full Analysis Set

|                       |    | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   | DifferencefromPlacebo (Active-Placcbo)   |
|-----------------------|----|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                       |    |                                          |                                          | 95%C                                     | 95%C                                     | 60%CT                                    | 60%CT                                    | D%0S                                     | D%0S                                     |
|                       | N  | Estimated                                | Estimate                                 | Lower                                    | Upper                                    | Lower                                    | U'pper                                   | Lower                                    | Upper                                    |
| Treatment             |    | Responve Rate                            |                                          |                                          |                                          |                                          |                                          |                                          |                                          |
| Tofacitimb 2mgBID     | 52 | 56.0                                     | 15.8                                     | 5.0                                      | 30.3                                     | 10.2                                     | 21.2                                     | 11.1                                     | 19.9                                     |
| Tofacitinib5mgBID     | 52 | 63.0                                     | 22.9                                     | 8.4                                      | 37.7                                     | 16.5                                     | 29.3                                     | 17.8                                     | 28.0                                     |
| Tofacitinib 10 mg BID | 52 | 67.4                                     | 27.3                                     | 10.7                                     | 43.4                                     | 20.3                                     | 34.4                                     | 21.8                                     | 33.0                                     |
| Piacebo               | 51 | 40.1                                     |                                          |                                          |                                          |                                          |                                          |                                          |                                          |

SommceTae142.1.11

Missing vales de lo a sbjet dopping frm te sudy forany reaon（eg.lack ofefficacy or adere evet)are hanled by setting the ASAS20 vale to non-tesponsive.Ifcomponents oftheASAS20 are mssing atWeek 12.LOCF mixedconponents areapplied

ASAS20 reipose is defined as≥20%and ≥1 it inat least3 domns ona scale of0-10adn woremg of20and≥1 mitinthe reiing doin The 4ASAS douaims are thePatiet Global Assesment ofDneae'(frm the CRF LabeledNUMERICALRATING SCALE-PatientGlobal Assementof Inflammation（from theBASDAlie.theaverage ofquestionSand 6fromtheBASDAl CRF)

Abbweviations:AS=ankylosing spondylitis.ASAS=Asessmeut ofSpcndyloAathritisinlermaionalSociety.ASAS20=≥2oincrease from Baseline and21 itincreasein at least3 doainson a scale of 0toI0,andno wrning of2oand≥1 itinte remainingdomain.BASDAI -BathAnkylosing Spondylitis DiseaseActivity Index.BASF-BathAnkylosingSpondylitisFunctionalIndexBID-twice a day.CI-credibleinterval.CRF-Cae Report FomuLoCF=lastobservationcarmied forwardN-mmberofssbjectswith available data or datainguted using fenon-responder/LOCFmethod

The ASAS20 response rate at Week 12 with missing response as non-response was 41.2% for placebo and 51.9%, 80.8%, 55.8% for tofacitinib 2 mg, 5 mg, and 10 mg BID, respectively (as shown in Table 39); the difference in response rates by normal approximation method between tofacitinib 5 mg BID and placebo was statistically significant (p&lt;0.001, without multiple comparison adjustment).

Table 39 . Normal Approximation to ASAS20 Response at Week 12, Comparison to Placebo -Full Analysis Set NRL/LOCF

|                  |    |    |                  |      | DifferencefromPlacebe' (Active-Placebo)   | DifferencefromPlacebe' (Active-Placebo)   | DifferencefromPlacebe' (Active-Placebo)   | DifferencefromPlacebe' (Active-Placebo)   | DifferencefromPlacebe' (Active-Placebo)   |
|------------------|----|----|------------------|------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Treatmeat        |    |    | Responw Rate (%) | SE   | Diffr                                     | SE                                        | Lower                                     | Upper                                     | p-Value                                   |
| Tofacitnb2mgBID  | 52 | 27 | 51.92            | 6.93 | 10.75                                     | 9.77                                      | -8.41                                     | 29.90                                     | 0.271                                     |
| TofacitinbSmgBID | 52 | 42 | 80.77            | 5.47 | 39.59                                     | 8.80                                      | 22.35                                     | 56.83                                     | <.001                                     |
| Tofxitinb10mgBID | 52 | 29 | 55.77            | 6.89 | 14.59                                     | 9.74                                      | -4.50                                     | 33.69                                     | 0.134                                     |
| Placrbo          | 51 | 21 | 41.18            | 6.89 |                                           |                                           |                                           |                                           |                                           |

Source:Tablo14.21.2.1

ASAS20response is defined as≥20and≥1mit inat least3 domainsonscaleof 0-10 and noworseningof≥20and≥1umit infhereainingdomain Ihe4ASASdomaimsare thePatient Global Assessment ofDiseate（from the CRFlabeledNUMfERICALRATENGSCALE-PatientGlobal Assesament of AS').Spinal Pain（from theNUMIERICAL RATING SCALE-Total BackPain),Functicn (average ofthe10 qaestioms fiom theBASFI CRF）and Inflammation（fiomtheBASDAlie.tbe averageofquestion5and 6from theBASDAI CRF)

AbbrevisticusASAS=AssessmentofSpondyloArthritisintermatiomalSociety.ASAS20=≥2oincrease fromBaseline and ≥l unitimctease in atleast 3domins cn ascale of0 to10.andno woneningof20%and≥1nit in theremaimingdomain,BASDAl-BathAniylosingSpondylitisDiseaseActivity Index.BASFI-Bath AnkylosingSpondylitis Functional Index.BID=wice daily.CI=confidence intervalCRF-Case Report Form.Diff-difference LOCF=lastobervation carried forwandN=mumber ofsubject withawalable data or data impted ing the nonrespeader LOCFmethodn=mnber of respooders,NRI=not-reipotdermptatiomSE=standarderror.

Nomlappromaton

The ASAS20 response rate in tofacitinib 5 mg BID was higher than placebo at Week 4 (55.8% versus 33.3%; p ≤ 0.05 without multiple comparison adjustment).

- At Week 12, there was a statistically significant higher ASAS40 response rate for tofacitinib 5 mg BID compared with placebo: 21.6% for placebo and 42.3% (p=0.020), 46.2% (p=0.006), and 38.5% (p=0.057) for tofacitinib 2, 5, and 10 mg BID, respectively (without multiple comparison adjustment).
- At Week 12, all ASAS family components showed greater mean reductions from baseline for tofacitinib 5 mg BID versus placebo (2-sided 95% CI for the difference between tofacitinib 5 mg BID and placebo excluded 0).

<div style=\"page-break-after: always\"></div>

- At Week 12, there was a statistically significant greater improvement from Baseline for the LS mean SPARCC MRI index of disease activity score of the SI joints and the spine and for the LS mean modified Berlin ASspiMRI Activity Score compared to placebo for the tofacitinib 5 mg BID (Table 40).

|                                                            | Tofacitinib 5 mg BID (N = 52)   | Placebo (N = 51)             |
|------------------------------------------------------------|---------------------------------|------------------------------|
| Primary efficacy endpoint                                  | Primary efficacy endpoint       | Primary efficacy endpoint    |
| ASAS20 response rate (Emax model) (%) a                    | 63.0                            | 40.1                         |
| Normal approximation to ASAS20 response rate, n (%) [N1] a | 42 (80.8)** [52]                | 21 (41.2) [51]               |
| Secondary efficacy endpoints                               | Secondary efficacy endpoints    | Secondary efficacy endpoints |
| Normal approximation to ASAS40 response rate, n (%) [N1] a | 24 (46.2)* [52]                 | 11 (21.6) [51]               |
| ∆ ASDAS(CRP), LSM (SE) [N1]                                | -1.41 (0.119)** [50]            | -0.68 (0.123) [45]           |
| ∆ hsCRP (mg/L), LSM (SE) [N1]                              | -7.00 (1.174)** [50]            | -1.00 (1.221) [45]           |
| ∆ ASQoL, LSM (SE) [N1] b                                   | -4.79 (0.615)* [52]             | -2.53 (0.627) [51]           |
| ∆ SF-36v2, LSM (SE) [N1] b                                 | ∆ SF-36v2, LSM (SE) [N1] b      | ∆ SF-36v2, LSM (SE) [N1] b   |
| PCS                                                        | 6.49 (0.914)** [52]             | 2.69 (0.932) [51]            |
| MCS                                                        | 4.15 (1.294) [52]               | 2.41 (1.318) [51]            |
| ∆ BASMI Score (Linear Method), LSM (SE) [N1] c             | -0.39 (0.108) [50]              | -0.15 (0.111) [46]           |
| ∆ FACIT-F Total Score, LSM (SE) [N1] c                     | 7.03 (1.145)* [50]              | 3.08 (1.178) [46]            |
| PGA, mean (SD) [N1]                                        | -2.8 (2.18) [50]                | -1.7 (2.54) [46]             |
| ∆ Total Back Pain, mean (SD) [N1]                          | -3.2 (2.19) [49]                | -2.0 (2.40) [46]             |
| ∆ Inflammation, mean (SD) [N1]                             | -3.17 (2.147) [50]              | -1.78 (2.260) [46]           |
| ∆ BASFI, LSM (SE) [N1] c                                   | -2.39 (0.260)* [50]             | -1.43 (0.266) [46]           |
| ASAS 5/6, n (%) [N1] a                                     | 36 (69.23)** [52]               | 12 (23.53) [51]              |
| ASAS Partial Remission, n (%) [N1] a                       | 10 (19.23) [52]                 | 6 (11.76) [51]               |
| ∆ Spinal mobility (Chest expansion, cm), LSM (SE) [N1] c   | 0.49 (0.187) [50]               | 0.31 (0.193) [46]            |
| BASDAI, LSM (SE) [N1] c                                    | -2.88 (0.276)* [50]             | -1.85 (0.283) [46]           |
| ASDAS Clinically Important Improvement, n (%) [N1] a,d     | 33 (63.46)** [52]               | 14 (27.45) [51]              |

<div style=\"page-break-after: always\"></div>

Table 40. Selected Efficacy Endpoints at Week 12 (FAS) -Study A3921119

|                                                        | Tofacitinib 5 mg BID (N = 52)   | Placebo (N = 51)    |
|--------------------------------------------------------|---------------------------------|---------------------|
| ASDAS Major Improvement, n (%) [N1] a,e                | 12 (23.08) [52]                 | 6 (11.76) [51]      |
| ASDAS Inactive Disease, n (%) [N1] a,f                 | 7 (13.46) [52]                  | 4 (7.84) [51]       |
| ∆ MASES, LSM (SE) [N1] c                               | -1.37 (0.259)* [50]             | -0.34 (0.265) [46]  |
| ∆ Swollen Joint Count, LSM (SE) [N1] c                 | -0.79 (0.362) [50]              | -0.99 (0.373) [46]  |
| ∆ EuroQoL EQ-5D-3L, LSM (SE) [N1] b                    |                                 |                     |
| Mobility                                               | -0.29 (0.063) [52]              | -0.11 (0.064) [51]  |
| Self-care                                              | -0.14 (0.055) [52]              | -0.19 (0.056) [51]  |
| Usual activities                                       | -0.29 (0.071) [52]              | -0.15 (0.073) [51]  |
| Pain/discomfort                                        | -0.30 (0.067) [52]              | -0.22 (0.068) [51]  |
| Anxiety/depression                                     | -0.17 (0.070) [52]              | -0.03 (0.071) [51]  |
| ∆ WPAI, LSM (SE) [N1] b                                |                                 |                     |
| Percent work time missed due to health problem         | -5.19 (1.488) [35]              | -1.40 (1.642) [29]  |
| Percent impairment while working due to health problem | -20.91 (3.394)* [36]            | -6.09 (3.780) [29]  |
| Percent overall work impairment due to health problem  | -21.67 (3.570)* [35]            | -5.39 (3.916) [29]  |
| Percent inactivity due to health problem               | -19.46 (3.131)** [50]           | -11.22 (3.270) [46] |
| ∆ SPARCC MRI spine, LSM (SE) [N1] b,g                  | -5.51 (1.063)** [52]            | -0.09 (1.085) [51]  |
| ∆ SPARCC MRI SI Joint, LSM (SE) [N1] b                 | -3.15 (0.788)* [52]             | -0.81 (0.806) [51]  |
| ∆ ASspiMRI, LSM (SE) [N1] b                            | -2.22 (0.364)** [52]            | -0.41 (0.372) [51]  |

Nominal *p≤0.05; **p&lt;0.001 tofacitinib 5 mg BID versus placebo at Week 12

N1 = number of patients evaluable at Week 12

a. NRI/LOCF Mixed Components

b. ANCOVA model includes fixed effects for treatment group and baseline value as a covariate with LOCF for imputing missing values.

c. The fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value were included, an unstructured covariance matrix was used.

d. ASDAS clinically important improvement is defined as change (decrease) from baseline of ≥1.1 units.

e. ASDAS major improvement is defined as change (decrease) from baseline of ≥2.0 units.

f. ASDAS inactive disease is defined as ASDAS &lt;1.3 units

<div style=\"page-break-after: always\"></div>

| Tofacitinib 5 mg BID   | Placebo   |
|------------------------|-----------|
|                        | (N = 51)  |
| (N = 52)               |           |

g. Index of disease activity score of the spine at Week 12

Figure 22. Line Graph of ASAS20 Response Rate (+/- SE) (Normal Approximation) by Visit Up to Week 12 -FAS, NRI/LOCF Mixed Components - Study A3921119

<!-- image -->

Figure 23. Line Graph of ASAS40 Response Rate (+/- SE) (Normal Approximation) by Visit Up to Week 12 -FAS, NRI/LOCF Mixed Components - Study A3921119

<!-- image -->

In the Phase 2 dose-ranging Study A3921119, at Week 12 patients with active AS receiving tofacitinib 2 mg, 5 mg, or 10 mg IR BID had a respective estimated ASAS20 response rate of 56.0%, 63.0%, or 67.4% compared to an estimated placebo response rate of 40.1% (primary analysis using an Emax model). Therefore, only the tofacitinib 10 mg BID treatment group met pre-specified statistical decision rules for the primary endpoint of the ASAS20, with an estimated difference from placebo of 27.3%, a 20.3% difference for the lower bound of the 2-sided 60% credible interval, and a 33.0% difference for the upper bound of the 2-sided 50% credible interval. Results from supportive analysis using the normal

<div style=\"page-break-after: always\"></div>

approximation method showed the ASAS20 response rate of 51.9%, 80.8%, 55.8% for tofacitinib 2 mg, 5 mg, and 10 mg BID, respectively, and 41.2% for placebo. Only the difference between tofacitinib 5 mg BID and placebo was statistically  significant  (p&lt;0.001).  Across  most  of  the  secondary  endpoint pertaining  to  disease  activity  and  physical  functions,  health  related  outcomes  and  radiological progression, tofacitinib 5 mg showed to be more effective than placebo, supporting results from phase 3 pivotal study. Regarding spinal mobility, which is an important efficacy parameter to support ASAS as primary endpoint (see also comment above on pivotal study), a major change in Linear BASMI Score at week 12 was observed in tofacitinib 5 mg BID group (-0.39) compared to placebo group (-0.15) which however did not reach the statistical significance, as well as the other spinal mobility score used to evaluate chest expansion (0.49 vs 0.31). Moreover, for other more stringent endpoint at week 12 such as ASAS partial remission, ASDAS major improvement and ASDAS inactive disease for tofacitinib 5 mg BID there were no statistically significant differences from placebo, although a slightly greater response rate was observed.

## Efficacy of Tofacitinib PR 11 mg QD in RA

The tofacitinib  PR  formulation  was  evaluated  in  the  RA  clinical  programme.  Brief  summaries  of  the efficacy results are reported below.

Study A3921215 was a completed Phase 3 Japan-specific study comparing head-to-head the tofacitinib tablet formulations of PR (11 mg QD) to IR (5 mg BID). Although, this study did not meet the noninferiority margin based on the stringent criteria (0.6 for the treatment difference of tofacitinib PR 11 mg QD versus IR 5 mg BID) requested by the Japanese Pharmaceutical and Medical Devices Agency, the point estimate of the difference in efficacy between the PR and IR formulations, based on the primary endpoint of DAS28, was within the pre-specified margin. While the data from this study are not sufficient to  conclude  statistical  similarity,  they  also  do  not  allow  conclusion  of  a  clinically  relevant  difference between the formulations. The results from this study support the following:

- Both  IR  and  PR  formulations  have  meaningful  efficacy  consistent  with  the  similarity  in  PK parameters between the formulations and previously established E-R relationships in patients with RA.
- The observed PR efficacy  results  were  well  aligned  with  the  model  predicted  dose-response profile  from  Phase  2  studies  with  the  IR  formulation  in  Japanese  patients  who  have  RA. Comparable and clinically meaningful responses at Week 12 were observed for both treatment arms.  Whilst  there  were  increased  responses  for  some  endpoints  for  IR  versus  PR,  these differences were not clinically relevant when considering an EU population. As noted in the RA PR CHMP assessment report (EMA/H/C/004214/X/0012 CHMP Assessment Report Section 2.5.3), it is possible that efficacy responses (JAK1 inhibition) are also increased in Japanese patients. Based  on  the  limited  comparison  of  baseline  characteristics  with  EU  patients  from  an international collaboration of RA registers, there is evidence that the A3921215 study population is not that generalisable to an EU RA population. In addition, the double-dummy design meant that patients on PR who were non-adherent were more likely to miss their entire daily dose than they would be in the real world (when they are not taking a dummy tablet). Therefore, there is uncertainty  when  extrapolating  the  observed  treatment  differences  to  an  un-blinded  EU population.

Study A3921192 was a global Phase 3b/4 study with a substantial number (N=355) of European patients that provided a global perspective on the efficacy and safety of PR formulation in patients with moderate to severe RA who were inadequate responders to MTX. This was a MTX withdraw study which included an open label run-in phase with all patients (N=694) treated with PR 11 mg QD + MTX; and a doubleblind phase during which patients that achieved LDA (low disease activity) were randomised (N=533) to

<div style=\"page-break-after: always\"></div>

either  continue  MTX  and  tofacitinib  PR  11  mg  QD  or  withdraw  MTX  and  receive  MTX  placebo  and tofacitinib 11 mg PR QD. The efficacy responses from both the open-label phase, and those from the double-blind  phase,  were  consistent  with  the  5  mg  IR  BID  data  from  previous  comparable  studies conducted with the IR formulation. The final data for Study A3921192 and the final CSR A3921192 were submitted during the RA PR procedure.

## Clinical Real-World Data for Patients with RA

## Corrona Effectiveness Report on Real World Data from US Corrona RA Registry

The US Corrona RA Registry provided tofacitinib PR data in the real world setting to supplement the clinical findings in the PR RA EU procedure. The US Corrona RA Registry comparative effectiveness study (A3921359) provided robust evidence from propensity-score based analyses, that in a real-world clinical population treated with tofacitinib, which included relatively more patients in a population considered more difficult to treat (TNFi experienced) than in RCTs, the PR and IR formulations behaved similarly with respect to effectiveness. The US Corrona RA Registry Study is now complete. The final analysis did not include additional efficacy analyses to compare PR to IR formulations because the number of patients did not substantially increase since the analysis for the previous submission.

## Observational Adherence Study A3921349

Study A3921349 was an observational adherence and effectiveness study conducted in an RA patient cohort within a US claims database that demonstrated greater patient adherence to tofacitinib 11 mg PR QD than patients initiating tofacitinib 5 mg IR BID, as well as comparable or higher effectiveness between 11 mg PR QD than 5 mg IR BID. These data were provided during the PR RA procedure

## Bridging Efficacy From Tofacitinib IR Formulation to PR Formulation for AS

Given the similarity of efficacy between the IR and PR formulations in RA, the demonstrated efficacy of the IR formulation in patients with AS, the similarity of PK parameters (equivalent AUC and Cmax, and slightly lower Cmin [29%]) between the IR and PR formulations, the Applicant believes that E-R analyses of efficacy data in AS patients that demonstrate the relevance of AUC for efficacy would provide an adequate basis for bridging IR to PR.

Therefore, the bridging of efficacy from tofacitinib IR 5 mg BID to tofacitinib PR 11 mg QD in AS patients is based upon E-R analyses of data from the 2 AS studies with the tofacitinib IR formulation supplemented by  i)  the  7  clinical  pharmacology  and  biopharmaceutic  studies  previously  provided  as  a  part  of  the approved tofacitinib RA PR Application, ii) the demonstrated E-R relationships in RA patients to bridge clinical efficacy data from the IR to the PR formulation and iii) the nonclinical E-R relationships previously demonstrated using the murine Collagen-Induced Arthritis (mCIA) inflammation model.

Briefly, as also described in the clinical pharmacology section, the application and subsequent approval for  the  use  of  tofacitinib  PR  11  mg  QD  in  RA  patients,  was  supported  by  the  following  clinical pharmacology and E-R evidence:

· Clinical pharmacology and biopharmaceutic studies in healthy patients demonstrated equivalent AUC and Cmax for the 11 mg PR formulation administered QD compared to the 5 mg IR formulation administered BID.

· E-R relationships from the tofacitinib IR RA Phase 2 studies, the contextualisation of efficacy in RA clinical trials using the PR formulation (A3921215 and A3921192) to the predicted E-R relationships based on the tofacitinib IR Phase 2 studies as well as nonclinical E-R modelling using mCIA data, also supported the conclusion of consistent efficacy between the 11 mg PR QD and 5 mg IR BID.

<div style=\"page-break-after: always\"></div>

Evaluations of the relationship between clinical efficacy and tofacitinib exposure (PK) from the  2 AS studies, A3921119 and A3921120, demonstrated that, as previously shown in RA and PsA patients, measures  reflective  of  overall  exposure  (i.e.,  Cavg  or  AUC)  are  the  exposure  metrics  most  closely associated with efficacy. Evidence includes:

- A delay (or time lag) in the attainment of steady-state clinical response in AS (just as the delay previously demonstrated for RA) relative to PK steady state.
- Characterisation of the relationship between tofacitinib exposure and clinical efficacy in adult patients with active AS using a Cavg-based E-R model.
- A similar prediction of efficacy using Cavg, Cmin, or Cmax as the exposure metric in the E-R model,  indicating  that  a  measure  of  overall  exposure  (such  as  Cavg)  can  adequately  describe  the observed efficacy responses, and metrics such as Cmin and Cmax (plasma concentrations at discrete time points) do not provide greater predictive value compared to Cavg.

The  E-R  evidence  supporting  the  bridging  of  efficacy  of  the  IR  formulation  (5  mg  BID)  to  the  PR formulation (11 mg QD) in patients with AS, is further described below.

## E-R of Efficacy in AS Patients using Cavg as the Relevant Parameter

As cytokine signalling promotes disease through the recruitment and activation of effector cells at sites of pathologic inflammation, the pharmacological effect of tofacitinib on clinical endpoints resulting from inhibition of cytokine signalling is indirect in all diseases where efficacy has been shown. Therefore, it is expected that clinical endpoints in these diseases, including AS, would be dependent on the overall average  tofacitinib  exposure  over  time,  as  measured  by  AUC  or  Cavg  (where  Cavg  =  AUC/dosing interval), and would not be significantly influenced by short-term fluctuations in plasma concentrations within the dosing interval. This was observed in RA and was supported by the E-R analyses provided in that population. This hypothesis is also supported in AS, as demonstrated by the E-R evidence using clinical data from the IR AS development programme as detailed below.

## Characterisation of Delay in Time Course of Efficacy Response in AS Patients

A longitudinal E-R analysis that evaluated the relationship between ASAS20 and ASAS40 response rates and tofacitinib exposure (Cavg) in AS patients after administration of tofacitinib IR doses of 2 mg, 5 mg or 10 mg BID using pooled data across 2 studies, A3921119 and A3921120, demonstrated a similar delay or time-lag in the attainment of steady-state clinical response as previously demonstrated for RA, compared to the attainment of PK steady state (24-48 hours)

<div style=\"page-break-after: always\"></div>

Figure 24. Longitudinal  Model-Predicted  ASAS20  and  ASAS40  Responses  in  bDMARDnaive AS Patients Pooled Across Studies A3921119 and A3921120

<!-- image -->

Source: Module 2.7.2, Figure 1.

Black solid squares correspond to observed ASAS20 or ASAS40 response rates, respectively. Blue line and  shaded  area  represent  median  and  95%  CI  of  estimated  ASAS20  or  ASAS40  response  rates, respectively.

The time of onset parameter from the longitudinal model was estimated to be 1.18 weeks demonstrating that following an early onset of efficacy by Week 2, the drug effect continues to increase up to Week 8. Placebo-corrected estimates of ASAS20 response rates after tofacitinib 5 mg IR BID were 28%, 31%, and 32%, at Week 4, 6, and 8, respectively, in AS patients who were bDMARD-naive, indicating that efficacy continued to increase beyond Week 4 and approached steady state (plateau) after Week 8. In the applicant's view t his delay in the attainment of efficacy (PD) steady state, compared to PK steady state, indicates that within-day fluctuations in the PK profile of tofacitinib and differences in the plasma concentration-time course between 5 mg IR BID and 11 mg PR QD are unlikely to confer differential effectiveness in AS. These data are consistent with the estimated onset half-life for clinical responses in RA and in PsA. The longitudinal E-R relationship in AS supports the conclusion that Cavg is the relevant parameter for efficacy and that the 29% lower Cmin for the PR formulation is not relevant to efficacy in AS.

## Assessment of the E-R of Efficacy Using Different PK Parameters in AS Patients

The predictive abilities of different tofacitinib exposure metrics were previously evaluated using data from  RA  patients.  These  evaluations  identified  Cavg  as  the  most  relevant  PK  parameter  in  the characterisation of E-R relationships of clinical response despite the high correlation among Cavg, Cmin, and Cmax. Furthermore, it was seen that Cmin did not provide additive predictive value over and above that of Cavg.

Based on this prior knowledge from the RA programme, a longitudinal ordered categorical E-R model was used to characterise the relationship between ASAS20 and ASAS40 responses in AS patients and tofacitinib  exposures,  using  Cavg  estimates  as  the  predictor  variable.  Model-predicted  estimates  of ASAS20 and ASAS40 were 67% and 44%, respectively after tofacitinib 5 mg BID in bDMARD-naive AS patients at Week 16. The predicted placebo-corrected estimates were 32% and 28%, respectively.

<div style=\"page-break-after: always\"></div>

Additionally,  in  order  to  compare  exposure  metrics,  E-R  models  using  Cavg,  Cmin,  or  Cmax  as  the predictor (univariate analysis) were assessed within the AS E-R dataset. Although this assessment did not show differences in model diagnostics that would identify any 1 exposure parameter (Cavg, Cmin, or Cmax) as more relevant than another for clinical efficacy due to the high correlation between the PK parameters (i.e., correlation coefficient = 0.85 between Cavg and Cmin), in applicant's view the results suggest that a measure of overall exposure (such as Cavg) can adequately describe the observed efficacy responses, and metrics such as Cmin and Cmax (plasma concentrations at discrete time points) do not provide greater predictive value compared to Cavg in AS. This is consistent with the indirect mechanism of action of tofacitinib as well as the demonstrated lag between the time to attain steady-state clinical response (PD) versus PK.

## Nonclinical Dose Fractionation Study

The non-clinical mCIA experiment which had previously demonstrated the superiority of Cavg over other PK parameters in predicting anti-inflammatory effect, is considered applicable to AS, as it is to RA in applicant's view . The dose-fractionation technique employed in this experiment was successfully used in other therapeutic areas to delineate the relative effect of various PK parameters on response. Results from this model could be informative of the E-R relationship in AS patients, given some level of similarity of disease pathogenesis and mechanism of action of tofacitinib between AS and RA.

## Summary of Efficacy Bridging

In conclusion, given that the efficacy of tofacitinib IR in AS has been demonstrated, the bridging of efficacy from tofacitinib IR (5 mg BID) to the PR formulation (11 mg QD) in AS patients, is supported in applicant's view by the following totality of E-R evidence:

- Previously  provided  results  from  Phase  1  studies  that  have  demonstrated  similarity  of  PK parameters between 11 mg PR QD and 5 mg IR BID (equivalent AUC and Cmax and slightly lower Cmin).
- Previously provided E-R analyses in RA have demonstrated that a metric of overall exposure (Cavg or AUC) is the relevant PK parameter to predict efficacy of tofacitinib.
- E-R analyses using efficacy data for the IR formulation in AS patients (ASAS20 and ASAS40 response rates) demonstrated that measurements reflective of Cavg are the exposure metrics most closely associated with efficacy.
- The time delay in the attainment of tofacitinib clinical response steady state versus PK steady state are consistent across multiple JAK-mediated inflammatory disorders including RA, PsA, and in AS supporting the conclusion that a measure of overall exposure (eg, AUC or Cavg) is the relevant parameter for efficacy, regardless of indication.

## 2.4.3. Discussion on clinical efficacy

No comparative clinical efficacy data with tofacitinib 11 mg PR formulation in SA patients have been provided within this application in order to demonstrate that the new modified release formulation is as effective as the existing IR formulation. However, given that the efficacy of tofacitinib IR formulation (5 mg BID) in AS has been demonstrated within the previous application (II/35), the MAH has proposed a bridging of the efficacy of tofacitinib IR formulation (5 mg BID) in AS to the PR formulation.

<div style=\"page-break-after: always\"></div>

The efficacy of IR 5 mg in AS bid has been demonstrated based on two studies (one phase 3 and one phase 2 study), as reported below. Similarly, the tofacitinib 11 mg PR QD formulation was assessed during the RA clinical programme and approved on the basis of the studies reported below.

## Design and conduct of clinical studies

## Tofacitinib IR 5 mg BID in AS

In support of tofacitinib IR 5 mg BID in the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy, the MAH provided: i) supportive data from  Study  A3921119  a  phase  2,  multicenter,  randomised,  double-blind,  placebo-controlled  dose ranging, parallel group efficacy and safety study designed to characterize the dose response of tofacitinib 2 mg BID, 5 mg BID and 10 mg BID in patients with active AS who had experienced an inadequate response  to  NSAIDs  and  were  naïve  to  previous  bDMARDs;  dose  of  5mg  BID  was  selected;  ii) confirmatory evidence from one pivotal study A3921120, a phase 3, randomized, double-blind, placebocontrolled, parallel group comparing tofacitinib 5mg dosed twice daily to placebo in subjects with active AS, who had experienced an inadequate response to NSAIDs (NSAID-IR) and were additionally either naïve to previous bDMARDs, or TNFi-IR or experienced to previous bDMARDs but without inadequate response (bDMARD Use [Non-IR]).  The study design included a 16-week double-blind treatment period, a 32-week open-label treatment period (all subjects were assigned to open-label tofacitinib 5 mg BID to Week 48) and a 28-day follow-up period (duration of participation for eligible subjects was approximately 56 weeks).

The  design  of  the  pivotal  study  could  be  acceptable,  however  since  tofacitinib  belongs  to  a  new therapeutic class for the AS indication and the study includes biological naïve patients a three-arm trial (including an accepted active comparator) would have been recommended as per the EMA guideline on the Clinical Investigation of Medicinal products for the treatment of Axial Spondyloarthritis (EMA/CPMP/EWP/4891/03 Rev.1, Corr 1*) , particularly for assessing a relative B/R balance. However, the MAH has performed a meta-analysis of approved treatments and also included the results of the tofacitinib trials (dose-finding and pivotal study) as supportive data.

The duration of the maintenance period is in line with the guideline although a longer OL period would have been recommended for assessing structural changes. Dose reduction/changing dose interval in ankylosing spondylitis (AS) patients after resolution of inflammation following tofacitinib treatment has not been evaluated and there are no data supporting changing dose interval, which has been acceptable. The  study  included  subjects  with  active  AS  defined  as:  Modified  New  York  Criteria  for  Ankylosing Spondylitis (1984), BASDAI score of ≥4 and back pain score (BASDAI Question 2) of ≥4 at both screening and baseline and that have had an inadequate response to at least 2 different NSAIDs. Additionally, bDMARD naïve, TNFi-IR, or bDMARD (non-IR) exposed were enrolled in this study.

Overall inclusion and exclusion criteria are adequate for selecting an active AS population and also for taking into account the safety profile of the drug.

The proportion of bDMARD-naïve and TNFi-IR or bDMARD use (non-IR i.e., discontinued the bDMARD due to other reasons than lack of efficacy or intolerance) was of approximately 80%/20%. Randomisation was stratified by prior treatment history: (1) bDMARD-naive and (2) TNFi-IR or bDMARD use (non-IR). From the Clinical Overview and from what can be derived from clinicaltrials.gov, it appears that no studies with tofacitinib in patients with non-radiographic axial spondyloarthritis are being performed. Upon request the MAH specified that at present there are no plans to conduct tofacitinib studies for patients with non-radiographic axial spondyloarthritis and therefore will not be applying for this subindication/therapeutic  claim.  Moreover,  criteria  for  defining  previous  or  concomitant  allowed,  or prohibited therapies and stable doses are considered acceptable. The MAH specified the criteria for using rescue therapy in both studies. The agents allowed (acetaminophen/paracetamol, opioid agents) were

<div style=\"page-break-after: always\"></div>

used primarily to relieve pain conditions and it seems to be unlikely that they could have affected the clinical course or the outcome of the disease, also considering that subjects were not dosed with rescue medication during the 24 hours prior to a study visit and that a small number of subjects used rescue therapy.

The study evaluates 1 primary endpoint, 1 key secondary endpoint, and other 20 secondary endpoints; moreover,  the  statistical  analysis  includes  3  estimands  for  binary  endpoint,  and  2  estimands  for continuous  secondary  endpoints.  This  choice  is  considered  suboptimal.  A  statistical  planning  more focussed on the relevant estimations by using more robust approaches would have been preferable.

The primary endpoint of the study was ASAS20 response at week 16. This is not in line with the current Guideline on the Clinical Investigation of Medicinal products for the treatment of Axial Spondyloarthritis (EMA/CPMP/EWP/4891/03  Rev.1,  Corr  1*) stating  that  the  ASAS  40  response  is  preferred  primary endpoint  for  biological  medicinal  products  or  products  from  a  new  therapeutic  class,  as  a  higher magnitude of the clinical response are expected. It is disappointing that the MAH did not seek advice to EMA on this choice nor considered a separate statistical analysis plans (SAPs), each using the endpoint preferred  by  the  approving  regulatory  agency.    ASAS40  was  therefore  defined  as  key  secondary endpoint.

The use of the Cochran-Mantel-Haenszel (CMH) test stratified by the randomization strata (bDMARDnaïve,  TNFi-IR  or  bDMARD  use)  for  the  analysis  of  the  primary  efficacy  endpoint  (ASAS20)  is acknowledged.

Numerous  secondary  endpoints  have  been  proposed.  However,  the  established  hierarchy  and  the absence  of  some  important  endpoint      assessing  the  clinical  benefit  of  the  drug  as  also  clearly recommended in the EMA GL is not completely understood. Analyses of key secondary endpoints using MMRM or ANCOVA models are recognized as adequate.

It should be noted that no endpoint that could monitor structural changes, as highly recommended in the EMA GL was included.

The MAH justified the lack of endpoints monitoring structural changes in Study A3921120 stating that the study design for Study A3921120 was not considered of sufficient duration to provide evidence of structural changes relative to placebo using radiography (modified Stoke Ankylosing Spondylitis Spinal Score [mSASS]) given that the placebo period was only of 16 weeks duration and the entire treatment duration was 48 weeks.

Sample size calculation for pivotal phase III study A3921120 was based on the response rate found in phase 2 dose-ranging, proof  of  concept  trial.  It  is  recognized  as  appropriate,  although  the  primary efficacy  endpoint  was  then  analysed  by  the  Cochran-Mantel-Haenszel  (CMH)  test  stratified  by  the randomization strata (prior treatment history).

A total of 269 patients in the A3921120 were treated and included in the FAS and 133 received tofacitinib 5 mg bid. Patient's disposition was balanced across the study.  The great majority completed the DB 16 weeks phase. A higher but similar number of subjects discontinued study drug up to 48 weeks: 15 in the Tofa-Tofa and 14 in the PLB-Tofa arm; the main reasons of discontinuation being the same safety and lack of efficacy although a higher number is registered in the Tofa-Tofa (8 and 6, respectively) as compared to PLB-Tofa (3 and 4) group.

Demographic and baseline characteristics were quite balanced between the two arms and representative of the target population i.e., active AS.  The majority of patients were white males with a mean age of 41 years. Patients from Europe were adequately represented being about 40% although enrolment was exclusively done in few countries.

Enrolled subjects had an active disease status as well indicated by a median value of 6.5 in BASDAI, of 3.9 in ASDAS (CRP) and a Patient's Assessment of Total Back Pain (NRS) and nocturnal spinal pain of 7.

<div style=\"page-break-after: always\"></div>

An involvement of the spine as shown by the spinal mobility index BASMI (mean 4.5, range 0-10) and chest expansion (mean 3, range 0-12, enthesis involvement in roughly 50% of subjects and swollen joints in slightly less than 30% and impaired quality of life i.e., ASQoL (mean 11-11.5, range 0-18). Considering  ASDAS  (CRP)  score,  the  majority  of  patients  (66.5%)  had  a  very  high  disease  activity [ASDAS (CRP) &gt;3.5] with an imbalance between tofacitinib and placebo group with a slightly higher number of patients (70.6%) with very high disease activity as compared to tofacitinib group (62.4%). According to the more recent EULAR management recommendations for axial spondyloarthritis (2016), ASDAS is considered a relevant measure to assess disease activity (it correlates far better with both patients' and physicians' level of disease activity) and an elevated ASDAS index is considered more predictive of a good response than an elevated BASDAI. Therefore, the higher representativeness of subjects with very high disease activity according to ASDAS(CRP) in the placebo arm could impact the response.

Patients were generally balanced across treatment groups in their csDMARD (57.1% for tofacitinib 5 mg BID group to 60.3% for placebo group), oral corticosteroid (14.3% to 11.0%), and NSAID (100.0% to 99.3%) use at baseline. The majority of patients were positive for HLA-B27 (87.4% of subjects) and the median AS diagnosis duration was of 4.9 years (range: 0.1, 42.8).

A minority of patients had extra-articular manifestations at baseline. Regarding peripheral arthritis, the number of patients with current symptoms in tofacitinib and placebo groups were respectively 19 and 26 corresponding to 86.4% and 89.7% of subjects with history of peripheral arthritis. Moreover, a higher percentage of subjects with any csDMARDs was observed in placebo group than in tofacitinib group (33% vs 22%) probably reflecting a higher number of patients with a history of peripheral arthritis (18.4% vs 15.8%).      However,  no  meaningful  differences  were  noted  between  patients  with  and  without concomitant csDMARDs with regard to ASAS40 and ASDAS(CRP) endpoints as well as with and without swollen joints. A slightly higher response in ASAS20 endpoint, a less stringent endpoint, was observed in  tofacitinib  group  with  concomitant  csDMARDs  (diff  from  plb:  30.88)  compared  to  those  without concomitant csDMARDs (diff from plb: 26.76), with the trend in favour of tofacitinib.

Almost all patients (99.6%) received prior NSAIDs, and a minor rate of patients received corticosteroids (16%). However, it was noted that a higher number of subjects was treated with corticosteroids in tofacitinib  5  mg  (19.5%)  compared  to  placebo  group  (12.5%)  both  with  oral  and  intrarticular administration, suggesting possible more severe manifestations. Moreover, this imbalance was mainly observed in highly treated patients (TNFi-IR and bDMARD use [non-IR]), in which a higher percentage of subjects in the tofacitinib 5 mg BID group (19.4%) compared to placebo (6.5%) had prior use of oral corticosteroids and this is expected likely due to a more difficult to treat disease. No important differences were reported in previous csDMARDs use. The majority of patients were bDMARDs naïve (77%) with a similar distribution between the two groups. A minor number of patients (31 subjects in each arm, 23%) were bDMARDs experienced (bDMARDs use or TNFi-IR), 2 subjects were bDMARDs use non-IR.

Concomitant  rescue  medications,  NSAIDs,  oral  corticosteroids,  intra-articular  corticosteroids,  and csDMARDs were taken by a similar proportion of subjects between treatment groups at baseline up to Week 48.

## Tofacitinib 11 mg PR QD in RA

Clinical efficacy data in the tofacitinib 11 mg PR QD formulation was provided from the phase 3 study A3921215  (a  phase  3,  12-week,  randomised,  double-blind,  parallel  group,  multicentre  study  to demonstrate non-inferiority for the efficacy of tofacitinib MR 11 mg QD compared to IR 5 mg BID in adult Japanese patients with RA on stable background MTX). In addition, the applicant has also provided single arm efficacy data from a US/EU study (study A3921192), observational comparative efficacy data from a US registry (CORRONA), and adherence data from a US insurance database retrospective cohort study (study A3921349) (data assessed in EMEA/H/C/004214/X/0012).

<div style=\"page-break-after: always\"></div>

## Efficacy data and additional analyses

## Tofacitinib IR 5 mg BID in AS

Primary endpoint: a statistically significant higher proportion of patients in the tofacitinib 5 mg BID group reached ASAS20 at week 16 in comparison to the placebo group (56.4% vs 29.4%, p&lt;0.0001), with a treatment difference of 27.08 (95% CI: 15.89, 38.28), which is in line with the 20% difference expected in the sample size calculation. Moreover, the primary analysis is supported by results from all the pre-specified supportive analyses.

ASAS20 is a weaker endpoint compared to the more stringent ASAS40, which is preferred by the EMA guidelines. The choice of ASAS20 has been discussed and agreed with FDA and not with EMA. ASAS40 has been used as the key secondary endpoint and this was also met from a statistical perspective with a higher response rate of subjects in tofacitinib 5 mg BID group (40.6%) compared to placebo group (12.5%) at week 16 (difference of 28.17, 95% CI: 18.26, 38.09 p&lt; 0.0001). The effect size being very similar to that observed for ASAS20. A post-hoc analysis for ASAS20 at week 16 has been provided for the main subgroups showing no important differences except for geographic region of North America in which a smaller difference between tofacitinib 5 mg and placebo is seen (however, the small sample size of this subgroup hampers any firm conclusion) and body weight. In the subgroup with a body weight &gt;100 kg the estimate of the treatment effect based on ASAS40 was -13% in favour of placebo. The MAH considers that the trend of ASAS40 at Week 16 in the Study A3921120 participants with a body weight &gt;100 kg is most likely explained by the small sample size (10 and 18 patients, respectively in placebo and tofacitinib groups). This was not seen in the subgroup analysis of body weight and ASAS20, where the treatment effect was 20% in patients &gt;100kg, 27% in patients 60-100kg and 38% in patients &lt;60kg. The treatment effect in the highest BMI classes was in line with the other results, for ASAS20 as well as ASAS40.

Moreover, no major differences in tofacitinib exposure over the range of body weights studied were reported and no clinically significant decrease in efficacy of tofacitinib has been observed in &gt;100 kg RA patients and according to SmPC section 5.2, systemic exposure (AUC) of tofacitinib in the extremes of body weight (40 kg, 140 kg) were similar (within 5%) to that of a 70 kg patient. Therefore, changes in the SmPC are not warranted at present.

A higher efficacy of tofacitinib 5 mg compared to placebo was observed in the subgroups with very high disease activity (ASDAS (CRP)&gt;3.5) (∆ 35.43 vs 12.61 of p atients with high disease activity) and higher baseline hsCRP (&gt;2.87 mg/L) (∆ 28.95 vs 17.02 of patients with lower baseline hsCRP), suggesting that tofacitinib could perform better in this target population. The same figure was also observed for ASAS40 endpoint.

For both ASAS20 and ASAS40 a better response rate between study drug and placebo is reported in bDMARDs naïve compared to TNF-IR subjects or bDMARD use [non-IR] (difference form placebo 28 versus 22.5 and 28.4 versus 23 for ASAS20 and 40, respectively; in the TNF-IR or bDMARD use due to the limited sample size wide CI are seen); the better performance of the active drug is clinically expected in bDMARD naïve patients. Results according to bDMARDs naïve or TNF-IR subjects/bDMARD use [nonIR] subgroups have been included in 5.1 section of the SmPC, in order to guide prescribers.

Many secondary endpoints (21, 1 key) controlled for multiplicity (step-down testing procedure with a fixed alpha level for each comparison at the 2-sided 5%) were selected by the MAH.

Secondary endpoint: ASDAS (CRP) is a validated and accepted method to assess disease activity and physical function considered a very important disease activity score a clinically important improvement of ≥1.1 is required to define a response. The LS mean change from baseline in ASDAS(CRP) showed a statistically significant decrease for tofacitinib 5 mg BID compared to placebo at Week 16 (-1.36 in the tofa arm and -0.39 in the PLB arm at week 16, delta of -0.98, p &lt;0.0001, FAS on drug data estimand

<div style=\"page-break-after: always\"></div>

4),  the  achieved difference was clinically relevant. Consistent results were shown by the supportive analysis (MMRM, Estimand 5, FAS, on-study data, no imputation) were consistent with the on-drug data. At week 48 improvement of ASDAS(CRP) from baseline is still seen in both arms similarly -1.70 and 1.50 for the TOFA-TOFA and PLB-TOFA, respectively.

However, as per EMA GL, to facilitate interpretation of the clinical relevance of the observed effect, responder analyses are preferable over mean absolute changes. The MAH has provided these analyses for secondary endpoints not controlled for type I error so results are only descriptive/supportive including ASDAS clinically important improvement (61.3 versus 19.1 delta 42.3), ASDAS major improvement (30 versus 4.6 delta 25.3), ASDAS inactive disease (6.7 versus 0 delta 6.7) at week 16 overall showing a greater response in the Tofa arm which is maintained at week 48 and with an effect size of clinical significance for endpoint measuring improvement. In view of available treatments for ax SpA, disease remission is increasingly regarded as an appropriate therapeutic goal, no validate definition still exists. Therefore, endpoints aimed at assessing low disease activity or partial remission are considered of key importance for establishing the clinical benefit of a drug meant for axial SpA treatment as highlighted by EMA GL. ASDAS inactive disease (6.7 versus 0 delta 6.7, p 0 ˂ 0.05) at week 16  and ASAS partial remission (a value of =2 (on a 0 to 10 scale) present in each domain, 15 versus 3, p 0 ˂ 0.001) were assessed  only  as  part  of  secondary  not  controlled  endpoints  showing  very/limited  effect  size  when inactive disease/partial remission was the goal, of interest is an increase of responders at week 48 (roughly 13-15% for ASDAS inactive and 18-23% for ASAS partial remission.

In  the  hierarchical  order  as  second  endpoint  the  MAH  selected  the  Change  from  baseline  of  an inflammatory marker i.e., hsCRP at Week 16 showing statistically significant decreases for tofacitinib 5 mg BID compared to placebo at Week 16 (-1.05 versus -0.09, p &lt;0.0001) based on the MMRM analysis (Estimand 4). Importantly this endpoint is not considered key for demonstration of tofacitinib clinical benefit but only regarded as supportive for effect on inflammation since no data support this biomarker as useful surrogate to assess efficacy in axial SpA.

## Patient reported outcomes

Descending in the established order there is the change in Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire (total scores range from 0 to 18, with higher scores representing worse QoL) at week 16 showing an improvement at week 16 (tofa -4 versus PLB -2 and increasing at -6 and -5 at week 48). The ASQoL is an AS specific QoL measure and improvement of this disease domain is within treatment objectives and as such patient reported outcomes and quality of life evaluation may also be considered as secondary endpoints as per EMA GL. The MAH gave priority to these QOL endpoints (3 out of 6 of type I controlled endpoints) over other endpoints. To support the validity of these three outcomes, the MAH has provided a study report summarising the psychometric properties of these QoL measures. These are used in SA and considered useful for the assessment of QoL, and overall results support clinically meaningful changes.

The inclusion among secondary endpoints (type I controlled) of a measure of spinal mobility i.e., BASMI: Linear BASMI (BASMI lin) composite score change at week 16, is supported being a relevant efficacy parameter in axial SpA. In particular, when ASAS is used as primary endpoint, as in this case, since this index does not include the assessment of the spine mobility should be supplemented with the assessment of spinal mobility as a secondary endpoint. Results showed a change at week 16 of -0.63 versus -0.11 for Tofa and PLB, respectively; similar change (-0.6-0.7) at week 48 in both arms showing a statistical significance  p  0.001  but  not  a  clinically  relevant  difference  for  which  improvement  of  &gt;  1  point  is expected. Another endpoint assessing spinal mobility i.e., change of spinal mobility (chest expansion, score 0-12) at week 16 was included with secondary endpoints not controlled for type I error showing a change of 0.59 versus 0.21 in the Tofa and PLB arm, not significant. Overall results on spinal mobility, which is an important domain of axSpA are not robust as those evaluating tofacitinib efficacy on sign and symptoms/inflammation of the disease.

<div style=\"page-break-after: always\"></div>

The individual components of the ASAS responses have been included within secondary endpoints (type I controlled) in general showing a consistent and similar (delta of -1.5-1.7 at week 16) improvement slightly higher at week 48 for all the components.

ASAS20 and 40 responses over time: the onset of efficacy for tofacitinib 5 mg BID was seen early in the ASAS20 and ASAS40 response rates. Tofacitinib 5 mg BID become superior to placebo at Week 2 for ASAS20 response rate and at Week 4 for ASAS40 response rate and was sustained after Week 16 to the end of the study (Week 48). However, a slightly decrease was noted at week 16 as compared to week 12, -7.5% for ASAS20 (from 63.91% at week 12 to 56.39 at week 16) and -2.3% for ASAS40, although subsequently increased again at week 24 reaching a plateau thereafter. The reduction observed at week 16 has been clarified by the MAH by given a plausible response assuming that the observed trend was due  to  a  random  variability,  since  ASAS20  comprises  subjective  (patient-reported)  components. However,  it  should  be  noted  that  a  \"real\"  decrease  may  have  occurred.  Moreover,  considering  the ASAS20 response rate, the same trend was observed with both Estimand 1 (on-drug data) and Estimand 2 (on-study data), with only 4/133 (3%) subjects discontinuing the investigational product; therefore, the intercurrent event of discontinuation which classifies the subject as non-responder for the visit of interest shouldn't have impacted the response rate at week 16. The issue was not further pursued.

According to the ASAS40 and all other secondary outcomes over time, the effect was maintained. In the group that was originally allocated to tofacitinib, the ASAS40 response at week 16 was 41%, which increased to 50% at week 48. In the patient group that was on placebo at week 16 and switched to tofacitinib, the proportion of patients with an ASAS40 response increased over time to 45% at week 48. Nevertheless,  the  increasing  response  after  week  16,  the  Applicant  was  asked  to  analyse  the  new occurrences of response over time, and to discuss the inclusion of a statement in the SmPC about when to stop tofacitinib if no response occurred. An update of the 4.2 section of the SmPC suggesting to carefully reconsidering to continue therapy in patients exhibiting no clinical improvement within 16 weeks was added.

The EMA GL recommends using as secondary endpoints if not selected as primary endpoints, measures of disease activity such as the ASAS 5/6 as well as the peripheral tender joints and swollen joint count which were included by the MAH only as secondary (not controlled type I error) endpoints. ASAS 5/6 results are consistent with those of the primary and key secondary endpoint showing a statistical and clinically relevant improvement (44% responders, delta of 36 at week 16 and maintained at week 48).

As measure of improvement of enthesitis the MAH had included the change in MASES index (total score ranging 0 -13) at week 16 as not controlled secondary endpoint showing an improvement of -2 versus -1.41, delta of -0.53 slightly increasing at week 48. Therefore, no significant statistical difference has been shown for this domain of the disease.

Other  measures  of  symptoms  and  physical  function  recommended  which  has  been  included  within secondary endpoints not controlled for multiplicity is the change of BASDAI at week 16 (showing an improvement of -2.55 at week 16 delta of -1.44). However, this is a widely used measure of disease activity  and  its  changes  with  treatment  should  be  assessed  as  secondary  endpoint.  Moreover,  the percentage of patients with clinical response as measured by an improvement of at least a 50% from the baseline score in BASDAI is considered useful to judge the clinical benefit of a treatment but was not included by the MAH.

Overall, results from Study A3921119 were supportive of the phase 3 study with regard to different endpoints pertaining to disease activity and physical functions, health related outcomes, spinal mobility.

## Indirect comparison with active treatments

The placebo-controlled trial did not include an active comparator. To indirectly compare the treatment effects of tofacitinib 5 mg BID with other treatments for AS, the MAH performed a systematic review and

<div style=\"page-break-after: always\"></div>

meta-analysis of placebo-controlled trials of EMA-approved biological DMARDs, including ASAS20/40 at week 12-16, in patients with AS with or without previous experience with biological DMARDs.

According  to  the  results,  ASAS20  and  ASAS40  responses  for  tofacitinib  5  mg  BID  across  Studies A3921119  and  A3921120,  were  similar  compared  with  adalimumab,  certolizumab,  etanercept, golimumab, infliximab, ixekizumab and secukinumab. The treatment effects on ASAS40 were 26% and 28% in the two tofacitinib trials, while the majority of treatment effects of the other biological DMARDs ranged  from  17%  (adalimumab,  COAST  V)  to  37%  (infliximab,  ASSERT).  The  MEASURE  4  trial  in secukinumab showed lower treatment effects than the other trials including MEASURE 2. MEASURE 1 and 3 were not included in the meta-analysis, because of the iv loading dose that was used in those trials, which is not in the approved posology of secukinumab.

## Tofacitinib 11 mg PR QD in RA

For Study A3921215, non-inferiority of the MR formulation to the IR formulation was not demonstrated according  to  the  pre-specified  margin  of  0.60  with  regard  to  the  primary  endpoint  of  change  from baseline  in  DAS28-4(CRP)  at  week  12.  Moreover,  although  ACR20  and  ACR50  response  rates  were comparable between the two formulations, the more stringent enspoints rates of remission (DAS284[CRP] or DAS28-4[ESR] &lt; 2.6) and ACR70 showed a statistically significant difference in favour of IR formulation. However, due to the possible increased efficacy responses (JAK1 inhibition) in Japanese patients and the limited comparison of baseline characteristics with EU patients from an international collaboration  of  RA  registers,  there  were  uncertainties  when  extrapolating  the  observed  treatment differences to an un-blinded EU population. Supportive studies were: a) Study A3921192 based on crosstrial  comparisons  with  blinded  RCTs,  11  mg  MR  QD  which  compared  favourably  with  5  mg  IR  BID, particularly at week 24, across a range of endpoints, including remission and ACR70. However, bias may remain due to differences in unknown factors between trials; b) CORRONA registry (updated analysis): an updated comprehensive sensitivity analysis (including data up to 31st August 2019) of the previously reported outcomes (30th September 2018) was performed and explore the effects of extending the window of the 6-month visit. The proportions achieving the primary outcome of MCID improvement in CDAI  from  initiation  to  6  months  were  27.6%  and  22.1%  in  the  11mg  MR  and  5  mg  IR  groups respectively (propensity score matched population). The adjusted odds ratio (95% CI) for improvement in the 11 mg MR group compared to the 5 mg BID group was 1.38 (0.81, 2.34). The results of supportive analyses were consistent with those in the propensity score matched population. The applicant has also provided analyses of change from baseline in CDAI. In the cohort with recent follow-up and a visit at 6 months ±3 months (cohort B), the mean (± SD) change in CDAI was -2.83 ± 13.93 and -2.71 ± 12.68 for MR and IR, respectively. The difference was 0.02 (95% CI: -2.31, 2.35). Supportive analyses in alternative matched and unmatched cohorts suggest close similarity between MR and IR; The MAH states that the US Corrona RA Registry Study is now complete, but the final analysis did not include additional efficacy analyses to compare PR to IR formulations because the number of patients did not substantially increase since the analysis for the previous submission c) Study A3921349 whose results suggested that after  12  months,  adherence  to  11mg  MR  QD  was  increased  compared  to  5  mg  IR  BID,  using  two measures of adherence.

The CHMP concluded that the RCT conducted in Japan suggested at less beneficial outcomes of the MR formulation to the IR formulation, particularly for the more stringent endpoints, but to an acceptable extent. However, due to higher variability of RA clinical endpoints compared to PK endpoints, the pivotal clinical study for this application was considered the comparative bioavailability study A3921212, whilst the clinical efficacy data were considered supportive. Therefore, comparable efficacy of the MR and IR formulations was expected based on the equivalent AUC at steady state and the observational registry data,  retrospective  adherence  data,  and  single  arm  US/EU  efficacy  data  were  compatible  with  the assumption of similar efficacy based on PK.

<div style=\"page-break-after: always\"></div>

No new efficacy data have been submitted within the current application. For discussion on the bridging strategy used in support of efficacy extrapolation in AS please refer to the section on clinical pharmacology.

## 2.4.4. Conclusions on the clinical efficacy

No comparative clinical efficacy and safety data with tofacitinib 11 mg PR formulation in SA patients have  been  provided  within  this  application  in  order  to  demonstrate  that  the  new  modified  release formulation is as safe and effective as the existing IR formulation. The MAH is supporting the extension of indication applying a bridging strategy of the efficacy of tofacitinib IR formulation (5 mg BID) in AS, which has been demonstrated (II/35), to the PR formulation relying on a well-defined E/R as considered in the EMA guideline on 'the pharmacokinetic and clinical evaluation of modified release dosage forms'.

Conclusion from tofacitinib IR 5 mg AS: a clinically relevant effect as measured by ASAS20/ASA40 has been demonstrated for tofacitinib IR 5 mg BD in the target population of adult patients  with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.  Most of the secondary endpoints measuring mainly signs and symptoms, inflammation and QoL endpoints provide supportive results. For other disease domains such as spinal mobility and enthesitis only limited or only a trend in effect was seen.

Conclusion from the 11 mg PR QD in RA population: the RCT conducted in Japan suggested at less beneficial  outcomes of the MR formulation to the IR formulation, particularly for the more stringent endpoints, the pivotal clinical study was considered the comparative bioavailability study A3921212, whilst the clinical efficacy data were considered supportive. Overall, comparable efficacy of the MR and IR formulations was expected based on the equivalent AUC at steady state and the observational registry data (CORRONA), retrospective adherence data (Study A3921349), and single arm US/EU efficacy data were compatible with the assumption of similar efficacy based on PK.

For conclusions on the bridging strategy used in support of efficacy extrapolation in AS please refer to the section on clinical pharmacology.

## 2.5. Clinical safety

## Introduction

No clinical studies with the PR formulation have been conducted in patients with AS.

As mentioned earlier, tofacitinib was approved in the EU at a dose of 5 mg IR BID on 22 Mar 2017 (MAA procedure EMEA/H/C/004214/0000) and at a dose of 11 mg PR QD on 16 Dec 2019 (MAA procedure EMEA/H/C/004214/X/0012) for the treatment of active moderate to severe RA in adult patients who have had an inadequate response or intolerance to MTX. The PR tablet formulation of tofacitinib was developed for patient 's convenience by enabling QD dosing as another oral treatment option for patients with AS.

The CHMP opinion was that the overall benefit/risk of tofacitinib 11 mg PR QD for patients with RA is favourable and that the efficacy and safety of the PR formulation in that population are expected to be comparable to that of the IR formulation based on totality of evidence (MAA procedure EMEA/H/C/004214/X/0012).

As described earlier, the approval of the PR formulation for RA was primarily based on a bridging strategy that demonstrated PK similarity between the PR and IR formulations as well as demonstrating the E-R relationships in RA patients, using the IR formulation.

<div style=\"page-break-after: always\"></div>

The MAH utilises the following totality of evidence approach to support the safety profile of tofacitinib 11 mg PR QD in patients with active AS:

- The previously established similar safety profile of tofacitinib 5 mg IR BID to 11 mg PR QD in patients with RA.
- The established safety profile of tofacitinib 5 mg IR BID in AS patients.
- The comparison of incidence rates of select AEs from the final integrated safety data for AS versus RA and PsA clinical development safety data demonstrated the overall safety profile of tofacitinib in AS is consistent with RA and PsA.
- Similar safety profile of PR in AS patients to the IR formulation is inferred as all exposure metrics for a QD regimen of the 11 mg PR formulation (e.g. Cmax, AUC, Cmin) are equivalent or slightly lower than those for a BID regimen using the 5 mg IR formulation.

Furthermore,  the  MAH  monitors  post-marketing  data  across  the  different  indications  and  for  both formulations.  The  MAH  notes  that  four  new  important  potential  risks  have  been  determined  for tofacitinib based on final data from Study A3921133: MACE, myocardial infarction, lymphoma, lung cancer. Study A3921133 was a Phase 3b/4 randomised, parallel-arm, open-label, safety endpoint study evaluating the safety of tofacitinib at 2 doses (5 mg BID and 10 mg BID) versus TNFi.

Of note, at the time of conclusion of this extension application the impact of the study A3921133 findings on tofacitinib safety and efficacy profile is being assessed in the parallel EMEA/HA20/1517/C/004214/0048 procedure.

In summary, in applicant's view the safety profile of the PR formulation characterised in RA patients is similar to that of the IR formulation and the PK and safety profile of tofacitinib 5 mg IR BID has shown to be consistent between indications (i.e., RA, PsA, and AS); therefore, the safety profile of tofacitinib 11 mg PR QD in patients with AS is expected to be similar to that of tofacitinib 5 mg IR BID in patients with AS. This is without prejudice to the outcome of the ongoing EMEA/H-A20/1517/C/004214/0048 procedure.

## Patient exposure

No AS patients have been exposed to tofacitinib PR formulations.

The next table provides an overview of the non-AS clinical trial populations used to determine the safety profile of tofacitinib 11 mg PR.

Table 41. Overview of safety populations in Non-AS clinical trials for PR and IR tablets

| Healthy volunteer PR Population   | Healthy volunteer PR Population   | RA PR Population                                                       | RA PR Population                                                       | RA P2P3 IR Population                          | RA P2P3 IR Population                          |
|-----------------------------------|-----------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Consists of 7 Phase 1 PK studies  | Consists of 7 Phase 1 PK studies  | Consists of 1 completed Phase 3 study and 1 completed Phase 3b/4 study | Consists of 1 completed Phase 3 study and 1 completed Phase 3b/4 study | Consists of completed Phase 2 and 3 IR studies | Consists of completed Phase 2 and 3 IR studies |
| Study Numbers                     | N (PY)                            | Study Numbers                                                          | N (PY)                                                                 | Study Numbers                                  | N (PY)                                         |
| A3921113                          | 172 (NA)                          | A3921215                                                               | 104 (NA)                                                               | RA P2P3                                        | 2664 (2476.66)                                 |
| A3921131                          |                                   | (11 mg PR QD                                                           |                                                                        | Studies (5 mg                                  |                                                |
| A3921132                          |                                   | arm)                                                                   |                                                                        | BID) described                                 |                                                |

<div style=\"page-break-after: always\"></div>

| Healthy volunteer PR Population   | RA PR Population      | RA P2P3 IR Population   |
|-----------------------------------|-----------------------|-------------------------|
| A3921163                          | A3921192 694 (539.29) | in Error!               |
| A3921180                          | 11 mg PR QD           | Reference               |
| A3921195                          |                       | source not              |
| A3921212                          |                       | found. .                |

Sources: RA PR Module 5.3.1.2 CSRs A3921113, A3921131, A3921132, A3921163, A3921212; RA PR Module 5.3.1.1 CSR A3921180; RA PR Module 5.3.1.3 CSR A3921195; UC PR Module 5.3.5.1 CSR A3921215 Table 14.1.2.1; Module 5.3.5.1 CSR A3921192 Table 14.1.1.1.1; Module 5.3.5.3 RA P2P3 Table 1571.2.1; Module 5.3.5.3 A3921192 Adhoc Analysis Table 1613.3.

RA P2P3: 01 Feb 2017 (final data)

RA P2P3 includes completed studies: A392-1019, -1025, -1032, -1035, -1039, -1040, -1044 (2 year data), -1045, -1046, 1064, -1068, -1069 (2 year data), -1073, -1129, -1187 and -1237.

## Adverse events

## Adverse events for (5 mg IR BID in AS)

The clinical safety profile of tofacitinib 5 mg IR BID in AS has been evaluated in the Phase 2 (A3921119) and Phase 3 (A3921120) clinical studies conducted in patients with AS.

The integrated safety analysis for AS IR is summarised in this document and, according to the MAH, is consistent with that for the RA and PsA clinical programmes with no new tofacitinib-related safety signals identified in AS patients.

There were no deaths in the AS programme and the incidence rates of SAEs and events of special interest in the AS programme, according to the MAH, were low and consistent with the rates seen in the RA and PsA safety datasets.

Therefore, most of the data presented from this point on, from the IR formulation, has been already included in the procedure for the IR formulation in AS patients (EMEA/H/C/004214/II/0035).

An overall summary of Treatment-Emergent Adverse Events in the AS Placebo-Controlled Cohort, for the IR formulation, is shown in the next table (Table 42).

Table 42 . Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) TreatmentEmergent Adverse Events (All Causalities) - Treatment Policy Estimand, AS Placebo-Controlled Cohort

| Number (%) of Subjects                                                        | Tofa 5 mg BID n (%)   | Placebo n (%)   |
|-------------------------------------------------------------------------------|-----------------------|-----------------|
| Subjects evaluable for adverse events                                         | 185                   | 187             |
| Number of adverse events                                                      | 205                   | 205             |
| Subjects with adverse events                                                  | 101 (54.6)            | 92 (49.2)       |
| Subjects with serious adverse events                                          | 3 (1.6)               | 2 (1.1)         |
| Subjects with severe adverse events                                           | 3 (1.6)               | 3 (1.6)         |
| Subjects discontinued from study due to adverse events (a)                    | 1 (0.5)               | 3 (1.6)         |
| Subjects discontinued study drug due to adverse events (b)                    | 4 (2.2)               | 4 (2.1)         |
| Subjects with dose reduced or temporary discontinuation due to adverse events | 12 (6.5)              | 6 (3.2)         |

<div style=\"page-break-after: always\"></div>

Table 42 . Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) TreatmentEmergent Adverse Events (All Causalities) - Treatment Policy Estimand, AS Placebo-Controlled Cohort

|                        | Tofa 5 mg BID   | Placebo   |
|------------------------|-----------------|-----------|
| Number (%) of Subjects | n (%)           | n (%)     |

The table is based on the data from OC AE only.

Except for the Number of Adverse Events subjects are counted only once per analysis group in each row.

(a) Subjects who have an AE record that indicates that the AE causes the subject to be discontinued from the study.

(b) Subjects who have an AE record that indicates that Action Taken with Study Treatment is Drug Withdrawn.

TEAE in A3921119 is defined as those on-treatment events which are new or worsened in severity relative to the pre-treatment period prior to Day 1.

TEAE in A3921120 is defined as those on-treatment events which start during the effective duration of treatment.

Percentages are calculated using number of subjects evaluable for adverse events as the denominator.

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adae Table Generation: 11NOV2020 (23:37)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCSPC\\_EU/adae\\_s010

Table C1.3.1.2.1-E is for Pfizer internal use.

The following table (Table 43) shows an overall summary in the AS All Tofa Cohort.

Table 43 . Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) TreatmentEmergent Adverse Events (All Causalities) - Treatment Policy Estimand, AS All Tofa Cohort

| Number (%) of Subjects                                                        | All Tofa 5 mg BID n (%)   | All Tofa n (%)   |
|-------------------------------------------------------------------------------|---------------------------|------------------|
| Subjects evaluable for adverse events                                         | 316                       | 420              |
| Number of adverse events                                                      | 507                       | 617              |
| Subjects with adverse events                                                  | 201 (63.6)                | 251 (59.8)       |
| Subjects with serious adverse events                                          | 10 (3.2)                  | 11 (2.6)         |
| Subjects with severe adverse events                                           | 7 (2.2)                   | 8 (1.9)          |
| Subjects discontinued from study due to adverse events (a)                    | 2 (0.6)                   | 3 (0.7)          |
| Subjects discontinued study drug due to adverse events (b)                    | 11 (3.5)                  | 12 (2.9)         |
| Subjects with dose reduced or temporary discontinuation due to adverse events | 30 (9.5)                  | 32 (7.6)         |

The table is based on the data from OC AE only.

Except for the Number of Adverse Events subjects are counted only once per analysis group in each row.

(a) Subjects who have an AE record that indicates that the AE causes the subject to be discontinued from the study.

(b) Subjects who have an AE record that indicates that Action Taken with Study Treatment is Drug Withdrawn.

TEAE in A3921119 is defined as those on-treatment events which are new or worsened in severity relative to the pre-treatment period prior to Day 1.

TEAE in A3921120 is defined as those on-treatment events which start during the effective duration of treatment.

Percentages are calculated using number of subjects evaluable for adverse events as the denominator.

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adae Table Generation: 12NOV2020 (02:05)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCS\\_EU/adae\\_s010

Table C2.3.1.2.1-E is for Pfizer internal use.

<div style=\"page-break-after: always\"></div>

## Most Common AEs

The most frequently reported TEAEs in the Placebo-controlled cohort, by SOC and PT ( ≥ 2% of patients), are documented in the table 44 (all causalities).

Table 44 . Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent Adverse Events in &gt;=2% of Subjects in Any Analysis Group by System Organ Class and Preferred Term (All Causalities) Treatment Policy Estimand, AS Placebo-Controlled Cohort

| Number of Subjects Evaluable for AEs                                         |            | Tofa 5 mg BID (N=185)   | Tofa 5 mg BID (N=185)   | Tofa 5 mg BID (N=185)   |            | Placebo (N=187)   | Placebo (N=187)   | Total     |
|------------------------------------------------------------------------------|------------|-------------------------|-------------------------|-------------------------|------------|-------------------|-------------------|-----------|
| Severity(a) Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term | Mild n (%) | Mod. n (%)              | Sev. n (%)              | Total n (%)             | Mild n (%) | Mod. n (%)        | Sev. n (%)        | n (%)     |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                                         | 2 (1.1)    | 0                       | 0                       | 2 (1.1)                 | 4 (2.1)    | 0                 | 0                 | 4 (2.1)   |
| EYE DISORDERS                                                                | 3 (1.6)    | 0                       | 1 (0.5)                 | 4 (2.2)                 | 4 (2.1)    | 0                 | 0                 | 4 (2.1)   |
| GASTROINTESTINAL DISORDERS                                                   | 20 (10.8)  | 4 (2.2)                 | 0                       | 24 (13.0)               | 25 (13.4)  | 3 (1.6)           | 0                 | 28 (15.0) |
| Abdominal pain upper                                                         | 0          | 0                       | 0                       | 0                       | 5 (2.7)    | 0                 | 0                 | 5 (2.7)   |
| Diarrhoea                                                                    | 7 (3.8)    | 0                       | 0                       | 7 (3.8)                 | 4 (2.1)    | 2 (1.1)           | 0                 | 6 (3.2)   |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                         | 8 (4.3)    | 2 (1.1)                 | 0                       | 10 (5.4)                | 6 (3.2)    | 1 (0.5)           | 0                 | 7 (3.7)   |
| Fatigue                                                                      | 3 (1.6)    | 1 (0.5)                 | 0                       | 4 (2.2)                 | 1 (0.5)    | 0                 | 0                 | 1 (0.5)   |
| INFECTIONS AND INFESTATIONS                                                  | 38 (20.5)  | 13 (7.0)                | 0                       | 51 (27.6)               | 33 (17.6)  | 10 (5.3)          | 0                 | 43 (23.0) |
| Influenza                                                                    | 5 (2.7)    | 1 (0.5)                 | 0                       | 6 (3.2)                 | 1 (0.5)    | 0                 | 0                 | 1 (0.5)   |
| Nasopharyngitis                                                              | 12 (6.5)   | 1 (0.5)                 | 0                       | 13 (7.0)                | 12 (6.4)   | 1 (0.5)           | 0                 | 13 (7.0)  |
| Respiratory tract infection viral                                            | 3 (1.6)    | 1 (0.5)                 | 0                       | 4 (2.2)                 | 0          | 0                 | 0                 | 0         |
| Upper respiratory tract infection                                            | 13 (7.0)   | 1 (0.5)                 | 0                       | 14 (7.6)                | 9 (4.8)    | 2 (1.1)           | 0                 | 11 (5.9)  |
| INJURY, POISONINGAND PROCEDURAL COMPLICATIONS                                | 4 (2.2)    | 1 (0.5)                 | 0                       | 5 (2.7)                 | 6 (3.2)    | 2 (1.1)           | 0                 | 8 (4.3)   |
| INVESTIGATIONS                                                               | 17 (9.2)   | 3 (1.6)                 | 1 (0.5)                 | 21 (11.4)               | 8 (4.3)    | 0                 | 0                 | 8 (4.3)   |
| Alanine aminotransferase increased                                           | 5 (2.7)    | 0                       | 1 (0.5)                 | 6 (3.2)                 | 1 (0.5)    | 0                 | 0                 | 1 (0.5)   |
| Aspartate aminotransferase increased                                         | 3 (1.6)    | 0                       | 1 (0.5)                 | 4 (2.2)                 | 0          | 0                 | 0                 | 0         |
| Protein urine present                                                        | 4 (2.2)    | 1 (0.5)                 | 0                       | 5 (2.7)                 | 2 (1.1)    | 0                 | 0                 | 2 (1.1)   |
| METABOLISM AND NUTRITION DISORDERS                                           | 4 (2.2)    | 0                       | 0                       | 4 (2.2)                 | 6 (3.2)    | 0                 | 0                 | 6 (3.2)   |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS                              | 7 (3.8)    | 8 (4.3)                 | 0                       | 15 (8.1)                | 13 (7.0)   | 7 (3.7)           | 1 (0.5)           | 21 (11.2) |
| Arthralgia                                                                   | 1 (0.5)    | 2 (1.1)                 | 0                       | 3 (1.6)                 | 5 (2.7)    | 3 (1.6)           | 0                 | 8 (4.3)   |
| Arthritis                                                                    | 2 (1.1)    | 2 (1.1)                 | 0                       | 4 (2.2)                 | 1 (0.5)    | 0                 | 0                 | 1 (0.5)   |
| Spinal pain                                                                  | 0          | 1 (0.5)                 | 0                       | 1 (0.5)                 | 2 (1.1)    | 1 (0.5)           | 1                 | 4 (2.1)   |
| NERVOUS SYSTEM DISORDERS                                                     | 7 (3.8)    | 1 (0.5)                 | 0                       | 8 (4.3)                 | 9 (4.8)    | 1 (0.5)           | 0                 | 10 (5.3)  |
| Dizziness                                                                    | 1 (0.5)    | 0                       | 0                       | 1 (0.5)                 | 4 (2.1)    | 0                 | 0                 | 4 (2.1)   |
| Headache                                                                     | 3 (1.6)    | 1 (0.5)                 | 0                       | 4 (2.2)                 | 4 (2.1)    | 0                 | 0                 | 4 (2.1)   |

<div style=\"page-break-after: always\"></div>

Table 44 . Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent Adverse Events in &gt;=2% of Subjects in Any Analysis Group by System Organ Class and Preferred Term (All Causalities) Treatment Policy Estimand, AS Placebo-Controlled Cohort

| Number of Subjects Evaluable for AEs                             | Tofa 5 mg BID (N=185)   | Tofa 5 mg BID (N=185)   | Tofa 5 mg BID (N=185)   | Tofa 5 mg BID (N=185)   | Placebo (N=187)   | Placebo (N=187)   | Placebo (N=187)   | Placebo (N=187)   |
|------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------|-------------------|-------------------|-------------------|
| Severity(a)                                                      | Mild                    | Mod.                    | Sev.                    | Total                   | Mild              | Mod.              | Sev.              | Total             |
| Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term | n (%)                   | n (%)                   | n (%)                   | n (%)                   | n (%)             | n (%)             | n (%)             | n (%)             |
| PSYCHIATRIC DISORDERS                                            | 1 (0.5)                 | 0                       | 0                       | 1 (0.5)                 | 4 (2.1)           | 0                 | 0                 | 4 (2.1)           |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS                  | 9 (4.9)                 | 1 (0.5)                 | 0                       | 10 (5.4)                | 9 (4.8)           | 1 (0.5)           | 0                 | 10 (5.3)          |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                           | 5 (2.7)                 | 0                       | 0                       | 5 (2.7)                 | 6 (3.2)           | 1 (0.5)           | 0                 | 7 (3.7)           |

(a) If the same subject in a given treatment has more than one occurrence in the same preferred term event category, only the most severe occurrence is counted.

Subjects are counted only once per treatment per event. For the TESS algorithm any missing severities have been imputed as severe unless the subject experiences another occurrence of the same event in a given treatment for which severity is recorded. In this case, the reported severity is summarized.

Maximum severity at any dictionary level is calculated after the report subset criteria is applied.

TEAE in A3921119 is defined as those on-treatment events which are new or worsened in severity relative to the pre-treatment period prior to Day 1.

TEAE in A3921120 is defined as those on-treatment events which start during the effective duration of treatment.

N: Number of subjects included in the Safety Analysis Set; n (%): Number of subjects with the events (Percentages are based on N).

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

Each SOC row counts all the events. Each SOC or PT row shows AE in &gt;=2% of subjects in any treatment group (Total column).

PFIZER CONFIDENTIAL Source Data: adae Table Generation: 17NOV2020 (10:41)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCSPC\\_EU/adae\\_s160

Table C1.3.1.2.3.2-E is for Pfizer internal use.

The most frequent TEAEs by SOC in the Placebo-controlled Cohort were as follows:

- Infections and infestations (Tofa 5 mg BID: 27.6%, Placebo: 23.0%)
- GI disorders (Tofa 5 mg BID: 13.0%, Placebo: 15.0%)
- Investigations (Tofa 5 mg BID: 11.4%, Placebo: 4.3%)
- Musculoskeletal and connective tissue disorders (Tofa 5 mg BID: 8.1%, Placebo: 11.2%)

TEAE frequencies by PT that were higher (&gt;1% difference between treatment groups) in the Tofa 5 mg BID group compared to the Placebo group included:

- Fatigue, influenza, respiratory tract infection viral, upper respiratory tract infection, ALT increased, AST increased, protein urine present, and arthritis.

In contrast, the following PTs were higher (&gt;1% difference between treatment groups) for the Placebo group compared to the Tofa 5 mg BID group:

- Abdominal pain upper, arthralgia, spinal pain, and dizziness.

<div style=\"page-break-after: always\"></div>

The most frequently reported TEAEs in the All Tofa cohort, by SOC and PT ( ≥ 2% of patients), are documented in table 45.

Table 4 5 . Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent Adverse Events in &gt;=2% of Subjects in Any Analysis Group by System Organ Class and Preferred Term (All Causalities) Treatment Policy Estimand, AS All Tofa Cohort

| Number of Subjects Evaluable for AEs                                         | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa (N=420)   | All Tofa (N=420)   | All Tofa (N=420)   |             |
|------------------------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|--------------------|--------------------|--------------------|-------------|
| Severity(a) Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term | Mild n (%)                  | Mod. n (%)                  | Sev. n (%)                  | Total n (%)                 | Mild n (%)         | Mod. n (%)         | Sev. n (%)         | Total n (%) |
| EYE DISORDERS                                                                | 6 (1.9)                     | 4 (1.3)                     | 1 (0.3)                     | 11 (3.5)                    | 7 (1.7)            | 5 (1.2)            | 2 (0.5)            | 14 (3.3)    |
| GASTROINTESTINAL DISORDERS                                                   | 41 (13.0)                   | 11 (3.5)                    | 0                           | 52 (16.5)                   | 53 (12.6)          | 15 (3.6)           | 0                  | 68 (16.2)   |
| Abdominal pain upper                                                         | 5 (1.6)                     | 0                           | 0                           | 5 (1.6)                     | 9 (2.1)            | 1 (0.2)            | 0                  | 10 (2.4)    |
| Diarrhoea                                                                    | 14 (4.4)                    | 0                           | 0                           | 14 (4.4)                    | 15 (3.6)           | 1 (0.2)            | 0                  | 16 (3.8)    |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                         | 14 (4.4)                    | 3 (0.9)                     | 0                           | 17 (5.4)                    | 17 (4.0)           | 3 (0.7)            | 0                  | 20 (4.8)    |
| Fatigue                                                                      | 7 (2.2)                     | 2 (0.6)                     | 0                           | 9 (2.8)                     | 8 (1.9)            | 2 (0.5)            | 0                  | 10 (2.4)    |
| HEPATOBILIARY DISORDERS                                                      | 10 (3.2)                    | 4 (1.3)                     | 0                           | 14 (4.4)                    | 13 (3.1)           | 4 (1.0)            | 0                  | 17 (4.0)    |
| Hepatic function abnormal                                                    | 6 (1.9)                     | 2 (0.6)                     | 0                           | 8 (2.5)                     | 7 (1.7)            | 2 (0.5)            | 0                  | 9 (2.1)     |
| INFECTIONS AND INFESTATIONS                                                  | 79 (25.0)                   | 35 (11.1)                   | 0                           | 114 (36.1)                  | 93 (22.1)          | 42 (10.0)          | 0                  | 135 (32.1)  |
| Influenza                                                                    | 7 (2.2)                     | 2 (0.6)                     | 0                           | 9 (2.8)                     | 7 (1.7)            | 2 (0.5)            | 0                  | 9 (2.1)     |
| Nasopharyngitis                                                              | 23 (7.3)                    | 2 (0.6)                     | 0                           | 25 (7.9)                    | 28 (6.7)           | 3 (0.7)            | 0                  | 31 (7.4)    |
| Upper respiratory tract infection                                            | 27 (8.5)                    | 5 (1.6)                     | 0                           | 32 (10.1)                   | 33 (7.9)           | 6 (1.4)            | 0                  | 39 (9.3)    |
| INJURY, POISONINGAND PROCEDURAL COMPLICATIONS                                | 7 (2.2)                     | 5 (1.6)                     | 0                           | 12 (3.8)                    | 13 (3.1)           | 6 (1.4)            | 0                  | 19 (4.5)    |
| INVESTIGATIONS                                                               | 45 (14.2)                   | 7 (2.2)                     | 1 (0.3)                     | 53 (16.8)                   | 50 (11.9)          | 8 (1.9)            | 1 (0.2)            | 59 (14.0)   |
| Alanine aminotransferase increased                                           | 7 (2.2)                     | 3 (0.9)                     | 1 (0.3)                     | 11 (3.5)                    | 8 (1.9)            | 3 (0.7)            | 1 (0.2)            | 12 (2.9)    |
| Aspartate aminotransferase increased                                         | 3 (0.9)                     | 3 (0.9)                     | 1 (0.3)                     | 7 (2.2)                     | 3 (0.7)            | 3 (0.7)            | 1 (0.2)            | 7 (1.7)     |
| Blood creatine phosphokinase increased                                       | 7 (2.2)                     | 1 (0.3)                     | 0                           | 8 (2.5)                     | 8 (1.9)            | 1 (0.2)            | 0                  | 9 (2.1)     |
| Protein urine present                                                        | 10 (3.2)                    | 1 (0.3)                     | 0                           | 11 (3.5)                    | 10 (2.4)           | 1 (0.2)            | 0                  | 11 (2.6)    |
| Weight increased                                                             | 9 (2.8)                     | 1 (0.3)                     | 0                           | 10 (3.2)                    | 9 (2.1)            | 1 (0.2)            | 0                  | 10 (2.4)    |
| METABOLISM AND NUTRITION DISORDERS                                           | 8 (2.5)                     | 1 (0.3)                     | 0                           | 9 (2.8)                     | 11 (2.6)           | 1 (0.2)            | 0                  | 12 (2.9)    |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS                              | 18 (5.7)                    | 15 (4.7)                    | 3 (0.9)                     | 36 (11.4)                   | 23 (5.5)           | 18 (4.3)           | 3 (0.7)            | 44 (10.5)   |
| Arthralgia                                                                   | 4 (1.3)                     | 3 (0.9)                     | 0                           | 7 (2.2)                     | 4 (1.0)            | 4 (1.0)            | 0                  | 8 (1.9)     |
| NERVOUS SYSTEM DISORDERS                                                     | 14 (4.4)                    | 3 (0.9)                     | 0                           | 17 (5.4)                    | 21 (5.0)           | 3 (0.7)            | 0                  | 24 (5.7)    |
| Headache                                                                     | 9 (2.8)                     | 2 (0.6)                     | 0                           | 11 (3.5)                    | 13 (3.1)           | 2 (0.5)            | 0                  | 15 (3.6)    |
| RENAL AND URINARY DISORDERS                                                  | 7 (2.2)                     | 1 (0.3)                     | 0                           | 8 (2.5)                     | 10 (2.4)           | 1 (0.2)            | 0                  | 11 (2.6)    |

<div style=\"page-break-after: always\"></div>

Table 4 5 . Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent Adverse Events in &gt;=2% of Subjects in Any Analysis Group by System Organ Class and Preferred Term (All Causalities) Treatment Policy Estimand, AS All Tofa Cohort

| Number of Subjects Evaluable for AEs                                                                             | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa (N=420)   | All Tofa (N=420)   | All Tofa (N=420)   | All Tofa (N=420)   |
|------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Severity(a)                                                                                                      | Mild                        | Mod.                        | Sev.                        | Total                       | Mild               | Mod.               | Sev.               | Total              |
| Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | n (%) 18 (5.7)              | n (%) 4 (1.3)               | n (%) 1 (0.3)               | n (%) 23 (7.3)              | n (%) 23 (5.5)     | n (%) 4 (1.0)      | n (%) 1 (0.2)      | n (%) 28 (6.7)     |
| Cough                                                                                                            | 4 (1.3)                     | 3 (0.9)                     | 0                           | 7 (2.2)                     | 6 (1.4)            | 3 (0.7)            | 0                  | 9 (2.1)            |
| Oropharyngeal pain                                                                                               | 8 (2.5)                     | 0                           | 0                           | 8 (2.5)                     | 9 (2.1)            | 0                  | 0                  | 9 (2.1)            |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                           | 9 (2.8)                     | 2 (0.6)                     | 0                           | 11 (3.5)                    | 10 (2.4)           | 2 (0.5)            | 0                  | 12 (2.9)           |

(a) If the same subject in a given treatment has more than one occurrence in the same preferred term event category, only the most severe occurrence is counted.

Subjects are counted only once per treatment per event. For the TESS algorithm any missing severities have been imputed as severe unless the subject experiences another occurrence of the same event in a given treatment for which severity is recorded. In this case, the reported severity is summarized.

Maximum severity at any dictionary level is calculated after the report subset criteria is applied.

TEAE in A3921119 is defined as those on-treatment events which are new or worsened in severity relative to the pre-treatment period prior to Day 1.

TEAE in A3921120 is defined as those on-treatment events which start during the effective duration of treatment.

N: Number of subjects included in the Safety Analysis Set; n (%): Number of subjects with the events (Percentages are based on N).

Each SOC row counts all the events. Each SOC or PT row shows AE in &gt;=2% of subjects in any treatment group (Total column).

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adae Table Generation: 17NOV2020 (10:52)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCS\\_EU/adae\\_s161

Table C2.3.1.2.3.2-E is for Pfizer internal use.

Table 46 shows incidence and severity of Treatment Related TEAEs in &gt;=2% of Subjects in Any Analysis Group by System Organ Class and Preferred Term - Treatment Policy Estimand, AS PlaceboControlled Cohort.

Table 46. Incidence and Severity of Treatment Related TEAEs

TofacitinibSummaryofClinicalSafety(AnkylosingSpondylitis)

Incidence andSeverity of Treatment-EmergentAdverseEventsin&gt;=2%of Subjects inAnyAnalysisGroupbySystem OrganClass andPreferredTerm (TreatmentRelated)-TreatmentPolicyEstimand,ASPlacebo-ControlledCohort

| NumberofSubjectsEvaluableforAEs                           | Tofa5mgBID (N=185)   | Tofa5mgBID (N=185)   | Tofa5mgBID (N=185)   | Tofa5mgBID (N=185)   | Placebo (N=187)   | Placebo (N=187)   | Placebo (N=187)   | Placebo (N=187)   |
|-----------------------------------------------------------|----------------------|----------------------|----------------------|----------------------|-------------------|-------------------|-------------------|-------------------|
| Severity(a)                                               | Mild                 | Mod.                 | Sev.                 | Total                | Mild              | Mod.              | Sev.              | Total             |
| Number(%)of Subjects: bySYSTEMORGANCLASS andPreferredTerm | n (%)                | n (%)                | n (%)                | (%)                  | n (%)             | n (%)             | (%)               | n (%)             |
| GASTROINTESTINALDISORDERS                                 | 4 (2.2)              | 1 (0.5)              | 0                    | 5 (2.7)              | 12 ( 6.4)         | 0                 | 0                 | 12 ( 6.4)         |
| INFECTIONSANDINFESTATIONS                                 | 10 (5.4)             | 3 (1.6)              | 0                    | 13 (7.0)             | 11 ( 5.9)         | 2 (1.1)           | 0                 | 13 ( 7.0)         |
| Upper respiratory tract infection                         | 7 (3.8)              | 1 (0.5)              | 0                    | 8 (4.3)              | 5( 2.7)           | 0                 | 0                 | 5( 2.7)           |
| INVESTIGATIONS                                            | 10 (5.4)             | 1( 0.5)              | 1 (0.5)              | 12（ 6.5)             | 5( 2.7)           | 0                 | 0                 | 5（ 2.7)           |
| NERVOUSSYSTEMDISORDERS                                    | 3( 1.6)              | 1( 0.5)              | 0                    | 4( 2.2)              | 2（ 1.1)           | 0                 | 0                 | 2( 1.1)           |
| RESPIRATORY,THORACICAND MEDIASTINALDISORDERS              | 4（ 2.2)              | 1 (0.5)              | 0                    | 5 (2.7)              | 4( 2.1)           | 0                 | 0                 | 4( 2.1)           |
| SKINANDSUBCUTANEOUS TISSUEDISORDERS                       | 1 ( 0.5)             | 0                    | 0                    | 1 ( 0.5)             | 4（ 2.1)           | 1 ( 0.5)          | 0                 | 5 (2.7)           |

<div style=\"page-break-after: always\"></div>

Subjects are counted only once per treatment per event. For the TESS algorithm any missing severities have been imputed as severe unless the subject experiences another occurenceof thesameeventin agiventreatmentforwhichseverityisrecorded.Inthis case,thereportedseverityissummarized. Maximumseverity at any dictionarylevelis calculated after the report subset criteria is applied.

TEAEinA3921119isdefined as thoseon-treatmenteventswhich areneworworsenedinseverityrelative tothepre-treatmentperiodpriortoDay1.

TEAEinA3921120isdefined asthoseon-treatmenteventswhichstartduringtheeffectivedurationoftreatment.

N: Number of subjects included in the Safety Analysis Set; n (%): Number of subjects with the events (Percentages are based on N).

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

Each SOC row counts all the events. Each SOC or PT row shows AE in &gt;=2% of subjects in any treatment group (Total column).

PFIZERCONFIDENTIAL

(Final Data:10Sep2020)

Tofacitinib Sunmary of Clinical Safety (Ankylosing Spondylitis)

SourceData:adaeTableGeneration:21NOV2020(07:54)

OutputFile:./unblind\\_1120/A392\\_SCSPC\\_EU/adae\\_s183\\_1

IncidenceandSeverityofTreatment-EmergentAdverseEventsin&gt;=2%ofSubjectsinAnyAnalysisGroupbySystemOrganClassandPreferredTerm (TreatmentRelated)-TreatmentPolicyEstimand,ASAllTofaCohort

| NumberofSubjectsEvaluableforAEs                                | AllTofa5mgBID (N=316)   | AllTofa5mgBID (N=316)   | AllTofa5mgBID (N=316)   | AllTofa5mgBID (N=316)   | All Tofa (N=420)   | All Tofa (N=420)   | All Tofa (N=420)   | All Tofa (N=420)   |
|----------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|--------------------|--------------------|--------------------|--------------------|
| Severity(a)                                                    | Mild                    | Mod.                    | Sev.                    | Total                   | Mild               | Mod.               | Sev.               | Total              |
| Number(%) of Subjects: by SYSTEMORGAN CLASS and Preferred Term | (%)                     | (%)                     | (%)                     | (%)                     | (%)                | (%)                | (%)                | 11 (%)             |
| GASTROINTESTINALDISORDERS                                      | 12 (3.8)                | 1( 0.3)                 | 0                       | 13 (4.1)                | 19 (4.5)           | 3( 0.7)            | 0                  | 22 (5.2)           |
| HEPATOBILIARYDISORDERS                                         | 6（ 1.9)                 | 1( 0.3)                 | 0                       | 7 (2.2)                 | 8( 1.9)            | 1 ( 0.2)           | 0                  | 9 (2.1)            |
| INFECTIONSANDINFESTATIONS                                      | 28( 8.9)                | 8( 2.5)                 | 0                       | 36 ( 11.4)              | 35 ( 8.3)          | 11 ( 2.6)          | 0                  | 46 ( 11.0)         |
| Upper respiratory tract infection                              | 13 ( 4.1)               | 1( 0.3)                 | 0                       | 14 ( 4.4)               | 16 ( 3.8)          | 1 ( 0.2)           | 0                  | 17 ( 4.0)          |
| INVESTIGATIONS                                                 | 31( 9.8)                | 3( 0.9)                 | 1（ 0.3)                 | 35 ( 11.1)              | 34 ( 8.1)          | 4 ( 1.0)           | 1( 0.2)            | 39（ 9.3)           |
| Protein urine present                                          | 7( 2.2)                 | 0                       | 0                       | 7 (2.2)                 | 7( 1.7)            | 0                  | 0                  | 7( 1.7)            |
| Weight increased                                               | 7( 2.2)                 | 0                       | 0                       | 7( 2.2)                 | 7( 1.7)            | 0                  | 0                  | 7( 1.7)            |
| NERVOUSSYSTEMDISORDERS                                         | 6 ( 1.9)                | 2( 0.6)                 | 0                       | 8( 2.5)                 | 9( 2.1)            | 2( 0.5)            | 0                  | 11 ( 2.6)          |
| RESPIRATORY,THORACICAND MEDIASTINALDISORDERS                   | 8（ 2.5)                 | 1( 0.3)                 | 0                       | 9 (2.8)                 | 9（ 2.1)            | 1( 0.2)            | 0                  | 10 (2.4)           |

(a)If thesamesubjectinagiventreatment hasmorethanoneoccurrenceinthesamepreferredtermeventcategory,onlythemostsevereoccurrenceiscounted. Subjects are counted only once per treatment per event.For the TESS algorithm any missing severities have been imputed as severe unless the subject experiences another occurrence of the same event in a given treatment for which severity is recorded. In this case, the reported severity is summarized.

TEAE in A3921119 is defined as those on-treatment events which are new or worsened in severity relative to the pre-treatment period prior to Day 1.

TEAEinA3921120isdefined asthoseon-treatmenteventswhichstartduringtheeffectivedurationof treatment.

N: Number of subjects included in theSafetyAnalysisSet; n(%): Numberof subjects with the events (Percentages arebased on N).

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

PFIZER CONFIDENTIAL

(Final Data: 10Sep2020)

## AEs of special interest

Summaries on selected signals of interest for tofacitinib are presented below from the AS pooled safety analysis. These signals of interest were derived from clinical experience with tofacitinib in RA and PsA patients and were as follows:

- Infection including serious infections, adjudicated OIs, all HZ, and TB.
- Malignancy excluding NMSC.
- NMSC.
- Cardiovascular safety including adjudicated CV events and events of DVT, PE, ATE and VTE.
- GI perforation.
- EBV-related events.
- ILD.
- Hepatic function.
- Renal function.

Source Data:adae Table Generation: 21NOV2020 (07:57)

OutputFile:./unblind\\_1120/A392\\_SCS\\_EU/adae\\_s040\\_1

<div style=\"page-break-after: always\"></div>

- Rhabdomyolysis.
- Lipids.
- Haematological.
- Vital signs.

Incidence rates, incidence proportion and hazard ratio for selected adverse events in the Tofa 5 mg BID and Placebo groups of the Placebo-controlled Cohort are summarised in table 47.

Table 47 . Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Numbers of Subjects with Events, Incidence Proportions, Incidence Rates (Number of Subjects with Event per 100 PY) by Analysis Group, Hazard Ratio and Incidence Proportions (Estimand 4) for Selected Adverse Events - While on Treatment Estimand, AS Placebo-Controlled Cohort

|                                    | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Placebo N = 187 = 53.07 Patient-Years   | Exposure   | Placebo N = 187 = 53.07 Patient-Years   | Placebo N = 187 = 53.07 Patient-Years   | Comparison (Tofa 5 mg BID - Placebo)   |
|------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|-----------------------------------------|------------|-----------------------------------------|-----------------------------------------|----------------------------------------|
| Adverse Events                     | n (%)                                                  | n1 (%)                                                 | PY                                                     | IR (95% CI) per 100 PY                                 | n (%)                                   | n1 (%)     | PY                                      | IR (95% CI) per 100 PY                  | HR (95% CI)                            |
| General                            |                                                        |                                                        |                                                        |                                                        |                                         |            |                                         |                                         |                                        |
| TEAEs                              | 101 ( 54.59)                                           | 0                                                      | 37.74                                                  | 267.61 (215.42, 319.81)                                | 91 ( 48.66)                             | 1 ( 0.53)  | 38.41                                   | 237.37 (188.59, 286.14)                 | 1.12 (0.85, 1.49)                      |
| Serious AEs                        | 3 ( 1.62)                                              | 0                                                      | 56.76                                                  | 5.28 (0.00, 11.25)                                     | 2 ( 1.07)                               | 1 ( 0.53)  | 56.59                                   | 3.56 (0.00, 8.49)                       | 1.47 (0.25, 8.80)                      |
| Severe AEs                         | 3 ( 1.62)                                              | 0                                                      | 56.82                                                  | 5.27 (0.00, 11.24)                                     | 3 ( 1.60)                               | 0          | 56.68                                   | 5.41 (0.00, 11.98)                      | 0.96 (0.19, 4.78)                      |
| Discontinuation of study           | 2 ( 1.08)                                              | 0                                                      | 57.06                                                  | 3.49 (0.00, 8.33)                                      | 7 ( 3.74)                               | 0          | 57.02                                   | 12.35 (3.20, 21.50)                     | 0.28 (0.06, 1.36)                      |
| Discontinuation of study treatment | 5 ( 2.70)                                              | 0                                                      | 56.79                                                  | 8.82 (1.09, 16.55)                                     | 9 ( 4.81)                               | 0          | 56.80                                   | 15.90 (5.51, 26.29)                     | 0.55 (0.18, 1.65)                      |
| Discontinuation due to AEs         | 4 ( 2.16)                                              | 0                                                      | 56.85                                                  | 7.04 (0.14, 13.94)                                     | 4 ( 2.14)                               | 0          | 56.95                                   | 7.10 (0.14, 14.05)                      | 0.97 (0.24, 3.90)                      |
| Death (Mortality)                  | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Infections                         |                                                        |                                                        |                                                        |                                                        |                                         |            |                                         |                                         |                                        |
| Serious Infections                 | 1 ( 0.54)                                              | 0                                                      | 56.98                                                  | 1.77 (0.00, 5.89)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NC (0.00, Inf.)                        |
| Opportunistic Infections*          | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Pneumonia                          | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Serious Pneumonia                  | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Herpes Zoster                      | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Serious Herpes Zoster              | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Urinary Tract Infection            | 2 ( 1.08)                                              | 0                                                      | 56.96                                                  | 3.53 (0.00, 8.92)                                      | 2 ( 1.07)                               | 0          | 56.86                                   | 3.50 (0.00, 8.87)                       | 1.00 (0.14, 7.07)                      |
| Cellulitis                         | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |
| Tuberculosis*                      | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                       | 0          | 57.02                                   | 0.00 (0.00, 3.31)                       | NE (-, -)                              |

<div style=\"page-break-after: always\"></div>

Table 47 . Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Numbers of Subjects with Events, Incidence Proportions, Incidence Rates (Number of Subjects with Event per 100 PY) by Analysis Group, Hazard Ratio and Incidence Proportions (Estimand 4) for Selected Adverse Events - While on Treatment Estimand, AS Placebo-Controlled Cohort

|                                         | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Placebo N = 187 Exposure = 53.07 Patient-Years   | Placebo N = 187 Exposure = 53.07 Patient-Years   | Placebo N = 187 Exposure = 53.07 Patient-Years   | Placebo N = 187 Exposure = 53.07 Patient-Years   | Comparison (Tofa 5 mg BID - Placebo) HR (95% CI)   |
|-----------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|
| Adverse Events                          | n (%)                                                  | n1 (%)                                                 | PY                                                     | IR (95% CI) per 100 PY                                 | n (%)                                            | n1 (%)                                           | PY                                               | IR (95% CI) per 100 PY                           | Comparison (Tofa 5 mg BID - Placebo) HR (95% CI)   |
| Candidiasis*                            | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| Pneumocystis Jirovecii Pneumonia*       | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| Malignancy Malignancy excluding NMSC*   | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| NMSC*                                   | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| GI                                      |                                                        |                                                        |                                                        |                                                        |                                                  |                                                  |                                                  |                                                  |                                                    |
| GI Perforation*                         | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| Cardiovascular Events Total MACE*       | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| Deep vein thrombosis*                   | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| Pulmonary embolism*                     | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| Arterial thromboembolism*               | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| Venous thromboembolism a *              | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| Thromboembolism b *                     | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| Additional Adverse Events               |                                                        |                                                        |                                                        |                                                        |                                                  |                                                  |                                                  |                                                  |                                                    |
| Epstein-Barr Virus (EBV)-Related Events | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| Interstitial Lung Disease (ILD)*        | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| Rhabdomyolysis                          |                                                        |                                                        |                                                        |                                                        |                                                  |                                                  |                                                  |                                                  |                                                    |
| Rhabdomyolysis                          | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |
| Creatine Kinase (CK) Elevation          | 3 ( 1.62)                                              | 0                                                      | 56.64                                                  | 5.26 (0.00, 11.20)                                     | 2 ( 1.07)                                        | 0                                                | 56.65                                            | 3.55 (0.00, 8.46)                                | 1.50 (0.25, 9.00)                                  |
| Renal                                   |                                                        |                                                        |                                                        |                                                        |                                                  |                                                  |                                                  |                                                  |                                                    |
| Acute Renal Failure                     | 5 ( 2.70)                                              | 0                                                      | 56.50                                                  | 8.92 (0.78, 17.05)                                     | 2 ( 1.07)                                        | 0                                                | 56.93                                            | 3.49 (0.00, 8.85)                                | 2.57 (0.50, 13.27)                                 |
| Serum Creatinine Elevations             | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                                          |

<div style=\"page-break-after: always\"></div>

Table 47 . Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Numbers of Subjects with Events, Incidence Proportions, Incidence Rates (Number of Subjects with Event per 100 PY) by Analysis Group, Hazard Ratio and Incidence Proportions (Estimand 4) for Selected Adverse Events - While on Treatment Estimand, AS Placebo-Controlled Cohort

|                         | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Tofa 5 mg BID N = 185 Exposure = 52.77 Patient-Years   | Placebo N = 187 Exposure = 53.07 Patient-Years   | Placebo N = 187 Exposure = 53.07 Patient-Years   | Placebo N = 187 Exposure = 53.07 Patient-Years   | Placebo N = 187 Exposure = 53.07 Patient-Years   | Comparison (Tofa 5 mg BID - Placebo)   |
|-------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------|
| Adverse Events          | n (%)                                                  | n1 (%)                                                 | PY                                                     | IR (95% CI) per 100 PY                                 | n (%)                                            | n1 (%)                                           | PY                                               | IR (95% CI) per 100 PY                           | HR (95% CI)                            |
| Hepatic Steatosis       | 2 ( 1.08)                                              | 0                                                      | 56.84                                                  | 3.54 (0.00, 8.94)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NC (0.00, Inf.)                        |
| Transaminase Elevations | 8 ( 4.32)                                              | 0                                                      | 56.11                                                  | 14.27 (4.38, 24.16)                                    | 2 ( 1.07)                                        | 0                                                | 56.73                                            | 3.55 (0.00, 8.47)                                | 4.03 (0.86, 18.97)                     |
| Hematologic             |                                                        |                                                        |                                                        |                                                        |                                                  |                                                  |                                                  |                                                  |                                        |
| Lymphopenia             | 1 ( 0.54)                                              | 0                                                      | 56.98                                                  | 1.73 (0.00, 5.88)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NC (0.00, Inf.)                        |
| Neutropenia             | 0                                                      | 0                                                      | 57.06                                                  | 0.00 (0.00, 3.28)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NE (-, -)                              |
| Thrombocytopenia        | 1 ( 0.54)                                              | 0                                                      | 56.83                                                  | 1.77 (0.00, 5.91)                                      | 0                                                | 0                                                | 57.02                                            | 0.00 (0.00, 3.31)                                | NC (0.00, Inf.)                        |
| Anemia                  | 1 ( 0.54)                                              | 0                                                      | 56.98                                                  | 1.76 (0.00, 5.89)                                      | 2 ( 1.07)                                        | 0                                                | 56.88                                            | 3.50 (0.00, 8.87)                                | 0.51 (0.05, 5.57)                      |
| Vital Signs             |                                                        |                                                        |                                                        |                                                        |                                                  |                                                  |                                                  |                                                  |                                        |
| Hypertension            | 4 ( 2.16)                                              | 0                                                      | 56.35                                                  | 7.14 (0.00, 14.51)                                     | 2 ( 1.07)                                        | 0                                                | 56.51                                            | 3.52 (0.00, 8.92)                                | 2.05 (0.37, 11.17)                     |
| Weight Increase         | 2 ( 1.08)                                              | 0                                                      | 56.75                                                  | 3.55 (0.00, 8.97)                                      | 1 ( 0.53)                                        | 0                                                | 56.90                                            | 1.79 (0.00, 6.03)                                | 2.00 (0.18, 22.10)                     |
| Lipids                  |                                                        |                                                        |                                                        |                                                        |                                                  |                                                  |                                                  |                                                  |                                        |
| Hyperlipidemia          | 4 ( 2.16)                                              | 0                                                      | 56.29                                                  | 7.11 (0.14, 14.08)                                     | 2 ( 1.07)                                        | 0                                                | 56.51                                            | 3.56 (0.00, 8.50)                                | 2.01 (0.37, 10.95)                     |

Exposure is the sum of treatment exposures of all the subjects in the group. * Adjudicated events in all studies. a. Venous thromboembolism includes deep vein thrombosis and/or pulmonary embolism. b. Thromboembolism includes deep vein thrombosis, pulmonary embolism and/or arterial thromboembolism.

The Ankylosing Spondylitis Placebo-Controlled Cohort includes safety data from the double-blind placebo-controlled periods of the two studies, completed A3921119

(Up to Week 12) and completed A3921120 (Up to Week 16). Under While on Treatment Estimand, PY (ie, denominator for IR) is the sum of the times to the first event for subjects with an event or the risk periods for subjects without an event within the 28-Day While on Treatment Risk Period. n is the number of subjects with an event within the 28-Day While on Treatment Risk Period. n1 is the number of subjects with an event beyond the 28-Day While on

Treatment Risk Period which are not included in the IR estimation. Incidence proportions, PYs, IRs, and HRs are estimated based on n under this estimand/risk period.

IRs (95% CI) by analysis group are estimated using Cochran-Mantel-Haenszel weighting method adjusting to study. HR and its associated CI are estimated from a Cox regression model including fixed effects of treatment and study. MedDRA v23.0 coding dictionary applied.

NC: not calculated, 0 events in one analysis group of the comparison. NE: not estimable, 0 events in both analysis groups of the comparison.

PFIZER CONFIDENTIAL Source Data: adae &amp; adsaec &amp; adaj &amp; adds Table Generation: 24NOV2020 (05:07) (Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCSPC\\_EU/adae\\_ir\\_combine\\_3 Table C1.5.15.2.3-E is for Pfizer internal use.

<div style=\"page-break-after: always\"></div>

## Serious infections

In the Placebo-controlled Cohort:

- -1  patient  in  the  Tofa  5  mg  BID  group  experienced  a  serious  infection,  meningitis  aseptic, representing an incidence rate (While on Treatment Estimand) of 1.77 patients with events per 100  PY.  This  serious  infection  was  not  considered  to  be  opportunistic  by  the  independent adjudication committee.
- -No serious infections were reported in the Placebo group.

Overall, 1 serious infection of meningitis aseptic was reported for the All Tofa Cohort representing an incidence rate (While on Treatment Estimand) of 0.43 patients with events per 100 PY for the All Tofa 5 mg BID group.

No cases of tuberculosis were reported in the AS Programme.

## Herpes Zoster

There were 7 patients with HZ reported in the All Tofa Cohort as follows:

-All  Tofa  5  mg  BID  group:  5  patients  reported  HZ,  which  represented  an  incidence  rate  (While  on Treatment Estimand) of 2.18 patients with events per 100 PY.

- All Tofa group: In addition to the 5 patients who reported HZ in the All Tofa 5 mg BID group, there were 2 additional patients (1 received tofacitinib 2 mg BID and the other received tofacitinib 10 mg BID) reporting HZ representing an incidence rate (While on Treatment Estimand) of 2.68 patients with events per 100 PY.

None of the events were serious.

- -1 event occurred in a patient who received tofacitinib 2 mg BID.
- -5 events occurred in patients who received tofacitinib 5 mg BID.
- -1 event occurred in a patient who received tofacitinib 10 mg BID.

## Hypertension

There were 6 patients with hypertension in the Placebo-controlled Cohort and are described as follows:

- Tofa 5 mg BID group: 4 (2.16%) patients had events of hypertension representing an incidence rate (While on Treatment Estimand) of 7.14 patients with events per 100 PY.

- Placebo group: 2 (1.07%) patients had events of hypertension representing an incidence rate (While on Treatment Estimand) of 3.52 patients with events per 100 PY.

Overall, there were 11 patients with hypertension in the All Tofa Cohort and are described as follows:

- All Tofa 5 mg BID group: 9 (2.85%) patients had events of hypertension representing an incidence rate (While on Treatment Estimand) of 3.97 (95% CI: 1.81, 7.53) patients with events per 100 PY.

- All Tofa group: 11 (2.62%) patients had events of hypertension representing an incidence rate (While on Treatment Estimand) of 4.26 (95% CI: 2.13, 7.62) patients with events per 100 PY.

## Hepatic AEs

Treatment with tofacitinib is associated with an increased incidence of liver enzyme elevations compared to placebo. As part of the evaluation of hepatic safety within the AS Programme, a SMQ search was performed  to  identify  hepatic-related  adverse  events,  specifically  events  of  hepatic  steatosis  and

<div style=\"page-break-after: always\"></div>

transaminase elevations, which were then summarised for the Placebo-controlled Cohort and the All Tofa Cohort.

Adverse events of transaminase elevations in the Placebo-controlled Cohort are described as follows:

- -Tofa 5 mg BID Group: 8 (4.32%) patients had transaminase elevations representing an incidence rate (While on Treatment Estimand) of 14.27 patients with events per 100 PY.
- -Placebo Group: 2 (1.07%) patients had transamainase elevations representing an incidence rate (While on Treatment Estimand) of 3.55 patients with events per 100 PY.

Hepatic steatosis events in the Placebo-controlled Cohort are described as follows:

- -Tofa  5  mg  BID  group:  2  (1.08%)  patients  had  events  of  hepatic  steatosis  representing  an incidence rate (While on Treatment Estimand) of 3.54 patients with events per 100 PY.
- -Placebo group: No events.

A total of 3 patients in the Tofa 5 mg BID group had adverse events that met criteria for adjudication by the hepatic adjudication committee. None of these events met Hy's Law criteria, according to the MAH.

Adverse events of transaminase elevations in the All Tofa Cohort were as follows:

- -All  Tofa 5 mg BID group: 24 (7.59%) patients had transaminase elevations representing an incidence rate (While on Treatment Estimand) of 10.92 (95% CI: 7.00, 16.25) patients with events per 100 PY.
- -All Tofa group: 28 (6.67%) patients had transaminase elevations representing an incidence rate (While on Treatment Estimand) of 11.18 (95% CI: 7.43, 16.15) patients with events per 100 PY.

Hepatic steatosis events in the All Tofa Cohort were as follows:

- -All Tofa 5 mg BID group: 4 (1.27%) patients had events of hepatic steatosis representing an incidence rate (While on Treatment Estimand) of 1.74 (95% CI: 0.47, 4.45) patients with events per 100 PY.
- -All Tofa group: 5 (1.19%) patients had events of hepatic steatosis representing an incidence rate (While on Treatment Estimand) of 1.91 (95% CI: 0.62, 4.46) patients with events per 100 PY.

In addition to the events described above for the Placebo-controlled Cohort, 2 additional patients in the All Tofa Cohort (All Tofa 5 mg BID group) had adverse events that met criteria for adjudication by the hepatic adjudication committee. Neither event m et Hy's Law criteria.

## Renal Function

No AEs of serum creatinine elevations were observed in the Placebo-controlled Cohort.

There were 7 patients with AEs coding to PTs in the acute renal failure SMQ in the Placebo-controlled Cohort described as follows:

- Tofa 5 mg BID group: 5 (2.70%) patients had events of protein urine present representing an incidence rate (While on Treatment Estimand) of 8.92 patients with events per 100 PY.
- Placebo group: 2 (1.07%) patients had events of protein urine present representing an incidence rate (While on Treatment Estimand) of 3.49 patients with events per 100 PY.

Serum creatinine elevations in the All Tofa Cohort were as follows:

<div style=\"page-break-after: always\"></div>

- All  tofa  5  mg  BID  group:  1  (0.32%)  patient  representing  an  incidence  rate  rate  (While  on Treatment Estimand) of 0.43 patients with events per 100 PY.
- All  Tofa  group:  1  (0.24%)  patient  representing  an  incidence  rate  rate  (While  on  Treatment Estimand) of 0.38 patients with events per 100 PY.

There were 12 patients with AEs coding to PTs in the acute renal failure SMQ in the All Tofa Cohort described as follows:

- All Tofa 5 mg BID group: 12 (3.80%) patients had events of acute renal failure representing an incidence rate (While on Treatment Estimand) of 5.36 (95% CI: 2.77, 9.36) patients with events per 100 PY. Of these 11 patients had events of protein urine present and 1 patient had an event of blood creatinine increased.
- All Tofa group: 12 (2.86%) patients had events of acute renal failure representing an incidence rate (While on Treatment Estimand) of 4.70 (95% CI: 2.43, 8.21) patients with events per 100 PY. Of these 11 patients had events of protein urine present and 1 patient had an event of blood creatinine increased.

## Haematology

There were no patients with events of neutropenia in the Placebo-controlled Cohort.

AEs of lymphopenia reported in the Placebo-controlled Cohort were as follows:

- Tofa 5 mg BID group: 1 (0.54%) patient had an event of lymphopenia representing an incidence rate (While on Treatment Estimand) of 1.73 patients with events per 100 PY.
- Placebo group: No patients had events of lymphopenia.

AEs of thrombocytopenia reported in the Placebo-controlled Cohort were as follows:

- Tofa 5 mg BID group: 1 (0.54%) patient had an event of thrombocytopenia representing an incidence rate (While on Treatment Estimand) of 1.77 patients with events per 100 PY.
- Placebo group: No patients had events of thrombocytopenia.

AEs of anaemia reported in the Placebo-controlled Cohort were as follows:

- Tofa 5 mg BID group: 1 (0.54%) patient had an event of anaemia representing an incidence rate (While on Treatment Estimand) of 1.76 patients with events per 100 PY.
- Placebo group: 2 (1.07%) patients had events of anaemia representing an incidence rate (While on Treatment Estimand) of 3.50 patients with events per 100 PY.

AEs of lymphopenia reported in the All Tofa Cohort were as follows:

- All  Tofa  5  mg  BID  group:  1  (0.32%)  patient  had  an  event  of  lymphopenia  representing  an incidence rate (While on Treatment Estimand) of 0.43 (95% CI: 0.01, 2.41) patients with events per 100 PY.
- All Tofa group: 2 (0.48%) patients had events of lymphopenia representing an incidence rate (While on Treatment Estimand) of 0.76 (95% CI: 0.09, 2.75) patients with events per 100 PY.

AEs of neutropenia reported in the All Tofa Cohort were as follows:

- All Tofa 5 mg BID group: No patients had events of neutropenia.
- All Tofa group: 1 (0.24%) patient had an event of neutropenia representing an incidence rate (While on Treatment Estimand) of 0.38 (95% CI: 0.01, 2.12) patients with events per 100 PY.

<div style=\"page-break-after: always\"></div>

AEs of anaemia reported in the All Tofa Cohort were as follows:

- All Tofa 5 mg BID group: 3 (0.95%) patients had events of anaemia representing an incidence rate (While on Treatment Estimand) of 1.30 (95% CI: 0.27, 3.81) patients with events per 100 PY.
- All Tofa group: 3 (0.71%) patients had events of anaemia representing an incidence rate (While on Treatment Estimand) of 1.15 (95% CI: 0.24, 3.35) patients with events per 100 PY.

## Thrombocytopenia

AEs of thrombocytopenia reported in the All Tofa Cohort were as follows:

· All Tofa 5 mg BID group: 1 (0.32%) patient had an event of thrombocytopenia representing an incidence rate (While on Treatment Estimand) of 0.43 (95% CI: 0.01, 2.42) patients with events per 100 PY.

· All Tofa group: 1 (0.24%) patient had an event of thrombocytopenia representing an incidence rate (While on Treatment Estimand) of 0.38 (95% CI: 0.01, 2.13) patients with events per 100 PY.

See then section on platelets in the Laboratory Findings section.

In the AS programme were not observed cases of: Malignancies, NMSC, CV events of MACE or thrombosis (ATE, PE, and DVT), GI Perforation, Rhabdomyolysis.

## Safety of Tofacitinib in the RA and PsA development programmes

The safety databases from the RA and PsA programmes provide insight on the incidence rates and range of  AEs  reported  with  tofacitinib  treatment  in  the  AS  programme,  whilst  recognising  the  differences regarding the design of the RA (separate monotherapy and background csDMARD) and PsA (background csDMARD only) programmes.

A description of the RA P2P3, RA P123LTE, PsA Cohort 2a, and PsA Cohort 3 safety populations is in table 48.

Table 48. RA and PsA Safety Populations and Completed Studies Contributing to Safety Assessment for the AS Programme

| Analysis Set                                  | Brief Description                                                                                                                                          | Safety Analysis                                                                                                                            | Phase / Studies                                                                                                                                                               |
|-----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RA Safety Populations (for contextualisation) | RA Safety Populations (for contextualisation)                                                                                                              | RA Safety Populations (for contextualisation)                                                                                              | RA Safety Populations (for contextualisation)                                                                                                                                 |
| RA P2P3                                       | All patients randomised to tofacitinib 5 mg IR BID during the full randomised periods of the completed Phase 2 and 3 studies in the RA clinical programme. | The Tofa 5 mg BID group of the RA P2P3 Cohort will provide RA contextualisation for the All Tofa 5 mg BID group of the AS All Tofa Cohort. | Phase 3 A3921045; A3921046; A3921064; A3921032, A3921044; A3921069; A3921187; A3921237 Phase 2 A3921019; A3921025; A3921035; A3921039; A3921040; A3921073; A3921129; A3921068 |

<div style=\"page-break-after: always\"></div>

Table 48. RA and PsA Safety Populations and Completed Studies Contributing to Safety Assessment for the AS Programme

| Analysis Set                                   | Brief Description                                                                                                                                                                                                                                                                       | Safety Analysis                                                                                                                           | Phase / Studies                                                                                                                                  |
|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| RA P123LTE                                     | All patients exposed to at least 1 dose of tofacitinib from the completed Phase 1, 2, 3 and LTE studies                                                                                                                                                                                 | The All Tofa group of the Cohort RA P123LTE will provide RA contextualisation for the All Tofa group of the AS All Tofa Cohort.           | P2P3 Studies listed above Phase 1 A3921130; A3921152 Phase 2 A3921109 Phase 3 A3921192; A3921215 (Japan specific); LTE A3921024; A3921041 (Japan |
| PsA Safety Populations (for contextualisation) | PsA Safety Populations (for contextualisation)                                                                                                                                                                                                                                          |                                                                                                                                           |                                                                                                                                                  |
| Cohort 2a                                      | All patients randomised to tofacitinib 5 mg IR BID or placebo → tofacitinib 5 mg IR BID sequences and received at least 1 dose of tofacitinib 5 mg IR BID during the full randomised periods of the completed Phase 3 Studies A3921125 (up to 6 months) and A3921091 (up to 12 months). | The All Tofa 5 mg BID group of PsA Cohort 2a will provide PsA contextualisation for the All Tofa 5 mg BID group of the AS All Tofa Cohort | Phase 3 A3921125; A3921091                                                                                                                       |
| Cohort 3                                       | All patients who received at least 1 dose of tofacitinib (tofacitinib 5 or 10 mg BID) from the completed Phase 3 Studies A3921091, A3921125 and the long-term extension (LTE) Study A3921092.                                                                                           | The All Tofa group of the PsA Cohort 3 will provide PsA contextualisation for the All Tofa group of the AS All Tofa Cohort                | Phase 3 and LTE A3921125; A3921091; A3921092                                                                                                     |

## Comparison of incidence rates of select AEs from the final integrated safety data for AS versus RA and PsA clinical development safety data

The next table summarises the incidence rate (While on Treatment Estimand) per 100 PY (with 95% CIs) for the AEs of special interest in all patients treated with tofacitinib 5 mg IR BID comparing the AS All Tofa 5 mg BID group in the All Tofa Cohort to the PsA Cohort 2a All Tofa 5 mg BID group and the RA P2P3 Tofa 5 mg BID group.

<div style=\"page-break-after: always\"></div>

Table 49. Incidence Rates (Number of Patients with Event per 100 PYs) of SAEs and Adverse Events of Special Interest in Patients Treated with Tofacitinib 5 mg IR BID in AS (Randomised Phase 2 and 3 Studies), PsA (Randomised Phase 3 Studies) and RA (Randomised Phase 2 and 3 Studies) Programmes (While on Treatment Estimand)

| GI perforationd                                       |   0 |   0 |   231.35 | 0.00 (0.00, 1.59)   | 1   | 0.3   | 201.02   | 0.50 (0.01, 2.77)   |   0 |   0 |   2584.41 | 0.00 (0.00,0.14)   |
|-------------------------------------------------------|-----|-----|----------|---------------------|-----|-------|----------|---------------------|-----|-----|-----------|--------------------|
| ILDi                                                  |   0 |   0 |   231.35 | 0.00 (0.00, 1.59)   | 0   | 0.0   | 201.10   | 0.00 (0.00, 1.83)   |   3 | 0.1 |   2583.22 | 0.12 (0.02,0.34)   |
| All-cause mortality                                   |   0 |   0 |   231.35 | 0.00 (0.00,1.59)    | 1   | 0.3   | 201.10   | 0.50 (0.01, 2.77)   |   8 | 0.3 |   2584.41 | 0.31 (0.13,0.61)   |
| All-cause mortality (all Event Last Dose Algorithm)ji |   0 |   0 |   261.97 | 0.00 (0.00, 1.41)   | NA  | NA    | NA       | NA                  |  15 | 0.6 |   2584.41 | 0.58 (0.32,0.96)   |

<!-- image -->

Table 50 summarises the incidence rate (While on Treatment Estimand) per 100 PY (with 95% CIs) for the AEs of special interest in All Tofa doses comparing the AS All Tofa group in the All Tofa Cohort to the PsA Cohort 3 All Tofa group and the RA P123LTE All Tofa group.

<div style=\"page-break-after: always\"></div>

Table 50. Incidence rate (While on Treatment Estimand) per 100 PY (with 95% CIs) for the AEs of special interest in All Tofa doses comparing the AS All Tofa group in the All Tofa Cohort to the PsA Cohort 3 All Tofa group and the RA P123LTE All Tofa group

<!-- image -->

| AdverseEvents                                      | Ankylosing Spondylitis (All Tofa Cohort) All Tofa N =420 Exposure (patient-years) = 232.98   | Ankylosing Spondylitis (All Tofa Cohort) All Tofa N =420 Exposure (patient-years) = 232.98   | Ankylosing Spondylitis (All Tofa Cohort) All Tofa N =420 Exposure (patient-years) = 232.98   | Ankylosing Spondylitis (All Tofa Cohort) All Tofa N =420 Exposure (patient-years) = 232.98   | Psoriatic Arthritis (Cohort 3) All Tofa N=783 Exposure (patient-years) = 2037.97   | Psoriatic Arthritis (Cohort 3) All Tofa N=783 Exposure (patient-years) = 2037.97   | Psoriatic Arthritis (Cohort 3) All Tofa N=783 Exposure (patient-years) = 2037.97   | Psoriatic Arthritis (Cohort 3) All Tofa N=783 Exposure (patient-years) = 2037.97   | Rheumatoid Arthritis (Cohort RA P123LTE) All Tofa N=7964 Exposure (patient-years) =23496.73   | Rheumatoid Arthritis (Cohort RA P123LTE) All Tofa N=7964 Exposure (patient-years) =23496.73   | Rheumatoid Arthritis (Cohort RA P123LTE) All Tofa N=7964 Exposure (patient-years) =23496.73   | Rheumatoid Arthritis (Cohort RA P123LTE) All Tofa N=7964 Exposure (patient-years) =23496.73   |
|----------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
|                                                    |                                                                                              | %                                                                                            | PY                                                                                           | Incidence rate (95% CI) Per 100 PY                                                           | n                                                                                  | %                                                                                  | PY                                                                                 | Incidence rate (95% CI) Per 100 PY                                                 |                                                                                               | %                                                                                             | PY                                                                                            | Incidence rate (95% CI) Per 100PY                                                             |
| SAEs                                               | 9                                                                                            | 2.14                                                                                         | 260.64                                                                                       | 3.45 (1.58, 6.55)                                                                            | 135                                                                                | 17.2                                                                               | 1938.22                                                                            | 6.97 (5.84, 8.24)                                                                  | 1913                                                                                          | 24.0                                                                                          | 21361.14                                                                                      | 8.96 (8.56, 9.37)                                                                             |
| Serious infections                                 | 1                                                                                            | 0.24                                                                                         | 262.75                                                                                       | 0.38 (0.01, 2.12)                                                                            | 24                                                                                 | 3.1                                                                                | 2091.93                                                                            | 1.15 (0.74, 1.71)                                                                  | 592                                                                                           | 7.4                                                                                           | 23883.77                                                                                      | 2.48 (2.28, 2.69)                                                                             |
| OIab                                               | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 7                                                                                  | 0.9                                                                                | 2089.54                                                                            | 0.34 (0.13, 0.69)                                                                  | 133                                                                                           | 1.7                                                                                           | 24054.65                                                                                      | 0.55 (0.46, 0.66)                                                                             |
| TBa                                                | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 0                                                                                  | 0.0                                                                                | 2099.94                                                                            | 0.00 (0.00, 0.18)                                                                  | 38                                                                                            | 0.5                                                                                           | 24134.75                                                                                      | 0.16 (0.11, 0.22)                                                                             |
| HZ                                                 | 7                                                                                            | 1.67                                                                                         | 260.89                                                                                       | 2.68 (1.08, 5.53)                                                                            | 36                                                                                 | 4.6                                                                                | 2045.98                                                                            | 1.76 (1.23, 2.44)                                                                  | 795                                                                                           | 10.0                                                                                          | 22198.96                                                                                      | 3.58 (3.34, 3.84)                                                                             |
| Malignancies excluding NMSCa                       | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 15                                                                                 | 1.9                                                                                | 2098.40                                                                            | 0.71 (0.40, 1.18)                                                                  | 179                                                                                           | 2.2                                                                                           | 24108.42                                                                                      | 0.74 (0.64, 0.86)                                                                             |
| Lymphomaa                                          | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 1                                                                                  | 0.1                                                                                | 2099.86                                                                            | 0.05 (0.00, 0.27)                                                                  | 12                                                                                            | 0.2                                                                                           | 24137.17                                                                                      | 0.05 (0.03,0.09)                                                                              |
| NMSCa                                              | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 16                                                                                 | 2.0                                                                                | 2076.76                                                                            | 0.77 (0.44, 1.25)                                                                  | 133                                                                                           | 1.7                                                                                           | 23860.11                                                                                      | 0.56 (0.47, 0.66)                                                                             |
| MACEa                                              | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 6                                                                                  | 0.8                                                                                | 2095.81                                                                            | 0.29 (0.11, 0.62)                                                                  | 85                                                                                            | 1.2                                                                                           | 22966.82                                                                                      | 0.37 (0.30, 0.46)                                                                             |
| DVTc                                               | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 1                                                                                  | 0.1                                                                                | 2099.86                                                                            | 0.05 (0.00, 0.27)                                                                  | 37                                                                                            | 0.5                                                                                           | 24083.96                                                                                      | 0.15 (0.11, 0.21)                                                                             |
| PEC                                                | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 1                                                                                  | 0.1                                                                                | 2098.46                                                                            | 0.05 (0.00, 0.27)                                                                  | 31                                                                                            | 0.4                                                                                           | 24107.10                                                                                      | 0.13 (0.09, 0.18)                                                                             |
| ATE                                                | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 1                                                                                  | 0.9                                                                                | 2086.35                                                                            | 0.34 (0.13, 0.69)                                                                  | 85                                                                                            | 1.1                                                                                           | 23957.05                                                                                      | 0.35 (0.28, 0.44)                                                                             |
| VTEcd                                              | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 2                                                                                  | 0.3                                                                                | 2098.38                                                                            | 0.10 (0.01, 0.34)                                                                  | 61                                                                                            | 0.8                                                                                           | 24064.63                                                                                      | 0.25 (0.19, 0.33)                                                                             |
| Thrombosisce                                       | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 9                                                                                  | 1.1                                                                                | 2084.79                                                                            | 0.43 (0.20, 0.82)                                                                  | 145                                                                                           | 1.8                                                                                           | 23887.58                                                                                      | 0.61 (0.51, 0.71)                                                                             |
| GI perforationa                                    | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 1                                                                                  | 0.1                                                                                | 2099.86                                                                            | 0.05 (0.00, 0.27)                                                                  | 27                                                                                            | 0.3                                                                                           | 24135.92                                                                                      | 0.11 (0.07, 0.16)                                                                             |
| ILDE                                               | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 1                                                                                  | 0.1                                                                                | 2099.59                                                                            | 0.05 (0.00, 0.27)                                                                  | 45                                                                                            | 0.6                                                                                           | 24084.98                                                                                      | 0.19 (0.14, 0.25)                                                                             |
| All-cause mortality                                | 0                                                                                            | 0                                                                                            | 262.82                                                                                       | 0.00 (0.00, 1.40)                                                                            | 2                                                                                  | 0.3                                                                                | 2099.94                                                                            | 0.10 (0.01, 0.34)                                                                  | 59                                                                                            | 0.7                                                                                           | 24139.28                                                                                      | 0.24 (0.19, 0.32)                                                                             |
| All-cause mortality (all EventLast Dose Algorithm) | 0                                                                                            | 0                                                                                            | 297.13                                                                                       | 0.00 (0.00, 1.24)                                                                            | 7                                                                                  | 0.9                                                                                | 2037.38                                                                            | 0.34 (0.14, 0.71)                                                                  | 121                                                                                           | 1.5                                                                                           | 24139.28                                                                                      | 0.50 (0.42, 0.60)                                                                             |

Source:Module5.3.5.3SCSTab1esC2.3.3.3.2-E,C2.6.1.1-E,C2.5.1.2.1-E,C2.5.2.2.1-E,C2.5.4.2.1-E,C2.5.10.2.1-E,C2.5.11.2.1-E,C2.3.3.3.1-E,C2.3.1.3.6-E;PsAIR Module 5.3.5.3 PsA Cohort 3 Tables 00118.C3.10.1.2.3, 00118.C3.10.2.1.a, 00118.C3.10.2.1, 00118.C3.2.10.1, 00118.C3.2.8.1,00118.C3.2.19.1, 00118.C3.2.5.1, 1582.4.1.1,1582.10.4,1571.10.2.1.1,1571.11.2.1.1,1571.12.2.1.

a.Adjudicatedeventsin allstudies.

b. Opportunistic infections exclude Tuberculosis.

c.Adjudicated events in AS studies only.

d.VTE includes DVT and/or PE.

e. Thrombosis includes DVT, PE and/or ATE.

f.Adjudicatedevents by aPfizerInternalReviewCommittee.

g. The numerator counts all the events occurred either on- or off-treatment, while PY (the denominator) is calculated to subject's Treatment Policy Risk Period in AS, subject's last dose inPsA and subject's last dose + 28 days in RA.

Exposureis thesum of treatment exposuresof all thesubjects.Riskperiodistosubject'slast dose+28daysortotheendof the cohort exceptfor all-causemortality(allevent last dose algorithm)noted above.Events are countedwithin the riskperiod.

PY (in patient-year) is the sum of the times to the first event for subjects with event or to the end of the risk period for subjects without event and is the denominator for the incidenceratecalculation.

Incidence rate was a naive estimate without adjustingfor study.ExactPoisson(adjusted forPY)95%CIis provided for the incidence rate.

PsA Cohort 3 A11 Tofa group includes completed randomised Phase 3 Studies A3921091, A3921125 and LTE Study A3921092.

AS Al1 Tofa Cohort All Tofa group includes completed randomised Phase 2 Study A3921119 and Phase 3 Study A3921120.

RA Cohort RA P123LTE Al1 Tofa group includes completed randomised Phase 2, 3 and LTE Studies A392-1019, 1024 (LTE), 1025, 1032, 1035, 1039, 1040, 1041 (LTE), 1044 (2 years), 1045, 1046, 1064, 1068,1069 (2 years), 1073, 1109, 1129, 1130, 1152, 1187,1192,1215, and 1237.

## Serious adverse event/deaths/other significant events

## Ankylosing Spondylitis

## Deaths

No deaths were reported in the AS IR clinical programme.

## SAEs

The proportion of patients reporting SAEs for each treatment group and the associated incidence rates (While on Treatment Estimand) are as follows:

<div style=\"page-break-after: always\"></div>

- -Tofa 5 mg BID group: 3 (1.62%) patients representing an incidence rate of 5.28 patients with events per 100 PY.
- -Placebo group: 2 (1.07%) patients representing an incidence rate of 3.56 patients with events per 100 PY. There was an additional patient who experienced 3 SAEs (Foetal death, Vaginal haemorrhage, and Uterine spasm) outside the 28-Day While on Treatment Risk Period; these events were not included in the incidence rate calculation.

SAEs in the Placebo-controlled Cohort are reported in table 51.

| Table 51 . Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Summary of Serious Adverse Events by System Organ Class and Preferred Term (All Adverse Events) - Treatment Policy Estimand, AS Placebo-Controlled Cohort   | Table 51 . Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Summary of Serious Adverse Events by System Organ Class and Preferred Term (All Adverse Events) - Treatment Policy Estimand, AS Placebo-Controlled Cohort   | Table 51 . Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Summary of Serious Adverse Events by System Organ Class and Preferred Term (All Adverse Events) - Treatment Policy Estimand, AS Placebo-Controlled Cohort   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number of Subjects Evaluable for Adverse Events                                                                                                                                                                                        | Tofa 5 mg BID (N=185)                                                                                                                                                                                                                  | Placebo (N=187)                                                                                                                                                                                                                        |
| Number (%) of Subjects with Serious Adverse Events (a): by SYSTEM ORGAN CLASS and Preferred Term                                                                                                                                       | n (%)                                                                                                                                                                                                                                  | n (%)                                                                                                                                                                                                                                  |
| EAR AND LABYRINTH DISORDERS                                                                                                                                                                                                            | 1 (0.5)                                                                                                                                                                                                                                | 1 (0.5)                                                                                                                                                                                                                                |
| Hypoacusis                                                                                                                                                                                                                             | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| Vertigo                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| EYE DISORDERS                                                                                                                                                                                                                          | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| Iridocyclitis                                                                                                                                                                                                                          | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                                                                                                                                   | 1 (0.5)                                                                                                                                                                                                                                | 1 (0.5)                                                                                                                                                                                                                                |
| Condition aggravated                                                                                                                                                                                                                   | 1 (0.5)                                                                                                                                                                                                                                | 1 (0.5)                                                                                                                                                                                                                                |
| INFECTIONS AND INFESTATIONS                                                                                                                                                                                                            | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| Meningitis aseptic                                                                                                                                                                                                                     | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| INJURY, POISONINGAND PROCEDURAL COMPLICATIONS                                                                                                                                                                                          | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| Thoracic vertebral fracture                                                                                                                                                                                                            | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| PREGNANCY, PUERPERIUM AND PERINATAL CONDITIONS                                                                                                                                                                                         | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| Foetal death                                                                                                                                                                                                                           | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| REPRODUCTIVE SYSTEM AND BREAST DISORDERS                                                                                                                                                                                               | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| Uterine spasm                                                                                                                                                                                                                          | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| Vaginal haemorrhage                                                                                                                                                                                                                    | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| Total preferred term events (b)                                                                                                                                                                                                        | 4                                                                                                                                                                                                                                      | 6                                                                                                                                                                                                                                      |
| Total Number of Cases (c)                                                                                                                                                                                                              | 3                                                                                                                                                                                                                                      | 4                                                                                                                                                                                                                                      |
| Total Number of Subjects with Serious Adverse Events (d)                                                                                                                                                                               | 3                                                                                                                                                                                                                                      | 3                                                                                                                                                                                                                                      |
| Total Number of Subjects with Serious Adverse Events (e): 6                                                                                                                                                                            | Total Number of Subjects with Serious Adverse Events (e): 6                                                                                                                                                                            | Total Number of Subjects with Serious Adverse Events (e): 6                                                                                                                                                                            |

(a) SAEs are counted at MedDRA preferred term/analysis group with each individual SAE counted only once per subject per analysis group.

(b) Total number of events per subject per analysis group. (c) Number of cases that started in the analysis group.

(d) Total number of subjects having an event that started in the analysis group. (e) Overall count of subjects that had a Serious adverse Event in any analysis group.

A case is a single event or a series of related events not separated in time occurring in a single subject.

Source of Analysis Group is OC(Oracle Clinical). Source of SAE is SDW(Safety Data Warehouse).

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v.23.0J coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adsaec Table Generation: 11NOV2020 (20:46)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCSPC\\_EU/adsae\\_s001

Table C1.3.3.2-E is for Pfizer internal use.

<div style=\"page-break-after: always\"></div>

SAEs reported in the All Tofa Cohort are summarised in table 52.

## Table 52. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Summary of Serious Adverse Events by System Organ Class and Preferred Term (All Adverse Events) - Treatment Policy Estimand, AS All Tofa Cohort

| Number of Subjects Evaluable for Adverse Events                                                  | All Tofa 5 mg BID (N=316)   | All Tofa (N=420)   |
|--------------------------------------------------------------------------------------------------|-----------------------------|--------------------|
| Number (%) of Subjects with Serious Adverse Events (a): by SYSTEM ORGAN CLASS and Preferred Term | n (%)                       | n (%)              |
| EAR AND LABYRINTH DISORDERS                                                                      | 1 (0.3)                     | 1 (0.2)            |
| Hypoacusis                                                                                       | 1 (0.3)                     | 1 (0.2)            |
| EYE DISORDERS                                                                                    | 1 (0.3)                     | 1 (0.2)            |
| Iridocyclitis                                                                                    | 1 (0.3)                     | 1 (0.2)            |
| GASTROINTESTINAL DISORDERS                                                                       | 1 (0.3)                     | 1 (0.2)            |
| Abdominal adhesions                                                                              | 1 (0.3)                     | 1 (0.2)            |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                             | 1 (0.3)                     | 1 (0.2)            |
| Condition aggravated                                                                             | 1 (0.3)                     | 1 (0.2)            |
| HEPATOBILIARY DISORDERS                                                                          | 1 (0.3)                     | 1 (0.2)            |
| Hyperplastic cholecystopathy                                                                     | 1 (0.3)                     | 1 (0.2)            |
| INFECTIONS AND INFESTATIONS                                                                      | 1 (0.3)                     | 1 (0.2)            |
| Meningitis aseptic                                                                               | 1 (0.3)                     | 1 (0.2)            |
| INJURY, POISONINGAND PROCEDURAL COMPLICATIONS                                                    | 1 (0.3)                     | 2 (0.5)            |
| Rib fracture                                                                                     | 1 (0.3)                     | 1 (0.2)            |
| Tendon injury                                                                                    | 0                           | 1 (0.2)            |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS                                                  | 1 (0.3)                     | 1 (0.2)            |
| Spinal osteoarthritis                                                                            | 1 (0.3)                     | 1 (0.2)            |
| NERVOUS SYSTEM DISORDERS                                                                         | 1 (0.3)                     | 1 (0.2)            |
| Migraine                                                                                         | 1 (0.3)                     | 1 (0.2)            |
| RENAL AND URINARY DISORDERS                                                                      | 1 (0.3)                     | 1 (0.2)            |
| Ureterolithiasis                                                                                 | 1 (0.3)                     | 1 (0.2)            |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS                                                  | 1 (0.3)                     | 1 (0.2)            |
| Pneumothorax                                                                                     | 1 (0.3)                     | 1 (0.2)            |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                           | 1 (0.3)                     | 1 (0.2)            |
| Subcutaneous emphysema                                                                           | 1 (0.3)                     | 1 (0.2)            |
| Total preferred term events (b)                                                                  | 12                          | 13                 |
| Total Number of Cases (c)                                                                        | 9                           | 10                 |
| Total Number of Subjects with Serious Adverse Events (d)                                         | 9                           | 10                 |
| Total Number of Subjects with Serious Adverse Events (e): 10                                     |                             |                    |

<div style=\"page-break-after: always\"></div>

Table 52. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Summary of Serious Adverse Events by System Organ Class and Preferred Term (All Adverse Events) - Treatment Policy Estimand, AS All Tofa Cohort

| Number of Subjects Evaluable for Adverse Events                                                  | All Tofa 5 mg BID (N=316)   | All Tofa (N=420)   |
|--------------------------------------------------------------------------------------------------|-----------------------------|--------------------|
| Number (%) of Subjects with Serious Adverse Events (a): by SYSTEM ORGAN CLASS and Preferred Term | n (%)                       | n (%)              |

(a) SAEs are counted at MedDRA preferred term/analysis group with each individual SAE counted only once per subject per analysis group.

(b) Total number of events per subject per analysis group. (c) Number of cases that started in the analysis group.

(d) Total number of subjects having an event that started in the analysis group.

(e) Overall count of subjects that had a Serious adverse Event in any analysis group.

A case is a single event or a series of related events not separated in time occurring in a single subject.

Source of Analysis Group is OC(Oracle Clinical). Source of SAE is SDW(Safety Data Warehouse). Included Protocols:

A3921119, A3921120 (Final Data).

MedDRA v.23.0J coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adsaec Table Generation: 11NOV2020 (22:32)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCS\\_EU/adsae\\_s001

Table C2.3.3.2-E is for Pfizer internal use.

The proportion of patients reporting SAEs for the All Tofa 5 mg BID group and the associated incidence rate (While on Treatment Estimand) are: All Tofa 5 mg BID group: 8 (2.53%) patients representing an incidence rate of 3.49 (95% CI: 1.51, 6.87) patients with events per 100 PY.

## Laboratory findings

The pooled safety population has been used to evaluate changes from baseline in laboratory parameters of AS patients. For the Placebo-controlled Cohort, data for both A3921119 and A3921120 were pooled through Week 16. For the A3921119 study, the last dose of study medication was at the Week 12 visit. The Week 16 visit was a follow up visit 4 weeks after the last dose of study medication and was also included in the pooled safety population datasets.

Incidence of laboratory abnormalities are shown in table 53, without regard to baseline abnormality for the Placebo-controlled Cohort.

<div style=\"page-break-after: always\"></div>

## Table 53. Tofacitinib Summary of Clinical Safety

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| LaboratoryAbnormalities: NumberofSubjectsEvaluableforLaboratoryAbnormalities: Number(%)ofSubjectswithLaboratoryAbnonmalities:   | LaboratoryAbnormalities: NumberofSubjectsEvaluableforLaboratoryAbnormalities: Number(%)ofSubjectswithLaboratoryAbnonmalities:   | LaboratoryAbnormalities: NumberofSubjectsEvaluableforLaboratoryAbnormalities: Number(%)ofSubjectswithLaboratoryAbnonmalities:   | Tofa5mgBID 184 76 (41.3%)   | Tofa5mgBID 184 76 (41.3%)   | Placebo 184 89 (48.4%)   | Placebo 184 89 (48.4%)   |
|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------|--------------------------|--------------------------|
| Group                                                                                                                           | Parameter(Units)                                                                                                                | Primary Criteria                                                                                                                | N                           | n (%)                       | N                        | n (%)                    |
|                                                                                                                                 | URINE Leukocytes(/HPF)                                                                                                          | =20                                                                                                                             | 74                          | 4 (5.4)                     | 79                       | 3 (3.8)                  |
|                                                                                                                                 | HyalineCasts (/LPF)                                                                                                             | >1                                                                                                                              | 4                           | 3 ( 75.0)                   | 8                        | 6 ( 75.0)                |

NOTE: N = total number of subjects in the Safety Analysis Set with at least one observation of the given laboratory test while on study treatment or during lag time. n = number of subjects with a laboratory abnormality meeting specified criteria while on study treatment or during lag time. Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable subjects. Included Protocols:A3921119,A3921120(Final Data).

Patients  who  had  abnormalities  for  selected  laboratory  evaluations  of  interest  for  tofacitinib  were required to promptly retest a laboratory parameter or discontinue study medication due to the laboratory abnormalities.  The  number of patients who met the criteria for retesting a laboratory parameter of interest, or had to discontinue study medication due to laboratory abnormalities are presented in the table below for the Placebo-controlled Cohort.

<div style=\"page-break-after: always\"></div>

Table  54.  Tofacitinib  Summary  of  Clinical  Safety  (Ankylosing  Spondylitis)  Incidence  of Laboratory Values Meeting Protocol Criteria for Monitoring and Discontinuation of Study Drug - Treatment Policy Estimand, AS Placebo-Controlled Cohort

|                                                                                                             | Tofa 5 mg BID (N=185) n (%)   | Placebo (N=187) n (%)   |
|-------------------------------------------------------------------------------------------------------------|-------------------------------|-------------------------|
| Category: Monitoring Criteria                                                                               |                               |                         |
| Met any monitoring criteria                                                                                 | 4 (2.2)                       | 9 (4.8)                 |
| Any single hemoglobin drops >2 g/dL belowbaseline                                                           | 0                             | 4 (2.1)                 |
| Absoluteneutrophilcount<1.2x10**9/L                                                                         | 1 (0.5)                       | 0                       |
| Absolute lymphocyte count <0.5 x 10**9/L                                                                    | 1 (0.5)                       | 0                       |
| Plateletcount<100x10**9/L                                                                                   | 0                             | 1 (0.5)                 |
| Serum creatinine increase >50% or increase >0.5 mg/dL over the average of screening andbaselinevalues       | 0                             | 1 (0.5)                 |
| Any creatinekinase (CK)>5x ULN                                                                              | 2 (1.1)                       | 3 (1.6)                 |
| Category:DiscontinuationCriteria                                                                            |                               |                         |
| Met any discontinuation criteria                                                                            | 1 (0.5)                       | 1 (0.5)                 |
| Two sequential absolute neutrophil counts <1.0 x 10**9/L                                                    | 0                             | 0                       |
| Two sequential absolute lymphocyte counts <500 lymphocytes/mm**3                                            | 0                             | 0                       |
| Two sequential hemoglobin <8.0 g/dL or decreases of >30% from baseline value                                | 0                             | 0                       |
| Two sequential platelet counts <75 x 10**9/L                                                                | 0                             | 0                       |
| Two sequential AST or ALT elevations >=3x ULN with at least one total bilirubin >= 2x ULN                   | 0                             | 0                       |
| Two sequential AST or ALT elevations >=3x ULN accompanied by hepatic injury (eg, new onset elevated PT/INR) | 0                             | 0                       |
| Two sequential AST or ALT elevations >5x ULN                                                                | 1 (0.5)                       | 0                       |
| Twosequentialserumcreatinineincrease>50%andincrease>0.5mg/dLoverthe average of screening and baselinevalues | 0                             | 0                       |
| Two sequential creatine kinase (CK) elevations >10x ULN                                                     | 0                             | 0                       |
| A confirmed positive urine pregnancy test in a woman of childbearing potential                              | 0                             | 1 (0.5)                 |

Asubjectmayhavemetmultiplecriteria.Eachsubjectiscountedonlyonceforeachrow.

Baseline is defined as last non-missing assessment prior to first dose of investigational product (including Placebo).

N: Number of subjects included in the Safety Analysis Set; n (%): Number of subjects who meet the criteria (Percentages are based on N).

IncludedProtocols:A3921119,A3921120(FinalData)

PFIZERCONFIDENTIALSourceData:adlbTableGeneration:11NOV2020(08:37)

(Final Data: 10Sep2020) Output File: ./unblind 1120/A392 SCSPC EU/adlb s401

Table C1.3.4.4-E is for Pfizer internal use.

## Haemoglobin

Tofacitinib  is  associated  with  increased  incidence  of  anaemia.  Therefore,  patient  selection  based  on threshold Hb values was an exclusion criterion. Patients were required to have Hb levels ≥ 10 g/dL at the study enrollment visit to enroll in the AS studies.

Hb changes over time are presented for the Placebo-controlled Cohort in the figure below and All Tofa Cohort in the following figure. There were no patient discontinuations due to decreases in Hb.

<div style=\"page-break-after: always\"></div>

Figure  25.  Tofacitinib  Summary  of  Clinical  Safety  -  Mean  (±  SE)  Change  from  Baseline  in Haemoglobin (g/dL) -AS Placebo-controlled Cohort

<!-- image -->

Source:Module 5.3.5.3 SCS Figure C1.3.4.3.4.4-E

Figure 26. Tofacitinib Summary of Clinical Safety -Mean (± SE) Change from Baseline in Haemoglobin (g/dL) -AS All Tofa Cohort

<!-- image -->

Source: Module 5.3.5.3 SCS Figure C2.3.4.3.4.4-E

<div style=\"page-break-after: always\"></div>

Tofacitinib has been associated with an increased incidence of neutropenia, therefore patient selection based on threshold ANC values was an exclusion criterion. The mean (± SE) Change from Baseline in Absolute Neutrophil Count is reported in the next table.

Figure 27. Tofacitinib Summary of Clinical Safety - Mean (± SE) Change from Baseline in Absolute Neutrophil Count (10 3 /mm 3 ) -AS Placebo-controlled Cohort

<!-- image -->

Source: Module 5.3.5.3 SCS Figure C1.3.4.3.4.4-E

## Platelets

Patient selection based on threshold platelet counts was implemented as exclusion criteria in clinical trials.  To  enrol  in  the  AS  programme,  patients  were  required  to  have  a  platelet  count  ≥100,000 platelets/mm3 at the study enrolment visit. Platelet count changes over time are presented for the Placebo-controlled  Cohort  in  the  Figure  below.  In  the  Placebo-controlled  Cohort,  there  was  a  mean decrease from baseline to Week 4 for the Tofacitinib 5 mg IR BID group. Platelet counts decreased around  40,000  averagely  from  baseline  during  the  first  4  weeks.  Afterwards,  the  platelet  counts increased slightly until 16 weeks but remained averagely 30,000 under the baseline average count. Platelet change in the placebo arm was not considerable and remained almost unchanged compared to the baseline. In the placebo-controlled phase, there were no patients that had to discontinue because of 2 sequential platelet counts &lt;75 x 10**9/L.

The mean platelet counts were lower in the Tofacitinib 5 mg IR BID group compared to the Placebo group up to Week 16. The mean and median platelet counts remained within the normal range for all visits.

<div style=\"page-break-after: always\"></div>

Figure  28.  Tofacitinib  Summary  of  Clinical  Safety  -  Mean  (±  SE)  Change  from  Baseline  in Platelets (10 3 /mm 3 ) -AS Placebo-controlled Cohort

<!-- image -->

Source:Module5.3.5.3SCSFigureC1.3.4.3.4.4-E

Platelet  counts  decreased  during  the  first  4  weeks  of  tofacitinib  treatment  significantly  (mean  of approximately -45,000 in tofacitinib 5mg BID group).  After 4 th  week the platelet counts increased slightly but still remained significantly lower than the baseline (mean decrease of -30,000 until week 48).

Figure  29.  Tofacitinib  Summary  of  Clinical  Safety -Mean  (±SE)  Change  from  Baseline  in Platelets (103/mm3) -AS All Tofa Cohort

<!-- image -->

<div style=\"page-break-after: always\"></div>

Tables 55 show a comparison of platelet counts in AS vs RA/PsA clinical programs.

Table 55. Platelet Count (10 3 /mm 3 ) by Visit for AS Placebo-controlled Cohort versus RA and PsA -3-month data

|          |                                | AS Placebo- controlled cohort   | AS Placebo- controlled cohort   | RA All Phase 3 Tofa 5 mg BID   | RA All Phase 3 Tofa 5 mg BID   | PsA Cohort 1            | PsA Cohort 1            |
|----------|--------------------------------|---------------------------------|---------------------------------|--------------------------------|--------------------------------|-------------------------|-------------------------|
| Visit    | Summary Statistics             | Tofa 5 mg BID                   | Placebo                         | Tofa 5 mg BID                  | Placebo                        | Tofa 5 mg BID           | Placebo                 |
| Baseline | N1                             | 185                             | 187                             | 1183                           | 666                            | 238                     | 236                     |
|          | Mean (SD)                      | 296.60 (81.705)                 | 307.26 (84.463)                 | 328.21 (95.81)                 | 325.16 (93.87)                 | 280.24 (86.30)          | 283.99 (88.04)          |
|          | Median (min, max)              | 285.00 (138.00, 666.00)         | 298.00 (156.00, 593.00)         | 314.0 (81.0, 849.0)            | 311.0 (38.0, 833.0)            | 271.00 (153.00, 703.00) | 268.50 (125.00, 703.00) |
| Week 4   | N1                             | 183                             | 179                             | 1150                           | 630                            | 233                     | 226                     |
|          | Mean (SD)                      | 251.04 (61.375)                 | 304.13 (82.488)                 | 295.57 (82.28)                 | 327.23 (97.47)                 | 257.67 (72.07)          | 280.24 (81.70)          |
|          | Median (min, max)              | 247.00 (109.00, 412.00)         | 294.00 (151.00, 584.00)         | 286.0 (67.0,746.0)             | 309.0 (125.0, 834.0)           | 248.00 (117.00, 540.00) | 274.00 (105.00, 678.00) |
|          | Mean Change from Baseline (SD) | -45.03 (54.579)                 | -2.78 (44.965)                  | -33.08 (58.40)                 | -0.26 (51.43)                  | -22.79 (51.11)          | -1.70 (47.19)           |
| Week 8   | N1                             | 52                              | 51                              | -                              | -                              | 227                     | 222                     |
|          | Mean (SD)                      | 260.27 (62.552)                 | 291.25 (74.371)                 | -                              | -                              | 262.87 (67.36)          | 275.50 (78.16)          |
|          | Median (min, max)              | 250.00 (165.00, 452.00)         | 279.00 (160.00, 537.00)         | -                              | -                              | 257.00 (138.00, 547.00) | 265.00 (94.00, 594.00)  |
|          | Mean Change from Baseline (SD) | -34.04 (54.349)                 | -3.57 (36.120)                  | -                              | -                              | -17.90 (52.83)          | -5.44 (49.79)           |
| Week 12  | N1                             | 178                             | 168                             | 1105                           | 606                            | 225                     | 216                     |
|          | Mean (SD)                      | 264.25 (57.953)                 | 304.09 (82.642)                 | 298.42 (82.69)                 | 326.22 (97.79)                 | 264.97 (73.14)          | 276.53 (90.24)          |
|          | Median (min, max)              | 261.50 (119.00, 418.00)         | 293.00 (86.00, 548.00)          | 289.0 (48.0,833.0)             | 312.0 (112.0, 833.0)           | 259.00 (108.00, 647.00) | 262.00 (76.00, 759.00)  |
|          | Mean Change from Baseline (SD) | -31.92 (56.558)                 | 0.08 (48.507)                   | -29.17 (65.69)                 | 0.52 (60.12)                   | -16.23 (53.19)          | -4.19 (54.04)           |
| Week 16* | N1                             | 179                             | 175                             | -                              | -                              | 237                     | 234                     |
|          | Mean (SD)                      | 270.58 (61.094)                 | 304.48 (89.657)                 | -                              | -                              | 264.57 (73.25)          | 278.32 (92.01)          |
|          | Median (min, max)              | 274.00 (124.00, 440.00)         | 293.00 (160.00, 604.00)         | -                              | -                              | 259.00 (108.00, 647.00) | 262.50 (76.00, 759.00)  |
|          | Mean Change from               | -26.98 (61.020)                 | -3.10 (56.815)                  | -                              | -                              | -15.52 (52.95)          | -4.91 (56.60)           |

<div style=\"page-break-after: always\"></div>

| Baseline (SD)   |
|-----------------|

Source: S0113 Module 5.3.5.3 SCS Tables C1.3.4.3.4.1-E and C1.3.4.3.4.3-E; S0000 Module 5.3.5.3 All Phase 3 Tables 14.2.2 and 14.2.3; S0014 Module 5.3.5.3 PsA Cohort 1 Tables C1.6.1.1 and C1.6.1.2

Abbreviation: AS = ankylosing spondylitis; BID = twice a day; max = maximum; min = minimum; N1= number of participants; PsA = psoriatic arthritis; RA= rheumatoid arthritis; SD = standard deviation; Tofa = tofacitinib.

Baseline is the latest pre-study treatment (Tofacitinib or placebo) dose measurement.

Includes subjects with a Baseline measurement and at least one post Baseline measurement.

AS Placebo-Controlled Cohort: Includes Protocols A3921119 and A3921120.

RA All Phase 3:  Includes Protocols A3921032, A3921044(1 year), A3921045, A3921046 and A3921064.

PsA Cohort 1: Includes Protocols A3921091 and A3921125.

*PsA Cohort 1 last observation

Table 56. Platelet Count (10 3 /mm 3 ) by Visit in AS for All Tofa Cohort versus RA and PsA -1-year data

|          |                    | AS All Tofa Cohort All Tofa 5 mg BID   | RA All Phase 3 Tofa 5 mg BID   | PsA All PsA Average Tofa 5 mg BID   |
|----------|--------------------|----------------------------------------|--------------------------------|-------------------------------------|
| Visit    | Summary Statistics |                                        |                                |                                     |
| Baseline | N1                 | 316                                    | 1183                           | 445                                 |
| Baseline | Mean (SD)          | 302.26 (84.419)                        | 328.21 (95.81)                 | 274.48 (80.18)                      |
| Baseline | Median (Min, Max)  | 292.50 (138.00, 666.00)                | 314.0 (81.0, 849.0)            | 262.00 (76.0, 703.0)                |
| Week 4   | N1                 | 185                                    | 1150                           | 442                                 |
| Week 4   | Mean (SD)          | 251.87 (61.586)                        | 295.57 (82.28)                 | 254.46 (69.27)                      |
| Week 4   | Median (Min, Max)  | 247.00 (109.00, 412.00)                | 286.0 (67.0,746.0)             | 245.50 (105.0, 658.0)               |
| Week 4   | Mean Change from   | -45.50 (54.922)                        | -33.08 (58.40)                 | -20.08 (53.22)                      |
| Week 8   | N1                 | 181                                    | -                              | -                                   |
| Week 8   | Mean (SD)          | 281.24 (75.193)                        | -                              | -                                   |
| Week 8   | Median (Min, Max)  | 268.00 (121.00, 556.00)                | -                              | -                                   |
| Week 8   | Mean Change from   | -24.41 (55.588)                        | -                              | -                                   |
| Week 12  | N1                 | 178                                    | 1105                           | 437                                 |
| Week 12  | Mean (SD)          | 264.25 (57.953)                        | 298.42 (82.69)                 | 264.90 (70.14)                      |
| Week 12  | Median (Min, Max)  | 261.50 (119.00, 418.00)                | 289.0 (48.0,833.0)             | 259.00 (108.0, 647.0)               |
| Week 12  | Mean Change from   | -31.92 (56.558)                        | -29.17 (65.69)                 | -10.04 (55.12)                      |
| Week 16  | N1                 | 305                                    | -                              | -                                   |
| Week 16  | Mean (SD)          | 274.40 (65.597)                        | -                              | -                                   |
| Week 16  | Median (Min, Max)  | 276.00 (124.00, 612.00)                | -                              | -                                   |
| Week 16  | Mean Change from   | -27.90 (63.231)                        | -                              | -                                   |
| Week 24  | N1                 | 256                                    | 1252                           | 412                                 |
| Week 24  | Mean (SD)          | 278.95 (72.070)                        | 294.05 (84.79)                 | 263.04 (64.91)                      |
| Week 24  | Median (Min, Max)  | 270.00 (122.00, 577.00)                | 287.0 (95.0, 694.0)            | 254.00 (105.0, 514.0)               |
| Week 24  | Mean Change from   | -24.97 (57.480)                        | -36.12 (67.57)                 | -12.28 (58.56)                      |

<div style=\"page-break-after: always\"></div>

| Week 32   | N1                | 247                     | -                   | -                      |
|-----------|-------------------|-------------------------|---------------------|------------------------|
| Week 32   | Mean (SD)         | 278.57 (74.249)         | -                   | -                      |
| Week 32   | Median (Min, Max) | 271.00 (118.00, 552.00) | -                   | -                      |
| Week 32   | Mean Change from  | -26.81 (58.408)         | -                   | -                      |
| Week 36   | N1                | -                       | 871                 | 396                    |
| Week 36   | Mean (SD)         | -                       | 282.57 (81.88)      | 262.64 (68.38)         |
| Week 36   | Median (Min, Max) | -                       | 275.0 (88.0, 694.0) | 251.50 (119.0, 602.0)  |
| Week 36   | Mean Change from  | -                       | -41.39 (67.81)      | -12.32 (62.11)         |
| Week 40   | N1                | 214                     | -                   | -                      |
| Week 40   | Mean (SD)         | 282.83 (76.655)         | -                   | -                      |
| Week 40   | Median (Min, Max) | 270.50 (115.00, 569.00) | -                   | -                      |
| Week 40   | Mean Change from  | -22.06 (63.704)         | -                   | -                      |
| Week 48   | N1                | 124                     | -                   | -                      |
| Week 48   | Mean (SD)         | 264.94 (58.191)         | -                   | -                      |
| Week 48   | Median (Min, Max) | 257.50 (117.00, 459.00) | -                   | -                      |
| Week 48   | Mean Change from  | -32.13 (55.047)         | -                   | -                      |
| Week 52   | N1                | -                       | 820                 | 383                    |
| Week 52   | Mean (SD)         | -                       | 288.42 (80.06)      | 262.52 (67.87)         |
| Week 52   | Median (Min, Max) | -                       | 282.0 (98.0, 910.0) | 253.00 (107.0, 583.0)  |
| Week 52   | Mean Change from  | -                       | -35.38 (64.14)      | 583.00) -13.34 (62.53) |

Baseline (SD) Source:  S0113 Module 5.3.5.3 SCS Tables C2.3.4.3.4.1-E and C2.3.4.3.4.3-E; S0000 Module 5.3.5.3 All Phase 3 Table 14.2.2 and 14.2.3; S0014 Module 5.3.5.3 PsA Cohort 3 Tables 00118.C3.6.1.1 and 00118.C3.6.1.2

Abbreviation: AS = ankylosing spondylitis; BID = twice a day; max = maximum; min = minimum; N1= number of participants; PsA = psoriatic arthritis; RA= rheumatoid arthritis; SD = standard deviation; Tofa = tofacitinib.

Baseline is the latest pre-Tofacitinib dose measurement.

Includes subjects with a Baseline measurement and at least one post Baseline measurement.

AS All Tofa Cohort: Includes Protocols A3921119 and A3921120.

RA All Phase 3:  Includes Protocols A3921032, A3921044(1 year), A3921045, A3921046 and A3921064.

PsA Average Tofa 5 mg : Subjects with an average total daily dose of &lt;15 mg from Day 1 on Tofa. Includes Protocols A3921091,

A3921125 and A3921092. Cohort 3 Includes all Tofacitinib exposed subjects.

## Liver Parameters

Tofacitinib has been associated with increases in liver test values compared to placebo. Most of these abnormalities have occurred in studies with background DMARD (primarily MTX) therapy.

Changes in AST in the placebo-controlled period are shown in the next figure.

<div style=\"page-break-after: always\"></div>

## Figure 30.  Tofacitinib Summary of Clinical Safety -Mean (±SE) Change from Baseline in AST (U/L) -AS Placebo-controlled Cohort

Module 5.3.5.3 SCS Figure C1.3.4.3.1.4-E

<!-- image -->

The change of AST (U/L) levels at 16 week from baseline was: mean (SD) 2.94 (11.588) in tofacitinib 5 mg vs  0.18 (6.903) in placebo.

Changes in ALT in the placebo-controlled period are shown in the next figure.

## Figure 31. Tofacitinib Summary of Clinical Safety -Mean (± SE) Change from Baseline in ALT (U/L) -AS Placebo-controlled Cohort

Module 5.3.5.3 SCS Figure C1.3.4.3.1.4-E

<!-- image -->

The change of AST (U/L) levels at 16 week from baseline was: mean (SD) 4.62 (20.662) in tofacitinib 5 mg vs  0.44 (10.134) in placebo.

<div style=\"page-break-after: always\"></div>

An analysis of the proportion of patients who experienced confirmed liver test values (2 consecutive elevations)  at  multiples  of  the  ULN  is  presented  for  the  Placebo-controlled  Cohort  is  shown  in  the following table (Table 57).

Table 57. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Number (%) of Subjects With Confirmed Liver Test Values as Multiples of Upper Limit of Normal (Without Regard to Baseline Abnormality) - Treatment Policy Estimand, AS Placebo-Controlled Cohort

|                 | Tofa5mgBID (N=184) n (%)   | Placebo (N=184) (%) I   |
|-----------------|----------------------------|-------------------------|
| ALT             |                            |                         |
| >=2xULN         | 4 (2.2)                    | 1 (0.5)                 |
| >=3 xULN        | 1 (0.5)                    | 0                       |
| >=5xULN         | 1 (0.5)                    | 0                       |
| >=10 x ULN      | 0                          | 0                       |
| AST             |                            |                         |
| >=2xULN         | 3 (1.6)                    | 0                       |
| >=3xULN         | 1 (0.5)                    | 0                       |
| >=5xULN         | 0                          | 0                       |
| >=10 xULN       | 0                          | 0                       |
| Total Bilinubin |                            |                         |
| >=2xULN         | 0                          | 0                       |
| >=3 xULN        | 0                          | 0                       |

Confirmed=at least 2 consecutive measurements with the subject.

N: Number of subjects who have a post-baseline observation for AST, ALT or total bilirubin; n (%): Number of subjects with the events (percentage based on N).

Included Protocols: A3921119,A3921120 (Final Data).

PFIZER CONFIDENTIAL Source Data: adlb Table Generation: 09NOV2020 (21:09)

(FinalData:10Sep2020)Output File:/unblind 1120/A392SCSPC EU/adlb s003 4

Table C1.3.4.3.4.8-E is for Pfizer intermal use.

## Renal Function Testing

Studies in RA patients treated with tofacitinib have demonstrated small mean increases in serum creatinine, which remained within the normal reference range. The mean change from baseline for creatinine is shown in the following figure (Fig. 32) for the Placebo-controlled Cohort.

<div style=\"page-break-after: always\"></div>

Figure 32. Tofacitinib Summary of Clinical Safety - Mean (± SE) Change from Baseline in creatinine (mg/dL) -AS Placebo-controlled Cohort

<!-- image -->

Module 5.3.5.3 SCS Figure C1.3.4.3.2.4-E

The changes of serum creatine at week 16 from baseline was: Mean (SD) 0.04 (0.100) in tofacitinib 5 mg vs 0.02 (0.095) in placebo.

## Lipid Parameters

Treatment  with  tofacitinib  has  been  associated  with  dose-dependent  increases  in  lipid  parameters including total cholesterol, LDL cholesterol and HDL cholesterol. Maximum effects have generally been observed within 6 weeks.

The mean change from baseline for cholesterol is shown in the following figure (Fig. 33) for the Placebocontrolled Cohort.

Figure 33. Tofacitinib Summary of Clinical Safety - Mean (± SE) Percent Change from Baseline in Cholesterol (mg/dL) -AS Placebo-controlled Cohort

<!-- image -->

Module 5.3.5.3 SCS Figure C1.3.4.3.3.4-E

<div style=\"page-break-after: always\"></div>

The changes from baseline for cholesterol were: mean (SD) 8.60 (15.164) in tofacitinib 5 mg vs 1.69 (13.083) in placebo.

The mean changes from baseline for HDL cholesterol are shown in the following figure (Fig. 34) for the Placebo-controlled Cohort.

Figure 34 . Tofacitinib Summary of Clinical Safety -Mean (± SE) Percent Change from Baseline in HDL Cholesterol (mg/dL) -AS Placebo-controlled Cohort

<!-- image -->

Module 5.3.5.3 SCS Figure C1.3.4.3.3.4-E

The changes at week 16 from baseline for HDL (mg/dL) cholesterol were: mean (SD) 5.04 (19.951) in tofacitinib 5 mg vs -0.49 (16.540) in placebo.

The mean changes from baseline for LDL cholesterol are shown in Figure 35 for the Placebo-controlled Cohort.

<div style=\"page-break-after: always\"></div>

Figure 35 . Tofacitinib Summary of Clinical Safety - Mean (± SE) Percent Change from Baseline in LDL Cholesterol (mg/dL) -AS Placebo-controlled Cohort

<!-- image -->

Module 5.3.5.3 SCS Figure C1.3.4.3.3.4-E

The changes at week 16 from baseline for LDL (mg/dL) cholesterol were: mean (SD) 10.37 (21.387) in tofacitinib 5 mg vs 4.46 (23.451) in placebo.

The mean changes from baseline for Triglycerides are shown in the following figure for the Placebocontrolled Cohort.

Figure 36 . Tofacitinib Summary of Clinical Safety - Mean (± SE) Percent Change from Baseline in Triglycerides (mg/dL) -AS Placebo-controlled Cohort

<!-- image -->

Module 5.3.5.3 SCS Figure C1.3.4.3.3.4-E

<div style=\"page-break-after: always\"></div>

The changes at week 16 from baseline for Triglycerides (mg/dL) were: mean (SD) 14.58 (39.489) in tofacitinib 5 mg vs 10.62 (74.379) in placebo.

## Blood pressure

Changes at week 16 from baseline for systolic blood pressure (mmHg) were, mean (SD): -0.1 (10.91) in tofacitinib 5 mg vs -0.2 (10.73) in placebo.

Changes at week 48 from baseline for systolic blood pressure (mmHg) were, mean (SD): -0.4 (11.20) in tofacitinib 5 mg BID and All tofa doses.

Changes at week 16 from baseline for diastolic blood pressure (mmHg) were, mean (SD): -0.1 (7.05) in tofacitinib 5 mg vs -0.5 (8.73) in placebo.

The next table shows the categorisation of changes in blood pressure parameters.

Table 58. Tofacitinib Summary of Clinical Safety (AS) -Categorisation of Vital Signs Data

TableC2.3.5.2-E

TofacitinibSummaryof Clinical Safety(AnkylosingSpondylitis)

CategorizationofVital SignsData-TreatmentPolicyEstimand,ASAllTofaCohort

<!-- image -->

|                                         |                        | AllTofa5mgBID (N=316)   | AllTofa5mgBID (N=316)   | AllTofa5mgBID (N=316)   | All Tofa (N=420)   | All Tofa (N=420)   | All Tofa (N=420)   |
|-----------------------------------------|------------------------|-------------------------|-------------------------|-------------------------|--------------------|--------------------|--------------------|
| Parameter(units)                        | Criteria               | N1                      | n (%)                   | n (%)                   | N1                 | (%)                | (%)                |
| SITTING SYSTOLIC BLOODPRESSURE (MMHG)   | Value <90mmHg          | 314                     | 1(                      | 0.3)                    | 415                | 1(                 | 0.2)               |
| SITTING SYSTOLIC BLOODPRESSURE (MMHG)   | Chg >= 30mmHg increase | 314                     | 11（                     | 3.5)                    | 415                | 12（                | 2.9)               |
| SITTING SYSTOLIC BLOODPRESSURE (MMHG)   | Chg >= 30mmHg decrease | 314                     | 8（                      | 2.5)                    | 415                | 11 (               | 2.7)               |
| SITTING DIASTOLIC BLOOD PRESSURE (MMHG) | ）Value <50 mmHg        | 314                     | 0                       |                         | 415                | 2（                 | 0.5)               |
| SITTING DIASTOLIC BLOOD PRESSURE (MMHG) | Chg >= 20mmHg increase | 314                     | 16 (                    | 5.1)                    | 415                | 19 (               | 4.6)               |
| SITTING DIASTOLIC BLOOD PRESSURE (MMHG) | Chg >= 20mmHg decrease | 314                     |                         | 16 (5.1)                | 415                | 23 (               | 5.5)               |
| SITTING PULSE RATE (BPM)                | Value <40 bpm          | 314                     | 0                       |                         | 415                | 0                  |                    |
| SITTING PULSE RATE (BPM)                | Value >120 bpm         | 314                     |                         | 1 (0.3)                 | 415                | 1（                 | 0.2)               |

## Body weight

Changes at week 16 from baseline for weight (kg) were, mean (SD): 1.8 (4.96) in tofacitinib 5 mg vs 0.5 (2.93) in placebo (see figure below).

<div style=\"page-break-after: always\"></div>

Figure 37. Tofacitinib Summary of Clinical Safety - Mean (± SE) Change from Baseline Weight (Kg) -AS Placebo-controlled Cohort

Module 5.3.5.3 SCS Figure C1.3.5.1.3-E

<!-- image -->

The changes of the weight from baseline among the All tofacitinib patients is shown in the following figure (Fig. 38).

Figure 38. Tofacitinib Summary of Clinical Safety - Mean (± SE) Change from Baseline in Weight (Kg) -AS All Tofa Cohort

Module 5.3.5.3 SCS Figure C2.3.5.1.3-E

<!-- image -->

At 48 weeks the change from baseline of the weight (kg) was, mean (SD) 2.2 (4.59) in the tofacitinib cohort in both arms (tofacitinib 5 mg and all tofacitinib doses).

The next table (Table 59) shows the shift in BMI categories.

<div style=\"page-break-after: always\"></div>

Table 59. Shift Table of BMI Categories Relative to Baseline by Visit (Safety Analysis Set) (Final Analysis) - A3921120

|         |                                      | BMI Category at Visit (kg/m 2 )   | BMI Category at Visit (kg/m 2 )   | BMI Category at Visit (kg/m 2 )   | BMI Category at Visit (kg/m 2 )   | BMI Category at Visit (kg/m 2 )   | BMI Category at Visit (kg/m 2 )        | BMI Category at Visit (kg/m 2 )        | BMI Category at Visit (kg/m 2 )        | BMI Category at Visit (kg/m 2 )        | BMI Category at Visit (kg/m 2 )        |
|---------|--------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
|         |                                      | Tofacitinib 5 mg BID (N=133)      | Tofacitinib 5 mg BID (N=133)      | Tofacitinib 5 mg BID (N=133)      | Tofacitinib 5 mg BID (N=133)      | Tofacitinib 5 mg BID (N=133)      | Placebo → Tofacitinib 5 mg BID (N=136) | Placebo → Tofacitinib 5 mg BID (N=136) | Placebo → Tofacitinib 5 mg BID (N=136) | Placebo → Tofacitinib 5 mg BID (N=136) | Placebo → Tofacitinib 5 mg BID (N=136) |
| Visit   | BMI Catego ry at Baselin e (kg/m 2 ) | N                                 | N1                                | <25 n (%)                         | ≥25 to  35 n (%)                 | ≥35 n (%)                         | N                                      | N1                                     | <25 (%)                                | ≥25 to  35 n (%)                      | ≥35 n (%)                              |
| Week 16 | <25                                  | 50                                | 50                                | 46 (92.0)                         | 4 (8.0)                           | 0                                 | 59                                     | 58                                     | 52 (89.7)                              | 6 (10.3)                               | 0                                      |
|         | ≥25 to  35                          | 74                                | 73                                | 2 (2.7)                           | 67 (91.8)                         | 4 (5.5)                           | 69                                     | 68                                     | 3 (4.4)                                | 65 (95.6)                              | 0                                      |
|         | ≥35                                  | 8                                 | 8                                 | 0                                 | 0                                 | 8 (100.0)                         | 8                                      | 7                                      | 0                                      | 0                                      | 7 (100.0)                              |
| Week 48 | <25                                  | 50                                | 49                                | 42 (85.7)                         | 7 (14.3)                          | 0                                 | 59                                     | 54                                     | 46 (85.2)                              | 8 (14.8)                               | 0                                      |
|         | ≥25 to  35                          | 74                                | 68                                | 1 (1.5)                           | 64 (94.1)                         | 3 (4.4)                           | 69                                     | 66                                     | 1 (1.5)                                | 63 (95.5)                              | 2 (3.0)                                |
|         | ≥35                                  | 8                                 | 7                                 | 0                                 | 0                                 | 7 (100.0)                         | 8                                      | 5                                      | 0                                      | 0                                      | 5 (100.0)                              |

Source: S0113 Module 5.3.5.1 A3921120 Table 420a.1.4

Abbreviations: BID= twice a day; BMI= body mass index; N = number of subjects in the Safety Analysis Set; N1 = number of subjects with observations at baseline and at post-baseline visits.

Baseline was defined as last non-missing assessment on or before day 1 and prior to first dose of investigational product. One subject in tofacitinib 5 mg BID has missing baseline BMI.

Percentages of BMI categories at post-baseline visit is calculated using N1 as denominator, conditioned on BMI category at baseline.

BMI at Week 16 and Week 48 are calculated using Height at Screening and Weight at Week 16 and Week 48 respectively.

## ECG

The following table shows the ECG parameters categorisation for the placebo-controlled cohort.

<div style=\"page-break-after: always\"></div>

## Table 60. Tofacitinib Summary of Clinical Safety (AS) -Categorisation of ECG Data

<!-- image -->

## Safety in special populations

## Age

The incidence proportions and incidence rates (While on Treatment Estimand) for TEAEs by Age Group for the AS All Tofa Cohort are presented in the next table.

<div style=\"page-break-after: always\"></div>

Table 61. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence Proportions and Incidence Rates for General Events and Infections by Age Group - While on Treatment Estimand, AS All Tofa Cohort

<!-- image -->

## Gender

<div style=\"page-break-after: always\"></div>

The incidence proportions and incidence rates (While on Treatment Estimand) for TEAEs SAEs, and discontinuations due to AEs by Gender for the AS All Tofa Cohort are presented in the next table (Table 62).

| Events Category                 | Gender      | Analysis Group             | N         | n(%)                       | (%) IUI            | PY                  | IR (95% CI) per 100 PY                          |
|---------------------------------|-------------|----------------------------|-----------|----------------------------|--------------------|---------------------|-------------------------------------------------|
| TEAEs                           | Male        | All Tofa 5 mg BID          | 261       | 160 ( 61.30)               | 3 (1.15)           | 107.68              | 148.59 (126.46, 173.48)                         |
|                                 |             | All Tofa                   | 333       | 189 ( 56.76)               | 3 (0.90)           | 123.81              | 152.65 (131.66, 176.03)                         |
|                                 | Female      | All Tofa 5 mg BID All Tofa | 55 87     | 38 (69.09)                 | 0 0                | 18.37 23.65         | 206.85 (146.38, 283.92) 249.48 (189.91, 321.81) |
|                                 | Male        | All Tofa 5 mg BID All Tofa | 261       | 59 ( 67.82) 6 (2.30)       | 1(0.38) 1 (0.30) 0 | 193.78 215.52 35.61 | 3.10 (1.14, 6.74) 3.25 (1.31, 6.69)             |
| SAEs                            | Female Male | All Tofa 5 mg BID All Tofa | 333 55 87 | 7 (2.10) 2 (3.64) 2 (2.30) | 0                  | 45.12               | 5.62 (0.68, 20.29) 4.43 (0.54, 16.01)           |
| Severe AEs                      |             | All Tofa 5 mg BID All Tofa | 261 333   | 6 (2.30) 6 (1.80) 1 (1.82) | 0 0 0              | 193.33              | 3.10 (1.14, 6.76) 2.79 (1.02, 6.07)             |
|                                 | Female      | All Tofa 5 mg BID          | 55        | 2 (2.30)                   |                    | 215.28 36.20        | 2.76 (0.07, 15.39)                              |
| Discontinuation ofstudy         | Male        | All Tofa                   | 87        |                            | 0 4 (1.53)         | 45.57               | 4.39 (0.53, 15.85)                              |
|                                 |             | All Tofa 5 mg BID All Tofa | 261 333   | 8 (3.07)                   | 4 (1.20)           | 195.10 217.05       | 4.10 (1.77, 8.08)                               |
|                                 | Female      | All Tofa 5 mg BID          | 55        | 12 (3.60) 2 (3.64)         | 1 (1.82)           |                     | 5.53 (2.86, 9.66)                               |
|                                 | Female      | All Tofa                   |           | 19 (7.28)                  | 2 (2.30)           | 45.77               | 5.52 (0.67, 19.93)                              |
|                                 |             | All Tofa All Tofa 5 mg BID | 87 261    | 3 (3.45)                   |                    | 36.25               | 6.56 (1.35, 19.16)                              |
| Discontinuationofstudytreatment | Male        |                            |           |                            | 0                  | 193.78              | 9.81 (5.90, 15.31)                              |
|                                 |             |                            | 333       | 23 (6.91)                  | 0                  | 215.72              | 10.66 (6.76, 16.00)                             |
|                                 |             |                            |           | 6 (10.91)                  |                    |                     |                                                 |
|                                 |             |                            |           |                            |                    |                     | 16.71 (6.13, 36.36)                             |
|                                 |             | All Tofa 5 mg BID          | 55        |                            | 0                  | 35.91               |                                                 |
|                                 |             | All Tofa                   | 87        | 8 (9.20)                   | 0                  | 45.30               | 17.66 (7.63, 34.80)                             |
| DiscontinuationduetoAEs         | Male        | All Tofa 5 mg BID          | 261       | 8 (3.07)                   | 0                  | 194.42              | 4.11 (1.78, 8.11)                               |
|                                 |             | All Tofa                   | 333       | 9 (2.70)                   | 0                  | 216.38              | 4.16 (1.90, 7.90)                               |

| Events Category    | Gender      | Analysis Group                            | N          | (%) uI                | nl (%)   | PY                  | IR (95% CI) per 100 PY                                 |
|--------------------|-------------|-------------------------------------------|------------|-----------------------|----------|---------------------|--------------------------------------------------------|
| All Infections     | Female      | All Tofa 5 mg BID All Tofa                | 55 87      | 3 (5.45) 3 (3.45)     | 0 0      | 36.10 45.61         | 8.31 (1.71, 24.29) 6.58 (1.36, 19.22)                  |
|                    | Female      | All Tofa 5 mg BID All Tofa                | 55 87 261  | 22 (40.00) 33 (37.93) | 0 0      | 26.75 34.07         | 82.25 (51.54, 124.52) 96.86 (66.67, 136.03)            |
| Serious Infections |             |                                           |            | 1(0.38)               | 0        |                     |                                                        |
|                    | Male Female | All Tofa 5 mg BID All Tofa All Tofa5mgBID | 333 55     | 1(0.30) 0             | 0 0      | 195.03 216.98 36.25 | 0.51 (0.01, 2.86) 0.46 (0.01, 2.57) 0.00 (0.00, 10.18) |
| Herpes Zoster      | Male        | All Tofa All Tofa 5 mg BID All Tofa       | 87 261 333 | 0 2(0.77) 3 (0.90)    | 0 0      | 45.77 194.60        | 0.00 (0.00, 8.06) 1.03 (0.12, 3.71)                    |
|                    |             | All Tofa 5 mg BID All Tofa                |            |                       | 0        | 216.48 35.13        | 1.39 (0.29, 4.05)                                      |
|                    | Female      |                                           | 55         | 3 (5.45)              |          |                     | 8.54 (1.76, 24.95)                                     |
|                    |             |                                           | 87         | 4 (4.60)              | 0 0      | 44.41               | 9.01 (2.45, 23.06)                                     |

Table 62. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence Proportions and Incidence Rates for General Events and Infections by Gender - While on Treatment Estimand, AS All Tofa Cohort

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Race

The incidence proportions and incidence rates (While on Treatment Estimand) for TEAEs SAEs, and discontinuations due to AEs by race for the AS All Tofa Cohort presented in the next table (Table 63).

Table 63. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence Proportions and Incidence Rates for General Events and Infections by Race - While on Treatment Estimand, AS All Tofa Cohort

<!-- image -->

| Events Category          | Race   | Analysis Group    |   N | (%) u        | nl (%)   |     PY | IR (95% C1) per 100 PY   |
|--------------------------|--------|-------------------|-----|--------------|----------|--------|--------------------------|
| TEAEs                    | White  | All Tofa 5 mg BID | 252 | 149 ( 59.13) | 3 (1.19) | 108.84 | 136.90 (115.80, 160.73)  |
|                          |        | All Tofa          | 334 | 183 ( 54.79) | 3 (0.90) | 126.79 | 144.33 (124.18, 166.82)  |
|                          | Asian  | All Tofa 5 mg BID |  63 | 49 (77.78)   | 0        |  16.21 | 302.22 (223.58,399.55)   |
|                          |        | All Tofa          |  85 | 65 (76.47)   | 0        |  19.67 | 330.47 (255.05, 421.22)  |
|                          | Other  | All Tofa 5 mg BID |   1 | 0            | 0        |   1    | 0.00 (0.00,369.14)       |
|                          |        | All Tofa          |   1 | 0            | 0        |   1    | 0.00 (0.00,369.14)       |
| SAEs                     | White  | All Tofa 5 mg BID | 252 | 6(2.38)      | 0        | 182.74 | 3.28 (1.20, 7.15)        |
|                          |        | All Tofa          | 334 | 7 (2.10)     | 0        | 207.02 | 3.38 (1.36, 6.97)        |
|                          | Asian  | All Tofa 5 mg BID |  63 | 2 (3.17)     | 1 (1.59) |  45.64 | 4.38 (0.53, 15.83)       |
|                          |        | All Tofa          |  85 | 2(2.35)      | 1 (1.18) |  52.62 | 3.80 (0.46, 13.73)       |
|                          | Other  | All Tofa 5 mg BID |   1 | 0            | 0        |   1    | 0.00 (0.00,369.14)       |
|                          |        | All Tofa          |   1 | 0            | 0        |   1    | 0.00 (0.00, 369.14)      |
| Severe AEs               | White  | All Tofa 5 mg BID | 252 | 7 (2.78)     | 0        | 182.43 | 3.84 (1.54, 7.91)        |
|                          |        | All Tofa          | 334 | 8 (2.40)     | 0        | 206.78 | 3.87 (1.67, 7.62)        |
|                          | Asian  | All Tofa 5 mg BID |  63 | 0            | 0        |  46.09 | 0.00 (0.00, 8.00)        |
|                          |        | All Tofa          |  85 | 0            | 0        |  53.08 | 0.00 (0.00, 6.95)        |
|                          | Other  | All Tofa 5 mg BID |   1 | 0            | 0        |   1    | 0.00 (0.00, 369.14)      |
|                          |        | All Tofa          |   1 | 0            | 0        |   1    | 0.00 (0.00, 369.14)      |
| Discontinuation of study | White  | All Tofa 5 mg BID | 252 | 8 (3.17)     | 3 (1.19) | 184.26 | 4.34 (1.87, 8.55)        |
|                          |        | All Tofa          | 334 | 13 (3.89)    | 4 (1.20) | 208.74 | 6.23 (3.32, 10.65)       |
|                          | Asian  | All Tofa 5 mg BID |  63 | 2 (3.17)     | 2 (3.17) |  46.09 | 4.34 (0.53, 15.67)       |
|                          |        | All Tofa          |  85 | 2 (2.35)     | 2 (2.35) |  53.08 | 3.77 (0.46, 13.61)       |
|                          | Other  | All Tofa 5 mg BID |   1 | 0            | 0        |   1    | 0.00 (0.00, 369.14)      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Events Category                 | Race   | Analysis Group             | N       | (%) uI              | nl (%)   | PY               | IR(95% C1) per 100 PY                   |
|---------------------------------|--------|----------------------------|---------|---------------------|----------|------------------|-----------------------------------------|
|                                 |        | All Tofa                   | 1       | 0                   | 0        | 1.00             | 0.00 (0.00, 369.14)                     |
| Discontinuationofstudytreatment | White  | All Tofa 5 mg BID          | 252     | 19 ( 7.54)          | 0        | 183.16           | 10.37 (6.25, 16.20)                     |
|                                 |        | All Tofa                   | 334     | 25 ( 7.49)          | 0        | 207.51           | 12.05 (7.80, 17.78)                     |
|                                 | Asian  | All Tofa 5 mg BID          | 63      | 6 (9.52) 6 (7.06)   | 0 0 0    | 45.53 52.51 1.00 | 13.18 (4.84, 28.68) 11.43 (4.19, 24.87) |
|                                 |        | All Tofa                   | 85      |                     |          | 1.00             | 0.00 (0.00, 369.14)                     |
|                                 | Other  | All Tofa 5 mg BID All Tofa | 1       | 0 0                 | 0 0      | 183.50           | 0.00 (0.00, 369.14)                     |
|                                 | White  | All Tofa                   | 1       |                     |          |                  | 5.45 (2.61,10.02)                       |
| Discontinuationdue toAEs        |        | All Tofa 5 mg BID          | 252 334 | 10 (3.97) 11 (3.29) | 0        | 207.99           | 5.29 (2.64, 9.46)                       |
|                                 | Asian  | AllTofa5mgBID All Tofa     | 63 85   | 1 (1.59) 1 (1.18)   | 0 0 0    | 46.02 53.00      | 2.17 (0.06, 12.11) 1.89 (0.05, 10.51)   |
|                                 | Other  | Al1 Tofa 5 mg BID          | 1       | 0                   | 0        | 1.00 1.00        | 0.00 (0.00,369.14) 0.00 (0.00,369.14)   |
|                                 | White  | All Tofa                   | 1 252   | 0 78 (30.95)        | 3 (1.19) | 144.98           | 53.80 (42.53, 67.14)                    |
| All Infections                  |        | All Tofa                   | 334     | 93 (27.84)          | 3 (0.90) | 166.80           |                                         |
|                                 | Asian  | All Tofa 5 mg BID          |         |                     |          |                  | 55.76 (45.00, 68.30)                    |
|                                 |        | All Tofa                   | 63      | 33 (52.38)          | 0        | 29.52            | 111.78 (76.94, 156.98)                  |
|                                 |        | All Tofa 5 mg BID          | 85      | 39 ( 45.88)         | 0        | 35.13            | 111.01 (78.94, 151.75)                  |
|                                 |        | Al1 Tofa 5 mg BID          | 1       | 0                   | 0        | 1.00             | 0.00 (0.00, 369.14)                     |
|                                 | Other  | All Tofa                   |         | 0                   | 0        | 1.00             | 0.00 (0.00, 369.14)                     |
|                                 | White  | All Tofa 5 mg BID          | 1       | 1(0.40)             | 0        | 184.18           | 0.54 (0.01, 3.03)                       |
| Serious Infections              |        | All Tofa                   | 252 334 | 1(0.30)             | 0        | 208.67           | 0.48 (0.01, 2.67)                       |
|                                 | Asian  | All Tofa 5 mg BID          | 63      | 0                   | 0        | 46.09            | 0.00 (0.00, 8.00)                       |
|                                 |        |                            |         | 0                   | 0        | 53.08            | 0.00 (0.00,6.95)                        |
|                                 |        | All Tofa                   | 85      |                     |          | 1.00             |                                         |
|                                 | Other  | All Tofa 5 mg BID          | 1       | 0                   | 0        |                  | 0.00 (0.00,369.14)                      |
|                                 |        | All Tofa                   |         | 0                   | 0        | 1.00             | 0.00 (0.00, 369.14)                     |

<!-- image -->

## Geographical region

The incidence proportions  and  incidence  rates  (While  on  Treatment  Estimand)  for  TEAEs  SAEs,  and discontinuations due to AEs by geographic region for the AS All Tofa Cohort are presented in Table 64.

<div style=\"page-break-after: always\"></div>

Table 64. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence Proportions and Incidence Rates for General Events and Infections by Geographic Region While on Treatment Estimand, AS All Tofa Cohort

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Events Category                 | Geographic Region                               | Analysis Group                                  | N   | (%) u      | nl (%)    | PY     | IR (95% C1) per 100 PY   |
|---------------------------------|-------------------------------------------------|-------------------------------------------------|-----|------------|-----------|--------|--------------------------|
| All Infections                  | North America(US andCanada)All Tofa5mgBID       |                                                 | 38  | 19 (50.00) | 0         | 16.78  | 113.23 (68.17, 176.82)   |
|                                 |                                                 | All Tofa                                        | 51  | 20 (39.22) | 0         | 20.07  | 99.65 (60.87, 153.89)    |
|                                 | European Union                                  | All Tofa 5 mg BID                               | 136 | 43 (31.62) | 0         | 74.92  | 57.40 (41.54, 77.31)     |
|                                 |                                                 | All Tofa                                        | 200 | 57 (28.50) | 0         | 91.89  | 62.03 (46.98, 80.37)     |
|                                 | Asia                                            | All Tofa 5 mg BID                               | 61  | 31 (50.82) | 0         | 28.44  | 109.02 (74.07, 154.74)   |
|                                 |                                                 | All Tofa                                        | 83  | 37 (44.58) | 0         | 34.05  | 108.68 (76.52, 149.80)   |
|                                 | Rest of World                                   | All Tofa 5 mg BID                               | 81  | 18 (22.22) | 3 (3.70)  | 55.37  | 32.51 (19.27, 51.38)     |
|                                 |                                                 | All Tofa                                        | 86  | 18 (20.93) | 3 (3.49)  | 56.92  | 31.62 (18.74, 49.98)     |
| SeriousInfections               | North America (US and Canada) All Tofa 5 mg BID | North America (US and Canada) All Tofa 5 mg BID | 38  | 0          | 0         | 24.47  | 0.00 (0.00, 15.07)       |
|                                 |                                                 | All Tofa                                        | 51  | 0          | 0         | 28.05  | 0.00 (0.00, 13.15)       |
|                                 | European Union                                  | All Tofa 5 mg BID                               | 136 | 0          | 0         | 97.00  | 0.00 (0.00,3.80)         |
|                                 |                                                 | All Tofa                                        | 200 | 0          | 0         | 116.36 | 0.00 (0.00,3.17)         |
|                                 | Asia                                            | All Tofa 5 mg BID                               | 61  | 0          | 0         | 44.05  | 0.00 (0.00, 8.37)        |
|                                 |                                                 | All Tofa                                        | 83  | 0          | 0         | 51.04  | 0.00 (0.00, 7.23)        |
|                                 | Rest of World                                   | All Tofa 5 mg BID                               | 81  | 1 (1.23)   | 0         | 65.74  | 1.52 (0.04, 8.47)        |
|                                 |                                                 | All Tofa                                        | 86  | 1 (1.16)   | 0         | 67.30  | 1.49 (0.04, 8.28)        |
| Herpes Zoster                   | North America(USand Canada)AllTofa5mgBID        | North America(USand Canada)AllTofa5mgBID        | 38  | 2(5.26)    | 0         | 23.53  | 8.50 (1.03, 30.71)       |
|                                 |                                                 | All Tofa                                        | 51  | 2(3.92)    | 0         | 27.11  | 7.38 (0.89, 26.65)       |
|                                 | European Union                                  | All Tofa 5 mg BID                               | 136 | 3 (2.21)   | 0         | 96.33  | 3.11 (0.64, 9.10)        |
|                                 |                                                 | All Tofa                                        | 200 | 4 (2.00)   | 0         | 115.61 | 3.46 (0.94, 8.86)        |
|                                 | Asia                                            | All Tofa 5 mg BID                               | 61  | 0          | 0         | 44.05  | 0.00 (0.00, 8.37)        |
|                                 |                                                 | All Tofa                                        | 83  | 1 (1.20)   | 0         | 50.80  | 1.97 (0.05, 10.97)       |
|                                 | RestofWorld                                     | All Tofa 5 mg BID                               | 81  | 0          | 0         | 65.82  | 0.00 (0.00, 5.60)        |
|                                 |                                                 | All Tofa                                        | 86  | 0          | 0         | 67.37  | 0.00 (0.00, 5.48)        |
| Events Category                 | Geographic Region                               | Analysis Group                                  | N   | (%) uI     | nl (%)    | PY     | IR (95% CI) per 100 PY   |
|                                 |                                                 | All Tofa                                        | 86  | 4 ( 4.65)  | 0         | 67.05  | 5.97 (1.63, 15.27)       |
| Discontinuation of study        | North America (US and Canada) All Tofa 5 mg BID |                                                 | 38  | 4 (10.53)  | 1(2.63)   | 24.47  | 16.34 (4.45, 41.85)      |
|                                 |                                                 | All Tofa                                        | 51  | 5 (9.80)   | 2 (3.92)  | 28.05  | 17.82 (5.79, 41.60)      |
|                                 | European Union                                  | All Tofa 5 mg BID                               | 136 | 2 (1.47)   | 2 ( 1.47) | 97.00  | 2.06 (0.25, 7.45)        |
|                                 |                                                 | All Tofa                                        | 200 | 6 (3.00)   | 2 (1.00)  | 116.36 | 5.16 (1.89, 11.22)       |
|                                 | Asia                                            | All Tofa 5 mg BID                               | 61  | 2 (3.28)   | 2 (3.28)  | 44.05  | 4.54 (0.55, 16.40)       |
|                                 |                                                 | All Tofa                                        | 83  | 2 (2.41)   | 2(2.41)   | 51.04  | 3.92 (0.47,14.16)        |
|                                 | Rest of World                                   | All Tofa 5 mg BID                               | 81  | 2 (2.47)   | 0         | 65.82  | 3.04 (0.37, 10.98)       |
|                                 |                                                 | All Tofa                                        | 86  | 2 (2.33)   | 0         | 67.37  | 2.97 (0.36, 10.72)       |
| Discontinuationofstudytreatment | North America (US and Canada)All Tofa 5 mg BID  |                                                 | 38  | 8 (21.05)  | 0         | 24.07  | 33.23 (14.35, 65.49)     |
|                                 |                                                 | All Tofa                                        | 51  | 10 (19.61) | 0         | 27.52  | 36.34 (17.43, 66.83)     |
|                                 | EuropeanUnion                                   | AllTofa5mgBID                                   | 136 | 6 (4.41)   | 0         | 96.59  | 6.21 (2.28, 13.52)       |
|                                 |                                                 | All Tofa                                        | 200 | 10 (5.00)  | 0         | 115.93 | 8.63 (4.14, 15.86)       |
|                                 | Asia                                            | All Tofa5mgBID                                  | 61  | 6 (9.84)   | 0         | 43.49  | 13.80 (5.06, 30.03)      |
|                                 |                                                 | All Tofa                                        | 83  | 6 (7.23)   | 0         | 50.47  | 11.89 (4.36, 25.87)      |
|                                 | Rest of World                                   | All Tofa 5 mg BID                               | 81  | 5(6.17)    | 0         | 65.54  | 7.63 (2.48, 17.80)       |
|                                 |                                                 | All Tofa                                        | 86  | 5 (5.81)   | 0         | 67.09  | 7.45 (2.42, 17.39)       |
| DiscontinuationduetoAEs         | North America (US and Canada) All Tofa 5 mg BID |                                                 | 38  | 3 (7.89)   | 0         | 24.29  | 12.35 (2.55, 36.10)      |
|                                 |                                                 | All Tofa                                        | 51  | 3 (5.88)   | 0         | 27.87  | 10.77 (2.22, 31.46)      |
|                                 | European Union                                  | All Tofa 5 mg BID                               | 136 | 4 (2.94)   | 0         | 96.66  | 4.14 (1.13, 10.60)       |
|                                 |                                                 | All Tofa                                        | 200 | 5 (2.50)   | 0         | 116.02 | 4.31 (1.40, 10.06)       |
|                                 | Asia                                            | All Tofa 5 mg BID                               | 61  | 1 (1.64)   | 0         | 43.98  | 2.27 (0.06, 12.67)       |
|                                 |                                                 | All Tofa                                        | 83  | 1 (1.20)   | 0         | 50.96  | 1.96 (0.05, 10.93)       |
|                                 | Rest of World                                   | All Tofa 5 mg BID                               | 81  | 3 (3.70)   | 0         | 65.59  | 4.57 (0.94, 13.37)       |
|                                 |                                                 | All Tofa                                        | 86  | 3 (3.49)   | 0         | 67.14  | 4.47 (0.92, 13.06)       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Concomitant and Prior Medications for AS

The impact of prior bDMARD medication use and csDMARD use at baseline on safety was assessed in the overall pooled safety population. In both Study A3921119 and Study A3921120, patients were prohibited from receiving bDMARDs during the study. In A3921119, patients with prior use of bDMARDs were excluded.  In  Study  A3921120,  patients  with  prior  use  of  bDMARDS  were  permitted  to  be  enrolled; however,  approximately  80%  were  required  to  be  bDMARD  naïve.  Patients  were  stratified  by  prior treatment history: (1) bDMARD-naive (approximately 80%) and (2) Tumor Necrosis Factor inhibitorinadequate responder or bDMARD use (without inadequate response) (approximately 20%).

The majority of patients with AS in the clinical programme were naive to bDMARDs, with 81.6% in the All Tofa 5 mg BID group in the All Tofa Cohort having no previous experience with bDMARDs.

The incidence and proportions and incidence rates for general events and infections by prior treatment history are presented in the next table (Table 65).

<div style=\"page-break-after: always\"></div>

Table 65. Tofacitinib Summary  of  Clinical  Safety (Ankylosing Spondylitis) Incidence Proportions and Incidence Rates for General Events and Infections by Prior Treatment History - While on Treatment Estimand, AS All Tofa Cohort

| Events Category                     | Prior Treatiment History                                            | Analysis Group                                                                | N                | n (%)                                         | nl (%)                     | PY                              | IR (95% C1) per 100 PY                                                                      |
|-------------------------------------|---------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------|-----------------------------------------------|----------------------------|---------------------------------|---------------------------------------------------------------------------------------------|
| TEAEs                               | bDMARD-naive                                                        | All Tofa 5 mg BID                                                             | 258              | 156 ( 60.47)                                  | 3(1.16)                    | 105.19                          | 148.31 (125.95, 173.49)                                                                     |
|                                     |                                                                     | All Tofa                                                                      | 362              | 206 ( 56.91)                                  | 3 (0.83)                   | 126.60 20.86                    | 162.72 (141.26, 186.52) 201.32 (145.09, 272.12)                                             |
|                                     | TNFi-IRorbDMARDUse(Non-All Tofa5mg BID IR)                          | All Tofa                                                                      | 58 58            | 42 ( 72.41) 42 ( 72.41)                       | 0 0                        | 20.86                           | 201.32 (145.09, 272.12)                                                                     |
| SAEs                                | bDMARD-naive                                                        | All Tofa5mgBID All Tofa                                                       | 258 362          | 6 (2.33) 7 (1.93)                             | 1 (0.39) 1 (0.28) 0        | 185.47 216.73                   | 3.23 (1.19, 7.04) 3.23 (1.30, 6.65)                                                         |
|                                     | TNFi-IR orbDMARD Use (Non-All Tofa 5 mg BID IR) bDMARD-naive        | All Tofa All Tofa5mgBID All Tofa TNFi-IR orbDMARD Use (Non- All Tofa 5 mg BID | 58 58 258 362 58 | 2 (3.45) 2 (3.45) 4 (1.55) 5 (1.38) 3 ( 5.17) | 0 0 0 0                    | 43.91 43.91 185.80 217.13 43.72 | 4.55 (0.55, 16.45) 4.55 (0.55,16.45) 2.15 (0.59, 5.51) 2.30 (0.75, 5.37) 6.86 (1.41, 20.05) |
| Severe AEs Discontinuation of study | bDMARD-naive TNFi-IRorbDMARDUse(Non-Al1 Tofa5mgBID IR) bDMARD-naive | All Tofa 5 mg BID All Tofa All Tofa                                           | 258 362 58       | 4 (1.55) 9 (2.49) 6 (10.34) 6 (10.34)         | 4 (1.55) 5 (1.38) 1 (1.72) | 187.26 218.73 44.09             | 2.14 (0.58, 5.47) 4.11 (1.88, 7.81) 13.61 (4.99, 29.62) 13.61 (4.99, 29.62)                 |
|                                     | IR)                                                                 |                                                                               | 58               | 12 ( 4.65) 18 ( 4.97)                         | 1 ( 1.72)                  | 44.09                           |                                                                                             |
| Discontinuationof study treatment   |                                                                     | All Tofa 5 mg BID All Tofa                                                    | 258 362 58       | 13 (22.41) 13 (22.41)                         | 0 0 0                      | 186.38                          | 6.44 (3.33, 11.25)                                                                          |
| Discontinuation duetoAEs            | TNFi-IR or bDMARD Use (Non- All Tofa 5 mg BID                       | All Tofa                                                                      | 58               | 5 (1.94)                                      | 0                          | 217.71 43.31 43.31              | 8.27 (4.90, 13.07) 30.02 (15.98, 51.33) 30.02 (15.98, 51.33)                                |
|                                     | bDMARD-naive                                                        |                                                                               | 258              | 6(1.66)                                       | 0 0                        |                                 |                                                                                             |
|                                     |                                                                     | All Tofa 5 mg BID                                                             | 362              |                                               |                            | 186.84                          | 2.68 (0.87, 6.25)                                                                           |
|                                     |                                                                     | All Tofa                                                                      | 58 58            | 6 (10.34)                                     |                            | 218.31                          | 2.75 (1.01, 5.98)                                                                           |
| All Infections                      | IR) bDMARD-naive                                                    | TNFi-IRorbDMARDUse (Non-All Tofa5mg BID All Tofa All Tofa 5 mg BID            | 258 362          | 6 (10.34) 86 (33.33)                          | 0 0 3 (1.16)               | 43.67 43.67                     | 13.74 (5.04, 29.90) 13.74 (5.04, 29.90)                                                     |
|                                     | TNFi-IR or bDMARD Use (Non- All Tofa 5 mg BID IR) bDMARD-naive      | All Tofa All Tofa                                                             | 58 58 258        | 107 (29.56) 25 (43.10) 25 (43.10)             | 3 (0.83) 0 0               | 143.93 171.36 31.58 31.58       | 59.75 (47.79, 73.79) 62.44 (51.17, 75.46) 79.17 (51.24, 116.88)                             |
| SeriousInfections                   |                                                                     | All Tofa 5 mg BID All Tofa                                                    | 362 58 58        | 1 (0.39) 1(0.28) 0                            | 0 0 0                      | 187.18 218.65                   | 79.17 (51.24, 116.88) 0.53 (0.01, 2.98) 0.46 (0.01, 2.55)                                   |
| Herpes Zoster                       | TNFi-IR or bDMARD Use (Non- All Tofa 5 mg BID IR)                   | All Tofa                                                                      |                  | 0                                             | 0                          | 44.09 44.09                     | 0.00 (0.00, 8.37) 0.00 (0.00, 8.37)                                                         |
|                                     | bDMARD-naive                                                        |                                                                               |                  | 3 (1.16)                                      | 0                          | 186.59                          | 1.61 (0.33, 4.70)                                                                           |
|                                     |                                                                     | All Tofa 5 mg BID                                                             |                  | 5 (1.38)                                      |                            |                                 |                                                                                             |
|                                     |                                                                     | All Tofa                                                                      | 258 362          |                                               |                            |                                 |                                                                                             |
|                                     |                                                                     |                                                                               |                  |                                               | 0                          | 217.74                          | 2.30 (0.75, 5.36)                                                                           |
|                                     |                                                                     |                                                                               |                  | 2 (3.45)                                      |                            | 43.15                           | 4.64 (0.56, 16.74)                                                                          |
|                                     | TNFi-IR or bDMARD Use (Non- All Tofa 5 mg BID IR)                   |                                                                               | 58               |                                               | 0                          |                                 |                                                                                             |
|                                     |                                                                     |                                                                               |                  |                                               | 0                          | 43.15                           | 4.64 (0.56, 16.74)                                                                          |
|                                     |                                                                     | AllTofa                                                                       | 58               | 2 (3.45)                                      |                            |                                 |                                                                                             |

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Concomitant csDMARDs

The majority (71.8%) of patients in the AS clinical programme were not taking concomitant csDMARDs (Day 1). The incidence and proportions and incidence rates for general events and infections by Day 1 concomitant csDMARD use are presented in the next table (Table 66).

Table 66. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence Proportions and Incidence Rates for General Events and Infections by Day 1 Concomitant csDMARD Use - While on Treatment Estimand, AS All Tofa Cohort

<!-- image -->

| Events Category                                             | Day1 Conconitant csDMARD Use   | Analysis Group                                     | N                          | n (%)                                               | nl (%)                              | PY                               | IR (95% C1) per 100 PY                                                           |
|-------------------------------------------------------------|--------------------------------|----------------------------------------------------|----------------------------|-----------------------------------------------------|-------------------------------------|----------------------------------|----------------------------------------------------------------------------------|
| TEAEs                                                       | Yes                            | All Tofa 5 mg BID                                  | 89                         | 52 ( 58.43)                                         | 1 (1.12)                            | 35.84                            | 145.11 (108.37, 190.29)                                                          |
|                                                             |                                | All Tofa                                           | 128                        | 74 ( 57.81)                                         | 1 (0.78)                            | 43.59                            | 169.76 (133.29, 213.11)                                                          |
|                                                             | No                             | All Tofa 5 mg BID                                  | 227                        | 146 ( 64.32)                                        | 2(0.88)                             | 90.21                            | 161.84 (136.65, 190.32)                                                          |
|                                                             |                                | All Tofa                                           | 292                        | 174 ( 59.59)                                        | 2(0.68)                             | 103.87                           | 167.52 (143.55, 194.34)                                                          |
| SAEs                                                        | Yes No                         | All Tofa 5 mg BID All Tofa                         | 89 128                     | 1 (1.12) 2 (1.56) 7 (3.08)                          | 1 (1.12) 1 (0.78) 0                 | 62.81 74.70                      | 1.59 (0.04, 8.87) 2.68 (0.32, 9.67) 4.20 (1.69, 8.66)                            |
|                                                             |                                |                                                    | 227                        |                                                     |                                     | 166.57                           |                                                                                  |
|                                                             | Yes                            | All Tofa5mgBID                                     | 292                        | 7 (2.40) 2 (2.25)                                   | 0 0                                 | 185.95 62.02                     | 3.76 (1.51, 7.76)                                                                |
| Severe AEs                                                  | No                             | All Tofa 5 mg BID All Tofa                         | 89                         | 2 (1.56) 5 (2.20) 6 (2.05)                          | 0 0                                 | 74.12 167.50                     | 3.22 (0.39, 11.65) 2.70 (0.33, 9.75)                                             |
|                                                             | All Tofa                       | All Tofa 5 mg BID                                  | 227 292                    |                                                     | 0                                   | 186.74                           | 2.99 (0.97, 6.97) 3.21 (1.18, 6.99)                                              |
|                                                             | Yes No                         | All Tofa All Tofa 5 mg BID All Tofa All Tofa5mgBID | 128 89 128 227             | 2 (2.25) 3 (2.34) 8 (3.52)                          | 1 (1.12) 1 (0.78) 4 (1.76) 5 (1.71) | 62.89 74.98 168.47               | 3.18 (0.39, 11.49) 4.00 (0.83, 11.69) 4.75 (2.05, 9.36) 6.39 (3.30, 11.16)       |
| Discontinuation of study Discontinuation of study treatment | Yes No                         | All Tofa All Tofa 5 mg BID All Tofa                | 292 89                     | 12 (4.11) 5 (5.62)                                  | 0 0 0                               | 62.56 74.65                      | 7.99 (2.59, 18.65) 8.04 (2.95, 17.49) 11.97 (7.31, 18.48)                        |
| Discontinuation due toAEs                                   |                                | All Tofa All Tofa 5 mg BID                         | 292                        | 25 (8.56)                                           |                                     | 187.84                           | 13.41 (8.68, 19.80)                                                              |
|                                                             | Yes                            | All Tofa 5mgBID                                    | 89                         | 2 (2.25)                                            | 0 0                                 | 167.13                           |                                                                                  |
|                                                             |                                |                                                    | 128 227                    | 6 (4.69) 20 ( 8.81)                                 |                                     |                                  |                                                                                  |
|                                                             | No Yes No                      | All Tofa AllTofa5mgBID All Tofa                    | 128 227 292 89 128 227 292 | 2 (1.56) 9 (3.96) 27 (30.34) 36 ( 28.13) 84 (37.00) | 0 0 10 (3.42) 0                     | 186.37 62.81 74.90 167.71        | 3.18 (0.39,11.50) 2.67 (0.32, 9.65) 5.37 (2.45, 10.19)                           |
| AllInfections                                               |                                | All Tofa All Tofa 5 mg BID                         | 89 128                     | 96 (32.88) 0 0                                      | 1 (1.12) 1 (0.78) 2(0.88) 2 (0.68)  | 187.08 49.00 59.53 126.50 143.40 | 5.35 (2.56, 9.83) 55.10 (36.31, 80.17) 60.47 (42.35, 83.71) 66.95 (54.23, 81.75) |
|                                                             | Yes No                         | All Tofa5mgBID All Tofa All Tofa 5 mg BID          |                            |                                                     | 0 0                                 | 62.89 74.98                      | 66.40 (52.96, 82.21)                                                             |
| SeriousInfections                                           |                                | All Tofa                                           | 89                         | 0                                                   | 0                                   | 168.39                           | 0.00 (0.00,4.92) 0.59 (0.02, 3.31)                                               |
|                                                             |                                |                                                    |                            | 1 (0.44) 1 (0.34)                                   |                                     |                                  | 0.00 (0.00, 5.87)                                                                |
|                                                             |                                |                                                    | 292                        |                                                     | 0                                   |                                  |                                                                                  |
|                                                             |                                | All Tofa 5 mg BID All Tofa                         | 227                        |                                                     |                                     |                                  | 0.53 (0.01, 2.97)                                                                |
|                                                             |                                |                                                    |                            |                                                     |                                     | 187.77                           |                                                                                  |
|                                                             | Yes                            |                                                    |                            |                                                     |                                     |                                  |                                                                                  |
| Herpes Zoster                                               |                                |                                                    |                            |                                                     | 0                                   | 62.89                            | 0.00 (0.00, 5.87)                                                                |
|                                                             |                                | All Tofa 5 mg BID                                  |                            | 0                                                   |                                     | 74.98                            | 0.00 (0.00, 4.92)                                                                |
|                                                             | No                             | All Tofa                                           | 128                        |                                                     | 0 0                                 | 166.85                           | 3.00 (0.97,6.99)                                                                 |
|                                                             |                                | All Tofa5mgBID                                     | 227                        | 5 (2.20)                                            |                                     |                                  |                                                                                  |
|                                                             |                                | All Tofa                                           | 292                        |                                                     | 0                                   |                                  | 3.77 (1.51, 7.76)                                                                |
|                                                             |                                |                                                    |                            | 7 (2.40)                                            |                                     |                                  |                                                                                  |
|                                                             |                                |                                                    |                            |                                                     |                                     | 185.91                           |                                                                                  |

<div style=\"page-break-after: always\"></div>

28-Day(WhileonTreatment)RiskPeriodisdefinedasthesmallestof[time(indays)tolastdose+28daysl,[timetodiscontinuationfromstudyl,[timetolast observationl,and[timetodeath].UnderWhileonTreatmentEstimand,PY（denominatorforIR)isthesumofthetimestothefirsteventforsubjectswithanevent ortheriskperiodsforsubjectswithoutaneventwithinthe28-Day(WhileonTreatment)RiskPeriod.N:NumberofsubjectsincludedintheSafetyAnalysisSet; n:Numberofsubjectswithaneventwithinthe28-Day(WhileonTreatment)RiskPeriod;n1:Numberofsubjectswithaneventbeyondthe28-Day(Whileon Treatment)RiskPeriodwhichare notincludedin theIRestimation.Incidence proportions,PYs andIRs are estimatedbased onnunder this estimand. 95%CIforIRisbasedonExactPoissonDistributionwithoutadjustment tostudy.ForsubjectsrandomizedtoPlacebo-&gt;Tofa5mgBID,thedateof firstdose referstothedateoffirstdoseoftofacitinibtreatment.DiscontinuationduetoAEsisamixtureofdiscontinuationofstudy(instudyA3921119)and discontinuationofstudytreatment(inshudyA3921120)duetoadverseevents.

IncludedProtocols:A3921119,A3921120(FinalData).MedDRAv23.0codingdictionaryapplied.

PFIZERCONFIDENTIALSourceData:adae&amp;adsaec&amp;addsTableGeneration:10NOV2020(03:45)

(FinalData:10Sep2020)OutputFile:./unblind1120/A392\\_SCSEU/adae\\_spe\\_s406tofe2s

TableC2.3.3.4.6-EisforPfizerintermaluse.

## Discontinuation due to adverse events

AEs leading to discontinuation of study drug in the Placebo-controlled Cohort, described in the next table, were infrequent in both treatment groups (&lt;3%). The proportion of patients reporting discontinuations of  study  drug  due  to  AEs  for  each  treatment  group  and  the  associated  incidence  rates  (While  on Treatment Estimand) are as follows (Table 67):

- Tofa 5 mg BID group: 4 (2.16%) patients representing an incidence rate of 7.04 patients with events per 100 PY.
- Placebo group: 4 (2.14%) patients representing an incidence rate of 7.10 patients with events per 100 PY.

| Table 6 7. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence of Adverse Events leading to Discontinuation by System Organ Class and Preferred Term - Treatment Policy Estimand, AS Placebo-Controlled Cohort   | Table 6 7. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence of Adverse Events leading to Discontinuation by System Organ Class and Preferred Term - Treatment Policy Estimand, AS Placebo-Controlled Cohort   | Table 6 7. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence of Adverse Events leading to Discontinuation by System Organ Class and Preferred Term - Treatment Policy Estimand, AS Placebo-Controlled Cohort   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number of Subjects Evaluable for AEs                                                                                                                                                                                                   | Tofa 5 mg BID (N=185)                                                                                                                                                                                                                  | Placebo (N=187)                                                                                                                                                                                                                        |
| Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term                                                                                                                                                                       | n (%)                                                                                                                                                                                                                                  | n (%)                                                                                                                                                                                                                                  |
| With Any Adverse Event                                                                                                                                                                                                                 | 4 (2.2)                                                                                                                                                                                                                                | 4 (2.1)                                                                                                                                                                                                                                |
| EAR AND LABYRINTH DISORDERS                                                                                                                                                                                                            | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| Hypoacusis                                                                                                                                                                                                                             | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                                                                                                                                   | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| Peripheral swelling                                                                                                                                                                                                                    | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| HEPATOBILIARY DISORDERS                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| Hypertransaminasaemia                                                                                                                                                                                                                  | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| INFECTIONS AND INFESTATIONS                                                                                                                                                                                                            | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| Meningitis                                                                                                                                                                                                                             | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| INVESTIGATIONS                                                                                                                                                                                                                         | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| Alanine aminotransferase increased                                                                                                                                                                                                     | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| Aspartate aminotransferase increased                                                                                                                                                                                                   | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| Gamma-glutamyltransferase increased                                                                                                                                                                                                    | 1 (0.5)                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                      |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS                                                                                                                                                                                        | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| Spinal pain                                                                                                                                                                                                                            | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| PREGNANCY, PUERPERIUM AND PERINATAL CONDITIONS                                                                                                                                                                                         | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| Pregnancy                                                                                                                                                                                                                              | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                                                                                                                                                 | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |
| Psoriasis                                                                                                                                                                                                                              | 0                                                                                                                                                                                                                                      | 1 (0.5)                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

Table 6 7. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence of Adverse Events leading to Discontinuation by System Organ Class and Preferred Term - Treatment Policy Estimand, AS Placebo-Controlled Cohort

| Number of Subjects Evaluable for AEs   | Tofa 5 mg BID (N=185)   | Placebo (N=187)   |
|----------------------------------------|-------------------------|-------------------|
| Number (%) of Subjects:                | n (%)                   | n (%)             |

Subjects are only counted once per treatment per event.

Totals for the No. of Subjects at a higher level are not necessarily the sum of those at the lower levels since a subject may report two or more different adverse events within the higher level category. The table is based on the data from OC AE only.

N: Number of subjects included in the Safety Analysis Set. n (%): Number of subjects with the event (Percentages are based on N).

Included Protocols: A3921119, A3921120 (Final Data). MedDRA v23.0 coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adae Table Generation: 10NOV2020 (03:04)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCSPC\\_EU/adae\\_s181\\_1

Table C1.3.1.1-E is for Pfizer internal use.

AEs leading to discontinuation of study drug in the All Tofa Cohort are described in the next table. In the All Tofa Cohort, the proportion of patients who discontinued study drug due to AEs for the All Tofa 5 mg BID group and the associated incidence rate (While on Treatment Estimand), which was similar to the All Tofa group is presented below (Table 68).

- All Tofa 5 mg BID group: 11 (3.48%) patients representing an incidence rate of 4.77 (95% CI: 2.38, 8.54) patients with events per 100 PY.

Table 6 8. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent Adverse Events leading to Discontinuation by System Organ Class and Preferred Term - Treatment Policy Estimand, AS All Tofa Cohort

| Number of Subjects Evaluable for AEs                                         | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa (N=420)   | All Tofa (N=420)   | All Tofa (N=420)   | All Tofa (N=420)   |
|------------------------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Severity(a) Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term | Mild n (%)                  | Mod. n (%)                  | Sev. n (%)                  | Total n (%)                 | Mild n (%)         | Mod. n (%)         | Sev. n (%)         | Total n (%)        |
| With Any Adverse Event                                                       | 1 (0.3)                     | 9 (2.8)                     | 1 (0.3)                     | 11 (3.5)                    | 1 (0.2)            | 10 (2.4)           | 1 (0.2)            | 12 (2.9)           |
| CARDIAC DISORDERS                                                            | 0                           | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0                  | 1 (0.2)            | 0                  | 1 (0.2)            |
| Tachycardia                                                                  | 0                           | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0                  | 1 (0.2)            | 0                  | 1 (0.2)            |
| EAR AND LABYRINTH DISORDERS                                                  | 0                           | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0                  | 1 (0.2)            | 0                  | 1 (0.2)            |
| Hypoacusis                                                                   | 0                           | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0                  | 1 (0.2)            | 0                  | 1 (0.2)            |
| GASTROINTESTINAL DISORDERS                                                   | 1 (0.3)                     | 1 (0.3)                     | 0                           | 2 (0.6)                     | 1 (0.2)            | 1 (0.2)            | 0                  | 2 (0.5)            |
| Abdominal adhesions                                                          | 0                           | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0                  | 1 (0.2)            | 0                  | 1 (0.2)            |
| Abdominal pain                                                               | 1 (0.3)                     | 0                           | 0                           | 1 (0.3)                     | 1 (0.2)            | 0                  | 0                  | 1 (0.2)            |

<div style=\"page-break-after: always\"></div>

Table 6 8. Tofacitinib Summary of Clinical Safety (Ankylosing Spondylitis) Incidence and Severity of Treatment-Emergent Adverse Events leading to Discontinuation by System Organ Class and Preferred Term - Treatment Policy Estimand, AS All Tofa Cohort

| Number of Subjects Evaluable for AEs                                         |            | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   | All Tofa 5 mg BID (N=316)   |            | All Tofa (N=420)   | All Tofa (N=420)   |             |
|------------------------------------------------------------------------------|------------|-----------------------------|-----------------------------|-----------------------------|------------|--------------------|--------------------|-------------|
| Severity(a) Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term | Mild n (%) | Mod. n (%)                  | Sev. n (%)                  | Total n (%)                 | Mild n (%) | Mod. n (%)         | Sev. n (%)         | Total n (%) |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                         | 0          | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0          | 1 (0.2)            | 0                  | 1 (0.2)     |
| Peripheral swelling                                                          | 0          | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0          | 1 (0.2)            | 0                  | 1 (0.2)     |
| HEPATOBILIARY DISORDERS                                                      | 0          | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0          | 1 (0.2)            | 0                  | 1 (0.2)     |
| Hepatic function abnormal                                                    | 0          | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0          | 1 (0.2)            | 0                  | 1 (0.2)     |
| INFECTIONS AND INFESTATIONS                                                  | 0          | 3 (0.9)                     | 0                           | 3 (0.9)                     | 0          | 4 (1.0)            | 0                  | 4 (1.0)     |
| Herpes zoster                                                                | 0          | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0          | 2 (0.5)            | 0                  | 2 (0.5)     |
| Meningitis                                                                   | 0          | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0          | 1 (0.2)            | 0                  | 1 (0.2)     |
| Pharyngitis streptococcal                                                    | 0          | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0          | 1 (0.2)            | 0                  | 1 (0.2)     |
| INVESTIGATIONS                                                               | 0          | 1 (0.3)                     | 1 (0.3)                     | 2 (0.6)                     | 0          | 1 (0.2)            | 1 (0.2)            | 2 (0.5)     |
| Alanine aminotransferase increased                                           | 0          | 1 (0.3)                     | 1 (0.3)                     | 2 (0.6)                     | 0          | 1 (0.2)            | 1 (0.2)            | 2 (0.5)     |
| Aspartate aminotransferase increased                                         | 0          | 1 (0.3)                     | 1 (0.3)                     | 2 (0.6)                     | 0          | 1 (0.2)            | 1 (0.2)            | 2 (0.5)     |
| Blood alkaline phosphatase increased                                         | 0          | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0          | 1 (0.2)            | 0                  | 1 (0.2)     |
| Gamma-glutamyltransferase increased                                          | 0          | 1 (0.3)                     | 1 (0.3)                     | 2 (0.6)                     | 0          | 1 (0.2)            | 1 (0.2)            | 2 (0.5)     |
| NERVOUS SYSTEM DISORDERS                                                     | 0          | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0          | 1 (0.2)            | 0                  | 1 (0.2)     |
| Dizziness                                                                    | 0          | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0          | 1 (0.2)            | 0                  | 1 (0.2)     |
| VASCULAR DISORDERS                                                           | 0          | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0          | 1 (0.2)            | 0                  | 1 (0.2)     |
| Hypertension                                                                 | 0          | 1 (0.3)                     | 0                           | 1 (0.3)                     | 0          | 1 (0.2)            | 0                  | 1 (0.2)     |
| Total preferred term events                                                  | 1          | 14                          | 3                           | 18                          | 1          | 15                 | 3                  | 19          |

(a) If the same subject in a given treatment had more than one occurrence in the same preferred term event category, only the most severe occurrence is counted. Subjects are counted only once per treatment per event. For the TESS algorithm any missing severities have been imputed as severe unless the subject experienced another occurrence of the same event in a given treatment for which severity was

recorded. In this case, the reported severity is summarized.

Maximum severity at any dictionary level is calculated after the report subset criteria is applied.

TEAE in A3921119 is defined as those on-treatment events which are new or worsened in severity relative to the pre-treatment period prior to Day 1.

TEAE in A3921120 is defined as those on-treatment events which start during the effective duration of treatment.

N: Number of subjects included in the Safety Analysis Set; n: Number of subjects with the events (Percentages are based on N). Included Protocols: A3921119, A3921120 (Final Data). The table is based on the data from OC AE only.

MedDRA v23.0 coding dictionary applied.

PFIZER CONFIDENTIAL Source Data: adae Table Generation: 10NOV2020 (07:26)

(Final Data: 10Sep2020) Output File: ./unblind\\_1120/A392\\_SCS\\_EU/adae\\_s040\\_tof

Table C2.1.1.3.3-E is for Pfizer internal use.

<div style=\"page-break-after: always\"></div>

## Post marketing experience

Tofacitinib received its first regulatory approval on 06 Nov 2012 for the IR formulation in the US and 22 Mar 2017 in the EU. The tofacitinib 11 mg PR formulation was subsequently approved on 23 Feb 2016 in the US and 16 Dec 2019 in the EU.

The clinical rationale for developing a PR formulation of tofacitinib is to enable QD dosing to enhance patient convenience. A QD dosing regimen provides a lower frequency of administration and thereby is likely to improve patient compliance in patients who can adhere better to a once daily regimen compared to the 5 mg IR BID dosing regimen.

The Sponsor monitors post-marketing data across the different indications and for both formulations, which reflect the safety profile of tofacitinib since marketing approval. Four new important potential risks have  been  determined  for  tofacitinib  based  on  final  data  from  Study  A3921133:  MACE,  myocardial infarction, lymphoma, lung cancer. Study A3921133 was a Phase 3b/4 randomised, parallel-arm, openlabel, safety endpoint study evaluating the safety of tofacitinib at 2 doses (5 mg BID and 10 mg BID) versus TNFi. As mentioned before the impact of the study results on tofacitinib safety and efficacy is being currently assessed in the EMEA/H-A20/1517/C/004214/0048 referral.

According to the MAH, updated post-marketing data provide evidence that the long-term safety of 11 mg PR QD in RA and PsA patients  in  the  real-world  setting  is  consistent  with  the  safety  profile  of tofacitinib 5 mg IR BID in AS patients observed in the clinical trial programme.

The cumulative worldwide exposure to tofacitinib in all indications and both formulations since product approval is estimated at 391,640 PY based on marketing experience as of data lock point 05 Nov 2020.

The next table presents exposure data by tofacitinib dosing regimen (5 mg IR BID and 11 mg PR QD) for the updated US Corrona RA Registry Study A3921205 subset analysis and post-marketing surveillance reports.

Table 6 9. Overview of Populations in Post-marketing Safety Data

| US Corrona RA Registry Study A3921205                        | US Corrona RA Registry Study A3921205            | Post-Marketing Surveillance Reports for RA a Consists of post-marketing spontaneous reports,   | Post-Marketing Surveillance Reports for RA a Consists of post-marketing spontaneous reports,   |
|--------------------------------------------------------------|--------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| interest for patients taking and 5 mg IR BID Treatment Group | tofacitinib 11 mg PR QD N (total follow-up PY) b | non-interventional solicited literature case reports Treatment Group                           | reports, and non-study Approximate Exposure (PY)* c                                            |
| Corrona Registry                                             | 937 (2409.75)                                    | Tofacitinib                                                                                    | 220,492 d                                                                                      |
| 5 mg IR BID                                                  |                                                  | 5 mg IR BID                                                                                    |                                                                                                |
| Corrona Registry                                             | 603 (647.67)                                     | Tofacitinib                                                                                    | 112,495 d                                                                                      |
| 11 mg PR QD                                                  |                                                  | 11 mg PR QD                                                                                    |                                                                                                |

Source: PsA PR Module 5.3.6 Corrona Safety Analysis; Module 5.3.6 November 2020 PSUR Table 3.

* Estimation of patient-years (PY) of exposure is based on estimated worldwide sales data

a. RA indication includes a combination of patients diagnosed with both seropositive RA and Other RA

b. US Corrona RA Registry Study A3921205 subset analysis dated 31 Jul 2020 (using final data 31 Jan 2019).

c. Total exposure across all indications from post-marketing surveillance as of 05 Nov 2020 is estimated at 391,640 PY

d. Dose split obtained from RX share calculations from IQVIA Health Prescriber Insights

## Data from US Corrona RA Registry

The  US  Corrona  RA  Registry  is  a  prospective,  multicentre,  observational,  disease-based  registry; established in 2000, is an ongoing longitudinal clinical registry that has enrolled &gt;45,000 patients with RA and accumulated &gt;155,000 patient years of data.

<div style=\"page-break-after: always\"></div>

The  US  Corrona  RA  Registry  Study  A3921205,  a  non-interventional  post-authorisation  safety  study (PASS), was completed in March 2020 using a 31 Jan 2019 data cut. The aim was to describe the rates of safety events in tofacitinib initiators compared with bDMARD initiators in real-world clinical use using data from the Corrona RA registry.

This section presents results from a post hoc subset analysis (report dated 31 Jul 2020) of the US Corrona RA Registry Study A3921205 (final data 31 Jan 2019) conducted to further characterise the post approval safety of tofacitinib 5 mg IR BID and 11 mg PR QD via the evaluation of incidence rates of select AEs of interest. This post hoc subset analysis is an update to previously submitted data that reflects events for the entire study period.

Demographic baseline characteristics of Tofacitinib Initiators by Dose (5 mg IR BID and 11 mg PR QD) are shown below:

Table 7 0. Patient Demographic and Clinical Characteristics of Tofacitinib Initiators by Dose (5 mg IR BID and 11 mg PR QD) - US Corrona RA Registry Study A3921205 (31 Jul 2020 subset analysis of final data 31 Jan 2019)

| At time of Tofacitinib initiation   | Tofacitinib 5 mg IR BID   | Tofacitinib 11 mg PR QD   | P-value   |
|-------------------------------------|---------------------------|---------------------------|-----------|
| Female : n (%)                      | N=937 751 (80.15)         | N=603 474 (78.61)         | 0.464     |
| Age (yrs)                           |                           |                           |           |
| Mean ± SD                           | 59.19 ± 12.02             | 59.91 ± 12.2              | 0.256     |
| Median (IQR)                        | 59 (52, 68)               | 60 (52, 68)               |           |
| Age Categories n (%)                |                           |                           |           |
| 18-<45                              | 99 (10.57)                | 68 (11.28)                | 0.661     |
| 45-<50                              | 84 (8.96)                 | 44 (7.30)                 | 0.247     |
| 50-<55                              | 126 (13.45)               | 67 (11.11)                | 0.177     |
| 55-<60                              | 162 (17.29)               | 112 (18.57)               | 0.520     |
| 60-<65                              | 153 (16.33)               | 85 (14.10)                | 0.237     |
| 65-<70                              | 126 (13.45)               | 100 (16.58)               | 0.089     |
| 70-<75                              | 99 (10.57)                | 63 (10.45)                | 0.941     |
| ≥75                                 | 88 (9.39)                 | 64 (10.61)                | 0.433     |
| Duration of RA (yrs): Mean ± SD     | 13.72 ± 9.63              | 13.42 ± 10.98             | 0.576     |
| Race : n (%)                        |                           |                           |           |
| White                               | 848 (90.5)                | 545 (90.38)               | 0.938     |
| Black/African American              | 36 (3.84)                 | 27 (4.48)                 | 0.539     |
| Asian                               | 11 (1.17)                 | 9 (1.49)                  | 0.590     |
| Other                               | 42 (4.48)                 | 22 (3.65)                 | 0.424     |
| Weight (lbs): Mean ± SD             | 182.74 ± 51.21            | 183.35 ± 45.93            | 0.814     |
| BMI Category : n (%)                |                           |                           |           |
| Normal/Under weight                 | 231 (24.79)               | 149 (25.04)               | 0.910     |
| Overweight                          | 262 (28.11)               | 182 (30.59)               | 0.299     |
| Obese                               | 439 (47.1)                | 264 (44.37)               | 0.296     |
| Smoking Status : n (%)              |                           |                           |           |
| Never                               | 445 (47.75)               | 288 (48.16)               | 0.874     |
| Prior                               | 291 (31.22)               | 179 (29.93)               | 0.594     |
| Current                             | 196 (21.03)               | 131 (21.91)               | 0.683     |
| Drinking Status : n (%)             |                           |                           |           |
| Not at All                          | 524 (58.29)               | 330 (57.19)               | 0.678     |
| Occasionally                        | 158 (17.58)               | 110 (19.06)               | 0.469     |
| 1-3 Per Week                        | 159 (17.69)               | 99 (17.16)                | 0.794     |
| 1-2 Per Day                         | 55 (6.12)                 | 36 (6.24)                 | 0.925     |
| 3 or More Daily                     | 3 (0.33)                  | 2 (0.35)                  | 0.967     |

<div style=\"page-break-after: always\"></div>

Table 7 0. Patient Demographic and Clinical Characteristics of Tofacitinib Initiators by Dose (5 mg IR BID and 11 mg PR QD) - US Corrona RA Registry Study A3921205 (31 Jul 2020 subset analysis of final data 31 Jan 2019)

| At time of Tofacitinib initiation                           | Tofacitinib 5 mg IR BID   | Tofacitinib 11 mg PR QD   | P-value   |
|-------------------------------------------------------------|---------------------------|---------------------------|-----------|
| Comorbid Conditions : n (%)                                 |                           |                           |           |
| Hx of Hypertension                                          | 306 (32.66)               | 229 (37.98)               | 0.032     |
| Hx of Diabetes                                              | 106 (11.31)               | 69 (11.44)                | 0.937     |
| Hx of Malignancy                                            | 73 (7.79)                 | 48 (7.96)                 | 0.904     |
| Hx of CV disease                                            | 399 (42.58)               | 300 (49.75)               | 0.006     |
| Hx of Serious Infections                                    | 141 (15.05)               | 84 (13.93)                | 0.545     |
| Hx of COPD                                                  | 28 (2.99)                 | 25 (4.15)                 | 0.224     |
| Medication History : n (%)                                  |                           |                           |           |
| Prior number of cDMARD (including current cDMARD) Mean ± SD | 2.31 ± 1.26               | 2.09 ± 1.07               |  0.001   |
| Prior TNFi Use n (%)                                        |                           |                           |           |
| 0 prior TNFi                                                | 124 (13.23)               | 115 (19.07)               | 0.002     |
| 1 prior TNFi                                                | 261 (27.85)               | 172 (28.52)               | 0.776     |
| 2+ prior TNFi                                               | 552 (58.91)               | 316 (52.4)                | 0.012     |
| Prior non-TNFi Use n (%)                                    |                           |                           |           |
| 0 prior non-TNFi                                            | 413 (44.08)               | 369 (61.19)               | <0.001    |
| 1 prior non-TNFi                                            | 288 (30.74)               | 135 (22.39)               | <0.001    |
| 2+ prior non-TNFi                                           | 236 (25.19)               | 99 (16.42)                | <0.001    |
| Prior Biologic Use n (%)                                    |                           |                           |           |
| 0 prior biologic                                            | 88 (9.39)                 | 90 (14.93)                | 0.001     |
| 1 prior biologic                                            | 171 (18.25)               | 141 (23.38)               | 0.014     |
| 2 prior biologic                                            | 213 (22.73)               | 155 (25.7)                | 0.182     |
| 3+ biologics                                                | 465 (49.63)               | 217 (35.99)               | <0.001    |
| Current Concomitant Medication n (%)                        |                           |                           |           |
| Monotherapy                                                 | 421 (44.93)               | 236 (39.14)               | 0.025     |
| Combination Therapy                                         |                           |                           |           |
| MTX Alone                                                   | 257 (27.43)               | 202 (33.5)                | 0.011     |
| MTX + other cDMARD                                          | 73 (7.79)                 | 38 (6.3)                  | 0.270     |
| Other cDMARD                                                | 186 (19.85)               | 127 (21.06)               | 0.565     |
| Prednisone Use n (%)                                        | 303 (32.34)               | 170 (28.19)               | 0.085     |
| Prednisone dose among users                                 |                           |                           |           |
| Dose ≤10 mg                                                 | 255 (88.54)               | 151 (92.07)               | 0.233     |
| Dose >10 mg                                                 | 33 (11.46)                | 13 (7.93)                 | 0.233     |
| Current Statin Use : n (%)                                  | 212 (22.63)               | 128 (21.23)               | 0.519     |
| Disease Activity : Mean ± SD                                |                           |                           |           |
| Tender Joint Count (28)                                     | 6.31 ± 6.91               | 6.55 ± 6.88               | 0.561     |
| Swollen Joint Count (28)                                    | 4.55 ± 5.13               | 4.4 ± 5                   | 0.639     |
| Physician Global Assessment (0-100)                         | 31.38 ± 21.79             | 32.93 ± 21.53             | 0.230     |
| Patient Global Assessment (0-100)                           | 46.64 ± 26.99             | 46.49 ± 26.87             | 0.922     |
| CDAI                                                        | 18.67 ± 13.15             | 18.89 ± 13.37             | 0.782     |
| Patient Pain (0-100)                                        | 50.18 ± 28.6              | 49.94 ± 28.42             | 0.889     |
| Patient reported fatigue (0-100)                            | 51.17 ± 29.96             | 50.09 ± 30.73             | 0.552     |
| EQ5D (0-1)                                                  | 0.97 ± 0.07               | 0.97 ± 0.07               | 0.113     |
| mDAS                                                        | 4.29 ± 1.41               | 4.34 ± 1.41               | 0.569     |
| DAS28 (CRP)                                                 | 3.69 ± 1.39               | 3.61 ± 1.4                | 0.380     |
| DAS28 (ESR)                                                 | 4.28 ± 1.47               | 4.15 ± 1.59               | 0.301     |
| Line of Therapy* n (%)                                      |                           |                           |           |
| 1st                                                         | 4 (0.43)                  | 5 (0.83)                  | 0.312     |
| 2nd                                                         | 84 (8.96)                 | 85 (14.1)                 | 0.002     |
| 3rd                                                         | 171 (18.25)               | 141 (23.38)               | 0.014     |
| 4th +                                                       | 678 (72.36)               | 372 (61.69)               | <0.001    |

Source: PsA PR Module 5.3.6 Corrona Safety Analysis Table 1.

Body Mass Index (BMI) is calculated as weight/(height*0.01)*2.

<div style=\"page-break-after: always\"></div>

Table 7 0. Patient Demographic and Clinical Characteristics of Tofacitinib Initiators by Dose (5 mg IR BID and 11 mg PR QD) - US Corrona RA Registry Study A3921205 (31 Jul 2020 subset analysis of final data 31 Jan 2019)

At time of Tofacitinib initiation

Tofacitinib 5 mg IR BID   Tofacitinib 11 mg PR QD

P-value

*Line of therapy definitions are consistent with previous reports:  1 st  line: Naïve to conventional synthetic DMARD-IR (csDMARDs) and all Biologic DMARD; 2nd line: csDMARDs, but biologic naïve; third line: Biologic DMARD-IR;fourth plus line: ≥2 Biologic DMARD-IR.)

Table 7 1. Crude Incidence Rates (per 100 PY) for Tofacitinib by Dose (5 mg IR BID versus 11 mg PR QD)   of US Corrona RA Registry Study A3921205 (31 Jul 2020 subset analysis of final data 31 Jan 2019)

| Event of Interest         | Tofacitinib 5 mg IR BID   | Tofacitinib 5 mg IR BID   | Tofacitinib 5 mg IR BID   | Tofacitinib 5 mg IR BID   | Tofacitinib 5 mg IR BID   | Tofacitinib 11 mg PR QD   | Tofacitinib 11 mg PR QD   | Tofacitinib 11 mg PR QD   | Tofacitinib 11 mg PR QD   | Tofacitinib 11 mg PR QD   |
|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|                           | N                         | PYR                       | Rate                      | 95% CI                    | 95% CI                    | N                         | PYR                       | Rate                      | 95% CI                    | 95% CI                    |
| Total CVD*                | 45                        | 1709.13                   | 2.63                      | 1.92                      | 3.52                      | 19                        | 554.67                    | 3.43                      | 2.06                      | 5.35                      |
| MACE †                    | 15                        | 1746.58                   | 0.86                      | 0.48                      | 1.42                      | 3                         | 563.57                    | 0.53                      | 0.11                      | 1.56                      |
| Total Serious Infections  | 49                        | 1701.19                   | 2.88                      | 2.13                      | 3.81                      | 26                        | 548.83                    | 4.74                      | 3.09                      | 6.94                      |
| Total Herpes Zoster       | 33                        | 1720.84                   | 1.92                      | 1.32                      | 2.69                      | 7                         | 561.23                    | 1.25                      | 0.50                      | 2.57                      |
| Serious Herpes Zoster     | 0                         | 1758.05                   | 0.00                      | 0.00                      | 0.21                      | 0                         | 564.02                    | 0.00                      | 0.00                      | 0.65                      |
| Non-serious Herpes Zoster | 33                        | 1720.84                   | 1.92                      | 1.32                      | 2.69                      | 7                         | 561.23                    | 1.25                      | 0.50                      | 2.57                      |
| GI Perforations           | 1                         | 1757.97                   | 0.06                      | 0.00                      | 0.32                      | 0                         | 564.02                    | 0.00                      | 0.00                      | 0.65                      |
| DVTor PE                  | 6                         | 1752.49                   | 0.34                      | 0.13                      | 0.75                      | 2                         | 562.63                    | 0.36                      | 0.04                      | 1.28                      |
| Total Cancer              | 63                        | 2330.67                   | 2.70                      | 2.08                      | 3.46                      | 13                        | 638.04                    | 2.04                      | 1.08                      | 3.48                      |
| Cancer excluding NMSC     | 29                        | 2389.28                   | 1.21                      | 0.81                      | 1.74                      | 7                         | 642.25                    | 1.09                      | 0.44                      | 2.25                      |
| Death                     | 23                        | 2419.98                   | 0.95                      | 0.60                      | 1.43                      | 4                         | 647.67                    | 0.62                      | 0.17                      | 1.58                      |

Source: PsA PR Module 5.3.6 Corrona Safety Analysis Table 2.

Important Statistical Note about Results: due to the small number of events observed, only rates and 95% CIs are presented. At this time, any comparisons between tofacitinib 5 mg IR BID group and tofacitinib 11 mg PR QD group would be underpowered. Caution is recommended when drawing any conclusions based on these analyses.

*Total CVD is defined as hypertension requiring hospitalisation, cardiac revascularisation procedure (CABG, stent, angioplasty), ventricular arrhythmia, cardiac arrest, myocardial Infarction, acute coronary syndrome, unstable angina, CHF requiring hospitalisation, stroke, transient ischemic attack, other cardiovascular event ( specify ), deep vein thrombosis, peripheral arterial thromboembolic event, urgent peripheral arterial revascularisation, peripheral ischemia or gangrene (necrosis) and pulmonary embolism.

† MACE is defined as MI, stroke, TIA and CV death.

Age and gender standardised incidence rates for serious infections are as follows:

- PR group: 26 patients representing an incidence rate of 4.23 (95% CI: 2.71, 6.31) patients with events per 100 PY.
- IR group: 49 patients representing an incidence rate of 2.88 (95% CI: 2.13, 3.81) patients with events per 100 PY.

Age and gender standardised incidence rates for Total HZ are as follows:

- PR group: 7 patients representing an incidence rate of 1.38 (95% CI: 0.55, 2.83) patients with events per 100 PY.
- IR group: 33 patients representing an incidence rate of 1.92 (95% CI: 1.32, 2.69) patients with events per 100 PY.

<div style=\"page-break-after: always\"></div>

When considering events stratified by line of therapy for RA, the CIs for the crude point estimates in the tofacitinib 5 mg IR BID group overlap with those in the 11 mg PR QD group with the exception of serious infections rates among patients taking tofacitinib as fourth plus line of therapy, which are presented below:

· PR group: 24 patients representing a crude incidence rate of 7.21 (95% CI: 4.62, 10.72) patients with events per 100 PY.

· IR group: 36 patients representing a crude incidence rate of 2.94 (95% CI: 2.06, 4.06) patients with events per 100 PY.

According to the MAH, the numerically higher incidence rate observed for serious infections within the tofacitinib 11 mg PR QD group relative to the 5 mg IR BID group in the fourth plus line of therapy stratum is  inconsistent both with the totality of tofacitinib safety data showing similarity between IR and PR formulations (similar PK parameters and E-R data between IR to PR in RA PR), and with other results from this subset analysis of the US Corrona RA Registry Study.

According to the MAH, the differences in the serious infection rates could be due to the difference in market authorisation timing and post tofacitinib initiation follow-up time between the tofacitinib PR and IR dosing regimens in RA. Due to the market authorisation timing, patients in the overall tofacitinib IR group had longer follow-up time (on average 2.57 years), while the average follow-up time was 1.07 years  in  the  overall  PR  group.  To  address  this  point,  the  MAH  presented  a  Kaplan-Meier  curve  to summarise incidence rates of serious infections at time intervals following tofacitinib initiation for all patients (next figure).

Maximum follow-up time in the US Corrona RA Registry Study A3921205 for tofacitinib PR was 36 months. Maximum follow-up time for tofacitinib IR was ~72 months; during the 36 to 72-month followup timeframe, 7 serious infection events were reported for the IR formulation.

<div style=\"page-break-after: always\"></div>

Figure 39.  Kaplan-Meier Curve of All Patients without Serious Infections Among Tofacitinib Initiators by Dose (5 mg IR BID versus 11 mg PR QD)

Table 7 2. Number of Patients with Serious Infection Events (5 mg IR BID versus 11 mg PR QD)

<!-- image -->

Time (Months)

| Number at risk   |     |     |     |     |     |     |     |
|------------------|-----|-----|-----|-----|-----|-----|-----|
| 5 mg IR          | 937 | 817 | 572 | 429 | 349 | 277 | 196 |
| 11 mg PR QD      | 603 | 454 | 217 |  95 |  35 |   5 |   0 |

| Time Frame (Months)   | Number of Patients with Serious Infection Events   | Number of Patients with Serious Infection Events   |
|-----------------------|----------------------------------------------------|----------------------------------------------------|
|                       | 5 mg IR BID                                        | 11 mg PR QD                                        |
| [0, 6]                | 8                                                  | 9                                                  |
| [6, 12]               | 14                                                 | 6                                                  |
| [12, 18]              | 7                                                  | 6                                                  |
| [18, 24]              | 4                                                  | 3                                                  |
| [24, 30]              | 6                                                  | 2                                                  |
| [30, 36]              | 3                                                  | 0                                                  |

Source: PsA PR Module 5.3.6 Corrona Safety Analysis Appendix A Figure 1

## Data from Post-Marketing Surveillance Reports

The RMP includes post-marketing data (data cut off 05 Nov 2019). Information from the post marketing setting  is  also  included  in  the  PSUR  submitted  to  the  EMA  at  1  year  intervals.  Findings  from  postmarketing data have been consistent with the safety profile for tofacitinib.

At the time of the November 2020 data cut, the cumulative worldwide exposure to tofacitinib since product approval is estimated to be 391,640 PY. The data were extrapolated for the third quarter of

<div style=\"page-break-after: always\"></div>

2020 by taking the average of previous 4 quarters and pro-rated to the end of the current reporting period.

There  are  limitations  to  the  interpretation  of  the  post-marketing  data:  under-reporting  of  AEs  and incomplete  clinical  information,  unknown  number  of  patients  taking  the  drug,  no  placebo  control, causality is uncertain. Therefore, the data presented should be interpreted with caution.

## Summary of Spontaneous Cases

There has been a total of 69,758 spontaneous case reports received. A cumulative summary of all cases and AEs, regardless of indication or dose, has been provided in the Annual PSUR with DLP 05 Nov 2019.

An overview of cases for tofacitinib by dosing regimen (11 mg PR QD, 5 mg IR BID) and indication for PsA and RA are presented in Table 73.

Table 73. Case Summary for Tofacitinib PR and IR in PsA and PR and IR in RA (Postmarketing Surveillance Spontaneous Reports) (DLP: 05 Nov 2019)

|                          | PsA a                     | PsA a                     | RA a                      | RA a                      |
|--------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|                          | Tofacitinib 11 mg PR QD b | Tofacitinib 5 mg IR BID c | Tofacitinib 11 mg PR QD b | Tofacitinib 5 mg IR BID c |
| Total Number of Cases, n | 677                       | 890                       | 10566                     | 29845                     |
| Number of AEs, n         | 1705                      | 2518                      | 31776                     | 99807                     |
| Gender, n (%)            |                           |                           |                           |                           |
| Male                     | 197 (29.1)                | 231 (26.0)                | 1738 (16.4)               | 4961 (16.6)               |
| Female                   | 472 (69.7)                | 642 (72.1)                | 8766 (83.0)               | 24437 (81.9)              |
| No Data                  | 8 (1.2)                   | 17 (1.9)                  | 62 (0.6)                  | 447 (1.5)                 |
| Age (yr)                 |                           |                           |                           |                           |
| Mean                     | 56.4                      | 55.6                      | 60.1                      | 60.3                      |
| Median                   | 58.0                      | 56.0                      | 61.0                      | 61.0                      |
| Case Seriousness, n (%)  |                           |                           |                           |                           |
| Serious                  | 105 (15.5)                | 175 (19.7)                | 2609 (24.7)               | 8679 (29.1)               |
| Nonserious               | 572 (84.5)                | 715 (80.3)                | 7957 (75.3)               | 21166 (70.9)              |
| Case Outcome, n (%)      |                           |                           |                           |                           |
| Fatal                    | 3 (0.4)                   | 4 (0.4)                   | 117 (1.1)                 | 513 (1.7)                 |
| Non-fatal d              | 674 (99.6)                | 886 (99.6)                | 10449 (98.9)              | 29332 (98.3)              |

Source: Data on file.

a. Patients included are those where the administered dose and indication were provided in the case report.

b. Tofacitinib 11 mg PR QD or total daily dose is 11 mg.

c. Tofacitinib 5 mg IR BID or total daily dose is 10 mg. Post-marketing cases for IR formulation included a very limited number of cases for which the total daily dose may be indicative of use of 10 mg tablet strength and a posology of 10 mg BID. d. Non-fatal includes not recovered/not resolved, recovered/resolved, recovered/resolved with sequel, recovering/resolving, unknown.

A total of 25,902 cases (which included 69,672 AEs) and 43,856 cases (which included 131,691 AEs) were reported for tofacitinib PR and IR (includes data for all approved indications as well as off-label use), respectively. The majority of the cases were non-serious (79.9% for PR and 74.9% for IR). There were 5,197 and 11,011 SAEs reported for PR and IR respectively. The proportion of serious cases and the proportion of fatal cases was similar for the PR and IR formulations, for both PsA and RA.

Table 74 presents the most frequently reported AEs by SOC and PT for tofacitinib PR and IR divided by indications of PsA and RA when the indication and dose were known for the case. The distribution of AEs by SOC and PT was similar for both IR and PR formulations and for both indications. These updated data provide support that the long-term safety of 11 mg PR QD in the real-world setting is consistent with the established safety profile of tofacitinib 5 mg IR BID.

<div style=\"page-break-after: always\"></div>

A comparison of post-marketing AEs for RA tofacitinib 11 mg PR QD to RA tofacitinib 5 mg IR BID demonstrated an identical rank order for the 10 SOCs within which AEs were most frequently reported (SOCs in rank order starting with highest reported proportions). In RA patients, the % of AEs within SOCs for which the % was ≥ 2% in either formulation were similar.

Table 74. Distribution of Post-Marketing Surveillance Adverse Events by SOC (all) and Preferred Term (≥2%) for PsA or RA (DLP: 05 Nov 2019)

|                                             | PsA a                     | PsA a                     | RA a                      | RA a                      |
|---------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| MedDRA SOC n (%) Preferred Term n (%)       | Tofacitinib 11 mg PR QD c | Tofacitinib 5 mg IR BID d | Tofacitinib 11 mg PR QD c | Tofacitinib 5 mg IR BID d |
| Blood and lymphatic                         | 7 (1.0)                   | 11 (1.2)                  | 136 (1.3)                 | 523 (1.8)                 |
| Disorders b                                 |                           |                           |                           |                           |
| Cardiac disorders b                         | 13 (1.9)                  | 20 (2.2)                  | 229 (2.2)                 | 798 (2.7)                 |
| Congenital familial and genetic disorders b | 0                         | 1 (0.1)                   | 11 (0.1)                  | 24 (0.1)                  |
| Ear and labyrinth disorders b               | 11 (1.6)                  | 5 (0.6)                   | 162 (1.5)                 | 496 (1.7)                 |
| Endocrine disorders b                       | 2 (0.3)                   | 3 (0.3)                   | 32 (0.3)                  | 102 (0.3)                 |
| Eye disorders b                             | 13 (1.9)                  | 23 (2.6)                  | 424 (4.0)                 | 1114 (3.7)                |
| Gastrointestinal disorders                  | 163 (24.1)                | 288 (32.4)                | 2958 (28.0)               | 10355 (34.7)              |
| Abdominal discomfort                        | 16 (2.4)                  | 31 (3.5)                  | 191 (1.8)                 | 893 (3.0)                 |
| Abdominal pain upper                        | 12 (1.8)                  | 18 (2.0)                  | 258 (2.4)                 | 741 (2.5)                 |
| Diarrhoea                                   | 32 (4.7)                  | 51 (5.7)                  | 497 (4.7)                 | 1734 (5.8)                |
| Nausea                                      | 27 (4.0)                  | 54 (6.1)                  | 413 (3.9)                 | 1715 (5.8)                |
| Vomiting                                    | 9 (1.3)                   | 14 (1.6)                  | 175 (1.7)                 | 597 (2.0)                 |
| General disorders and administration site   | 419 (61.9)                | 690 (77.5)                | 7952 (75.3)               | 25721 (86.2)              |
| conditions                                  |                           |                           |                           |                           |
| Condition aggravated                        | 38 (5.6)                  | 59 (6.6)                  | 1028 (9.7)                | 2881 (9.7)                |
| Drug ineffective                            | 120 (17.7)                | 170 (19.1)                | 1768 (16.7)               | 5666 (19.0)               |
| Fatigue                                     | 32 (4.7)                  | 68 (7.6)                  | 588 (5.6)                 | 2000(6.7)                 |
| Gait disturbance                            | 12 (1.8)                  | 11 (1.2)                  | 202 (1.9)                 | 656 (2.2)                 |
| Malaise                                     | 29 (4.3)                  | 62(7.0)                   | 692 (6.6)                 | 1848 (6.2)                |
| Pain                                        | 49 (7.2)                  | 40 (4.5)                  | 908 (8.6)                 | 2276 (7.6)                |
| Peripheral swelling                         | 18 (2.7)                  | 15 (1.7)                  | 380 (3.6)                 | 1104 (3.7)                |
| Pyrexia                                     | 12 (1.8)                  | 15 (1.7)                  | 189 (1.8)                 | 745 (2.5)                 |
| Therapeutic product effect incomplete       | 19 (2.8)                  | 76 (8.5)                  | 356 (3.4)                 | 2258 (7.6)                |
| Hepatobiliary disorders b                   | 7 (1.0)                   | 9 (1.0)                   | 109 (1.0)                 | 418 (1.4)                 |
| Immune system disorders b                   | 20 (3.0)                  | 28 (3.1)                  | 355 (3.4)                 | 754 (2.5)                 |
| Infections and infestations                 | 175 (25.8)                | 286 (32.1)                | 3929 (37.2)               | 12002 (40.2)              |
| Bronchitis                                  | 10 (1.5)                  | 19 (2.1)                  | 234 (2.2)                 | 592 (2.0)                 |
| Herpes Zoster                               | 11 (1.6)                  | 13 (1.5)                  | 236 (2.2)                 | 922 (3.1)                 |
| Infection                                   | 7 (1.0)                   | 16 (1.8)                  | 221 (2.1)                 | 647 (2.2)                 |
| Influenza                                   | 15 (2.2)                  | 23 (2.6)                  | 301 (2.9)                 | 1017 (3.4)                |
| Nasopharyngitis                             | 18 (2.7)                  | 40 (4.5)                  | 548 (5.2)                 | 1571 (5.3)                |
| Pneumonia                                   | 7 (1.0)                   | 8 (0.9)                   | 288 (2.7)                 | 969 (3.2)                 |
| Sinusitis                                   | 17 (2.5)                  | 15 (1.7)                  | 338 (3.2)                 | 697(2.3)                  |
| Upper respiratory tract infection           | 14 (2.1)                  | 7 (0.8)                   | 187 (1.8)                 | 331 (1.1)                 |
| Urinary tract infection                     | 15 (2.2)                  | 17 (1.9)                  | 289 (2.7)                 | 782 (2.6)                 |
| Injury, poisoning and                       | 270 (39.9)                | 293 (32.9)                | 2416 (22.9)               | 7300 (24.5)               |
| procedural complications Fall               | 10 (1.5)                  | 5 (0.6)                   | 211 (2.0)                 | 707 (2.4)                 |
| Off label use                               | 29 (4.3)                  | 46 (5.2)                  | 116 (1.1)                 | 493 (1.7)                 |
| Product dose omission                       | 29 (4.3)                  | 21 (2.4)                  | 547 (5.2)                 | 1131 (3.8)                |

<div style=\"page-break-after: always\"></div>

Table 74. Distribution of Post-Marketing Surveillance Adverse Events by SOC (all) and Preferred Term (≥2%) for PsA or RA (DLP: 05 Nov 2019)

|                                                                           | PsA a                     | PsA a                     | RA a                      | RA a                      |
|---------------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| MedDRA SOC n (%) Preferred Term n (%)                                     | Tofacitinib 11 mg PR QD c | Tofacitinib 5 mg IR BID d | Tofacitinib 11 mg PR QD c | Tofacitinib 5 mg IR BID d |
| Product use in unapproved indication                                      | 131 (19.4)                | 117 (13.1)                | 52 (0.5)                  | 109 (0.4)                 |
| Product use issue                                                         | 11 (1.6)                  | 33 (3.7)                  | 173 (1.6)                 | 708 (2.4)                 |
| Investigations                                                            | 90 (13.3)                 | 95 (10.7)                 | 1767 (16.7)               | 5002 (16.8)               |
| Weight increased                                                          | 11 (1.6)                  | 27 (3.0)                  | 294 (2.8)                 | 733 (2.5)                 |
| Metabolism and nutrition                                                  | 16 (2.4)                  | 22 (2.5)                  | 277 (2.6)                 | 910 (3.0)                 |
| disorders b                                                               |                           |                           |                           |                           |
| Musculoskeletal and connective tissue disorders                           | 109 (16.1)                | 164 (18.4)                | 3636 (34.4)               | 11638 (39.0)              |
| Arthralgia                                                                | 19 (2.8)                  | 21 (2.4)                  | 646 (6.1)                 | 1846 (6.2)                |
| Back pain                                                                 | 9 (1.3)                   | 14 (1.6)                  | 210 (2.0)                 | 694 (2.3)                 |
| Joint swelling                                                            | 4 (0.6)                   | 10 (1.1)                  | 297 (2.8)                 | 903 (3.0)                 |
| Musculoskeletal stiffness                                                 | 6 (0.9)                   | 3 (0.3)                   | 265 (2.5)                 | 621 (2.1)                 |
| Pain in extremity                                                         | 21 (3.1)                  | 26 (2.9)                  | 482 (4.6)                 | 1542 (5.2)                |
| Rheumatoid arthritis                                                      | 2 (0.3)                   | 5 (0.6)                   | 86 (0.8)                  | 912 (3.1)                 |
| Neoplasms benign, malignant and unspecified (includes cysts and polyps) b | 7 (1.0)                   | 8 (0.9)                   | 238 (2.3)                 | 807 (2.7)                 |
| Nervous system disorders                                                  | 116 (17.1)                | 198 (22.2)                | 2123 (20.1)               | 7072 (23.7)               |
| Dizziness                                                                 | 7 (1.0)                   | 26 (2.9)                  | 205 (1.9)                 | 928 (3.1)                 |
| Headache                                                                  | 43 (6.4)                  | 107 (12.0)                | 763 (7.2)                 | 2704 (9.1)                |
| Pregnancy, puerperium and perinatal conditions b                          | 0                         | 0                         | 2 (0.0)                   | 19 (0.1)                  |
| Product issues b                                                          | 2 (0.3)                   | 0                         | 32 (0.3)                  | 68 (0.2)                  |
| Psychiatric disorders b                                                   | 34 (5.0)                  | 60 (6.7)                  | 676 (6.4)                 | 2347 (7.9)                |
| Renal and urinary                                                         | 13 (1.9)                  | 19 (2.1)                  | 303 (2.9)                 | 971 (3.3)                 |
| Reproductive system and                                                   | 4 (0.6)                   | 1 (0.1)                   | 92 (0.9)                  | 293 (1.0)                 |
| breast disorders b Respiratory, thoracic and                              | 86 (12.7)                 | 122 (13.7)                | 2051 (19.4)               | 5677 (19)                 |
| Cough                                                                     | 10 (1.5)                  | 22 (2.5)                  | 368 (3.5)                 | 1119 (3.8)                |
| Dyspnoea                                                                  | 13 (1.9)                  | 21 (2.4)                  | 200 (1.9)                 | 695 (2.3)                 |
| Oropharyngeal pain                                                        | 6 (0.9)                   | 14 (1.6)                  | 244 (2.3)                 | 626 (2.1)                 |
| Skin and subcutaneous                                                     | 100 (14.8)                | 137 (15.4)                | 1381 (13.1)               | 3777 (12.7)               |
| tissue disorders                                                          |                           |                           |                           |                           |
| Psoriasis                                                                 | 13 (1.9)                  | 21 (2.4)                  | 30 (0.3)                  | 42 (0.1)                  |
| Rash                                                                      | 15 (2.2)                  | 20 (2.3)                  | 255 (2.4)                 | 636 (2.1)                 |
| Social circumstances b                                                    | 8 (1.2)                   | 5 (0.6)                   | 143 (1.4)                 | 466 (1.6)                 |
| Surgical and medical procedures b                                         | 0                         | 0                         | 6 (0.1)                   | 16 (0.1)                  |
| Vascular disorders b                                                      | 20 (3.0)                  | 30 (3.4)                  | 336 (3.2)                 | 1136 (3.8)                |

<div style=\"page-break-after: always\"></div>

Table 74. Distribution of Post-Marketing Surveillance Adverse Events by SOC (all) and Preferred Term (≥2%) for PsA or RA (DLP: 05 Nov 2019)

|                                       | PsA a                     | PsA a                     | RA a                      | RA a                      |
|---------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| MedDRA SOC n (%) Preferred Term n (%) | Tofacitinib 11 mg PR QD c | Tofacitinib 5 mg IR BID d | Tofacitinib 11 mg PR QD c | Tofacitinib 5 mg IR BID d |

The most frequent AEs by SOC for RA were as follows:

- General disorders and administration site condition
- Infections and infestations
- Musculoskeletal and connective tissue disorders.

A comparison of post-marketing AEs for PsA tofacitinib 11 mg PR QD to PsA tofacitinib 5 mg IR BID demonstrated the 10 SOCs within which AEs were most frequently reported were the same for the 2 formulations, with a few differences in rank order.

The most frequent AEs by SOC for PsA were as follows:

- General disorders and administration site condition
- Injury, poisoning and procedural complications
- Infections and infestations.

## 2.5.1. Discussion on clinical safety

No AS patient has been exposed to tofacitinib 11 mg PR formulation, since the MAH maintains that the safety profile of the PR formulation is expected to be similar to that of the IR formulation in the specific setting (i.e. AS), and to that of the PR formulation in the other indications where the PR formulation has been already tested/used (i.e. RA and PsA). This bridging approach is considered acceptable.

Known Safety Profile :  Tofacitinib,  in  the  already  approved  indications,  has  shown  a  safety  profile mainly  characterised  by  the  following:  serious  venous  thromboembolism  (VTE)  events  including pulmonary embolism (PE), some of which fatal, and deep vein thrombosis (DVT); serious and sometimes fatal  infections;  viral  reactivation  and  cases  of  herpes  virus  reactivation;  lymphomas  have  been observed; non-melanoma skin cancers (NMSC) have been reported; gastrointestinal perforation.

Moreover,  on  18  January  2021  the  MAH  informed  the  EMA  about  an  Emerging  Safety  Issue  (ESI) notification for tofacitinib pertaining to two signals identified from review of the final study data in Study A3921133,  specifically  including  the  increased  incidence  of  adjudicated  MACE  and  adjudicated malignancies (excluding NMSC). As mentioned before the impact of the study results on tofacitinib safety and efficacy is being currently assessed in the EMEA/H-A20/1517/C/004214/0048 referral.

Source of data: Two studies have tested the IR formulation in the AS indication: 1) one completed Phase 2, 12-week long randomised double-blind, placebo-controlled, dose-ranging Study A3921119 in patients with AS (tofacitinib IR was evaluated at doses of 2, 5 and 10 mg BID); 2) one completed pivotal Study A3921120, 48-week long phase 3, randomised, double-blind, placebo-controlled (first 16 weeks) study

<div style=\"page-break-after: always\"></div>

of the efficacy and safety of tofacitinib in patients with active AS (tofacitinib IR was evaluated at a dose of 5 mg BID).

The integrated analysis of safety included pooling of the two studies to assess: 1) short-term (0-16 weeks) safety of tofacitinib 5 mg IR BID in comparison to placebo in the combined trials (the 'Placebo -controlled Cohort'); 2) longer -term (0-48 weeks) s afety of tofacitinib in the combined trials' (the 'All Tofa Cohort'). The All Tofa Cohort has 2 analysis groups: All Tofa 5 mg IR BID (tofacitinib 5 mg IR BID in the combined trials) and All Tofa (tofacitinib IR 2 mg, 5 mg, and 10 mg BID in the combined trials).

Exposure : 253 patients were exposed to tofacitinib 5 mg IR BID (the intended dosage in AS) for at least 6 months (patients-year (PY)=194), and 108 patients for at least 1 year (PY=100). There were 108 patients with AS with an exposure longer than 12 months.  The number of patients exposed to a long-term treatment (e.g. 12 months) is limited, considering that the sought indication is a chronic disease requiring long-term therapy and also considering some safety concerns of the drug emerging with long term use. No patients were exposed to the PR formulation. In accordance with EMA guidelines, which consider appropriate to have data from periods longer than 12-month in this specific context, the MAH was asked to update the safety data and analysis for those subjects who experienced an exposure longer than 1 year. However, the MAH responded that during the AS program, no additional risks specific to AS emerged, and that the overall safety profile, including long-term safety, of the AS population is consistent with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Since RA and PsA are also chronic diseases requiring long-term therapy, the MAH, thus, considers the long-term safety data ( ≥ 1 year) for tofacitinib gathered from RA and PsA patients to be applicable to the AS population. Therefore, the MAH does not foresee to conduct a specific study to gather long-term data in the AS population. This is acceptable.

Adverse events : Overall, in the AS placebo-controlled cohort (short-term exposure, up to 16 weeks), the proportion of subject with AEs was slightly higher in tofacitinib IR than in placebo (54.6% vs 49.2%).

The most frequently reported TEAEs in the tofacitinib IR arm of the Placebo-controlled Cohort were within the  Infections  and  infestations  (27.6%),  Gastrointestinal  disorders  (13%),  Musculoskeletal  and connective tissue disorders SOCs (8.1%), and ALT/AST increase (3.2% and 2.2%). This was slightly lower in the placebo arm (23%, 15%, 11.2%, 0.5% and 0%, respectively). Similarly, the most frequently reported  TEAEs  in  the  All Tofa Cohort  were  within  the  Infections and  infestations  (32.1%), Gastrointestinal disorders (16.2%), Musculoskeletal and connective tissue disorders (10.5%) SOCs.

However, when the All Tofa cohort is considered, a higher incidence of AEs is found (as expected since the longer exposure): subjects with AEs were 63.6% in tofacitinib 5 mg IR BID.

Due to the limited number of patients studied in the placebo-controlled trial (185 in tofacitinib 5 mg IR BID) and the short duration of the placebo-controlled period (up to 16 weeks), it is very difficult to evaluate  the  observed  difference  in  the  incidence  of  AEs;  furthermore,  many  AEs  that  are  typically associated to tofacitinib treatment (such as herpes zoster), are not observed in the placebo-controlled period.

For the following AEs Hazard Ratios are higher in tofacitinib arm versus placebo: acute renal failure (HR=2.57),  hypertension  (2.05),  weight  increase  (2),  hyperlipidaemia  (2.01)  and  transaminase elevations  (4.03).  Hypertension,  weight  increase,  hyperlipidaemia  and  transaminase  elevation  are mentioned in SmPC 4.8. Seven cases of HZ (all non-serious) were reported in the AS clinical programme. The incidence rate per 100 PY was higher than in the PsA dataset and comparable to RA dataset (2.7, 1.7 and 3.6, respectively). Herpes zoster is already reported as a common AE in the table of the 4.8 section of the SmPC.

<div style=\"page-break-after: always\"></div>

Acute renal failure was observed in more cases in tofacitinib than in placebo, 5 (2.70%) vs 2 (1.07%). It was 3.8% in All Tofa cohort, all treated with tofacitinib 5mg IR BID. Almost all the events listed under the SMQ of 'acute renal failure' were coded as 'protein urine present'. Upon request, the MAH specified that in most of the cases the severity of the alteration was cl assified as 'trace' or '+1', only one patient had '+2' as severity of the finding and none had '+3' or '+4'. Moreover, all participants with AEs of 'protein urine present' had creatinine levels within normal limits at all visits. Therefore, it seems that the  severity  of  the  AEs  observed  was  mild  on  average.  The  risk  of  creatinine  increase  is  already recognized at the 4.8 tabular listing of ADRs in the SmPC.

Hepatic  AEs  (including:  Hepatic  Steatosis,  Transaminase  Elevations)  were  overall  observed  more frequently in tofacitinib than in placebo (5.40% vs 1.07%) and this is consistent with the known impact of tofacitinib on liver safety.

In the AS program were not observed cases of: Malignancies, NMSC, CV events of MACE or thrombosis (ATE, PE, and DVT), GI Perforation, Rhabdomyolysis. To interpret correctly these data, it must be taken into account the small number of patients and the short duration of the exposure.

When the incidence rate for AEs of special interest in patients treated with tofacitinib IR in the AS development program is compared to those observed in the PsA and RA programs, the incidences in the AS are lower, this is almost certainly due to the low exposure in the AS program compared to the other two  conditions.  An  exception  is  observed  for  herpes  zoster  incidence  that  is  higher  in  AS  patients (2.68/100 PY) compared to PsA (1.76/100 PY) but lower compared to RA (3.58/100 PY).

When compared to the RA/PsA programs, except for herpes zoster in patients taking tofacitinib 5 mg IR BID, all the SAEs were apparently less frequent in the AS program. This was most probably due to the very low exposure in the AS program (PYR=232.98 for tofacitinib IR all doses) compared to PsA in which exposure was about 10 times higher (2037.97) and RA in which it was 100 times higher (23496.73). Therefore,  no  conclusions  can  be  drawn  from  these  data  and  the  need  of  having  further  safety information  (even  if  only  from  a  post-marketing  setting)  from  a  higher  exposure  in  AS  subjects  is therefore foreseen.

SAEs and deaths : No deaths were reported in the AS clinical program. Incidence rate of SAEs (per 100 PY) was slightly higher in tofacitinib 5 mg IR than in placebo (5.28 vs 3.56) but the total number of cases was small (3 vs 2). In All tofacitinib IR doses the incidence rate was 3.49, that is similar to the placebo arm of the controlled cohort. There were 13 SAEs in 10 patients occurred under all tofa cohort (n=1 for each PT): Hypoacusis, Iridocyclitis, Abdominal adhesions, Condition aggravated, Hyperplastic cholecystopathy,  Meningitis  aseptic,  Rib  fracture,  Tendon  injury,  Spinal  osteoarthritis,  Migraine, Ureterolithiasis, Pneumothorax and Subcutaneous emphysema. The rate of SAEs is comparable in the tofacitinib  arm  as  compared to placebo. Since the small numbers, it is difficult to identify the most common SAEs, because virtually all the observed SAEs occurred each in a single subject. Most of the SAEs were mild in severity and many were managed by drug withdrawal.

## Laboratory findings

Inclusion  criteria  for  AS  trials  only  allowed  patients  with  a  platelet count  ≥100,000  platelets/mm 3 . Platelet counts showed a mean decrease of almost 30,000/mm 3  after 48 weeks in the All Tofa cohort. In the AS clinical program, a decrease in mean platelet counts was observed from baseline to Week 4 in the  Tofacitinib  5  mg  IR  twice  a  day  group:  platelets  decreased  of  about  30.000/mm3  at  Week  16, whereas in the placebo group there was no substantial change compared to baseline (data through Week 16). Furthermore, the reduction observed in the tofacitinib group persisted with the same magnitude (i.e. at least 30.000/mm 3 ) through Week 48. The MAH states that platelet profile changes over time similar to those in AS program were also seen in the rheumatoid arthritis (RA) and psoriatic arthritis (PsA) clinical programs. Pooled data were not used 'due to the differences in patient populations and

<div style=\"page-break-after: always\"></div>

study designs', according to the MAH. It is agreed that, from the data provided, a reduction in platelet count  is  also  observed  in  RA  and  PsA  patients,  and  the  magnitude  of  this  reduction  is  somehow comparable to what observed in SA. The lowest platelet count for an individual participant was 109,000 cells/mm 3   and  was  mild  in  severity  according  to  the  Rheumatology  Common  Toxicity  Criteria.  No participants had platelet counts meeting the criteria of moderate or severe laboratory abnormalities. Therefore, it can be concluded that the data presented by the MAH do not seem to indicate an AS-specific risk  of  platelet  reduction.  The  SmPC  section  4.8.  has  been  modified  to  reflect  the  fact  that  patients enrolled in the clinical program were required to have a platelet count &gt;100,000 /mm 3 .

AST, ALT and bilirubin increased in tofacitinib IR arm but were steady in the placebo arm (AST &gt;3.0x ULN: 2.2% vs 0.5%; ALT &gt;3.0x ULN: 2.7% vs 0.5%). This is mentioned adequately in 4.4 and 4.8 of the proposed SmPC.

Subjects with increased Triglycerides were also higher in tofacitinib than in placebo (&gt;1.3x ULN: 3.8% vs 1.6%). In general, the whole lipid profile was influenced by tofacitinib, with mild increase in total cholesterol, LDL, HDL and triglycerides; these AEs are already acknowledged in the SmPC.

Other laboratory result changes were comparable between tofacitinib arm and placebo arm in placebocontrolled cohort.

Vital signs No clinically significant changes were observed in blood pressure during the 16 weeks of the placebo-controlled period in patients taking tofacitinib or at the end of the 48 weeks (in the uncontrolled period); no alterations in the ECG parameters were found.

Special populations Effects by age are very difficult to estimate since the limited number of subjects (exposed to all tofacitinib doses) &gt;65 years (n=13) vs &lt;65 years (n=407) and thus no conclusions can be drawn). Data from the RA indication has shown a higher risk for serious infections in patients older than 65 years. This is reflected in the SmPC (4.4).

As to the gender, in almost all the categories of general events (and also for herpes zoster) female patients had higher incidence rates compared to male. However, the cohort was unbalanced since there were 594 males and 142 females.

Regarding the race most patients in the tofacitinib 5 mg BID group were White (n=252) and few were Asian (n=63). In general, more Asian patients in the tofacitinib 5 mg group experienced AEs (77.78%) compared to White (59.13%); more Asian subjects experienced Infections (52.38%) than White patients (30.95%). This is reflected in the SmPC, section 4.4.

Limited data regarding treatment with tofacitinib during pregnancy is available. No additional concerns are raised from AS pivotal trials.

## Concomitant medication

Recommendations regarding DDIs are extrapolated from RA and PsA studies. No additional DDI studies have been conducted for the AS indication. This is considered acceptable, because, considering the underlying pathophysiology of RA, PsA and AS (all auto-immune diseases) and treatment options, no additional interaction issues are expected for the AS indication.

Most patients (80%) were bDMARD-naïve, and only few (20%, n=58) had used TNF inhibitor or bDMARD (20%, n=58) prior to the start of the study. Overall, a consistent increase in general events (such as AEs, SAEs, discontinuations, etc) and infections was observed in patients with previous treatment with TNFi or bDMARD compared to those bDMARD-naïve: AEs were 72.41% vs 60.47%. The highest difference was observed for 'Discontinuation of study treatment', which involved 22.41% vs 4.65% of patients. The number of patients in the 'previously treated' group is small and thus any conclusion is difficult, but

<div style=\"page-break-after: always\"></div>

such results could be expected, since it is biologically plausible that patients already exposed to previous treatments develop more AEs when subsequently treated with tofacitinib.

## Discontinuation due to AEs

The rate of discontinuation due to AEs was low (n=11, 3.48%) in tofacitinib 5 mg IR BID arms. The most frequent SOC reported for discontinuation belongs to infections (n=3, 0.9%). Infection is a known risk of JAK-inhibitors and is adequately discussed in proposed text of tofacitinib SmPC. No new concerns are raised due to discontinuation after infection.

## Post-marketing experience

From the Corrona RA Registry Study A3921205, Total Serious Infections had a higher crude incidence (per 100 PY) with the PR 11 mg formulation (4.74, 95%CI: 3.09, 6.94) compared to the 5 mg IR (2.88, 95%CI: 2.13, 3.81); however, the Herpes zoster was more frequent in the IR use vs the PR.

When used as 4 th  or more line of therapy, serious infections were markedly higher with the PR formulation (7.21, 95% CI: 4.62, 10.72) compared to the IR formulation (2.94, 95% CI: 2.06, 4.06) with nonoverlapping CI limits.

This point was already discussed in the procedure of tofacitinib PR in PsA. Briefly, the MAH maintains that this result is inconsistent with data about 3 rd  line and with the overall safety data, and that it could be  due  to  the  different  timing  in  the  marketing  of  the  two  formulations  (more  recent  for  the  PR). However, 3 rd  line data are from few patients. It is acknowledged that the trend of the herpes zoster is in the opposite direction (i.e. higher risk with IR formulation vs PR), but this is considered not sufficient to rule out an overall increased risk of tofacitinib PR formulation for infections in general. However, it is recognised that the current exposure to the PR formulation is still not enough for a thorough assessment, and that the CI limits are often overlapping. Also, the Kaplan-Meier curves (used to compensate for the different marketing times of the two formulations) do not allow to rule out convincingly the possibility of an increased risk.

From the Corrona Registry also emerges a possible higher risk for CVD with the PR formulation compared to  the  IR:  (n=19,  PYR=554.67),  incidence  rate:  3.43  (95%CI:  2.06,  5.35)  with  PR  vs  (n=45, PYR=1709.13), incidence rate: 2.63 (95% CI, 1.92, 3.52) with IR.

Post-marketing data from surveillance do not seem to suggest a greater risk of any AE with the PR formulation respect to the IR (with the limits of the source of data).

## Bridging Safety Data from Tofacitinib IR Formulation to PR Formulation in AS Patients

The data and strategy that supported the bridging of safety from tofacitinib IR (5 mg BID) to PR (11 mg QD) using similarity in PK, and supportive E-R analyses of expected on-target (possibly mechanismbased) safety endpoints in patients with RA, that have indicated that Cav(or AUC) was the relevant predictor when an E-R relationship existed, is being proposed to justify the extrapolation of efficacy and safety data from 5 mg BI) to PR (11 mg QD) in AS.

The overall similarity of PK parameters (equivalent AUC and Cmax and slightly lower Cmin at steadystate) between the 2 formulations as demonstrated in healthy volunteers, provides assurance that the safety profile of PR is likely to be similar of that of IR in patients with AS. Inter- and intra-subject variability was similar between tofacitinib IR and PR formulations for all PK parameters.

Negligible  accumulation  of  systemic  exposure  (AUC  accumulation  ratio  of  1.12)  was  seen  following repeated dosing of tofacitinib PR. Similar to IR, more than 95% of PR is eliminated within 24 hours following discontinuation of treatment.

<div style=\"page-break-after: always\"></div>

In addition, the expected duration of steady state plasma concentrations above the in vitro, whole blood IC50 for JAK 1/3 inhibition (17 ng/mL) is approximately 12-13 hours for both formulations over a 24hour period. This suggests a similar level of target enzyme inhibition over the dosing interval. All these data suggest that the safety profile of the PR formulation in AS patients would be consistent with that of the IR formulation in AS.

Population PK analysis of tofacitinib in patients with active AS indicated that tofacitinib exposure, as measured by the steady-state AUC (over 24 hours) after 5 mg BID, was similar (differences between geometric means within 25%) among AS, PsA and RA patients. Geometric means of Cmax were also comparable between these 3 patient populations (AS IR PMAR-EQDD-A392k-sNDA-1064, PsA IR Module PMAR-EQDD-A392j-sNDA-601, RA IR PMAR- 00178). Furthermore, the similarities between the safety profile of tofacitinib 5 mg IR BID in AS subjects and the safety profile of tofacitinib 5 mg IR BID in RA and PsA support the conclusion that the safety profile of the PR formulation in AS would also be consistent with the PR formulation in RA.

## 2.5.2. Conclusions on clinical safety

No AS patients have been exposed to tofacitinib 11 mg PR formulation. Given that the entirety of data suggest the safety profile of the PR is similar to that of the IR formulation in the same indications and to the safety profile of the PR formulation in the other indications where it has already been tested or used, it is acceptable. From the data presented about the PR formulation, mainly post-marketing/registry data, an increase of serious infections seems to emerge with the PR formulation, especially when it is used as 4th or more line of therapy, compared to the IR. Also, a slightly higher CV risk seems to have been observed with the PR formulation vs the IR one. However, the nature of the data and the different exposure do not allow a thorough assessment of these signals and therefore it is difficult to reach a firm conclusion. The information about serious infections with the PR formulation, and the caution about its interpretation, are already reflected in the SmPC. In addition, as mentioned before the impact of the Study A3921133 results on tofacitinib safety and efficacy is being currently assessed in the EMEA/HA20/1517/C/004214/0048 referral.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application. The CHMP received the following PRAC Advice on the submitted Risk Management Plan: The PRAC considered that the risk management plan version 28.1 is acceptable.

The CHMP endorsed this advice without changes. The CHMP endorsed the Risk Management Plan version 28.1 with the following content:

<div style=\"page-break-after: always\"></div>

## Safety concerns

Table 75. Summary of Safety Concerns

| Important identified risks   | Venous thromboembolic events (DVT/PE)                                                                                              |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Serious and other important infections                                                                                             |
| Important identified risks   | HZ reactivation                                                                                                                    |
| Important identified risks   | Lung cancer                                                                                                                        |
| Important identified risks   | Lymphoma                                                                                                                           |
| Important identified risks   | Myocardial infarction                                                                                                              |
| Important identified risks   | Decrease in neutrophil counts and neutropenia                                                                                      |
| Important identified risks   | Decrease in lymphocyte counts and lymphopenia                                                                                      |
| Important identified risks   | Decrease in Hgb levels and anaemia                                                                                                 |
| Important identified risks   | Lipid elevations and hyperlipidaemia                                                                                               |
| Important identified risks   | NMSC                                                                                                                               |
| Important identified risks   | Transaminase elevation and potential for DILI                                                                                      |
| Important potential risks a  | Malignancy                                                                                                                         |
| Important potential risks a  | Cardiovascular risk (excl MI)                                                                                                      |
| Important potential risks a  | GI perforation                                                                                                                     |
| Important potential risks a  | ILD                                                                                                                                |
| Important potential risks a  | PML                                                                                                                                |
| Important potential risks a  | All-cause mortality                                                                                                                |
| Important potential risks a  | Increased immunosuppression when used in combination with biologics and immunosuppressants including B-lymphocyte depleting agents |
| Important potential risks a  | Increased risk of AEs when tofacitinib is administered in combination with MTX in RA or PsA patients                               |
| Important potential risks a  | Primary viral infection following live vaccination                                                                                 |
| Important potential risks a  | Increased exposure to tofacitinib when co-administered with CYP3A4 and CYP2C19 inhibitors                                          |
| Important potential risks a  | Higher incidence and severity of AEs in the elderly                                                                                |
| Missing information          | Effects on pregnancy and the foetus                                                                                                |
| Missing information          | Use in breastfeeding                                                                                                               |
| Missing information          | Effect on vaccination efficacy and the use of live/attenuated vaccines                                                             |
| Missing information          | Use in patients with mild, moderate, or severe hepatic impairment                                                                  |
| Missing information          | Use in patients with moderate or severe renal impairment                                                                           |
| Missing information          | Use in patients with evidence of hepatitis B or hepatitis C infection                                                              |
| Missing information          | Use in patients with malignancy                                                                                                    |
| Missing information          | Long-term safety in pJIA patients and juvenile PsA patients (e.g., growth or development disturbances)                             |

## Pharmacovigilance plan

Table 76. On-going and Planned Additional Pharmacovigilance Activities

| Study                                                                                                                      | Summary of Objectives                                                                                                      | Safety Concerns Addressed                                                                                                  | Milestones                                                                                                                 | Due Dates                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Status                                                                                                                     |                                                                                                                            |                                                                                                                            |                                                                                                                            |                                                                                                                            |
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation |
| None                                                                                                                       | None                                                                                                                       | None                                                                                                                       | None                                                                                                                       | None                                                                                                                       |

<div style=\"page-break-after: always\"></div>

Table 76. On-going and Planned Additional Pharmacovigilance Activities

| Study                                                                                                                                                                                             | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Safety Concerns Addressed                                                                                                                                                                                                           | Milestones                                                                                                                                                                                        | Due Dates                                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Status Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation | Status Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation                                                                                                                                                                                                                                                                                                                                                  | Status Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation                                   | Status Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation | Status Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation |
| None                                                                                                                                                                                              | None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | None                                                                                                                                                                                                                                | None                                                                                                                                                                                              | None                                                                                                                                                                                              |
| Required additional pharmacovigilance activities                                                                                                                                                  | Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Required additional pharmacovigilance activities                                                                                                                                                                                    | Required additional pharmacovigilance activities                                                                                                                                                  | Required additional pharmacovigilance activities                                                                                                                                                  |
| Category 3 - Study A3921133: Phase 3B/4 randomised safety endpoint study of 2 doses of tofacitinib in comparison to a TNF inhibitor in subjects with RA On-going                                  | To continue to evaluate the long- term safety of tofacitinib in patients with RA. The safety of tofacitinib at 2 doses versus adalimumab (co- primary endpoints include adjudicated MACEs and adjudicated malignancies excluding NMSC, secondary endpoints will evaluate adjudicated opportunistic OI events including TB and adjudicated hepatic events). Suspected PE cases are being adjudicated as part of the secondary endpoint of CV events other than MACE (adjudicated). All- cause mortality (adjudicated) is also a secondary endpoint. | - venous thromboembolic events (DVT/PE) - cardiovascular risk (excl MI) - MI - malignancy - NMSC - serious and other important infections - PML - transaminase elevation and potential for DILI - all-cause mortality               | Study start Study finish Final report                                                                                                                                                             | 14/03/2014 31/12/2020 a 31/10/2021 (Please note this study completed and was addressed in EU RMP version 21.1)                                                                                    |
| Prospective, non- interventional active surveillance studies embedded within the Corrona registry (A3921329 UC) On-going                                                                          | To provide additional longitudinal safety data regarding the use of tofacitinib in the US for UC patients. This study will address the concerns of venous thromboembolism (DVT/PE), serious infections, HZ reactivation, malignancies (including lymphoma and lung                                                                                                                                                                                                                                                                                 | - venous thromboembolic events (DVT/PE) - serious and other important infections - HZ reactivation - malignancy - lymphoma - lung cancer - NMSC - cardiovascular risk (excl MI) b - MI - PML - GI perforation - all-cause mortality | UC Study start Study finish Final report                                                                                                                                                          | 30/06/2019 30/06/2027 31/12/2027                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

Table 76. On-going and Planned Additional Pharmacovigilance Activities

| Study Status                                                                                                      | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                                                            | Milestones                                           | Due Dates                                     |
|-------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------|
| Prospective, non- interventional active surveillance study embedded within the ARTIS registry (A3921314) On-going | cancer), NMSC, cardiovascular risk (specifically MACE), MI, PML, GI perforation, all- cause mortality, higher incidence and severity of AEs in elderly patients (≥65 years) including infections. In the UC study, safety outcomes with 10 mg BID dose during maintenance will be evaluated in a separate sub- analysis.                                                                                                                                                                                                                                                   | - higher incidence and severity of AEs in the elderly                                                                                                                                                                                                                                                                                                                                |                                                      |                                               |
|                                                                                                                   | To describe safety outcomes among RA patients treated with Xeljanz and other new advanced targeted therapies in real- world clinical use in ARTIS (Sweden). This study will address the concerns of venous thromboembolism (DVT/PE), serious infections, HZ reactivation, NMSC, malignancy (including lymphoma and lung cancer), CV risk, b MI, GI perforation, PML, all-cause mortality, increased risk of AEs in patients treated with tofacitinib in combination use of MTX, higher incidence and severity of AEs in elderly patients (≥65 years) including infections. | - venous thromboembolic events (DVT/PE) - serious and other important infections - HZ reactivation - NMSC - malignancy - lymphoma - lung cancer - CV risk (excl MI) b - MI - GI perforation - PML - all-cause mortality - increased risk of AEs when tofacitinib is administered in combination with MTX in RA or PsA patients - higher incidence and severity of AEs in the elderly | Study start Interim report Study finish Final report | 30/09/2018 Year 2, 4, 6 30/09/2025 30/09/2026 |
| Prospective, non- interventional active surveillance study                                                        | To describe safety outcomes among RA patients treated with Xeljanz versus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | - venous thromboembolic events (DVT/PE)                                                                                                                                                                                                                                                                                                                                              | Study start Interim report                           | 30/09/2018 Year 2, 4, 6                       |

<div style=\"page-break-after: always\"></div>

Table 76. On-going and Planned Additional Pharmacovigilance Activities

| Study                                                                                                              | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                                                            | Milestones                                           | Due Dates                                     |
|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------|
| Status embedded within the BSRBR registry (A3921312) On-going                                                      | other new advanced targeted therapies in real- world clinical use in BSRBR (UK). This study will address the concerns of venous thromboembolism (DVT/PE), serious infections, HZ reactivation, NMSC, malignancy (including lymphoma and lung cancer), CV risk, b MI, GI perforation, PML, all-cause mortality, increased risk of AEs in patients treated with tofacitinib in combination use of MTX, higher incidence and severity of AEs in elderly patients (≥65 years) including infections. | - serious and other important infections - HZ reactivation - NMSC - malignancy - lymphoma - lung cancer - CV risk (excl MI) b - MI - GI perforation - PML - all-cause mortality - increased risk of AEs when tofacitinib is administered in combination with MTX in RA or PsA patients - higher incidence and severity of AEs in the elderly                                         | Study finish Final report                            | 30/09/2025 30/09/2026                         |
| Prospective, non- interventional active surveillance study embedded within the RABBIT registry (A3921317) On-going | To describe safety outcomes among RA patients treated with Xeljanz versus other new advanced targeted therapies in real- world clinical use in RABBIT (Germany) This study will address the concerns of venous thromboembolism (DVT/PE), serious infections, HZ reactivation, NMSC, malignancy (including lymphoma and lung cancer), CV risk, b MI, GI perforation, PML, all-cause mortality, increased risk of AEs in patients treated with tofacitinib in combination use of                  | - venous thromboembolic events (DVT/PE) - serious and other important infections - HZ reactivation - NMSC - malignancy - lymphoma - lung cancer - CV risk (excl MI) b - MI - GI perforation - PML - all-cause mortality - increased risk of AEs when tofacitinib is administered in combination with MTX in RA or PsA patients - higher incidence and severity of AEs in the elderly | Study start Interim report Study finish Final report | 30/09/2018 Year 2, 4, 6 30/09/2025 30/09/2026 |

<div style=\"page-break-after: always\"></div>

Table 76. On-going and Planned Additional Pharmacovigilance Activities

| Study Status                                                                                                                  | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                                                            | Milestones                                           | Due Dates                                                       |
|-------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------|
|                                                                                                                               | MTX, higher incidence and severity of AEs in elderly patients (≥65 years) including infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                      |                                                      |                                                                 |
| Prospective, non- interventional active surveillance study embedded within the BIOBADASER registry (A3921316) On-going        | To describe safety outcomes among RA patients treated with Xeljanz versus other new advanced targeted therapies in real- world clinical use in BIOBADASER (Spain). This study will address the concerns of venous thromboembolism (DVT/PE), serious infections, HZ reactivation, NMSC, malignancy (including lymphoma and lung cancer), CV risk, b MI, GI perforation, PML, all-cause mortality, increased risk of AEs in patients treated with tofacitinib in combination use of MTX, higher incidence and severity of AEs in elderly patients (≥65 years) including infections. | - venous thromboembolic events (DVT/PE) - serious and other important infections - HZ reactivation - NMSC - malignancy - lymphoma - lung cancer - CV risk (excl MI) b - MI - GI perforation - PML - all-cause mortality - increased risk of AEs when tofacitinib is administered in combination with MTX in RA or PsA patients - higher incidence and severity of AEs in the elderly | Study start Interim report Study finish Final report | 30/09/2018 Year 2, 4, 6 30/09/2025 30/09/2026                   |
| Prospective, non- interventional active surveillance pregnancy study embedded within the US OTIS registry (A3921203) On-going | To evaluate over a minimum of 5- years the potential increase in risk of birth defects, specifically a pattern of anomalies, in tofacitinib exposed pregnancies relative to 2 comparator populations.                                                                                                                                                                                                                                                                                                                                                                             | - effects on pregnancy and the foetus                                                                                                                                                                                                                                                                                                                                                | Study start                                          | RA: 30/04/2014 PsA: 30/06/2019 UC: 30/06/2019 pJIA: TBD AS: TBD |
| Prospective, non- interventional active surveillance pregnancy study embedded within the US OTIS registry (A3921203) On-going | This will address the concerns of birth defects and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | - effects on pregnancy and the foetus                                                                                                                                                                                                                                                                                                                                                | Study finish                                         | RA: 30/09/2023 PsA: 30/09/2023 UC: 30/09/2023 pJIA: TBD AS: TBD |

<div style=\"page-break-after: always\"></div>

Table 76. On-going and Planned Additional Pharmacovigilance Activities

| Study                                              | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Milestones                                                   | Due Dates                                               |
|----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------|
| Status                                             | pregnancy outcomes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Final report                                                 | RA: 30/09/2024 PsA: 30/09/2024 UC: 30/09/2024 pJIA: TBD |
| Prescribers' survey A3921334 (RA, PsA, UC) Planned | The research question is whether aRMMs implemented across Europe are effective in communicating the key risk messages associated with the use of tofacitinib to health care professionals. This study will address the concerns of venous thromboembolism (DVT/PE), serious and other important infections, HZ reactivation, malignancies (including NMSC), changes in laboratory parameters, GI perforation, liver injury, increased immunosuppression when tofacitinib is used with biologics, increased risk of adverse events in patients treated with tofacitinib in combination use of MTX, primary viral infection following live vaccination, higher incidence and severity of adverse events in elderly patients, effects on pregnancy and the foetus, use in breastfeeding, effects on vaccination efficacy, use in | - venous thromboembolic events (DVT/PE) - serious and other important infections - HZ reactivation - malignancy - NMSC - GI perforation - transaminase elevation and potential for DILI - increased immunosuppression when used in combination with biologics and immunosuppressants including B- lymphocyte depleting agents - increased risk of adverse events when tofacitinib is administered in combination with MTX in RA or PsA patients - primary viral infection following live vaccination - higher incidence and severity of adverse events in the elderly - effects on pregnancy and the foetus - use in breastfeeding - effects on vaccination efficacy and the use of live/attenuated vaccines - use in populations with mild, moderate, or severe hepatic impairment | Start of data collection End of data collection Final report | AS: TBD 01/11/2021 f 18/04/2022 g 18/04/2023 h          |

<div style=\"page-break-after: always\"></div>

Table 76. On-going and Planned Additional Pharmacovigilance Activities

| Study Status                            | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Safety Concerns Addressed                                                                                                                                                                                                                                                          | Milestones                                                                                                           | Due Dates                                                |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
|                                         | populations with severe hepatic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                    |                                                                                                                      |                                                          |
| Drug utilisation study A3921321 Planned | impairment. The research question is: Is there evidence that prescribers in the EU are compliant with the recommendations and limitations for use described in the tofacitinib aRMM materials? The primary objectives are to: 1. Describe the characteristics of patients treated with tofacitinib, stratified by study country (i.e., Sweden and Hungary) and indication (i.e., RA, PsA, and UC; off- label indications), in terms of: • Demographics (e.g., age, sex); and • Comorbidities and prior and current medication use. 2. Evaluate prescribers' adherence to the tofacitinib aRMMs, specifically: • Compliance to the recommended posology per indication (average daily dose) and duration of use; • Compliance to patient screening and laboratory monitoring prior to and during tofacitinib treatment; and • Compliance to recommendations for limitations of use, including: | - venous thromboembolism (DVT/PE) - use in patients with mild, moderate, or severe hepatic impairment - increased immunosuppression when used in combination with biologics and immunosuppressants including B- lymphocyte depleting agents - MI - use in patients with malignancy | Start of data collection j End of data collection j Interim study report 1 Interim study report 2 Final study report | 30/09/2022 31/10/2026 31/08/2023 31/08/2025 31/10/2027 k |

<div style=\"page-break-after: always\"></div>

Table 76. On-going and Planned Additional Pharmacovigilance Activities

| Study   | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Safety Concerns Addressed   | Milestones   | Due Dates   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------------|-------------|
| Status  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                             |              |             |
|         | • Use in patients with VTE risk factors; • Use in patients aged 65 years and older; • Use in patients with CV risk factors; • Use in patients with malignancy risk factors; • Contraindicated use; and • Use with concomitant medications not compatible with tofacitinib. The secondary objectives are to: 1. Describe prescribing patterns over time; and 2. To describe changes in the utilisation of tofacitinib following the updated recommendations and limitations for use implemented after the Article 20 referral and the 2021 signal evaluation procedure, specifically: • Use in patients with VTE risk factors; • Use in the elderly (patients aged 65 years and older); • Use in patients with CV risk factors; and • Use in patients with malignancy risk factors. |                             |              |             |

<div style=\"page-break-after: always\"></div>

Table 76. On-going and Planned Additional Pharmacovigilance Activities

| Study                                                                                         | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Safety Concerns Addressed                                                                                                                                                                                                                                                                            | Milestones                                           | Due Dates                                                                                                                                                                                    |
|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Status Prospective, non- interventional active surveillance study (SWIBREG) A3921344 On-going | To further understand and characterise the safety profile of tofacitinib within the clinical practice setting. Safety concerns addressed include venous thromboembolism (DVT/PE), serious infections, HZ reactivation, NMSC, malignancy (including lymphoma and lung cancer), MACE, MI, GI perforation, PML, all-cause mortality, higher incidence and severity of adverse events in elderly patients (≥65 years) including infections. Safety outcomes with 10 mg BID dose during maintenance will be evaluated in a separate sub- | - venous thromboembolic events (DVT/PE) - serious and other important infections - HZ reactivation - NMSC - malignancy - lymphoma - lung cancer - cardiovascular risk (excl MI) b - MI - GI perforation - PML - all-cause mortality - higher incidence and severity of adverse events in the elderly | Study start Interim report Study finish Final report | 31/03/2021 i Years 2 and 4 31/03/2026 31/03/2027                                                                                                                                             |
| Prospective, non- interventional active surveillance study (UR-CARE) A3921352 Planned         | analysis. To further understand and characterise the safety profile of tofacitinib within the clinical practice setting. Safety concerns addressed include venous thromboembolism (DVT/PE), serious infections, HZ reactivation, lymphoma, lung cancer, NMSC, malignancy, cardiovascular risk (specifically MACE), MI, GI perforation, PML, all-cause mortality, higher                                                                                                                                                             | - venous thromboembolic events (DVT/PE) - serious and other important infections - HZ reactivation - NMSC - malignancy - lymphoma - lung cancer - cardiovascular risk (excl MI) b - MI - GI perforation - PML - all-cause mortality - higher incidence and severity of adverse events in the elderly | Study start Interim report Study finish Final report | 30/06/2020 Years 2 and 4 31/10/2025 30/09/2026 (Please note, study start date and other milestone dates will be updated once protocol has been submitted and approved by PRAC through a PAM) |

<div style=\"page-break-after: always\"></div>

Table 76. On-going and Planned Additional Pharmacovigilance Activities

| Study Status                                                                                                                                          | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Safety Concerns Addressed                                                                                                                                                                                                 | Milestones                                                                                     | Due Dates                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|----------------------------------------------------------|
|                                                                                                                                                       | incidence and severity of adverse events in elderly patients (≥65 years) including infections. Safety outcomes with 10 mg BID dose during maintenance will be evaluated in a separate sub- analysis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                           |                                                                                                |                                                          |
| Drug utilisation and active surveillance, post-authorisation study examining utilisation patterns and tofacitinib safety in UC (US) A3921347 On-going | To understand the patterns of tofacitinib use in the US, as well as assess the risk of safety events of interest that may be associated with its use, a non- interventional, drug utilisation and active surveillance study will be conducted using data from an administrative healthcare claims database. This study will assess overall patterns of tofacitinib use, as well as potential off-label use among non-approved indications, use of 10 mg BID in patients without a recorded diagnosis of UC, and use of 10 mg maintenance therapy among UC patients at a high risk for thrombosis. Safety concerns include venous thromboembolism (DVT/PE), mortality, e malignancies (including lymphoma and lung | - venous thromboembolic events (DVT/PE) - all-cause mortality c - malignancy - lymphoma - lung cancer - serious and other important infections - HZ reactivation - cardiovascular risk (excl MI) b - MI - GI perforations | Start of data collection End of data collection Interim report 1 Interim report 2 Final report | 30/06/2020 d 30/06/2025 30/06/2022 30/06/2024 30/06/2026 |

<div style=\"page-break-after: always\"></div>

Table 76. On-going and Planned Additional Pharmacovigilance Activities

| Study Status                                                                                                                                                                                                                                                                                                                           | Summary of Objectives                                                                                                                                                                                                                | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                      | Milestones                            | Due Dates   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|-------------|
| Shingrix study Planned                                                                                                                                                                                                                                                                                                                 | separate sub- analysis. To determine the immune response from the new non- live zoster vaccine (Shingrix; Recombinant, adjuvanted zoster vaccine) vs placebo vaccine in UC and RA patients on background tofacitinib or TNF blocker. | - primary viral infection following live vaccination                                                                                                                                                                                                                                                                                           | Study start Study finish Final report | TBD TBD TBD |
| Post-Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the German Biologics in Pediatric Rheumatology Registry (BIKER) and the Juvenile Arthritis Methotrexate/Biologics long-term Observation (JuMBO) Registry Planned | To contextualise the rates of safety events observed among tofacitinib- treated polyarticular JIA and juvenile PsA patients                                                                                                          | - venous thromboembolism (DVT/PE) - serious and other important infections - malignancies - lymphoma - lung cancer - MI - GI perforation - cardiovascular risk (excl MI) b - long-term safety in pJIA patients and juvenile PsA patients (e.g., growth or development disturbances) - PML - all-cause mortality - HZ reactivation - NMSC - ILD | Study start Study finish Final report | TBD TBD TBD |
| Post-Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for                                                                                                                                                                                                                                      | To contextualise the rates of safety events observed among tofacitinib- treated polyarticular JIA                                                                                                                                    | - venous thromboembolic events (DVT/PE) - serious and other important infections - malignancies                                                                                                                                                                                                                                                | Study start Study finish Final report | TBD TBD TBD |

<div style=\"page-break-after: always\"></div>

Table 76. On-going and Planned Additional Pharmacovigilance Activities

| Study                                                                                                                                                                                                                                                                                        | Summary of Objectives                                                                                                                | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                                       | Milestones                            | Due Dates   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|-------------|
| Status Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry Planned                                                                                                                                                                         | and juvenile PsA patients                                                                                                            | - lung cancer - lymphoma - MI - GI perforation - cardiovascular risk (excl MI) b - long-term safety in pJIA patients and juvenile PsA patients (e.g., growth or development disturbances) - PML - all-cause mortality - HZ reactivation - NMSC - ILD                                                                                                            |                                       |             |
| Post-Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register Planned                                                                                  | To contextualise the rates of safety events observed among tofacitinib- treated polyarticular JIA and juvenile PsA patients          | - venous thromboembolic events (DVT/PE) - serious infections and other important infections - malignancies - lymphoma - lung cancer - MI - GI perforation - cardiovascular risk (excl MI) b - long-term safety in pJIA patients and juvenile PsA patients (e.g., growth or development disturbances) - PML - all-cause mortality - HZ reactivation - NMSC - ILD | Study start Study finish Final report | TBD TBD TBD |
| An Active Surveillance Post-Authorisation Safety Study (PASS) of Safety Events of Special Interest Among Patients in the United States Treated with Tofacitinib for Juvenile Idiopathic Arthritis Within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Planned | To evaluate risks (malignancies, serious infections [including opportunistic infections], and thrombosis) in pJIA patients in the US | - malignancies - NMSC - lymphoma - lung cancer - MI - serious and other important infections - venous thromboembolic events (DVT/PE) - long-term safety in pJIA patients and juvenile PsA patients (e.g., growth or development disturbances)                                                                                                                   | Study start Study finish Final report | TBD TBD TBD |

<div style=\"page-break-after: always\"></div>

Table 76. On-going and Planned Additional Pharmacovigilance Activities

| Study Status      | Summary of Objectives                                                                                                                                                                                                    | Safety Concerns Addressed                                                                       | Milestones                            | Due Dates          |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------|--------------------|
| A3921145 On-going | To determine the long-term safety and tolerability of tofacitinib for treatment of the signs and symptoms of JIA. To evaluate the persistence of efficacy of tofacitinib for treatment of the signs and symptoms of JIA. | - long-term safety in pJIA and juvenile PsA patients (e.g., growth or development disturbances) | Study start Study finish Final report | 18/03/2013 TBD TBD |

a. Database release b. Specifically, MACE

c. Due to limitations related to the claims database, only in-hospital mortality can be assessed d. This represents start of data collection for the active surveillance portion of the study. Start of data collection for the drug utilisation study will be 31 March 2021.

e. Due to limitations related to the claims database, only in-hospital mortality can be assessed.

f. The start of data collection will be contingent upon PRAC's endorsement of the protocol amendment/ modified questionnaire, completion of user testing of the translated questionnaire in study countries, and local submissions of the final study protocol. There is a potential for variability in start dates (e.g., related to submissions/approvals from local Health Authorities, Ethics Committees, and other privacy and/or disclosure organizations).

g. The survey will occur over a 12 week (3 month) period in each country.   The time between the start and end of data collection is more than 12 weeks because data collection in Germany is not estimated to begin until 16 February 2022.

h. The final study report will contain the pooled results from all 8 survey countries.  The date of the final study report submission will be dependent on the start of data collection for the last survey country.  Survey initiation may be delayed due to submissions to local Health Authorities, Ethics Committees, and/or other competent authorities.

i. Study protocol approved on 01/03/2021.  Study start date does not impact patient accrual as data can be obtained retrospectively.

j. Start and end of data collection refer to the start and end of data extraction, respectively, due to the approximate 2-year data lag associated with the databases. Interim study report 1 will cover data from 01 April 2016 through 31 December 2020. Interim study report 2 will cover data from 01 April 2016 through 31 December 2022. The final study report will cover data from 01 April 2016 through 31 December 2024.

k. If it is necessary to extend the study observation period for a country because the minimum number of tofacitinib patients (100 patients) per indication has not been met for all three indications by the end of the study observation period, the study observation period will be extended for those countries as the data are available and the MAH will submit the final study report later than 31 October 2027. For those countries that have met the minimum patient threshold of at least 100 tofacitinib patients per indication for all three indications at the end of the study observation period, a second interim study report will be submitted within 12 months after the planned end of data collection.

Please note, for Study A3921133, on 19 February 2019, the 10 mg dose was discontinued.

AE = Adverse Event; ARTIS = Anti-rheumatic Therapies In Sweden; AS = ankylosing spondylitis; bDMARD = biologic disease-modifying antirheumatic drug; BID = twice daily; BIKER = German Biologics in Pediatric Rheumatology Registry; BIOBADASER = Registro Español De Acontecimientos Adversos De Terapias Biológicas En Enfermedades Reumáticas; BSRBR = British Society For Rheumatology Biologics Register; CARRA = Childhood Arthritis and Rheumatology Research Alliance; CV = cardiovascular; EHR = electronic health care records; ENEIDA = Estudio Nacional en Enfermedad Inflamatoria intestinal sobre Determinantes genéticos y Ambientales; EU = European Union; excl = excluding; GI = gastrointestinal; JuMBO = Juvenile Arthritis Methotrexate/Biologics long-term Observation; MACE = major adverse cardiac event; MI = myocardial infarction; MTX = methotrexate; NMSC = non-melanoma Skin Cancer; OI = opportunistic infection; OTIS = Organisation Of Teratology Information Specialists; PAM = Post-Authorisation Measure; pJIA = polyarticular juvenile idiopathic arthritis; PML = progressive multifocal leukoencephalopathy; PRAC = Pharmacovigilance Risk Assessment Committee; PsA = psoriatic arthritis; RA = rheumatoid arthritis; RABBIT = Rheumatoide Arthritis -Beobachtung Der Biologika-Therapie; RMP = Risk Management Plan; SWIBREG = Swedish National Quality Registry for Inflammatory Bowel Disease, TB = tuberculosis; TBD = to be determined; TNF = tumour necrosis factor; UC = ulcerative colitis; UR-CARE = United Registries for Clinical Assessment and Research; US = United States; VTE = venous thromboembolism

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                        | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                                                                                                           | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks            | Important Identified Risks                                                                                                                                                                                                                                                                                                                                                                                                                                           | Important Identified Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Venous thromboembolic events (DVT/PE) | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects SmPC Section 5.1 Pharmacodynamic properties Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the German Biologics in Pediatric Rheumatology Registry (BIKER) and within the Juvenile Arthritis Methotrexate/Biologics long-term Observation (JuMBO) Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register •An Active Surveillance Post - Authorisation Safety Study (PASS) of Safety Events of Special Interest Among Patients in the United States Treated with Tofacitinib for Juvenile Idiopathic Arthritis Within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, n on-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                         | Risk Minimisation Measures                                                                                                                                                                                                                                                                                      | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                        |                                                                                                                                                                                                                                                                                                                 | BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment) •A3921321: An EU -based drug utilisation study using electronic health care records (aRMM effectiveness assessment) •Prospective, non -interventional active surveillance study using 2 European UC registries (Swedish National Quality Registry for Inflammatory Bowel Disease [SWIBREG] - A3921344, and the United Registries for Clinical Assessment and Research [UR- CARE] - A3921352), over 5 years. •A3921347 (UC): A drug utilisation and active surveillance, post-authorisation study in the US using data from an administrative healthcare claims database. • A3921133: A large, post- approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. (Please note this study completed and was addressed in |
| Serious and other important infections | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.3 Contraindications SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects SmPC Section 5.1 Pharmacodynamic properties Additional risk minimisation measures: | EU RMP version 21.1) Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within BIKER and within the JuMBO Registry •Post -Authorisation Active Safety Surveillance Program Among                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern   | Risk Minimisation Measures                                                                                                                                                              | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register •An Activ e Surveillance PASS of Safety Events of Special Interest Among Patients in the United States Treated with Tofacitinib for Juvenile Idiopathic Arthritis Within the CARRA Registry • A3921133: A large, post- approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non -interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment) •Prospective, non -interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR- CARE [A3921352]) over 5 years. •A3921347 (UC): A drug utilisation and active surveillance, post-authorisation study in the US using data from an administrative healthcare claims database. |
| HZ reactivation  | Routine risk minimisation measures:                                                                                                                                                     | Routine pharmacovigilance activities beyond adverse                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern   | Risk Minimisation Measures                                                                                                                                                                                                                                                                              | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Prescriber Brochure). | reaction reporting and signal detection: None Additional pharmacovigilance activities: •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within BIKER and within the JuMBO Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non -interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment) •Prospective, non -interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR- CARE [A3921352]) over 5 years. •A3921347 (UC): A drug utilisation and active surveillance, post-authorisation study in the US using data from an administrative healthcare |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern   | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                                                    | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Lung cancer      | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects SmPC Section 5.1 Pharmacodynamic properties Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within BIKER and within the JuMBO Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register •An Active Surveillance PASS of Safety Events of Special Interest Among Patients in the United States Treated with Tofacitinib for Juvenile Idiopathic Arthritis Within the CARRA Registry •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non -interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •Prospective, non -interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR- CARE [A3921352]) over 5 years. •A3921347 (UC): A drug utilisation and active |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern   | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                                                    | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Lymphoma         | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects SmPC Section 5.1 Pharmacodynamic properties Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within BIKER and within the JuMBO Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register •An Active Surveillance PASS of Safety Events of Special Interest Among Patients in the United States Treated with Tofacitinib for Juvenile Idiopathic Arthritis Within the CARRA Registry •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non -interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •Prospective, non -interventional active surveillance study using 2 European UC registries |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern        | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                                                    | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                       |                                                                                                                                                                                                                                                                                                                                                                                                               | (SWIBREG [A3921344] and UR- CARE [A3921352]) over 5 years. •A3921347 (UC): A drug utilisation and active surveillance, post-authorisation study in the US using data from an administrative healthcare claims database.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Myocardial infarction | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects SmPC Section 5.1 Pharmacodynamic properties Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within BIKER and within the JuMBO Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register •An Active Surveillance PASS of Safety Events of Special Interest Among Patients in the United States Treated with Tofacitinib for Juvenile Idiopathic Arthritis Within the CARRA Registry •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •P rospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                        | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                               |                                                                                                                                                                                                                                                                                                                                                                                   | [A3921317]) over at least 5 years. •Prospective, non -interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR- CARE [A3921352]) over 5 years. •A3921347 (UC): A drug utilisation and active surveillance, post-authorisation study in the US using data from an administrative healthcare claims database. • A3921133: A large, post- approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. (Please note this study completed and was addressed in EU RMP version 21.1) •A 3921321: An EU-based drug utilisation study using electronic health care records (aRMM effectiveness assessment) |
| Decrease in neutrophil counts and neutropenia | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Decrease in lymphocyte counts and lymphopenia | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects                                                                                                                                                                                         | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                       | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                             | Pharmacovigilance Activities                                                                                                                                                                                                                                          |
|--------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                      | Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure).                                                                                                                                                                                |                                                                                                                                                                                                                                                                       |
| Decrease in Hgb levels and anaemia   | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                       |
| Lipid elevations and hyperlipidaemia | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure).                                             | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                       |
| NMSC                                 | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and                                                                         | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern   | Risk Minimisation Measures                   | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|------------------|----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | prescribers (including Prescriber Brochure). | PsA within BIKER and within the JuMBO Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register •An Active Surveillance PASS of Safety Events of Special Interest Among Patients in the United States Treated with Tofacitinib for Juvenile Idiopathic Arthritis Within the CARRA Registry • A3921133: A large, post- approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. (Please note this study completed and was addressed in EU RMP version 21.1) • A3921329 (UC): observational PASS within the Corrona Registry over 5 years • Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment) •Prospective, non -interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR- |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                               | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Transaminase elevation and potential for DILI | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure).        | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: • A3921133: A large, post- approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. (Please note this study completed and was addressed in EU RMP version 21.1) • A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment)                                                                                                                                                                                                                                                                                                                                                     |
| Important Potential Risks                     | Important Potential Risks                                                                                                                                                                                                                                                                                                                                                | Important Potential Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Malignancy                                    | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 5.1 Pharmacodynamic properties Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within BIKER and within the JuMBO Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register •An Active Surveillance PASS of Safety Events of Special Interest Among Patients in the United |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                | Risk Minimisation Measures                                                                                                                                                                     | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                               |                                                                                                                                                                                                | States Treated with Tofacitinib for Juvenile Idiopathic Arthritis Within the CARRA Registry • A3921133: A large, post- approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. (Please note this study completed and was addressed in EU RMP version 21.1) •A 3921329 (UC): observational PASS within the Corrona Registry over 5 years • Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment) •Prospective, non -interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR- CARE [A3921352]) over 5 years. •A3921347 (UC): A drug utilisation and active surveillance, post-authorisation study in the US using data from an administrative healthcare |
| Cardiovascular risk (excl MI) | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 5.1 Pharmacodynamic properties Additional risk minimisation measures: None proposed | claims database. Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within BIKER and within the JuMBO Registry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern   | Risk Minimisation Measures                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  |                                                                                                                                      | Pharmacovigilance Activities •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register • A3921133: A large, post- approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. (Please note this study completed and was addressed in EU RMP version 21.1) •A3921329 (UC): observational PASS within the Corrona Registry over 5 years • Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •Prospective, non -interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR- CARE [A3921352]) over 5 years. •A3921347 (UC): A drug utilisation and active surveillance, post-authorisation study in the US using data from an administrative healthcare |
| GI perforation   | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: | claims database. Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern   | Risk Minimisation Measures                                                                                                                                                         | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | Development of an educational programme including additional communication to patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within BIKER and within the JuMBO Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register •A3921329 (UC): observational PASS within the Corrona Registry over 5 years • Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment) •Prospective, non -interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR- CARE [A3921352]) over 5 years. •A3921347 (UC): A drug utilisation and active surveillance, post-authorisation study in the US using data from an administrative healthcare |
| ILD              | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use                                                                                      | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern   | Risk Minimisation Measures                                                                                                                                                                                                | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | Additional risk minimisation measures: Development of an educational programme including additional communication to patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | Additional pharmacovigilance activities: •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within BIKER and within the JuMBO Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register                                                                                                   |
| PML              | Routine risk minimisation measures: Not applicable Additional risk minimisation measures: None proposed                                                                                                                   | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within BIKER and within the JuMBO Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern      | Risk Minimisation Measures                                                                                                           | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                     |                                                                                                                                      | • A3921133: A large, post- approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. (Please note this study completed and was addressed in EU RMP version 21.1) •A 3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non -interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •Prospective, non -interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR- CARE [A3921352]) over 5 years.      |
| All-cause mortality | Routine risk minimisation measures: SmPC Section 5.1 Pharmacodynamic properties Additional risk minimisation measures: None proposed | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within BIKER and within the JuMBO Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                                      | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                   | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                     |                                                                                                                                                                                                                                                                                                                              | PsA within the UK JIA Biologics Register •A3921329 (UC): observational PASS within the Corrona Registry over 5 years • Prospective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •Prospective, non -interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR- CARE [A3921352]) over 5 years • A3921133: A large, post- approval long-term clinical safety trial with an active comparator arm with primary focus of evaluating the safety of tofacitinib at 2 doses versus TNF inhibitor. (Please note this study completed and was addressed in EU RMP version 21.1) •A3921347 (UC): A drug utilisation and active surveillance, post-authorisation study in the US using data from an administrative healthcare claims database |
| Increased immunosuppression when used in combination with biologics and immunosuppressants including B- lymphocyte depleting agents | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | (in-hospital mortality) Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment) •A3921321: An EU -based drug utilisation study using electronic health care records (aRMM effectiveness assessment) Routine pharmacovigilance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Increased risk of AEs when tofacitinib is administered in combination with                                                          | Routine risk minimisation measures:                                                                                                                                                                                                                                                                                          | activities beyond adverse reaction reporting and signal detection:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                            | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                               | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                          |
|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MTX in RA or PsA patients                                                                 | SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Prescriber Brochure).                                                                                                                       | None Additional pharmacovigilance activities: •Pro spective, non-interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment) |
| Primary viral infection following live vaccination                                        | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber Brochure).                                                                                                    | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment) •Shingrix study                                                                                                |
| Increased exposure to tofacitinib when co-administered with CYP3A4 and CYP2C19 inhibitors | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.5 Interaction with other medicinal products and other forms of interaction Additional risk minimisation measures: Development of an educational programme including additional communication to patients (Patient Alert Card) and prescribers (including Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                                                                                       |
| Higher incidence and severity of AEs in the elderly                                       | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use SmPC Section 4.8 Undesirable effects                                                                                                                                                                                                                                                       | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities:                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                     | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                 | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                    | SmPC Section 5.1 Pharmacodynamic properties Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Prescriber Brochure).                                                                                                       | •A3921329 (UC): observational PASS within the Corrona Registry over 5 years •Prospective, non -interventional active surveillance safety study using 4 European RA registries (ARTIS [A3921314], BIOBADASER [A3921316], BSRBR [A3921312], and RABBIT [A3921317]) over at least 5 years. •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment) •Prospective, non -interventional active surveillance study using 2 European UC registries (SWIBREG [A3921344] and UR- |
| CARE [A3921352]) over 5 years. Missing Information | CARE [A3921352]) over 5 years. Missing Information                                                                                                                                                                                                                                                                                                         | CARE [A3921352]) over 5 years. Missing Information                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Effects on pregnancy and the foetus                | Routine risk minimisation measures: SmPC Section 4.3 Contraindications SmPC Section 4.6 Fertility, pregnancy, and lactation Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •Monitoring via an established pregnancy registry (US OTIS). •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment)                                                                                                                                                                                                        |
| Use in breastfeeding                               | Routine risk minimisation measures: SmPC Section 4.3 Contraindications SmPC Section 4.6 Fertility, pregnancy, and lactation Additional risk minimisation measures: Development of an educational programme including additional communication to both patients (Patient Alert Card) and prescribers (including Treatment Checklists, Prescriber Brochure). | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment)                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                         | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                             | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                               |
|------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effect on vaccination efficacy and the use of live/attenuated vaccines | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: Development of an educational programme including additional communication to patients (Patient Alert Card) and prescribers (including Treatment Checklists,                                                      | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment)                                                                                                                     |
| Use in patients with mild, moderate, or severe hepatic impairment      | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 4.3 Contraindications SmPC Section 5.2 Pharmacokinetic properties Additional risk minimisation measures: Development of an educational programme including additional communication to prescribers (including Treatment Checklists, Prescriber | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3921334 (RA, PsA, UC): An EU-based survey for prescribers (aRMM effectiveness assessment) •A3921321: An EU -based drug utilisation study using electronic health care records (aRMM effectiveness assessment) |
| Use in patients with moderate or severe renal impairment               | Routine risk minimisation measures: SmPC Section 4.2 Posology and method of administration SmPC Section 5.2 Pharmacokinetic properties Additional risk minimisation measures: None proposed                                                                                                                                                            | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                                                                                            |
| Use in patients with evidence of hepatitis B or C infection            | Routine risk minimisation measures: SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: None proposed                                                                                                                                                                                                     | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                                                                                            |
| Use in patients with malignancy                                        | Routine risk minimisation measures:                                                                                                                                                                                                                                                                                                                    | Routine pharmacovigilance activities beyond adverse                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

Table 77. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                         | Risk Minimisation Measures                                                                                     | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                        | SmPC Section 4.4 Special warnings and precautions for use Additional risk minimisation measures: None proposed | reaction reporting and signal detection: None Additional pharmacovigilance activities: •A3 921321: An EU-based drug utilisation study using electronic health care records (aRMM effectiveness assessment)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Long-term safety in pJIA patients and juvenile PsA patients (e.g., growth or development disturbances) | Routine risk minimisation measures: None Additional risk minimisation measures: None proposed                  | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: Additional pharmacovigilance activities: •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within BIKER and within the JuMBO Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the Swedish JIA Clinical Registry •Post -Authorisation Active Safety Surveillance Program Among Patients Treated with Tofacitinib for for Polyarticular Juvenile Idiopathic Arthritis and Juvenile PsA within the UK JIA Biologics Register •An Active Surveillance PASS of Safety Events of Special Interest Among Patients in the United States Treated with Tofacitinib for Juvenile Idiopathic Arthritis Within the CARRA Registry •Study A3921145: A Long Term, Open Label Follow Up Study of Tofacitinib for Treatment of JIA |

<div style=\"page-break-after: always\"></div>

AE = adverse event; ARTIS = Anti-rheumatic Therapies In Sweden; BIKER = German Biologics in Pediatric Rheumatology Registry; BIOBADASER = Registro Español De Acontecimientos Adversos De Terapias Biológicas En Enfermedades Reumáticas; BSRBR = British Society For Rheumatology Biologics Register; CARRA = Childhood Arthritis and Rheumatology Research Alliance; CYP = cytochrome P450; DILI = drug-induced liver injury; DVT = deep vein thrombosis; EU = European Union; Excl = excluding; GI = gastrointestinal; Hgb = haemoglobin; HZ = herpes zoster; IBD = inflammatory bowel disease; ILD = interstitial lung disease; JIA = juvenile idiopathic arthritis; JuMBO = Juvenile Arthritis Methotrexate/Biologics long-term Observation;MI = myocardial infarction; MTX = methotrexate; NMSC = non-melanoma skin cancer; OTIS = Organisation of Teratology Information Specialists; PASS = post-authorisation safety study; PE = pulmonary embolism; pJIA = polyarticular juvenile idiopathic arthritis; PML = progressive multifocal leukoencephalopathy; PRAC = Pharmacovigilance Risk Assessment Committee; PsA = psoriatic arthritis; RA = rheumatoid arthritis; RABBIT = Rheumatoide Arthritis -Beobachtung Der Biologika-Therapie; RMM = risk minimisation measure; RMP = Risk Management Plan; SmPC = Summary of Product Characteristics; SWIBREG = Swedish National Quality Registry for Inflammatory Bowel Disease, TNF = tumour necrosis factor; UC = ulcerative colitis; UR-CARE = United Registries for Clinical Assessment and Research; US = United States

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

The MAH will submit the results of a user consultation with target patient groups on the package leaflet that meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use following the conclusion of the ongoing variation and Art. 20 referral procedure.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The proposed indication for tofacitinib oral PR tablet 11 mg once daily is for the  treatment of adult patients  with  active  ankylosing  spondylitis  (AS)  who  have  responded  inadequately  to  conventional therapy.

AS is a chronic inflammatory rheumatic disease primarily affecting the sacroiliac joints and spine and is part of the family of related SpA disorders, which also includes PsA. AS or radiographic axial SpA is defined  by  the  presence  of  definitive  radiographic  sacroiliitis  based  upon  1984  Modified  New  York classification criteria. AS causes chronic inflammation at the insertion of ligaments and tendons in the axial skeleton (entheses) and may progress from inflammation in the sacroiliac joints to sacroiliac and spine  ankylosis over  time.  AS  is  also  associated  with  peripheral  arthritis,  and  enthesitis,  and  extraarticular  manifestations  such  as  anterior  uveitis,  psoriasis,  and  IBD.  Osteoporosis  is  a  common  AS comorbidity. AS is often present for many years before it is diagnosed and typically presents in people between 20 and 40 years of age, with a higher prevalence in males, leading to back pain, stiffness, fatigue, progressive disability and adverse effects on health.

Overall,  the  pathogenesis  of  AS  is  not  well  characterised  but  seems  to  include  both  genetic  and environmental components, which combine to elicit a chronic inflammatory response involving the innate and adaptive immune systems. A genetic link was noted. 90 - 95% of white Western European people with AS are positive for the HLA-B27 allele, and risk increases with HLA-B27-positive relatives. -related

<div style=\"page-break-after: always\"></div>

quality of life. Confirmation that TNFaplha (secreted by Th1 and T CD8+ cells) and IL-17 (secreted by Th17 and T CD8+ cells) contribute to the pathogenesis of AS has been provided by the efficacy of interventions such as TNFi and anti-IL-17 mAb. These biologic therapies directly inhibit the effect of 1 cytokine  pathway.  Tofacitinib,  a  small  molecule  inhibitor  of  JAK,  interferes  directly  (e.g.,  IL-23)  or indirectly (e.g., TNFalpha, IL-17) with the signalling of multiple AS-associated cytokines.

## 3.1.2. Available therapies and unmet medical need

Based on the current evidence and the considerations of ASAS and EULAR, NSAIDs and TNFi remain the primary classes of medications for the treatment of axial SpA (including AS). Sulfasalazine is considered only for the treatment of peripheral arthritis. IL-17i are recommended for patients with active disease in whom TNFi are contraindicated, and in primary nonresponders to TNFi. The use of IL-17i should be avoided in patients with active IBD, as TNFi monoclonal antibodies are better options. Moreover, recently, also another JAK inhibitor has been authorized in EU for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Treatments are available to control and delay the progression of symptoms of AS. However, additional therapy options are still needed as up to 50% of patients with AS continue to have active disease despite treatment with NSAIDsor biological agents.

The use of NSAIDs is limited by gastrointestinal and other adverse events. Other effective agents for the treatment of active AS are bDMARDs, which require parenteral administration and may be limited by loss of efficacy, often due to immunogenicity.

As a number of genes and cytokines have been implicated in the pathogenesis of AS, it is likely that the etiology  of  AS  is  complex  and  has  a  plethora  of  underlying  contributory  factors.  This  implies  that additional  treatment  options  with  mechanisms  of  action  distinct  from  those  currently  available,  are needed as options for different AS patients.

In summary, despite the advances that have been made in the last decade in the treatment of AS, a significant  number  of  patients  with  AS  still  have  active  disease  and  remain  refractory  to  currently available pharmacotherapies. Unmet medical need therefore remains for a new effective oral DMARD with a new MOA that provides a favourable benefit-risk profile and broadens the treatment options for adult patients with AS to achieve and sustain clinical benefit.

## 3.1.3. Main clinical studies

With this submission, the MAH seeks approval for tofacitinib PR tablets (11 mg QD) for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.

No comparative clinical efficacy and safety data with tofacitinib 11 mg PR formulation in SA patients have  been  provided  within  this  application  in  order  to  demonstrate  that  the  new  modified  release formulation is as effective as the existing IR formulation. However, given that the efficacy of tofacitinib IR formulation (5 mg BID) in AS has been demonstrated within the previous application (II/35), the MAH proposed a bridging of the efficacy of tofacitinib IR formulation (5 mg BID) in AS to the PR formulation (approved in the RA and PsA indications) relying on E/R relationship.

In support of the IR formulation (5 mg BID) in AS indication the MAH provided:

i)  supportive data from Study A3921119 a phase 2, multicentre, randomised, double-blind, placebocontrolled  dose  ranging,  parallel  group  efficacy  and  safety  study  designed  to  characterise  the  dose

<div style=\"page-break-after: always\"></div>

response  of  tofacitinib  2  mg  BID,  5  mg  BID  and  10  mg  BID  in  patients  with  active  AS  who  had experienced an inadequate response to NSAIDs and were naïve to previous bDMARDs;

ii)  confirmatory  evidence  from  one  pivotal  study  A3921120,  a  phase  3,  randomized,  double-blind, placebo-controlled, parallel group comparing tofacitinib 5mg dosed twice daily to placebo in subjects with  active  AS,  who  had  experienced  an  inadequate  response  to  NSAIDs  (NSAID-IR)  and  were additionally either naïve to previous bDMARDs, or TNFi-IR or experienced to previous bDMARDs but without inadequate response (bDMARD Use [Non-IR]). The study design included a 16-week doubleblind treatment period, a 32-week open-label treatment period (all subjects were assigned to open-label tofacitinib 5 mg BID to Week 48) and a 28-day follow-up period (duration of participation for eligible subjects was approximately 56 weeks).

## 3.2. Favourable effects

No efficacy data has been provided with the PR 11 mg QD formulation in AS.

The only possible and expected favourable effects of the 11 mg PR formulations in patients with AS is the greater adherence to treatment compared with their respective licensed IR formulations (5 mg BID) due to the one daily regimen.

The following aspects are referred to the IR 5mg formulation:

In the phase 3 pivotal A3921120 study in the IR 5 mg BID formulation in AS the primary endpoint showed a statistically significant higher proportion of patients in the tofacitinib 5 mg BID group reached ASAS20 at week 16 in comparison to the placebo group with a treatment difference of 27.08 (95% CI: 15.89, 38.28), which is in line with the 20% difference expected in the sample size calculation. Moreover, the primary analysis was supported by results from all the pre-specified supportive analyses.

The key secondary endpoint ASAS40 was also met from a statistical perspective with a higher response rate of subjects in tofacitinib 5 mg BID group (40.6%) compared to placebo group (12.5%) at week 16.

The effect size of ASAS40 being very similar to that observed for ASAS20 and of clinical relevance. Consistent results are shown by subgroup analyses. For both ASAS20 and ASAS40 a better response rate between study drug and placebo is reported in bDMARDs naïve compared to TNF-IR subjects or bDMARD [Non-IR].

The individual components of the ASAS responses (type I controlled) and ASAS 5/6 (not controlled) results were consistent with those of the primary and key secondary endpoint.

Numerous secondary endpoints controlled for multiplicity have been selected for assessing tofacitinib efficacy on different disease domains and this is supported, however limitations are foreseen.

Results from primary and key secondary endpoint were supported by an important secondary (type I controlled) endpoint ASDAS (CRP) which is a validated and accepted method to assess disease activity and physical function considered a very important disease activity. The LS mean change from baseline in ASDAS(CRP) showed a statistically significant decrease for tofacitinib 5 mg BID compared to placebo at Week 16 (-1.36 in the tofa arm and -0.39 in the PLB arm at week 16, delta of -0-98) showing a clinically relevant difference. At week 48 improvement of ASDAS(CRP) from baseline is still seen.

Other endpoint has been provided as secondary but not controlled for type I error supporting tofacitinib effect across important clinical measures i.e.: ASDAS clinically important improvement (61.3 versus 19.1 delta 42.3), ASDAS major improvement (30 versus 4.6 delta 25.3), ASDAS inactive disease (6.7 versus 0 delta 6.7) at week 16; a greater response in the Tofa arm which is maintained at week 48 and with an effect size of clinical significance for endpoints measuring improvement. Measure of partial remission

<div style=\"page-break-after: always\"></div>

was also supportive [i.e., ASDAS partial remission: a value of =2 (on a 0 to 10 scale) present in each domain, 15 versus 3, p 0 ˂ 0.001]

Supportive results were obtained from different Quality of Life endpoints (i.e., ASQoL).

Measures of spinal mobility, i.e., Linear BASMI (BASMI lin) composite score change at week 16, is a relevant efficacy parameter in axial SpA. Results were not robust as those evaluating tofacitinib efficacy on sign and symptoms/inflammation of the disease showing a change at week 16 (of -0.63 versus -0.11 for Tofa and PLB, respectively; similar change (-0.6-0.7) at week 48) statistically significant but not clinically relevant.

Results from Study A3921119 were supportive of the phase 3 study with regard to different endpoints mainly pertaining to disease activity and physical functions, health related outcomes.

## 3.3. Uncertainties and limitations about favourable effects

There are no dedicated clinical data with the 11 mg PR formulation in AS patients. This variation application is therefore based on a bridging strategy consisting of three points: two of them referring to previously submitted data/studies in RA patients and the third once refers to the E/R in AS using IR formulation. To predict the efficacy the Cavg has been chosen as the exposure metrics as previously done in RA and justified by the indirect mechanism of action of tofacitinib The simulated E/R relationship in AS appears to be flat, even flatter compared to observed data. It is worth mentioning that in all the E/R plots, the 10 mg Cavg values are even lower than the 5 mg, and, for the ASAS40 values (placebo-corrected), also lower than the 2 mg.

The E/R relationship per se is still considered not supportive (due to plausible hypothesis of an artefact) to waive the clinical study according to the EMA  Guideline on modified-release formulation (EMA/CHMP/EWP/280/96 Rev1).

However, the totality of data available show the following: i) the demonstrated BE between PR (11 mgx1) and IR formulations (5 mgx2) in terms of AUC and Cmax with only a difference in average Cmin (29% lower) not considered clinically relevant and ii)the Cavg as the primary PK parameter; iii) the approval of PR formulation for RA and PsA; iv) the same PK metrics are considered important for efficacy and safety in AS as in PsA; v) the similarities in disease between PsA and AS.

Considering all the above and taking into account that the safety profile is not expected to be different with the use of PR formulation as compared to IR formulation, the lack of a clear E/R relationship can be overcome and not further pursued.

In the absence of clinical data, the effect of increased adherence to treatment with the PR formulations remains hypothetical.

## 3.4. Unfavourable effects

All the safety data come from the clinical program in which the immediate release (IR) formulation has been used and they are extrapolated to cover the safety of the PR formulation for the current application.

The  safety  profile  of  tofacitinib  is  mainly  characterised  by  different  types  of  AEs,  included  venous thromboembolism and pulmonary embolism, serious infections, cases of non-melanoma skin cancers (NMSC), gastrointestinal perforation. Moreover, a recent Emerging Safety Issue (ESI) has been notified pertaining cardiovascular events (MACE) and malignancies.

<div style=\"page-break-after: always\"></div>

The proportion of subject with AEs (exposure up to 16 weeks) was slightly higher in tofacitinib IR than in placebo (54.6% vs 49.2%). However, when the All Tofa cohort is considered (longer exposure), a higher incidence of AEs is found: subjects with AEs were 63.6% in tofacitinib 5 mg BID.

The most frequently reported TEAEs in the tofacitinib arm of the Placebo-controlled Cohort were within the  Infections  and  infestations  (27.6%),  Gastrointestinal  disorders  (13%),  Musculoskeletal  and connective tissue disorders SOCs (8.1%), and ALT/AST increase (3.2% and 2.2%). The most frequently reported  TEAEs  in  the  All Tofa Cohort  were  within  the  Infections and  infestations  (32.1%), Gastrointestinal disorders (16.2%), Musculoskeletal and connective tissue disorders (10.5%) SOCs.

Among the most common AEs, those more common in tofacitinib  5  mg  BID,  and  with  the  highest differences vs placebo , were 'infections and infestations' (36.1% vs 23.0%) and 'investigations' AEs (16.8% vs 4.3%). Most of these investigation AEs were related to increased liver transaminases.

Acute renal failure was observed in more patients treated with tofacitinib than with placebo, 5 (2.70%) vs 2 (1.07%). The small number does not allow drawing any conclusion on this point, but most of the events were mild and creatine increase is already listed as AE in the SmPC.

Hepatic AEs were overall observed more frequently in tofacitinib than in placebo (5.40% vs 1.07%). Consistently with this, a higher proportion of subjects had increased liver transaminases in tofacitinib compared to placebo (AST &gt;3.0x ULN: 2.2% vs 0.5%; ALT &gt;3.0x ULN: 2.7% vs 0.5%).

Seven cases of HZ (all non-serious) were reported in the AS clinical programme. The incidence rate per 100 PY was higher than the incidence rate in the PsA dataset and comparable to the RA dataset (2.7, 1.7 and 3.6, respectively).

SAEs (per 100 PY) were higher in tofacitinib 5 mg than in placebo (5.28 vs 3.56) but occurred in a minority of subjects. Most SAEs were considered mild in severity, only one subject experienced a severe SAE in both tofacitinib 5 mg and tofacitinib all dose groups during the 48 weeks period.

The number of pat ients needing 'dose reduced or temporary discontinuation' was 9.5% vs 3.2% in tofacitinib 5   mg BID versus placebo.

The whole lipid profile was influenced by tofacitinib, with mild increase in total cholesterol, LDL, HDL and triglycerides; an increase in weight was observed among tofacitinib patients compared to placebo groups at 16 weeks (mean change from baseline, kg: 1.8 vs 0.5; in the All tofacitinib cohort at 48 weeks the increase was 2.2 kg) both potentially negatively impacting the CV risk of these patients.

Platelet counts showed a mean decrease of almost -30,000/mm3 after 48 weeks in the All Tofa cohort. AST, ALT and bilirubin increased in the tofacitinib arm but were steady in the placebo arm. However, only one patient had an AE of thrombocytopenia (considered as mild).

Incidence rates for TEAEs, discontinuation of study treatment, discontinuations due to AEs, all infections and HZ were generally higher for females compared to males and for patients &gt;= 65 years old compared to younger patients.

A worst safety profile was observed in patients with previous treatment with TNFi or bDMARD compared to  those  bDMARD-naïve:  AEs  were  72.41%  vs  60.47%.  The  highest  difference  was  observed  for 'Discontinuation of study treatment', which involved 22.41% vs 4.6 5% of patients.

## 3.5. Uncertainties and limitations about unfavourable effects

Even if the safety profile of PR formulation is not expected to be different as compared to IR formulation, still a degree of uncertainty is in place due to the absence of real data on PR formulation and to relying on an assumption.

<div style=\"page-break-after: always\"></div>

From a safety perspective, the limited exposure to tofacitinib IR in the sought indication could not be sufficient to unveil possible adverse effects that could be specific to AS. The placebo-controlled period was limited to 16 weeks; due to this fact, and also to the limited number of patients studied, it is very difficult to evaluate the observed difference in the incidence of AEs; furthermore, many AEs that are typically associated to tofacitinib treatment (such as herpes zoster), are not observed in the placebocontrolled period. This uncertainty applies to PR formulation as well.

Inclusion  criteria  for  AS  trials  only  allowed  inclusion  of  patients  with  a  platelet  count ≥ 100,000 platelets/mm 3 . It is not clear whether patients with lower platelet counts should safely be allowed to be treated with tofacitinib, as a general decrease in platelet count has been observed over time, not only in the AS program but also in the other approved indications (RA and PsA). Platelet counts showed a mean decrease of almost 30,000/mm 3  after 48 weeks in the All Tofa cohort. However, only one patient had an AE of  thrombocytopenia (considered as mild). The SmPC has been modified to  reflect the fact that patients enrolled in the clinical program were required to have a platelet count &gt;100,000 /mm 3 .

Although the incidence rate for most AEs of special interest observed in the AS development program is lower  compared  to  that  observed  in  the  PsA  and  RA  programs  and  cases  of  AEs  that  are  known components of the safety profile of tofacitinib in the other indications: Malignancies, NMSC, CV events of MACE or thrombosis (ATE, PE, and DVT), GI Perforation, Rhabdomyolysis could noy be excluded that these findings should be ascribed to the limited exposure.

Considering  that  the  sought  indication  is  a  chronic  disease  requiring  long-term  therapy  and  also considering some safety concerns of the drug emerging with long-term use, an update of safety data and analyses coming from AS subjects exposed more than 1 year was deemed important to provide reassurance  on  this  key  uncertainty.  However,  the  MAH  considers  the  long-term  safety  profile  of tofacitinib in the AS population as similar to what observed for RA and PsA patients and, thus, the MAH does not plan to conduct further studies to gather long-term safety data from the AS population. Of note, at the time of conclusion of this extension application the impact of the study A3921133 findings on tofacitinib safety and efficacy profile is being assessed in the parallel EMEA/HA20/1517/C/004214/0048 procedure.

Effects by age are very difficult to estimate since the limited number of subjects &gt;65 years (n=13) vs &lt;65 years (n=407).

Overall,  female  patients  had  higher  incidence  rates  of  AEs  compared  to  male,  but  the  cohort  was unbalanced since there were 594 males and 142 females.

Most patients in the tofacitinib 5 mg BID group were White and few were Asian (n=63). Higher incidence of AEs (including infections) was observed in Asian patients.

A  higher  incidence  of  venous  thromboembolism  has  been  observed  in  post-marketing  RA  study A3921133 compared to AS pivotal trials. Considering short follow up in AS pivotal trials, VTE events remain a concern for AS indication also.

## 3.6. Effects Table

Table 78. Effects Table for tofacitinib IR 5 mg in the AS indication

| Effect             | Short description          | Unit               | Tofacitini b 5mg BID   | Placeb o           | Uncertainties / Strength of evidence    | References         |
|--------------------|----------------------------|--------------------|------------------------|--------------------|-----------------------------------------|--------------------|
| Favourable Effects | Favourable Effects         | Favourable Effects | Favourable Effects     | Favourable Effects | Favourable Effects                      | Favourable Effects |
| ASAS20 Wk 16       | %patients achieving ASAS20 | %                  | 56.39%                 | 29.41%             | Difference in response 27.08 (p<0.0001) | Study A3921120     |

<div style=\"page-break-after: always\"></div>

| Effect                        | Short description                                      | Unit                 | Tofacitini b 5mg BID   | Placeb o             | Uncertainties / Strength of evidence    | References                    |
|-------------------------------|--------------------------------------------------------|----------------------|------------------------|----------------------|-----------------------------------------|-------------------------------|
|                               | response at Week 16                                    |                      |                        |                      |                                         |                               |
| ASAS40 Wk 16                  | %patients achieving ASAS40 response at Week 16         | %                    | 40.60%                 | 12.50%               | Difference in response 28.17 (p<0.0001) | Study A3921120                |
| ASDAS- CRP change at week     | Change from baseline in ASDAS-CRP at week 16           |                      | -1.36                  | -0.39                | p<0.0001 for comparison vs placebo      | Study A3921120                |
| ASQoL change at week 16       | Change from baseline in ASQoL units                    |                      | -4.03                  | -2.01                | p<0.001 for comparison vs placebo       | Study A3921120                |
| SF-36 v2 PCS change at week   | Change from baseline in SF- 36v2 PCS                   |                      | 6.69                   | 3.14                 | p<0.0001 for comparison vs placebo      | Study A3921120                |
| BASMI lin change at week      | Change from baseline in BASMIlin units                 |                      | -0.63                  | -0.11                | p<0.0001 for comparison vs placebo      | Study A3921120                |
| FACIT-F change at week        | Change from baseline in FACIT-F                        |                      | 6.54                   | 3.12                 | p<0.001 for comparison vs placebo       | Study A3921120                |
| Unfavourable Effects          | Unfavourable Effects                                   | Unfavourable Effects | Unfavourable Effects   | Unfavourable Effects | Unfavourable Effects                    | Unfavourable Effects          |
| %of n with AE                 | proportion of subject with AEs                         | %                    | 54.6                   | 49.2                 |                                         | Studies A3921120/ 119         |
| infectio ns and infestati ons | proportion of subject with infections and infestations | %                    | 36.1                   | 23                   |                                         | Studies Studies A3921120/ 119 |
| investig ation                | proportion of subject with investigation AEs           | %                    | 16.8                   | 4.3                  |                                         | Studies A3921120/ 119         |
| Hepatic AEs                   | proportion of subject with hepatic AEs                 | %                    | 5.40                   | 1.07                 |                                         | Studies A3921120/ 119         |
| SAEs                          | proportion of subject with SAEs                        | %                    | 5.28                   | 3.56                 |                                         | Studies A3921120/ 119         |

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The favourable effects of the 11 mg PR formulations in patients with AS is the greater adherence to treatment compared with their respective licensed IR formulations (5 mg BID) due to the one daily regimen. However, in the absence of clinical data, the effect of increased adherence to treatment with the PR formulations remains hypothetical.

## 3.7.2. Balance of benefits and risks

The benefits of using tofacitinib 11 mg QD PR formulation for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy are expected to be similar from the AEs perspective to 5 mg BID IR formulation in the same indication.

## 3.7.3. Additional considerations on the benefit-risk balance

EMA ' s safety committee, PRAC, has started a review of the safety of Janus kinase (JAK) inhibitors used to  treat  several  chronic  inflammatory  disorders  (rheumatoid  arthritis,  psoriatic  arthritis,  juvenile idiopathic arthritis, ankylosing spondylitis, ulcerative colitis and atopic dermatitis). Xeljanz is part of the products reviewed in the on-going referral. The review of JAK inhibitors in the treatment of inflammatory disorders  has  been  initiated  at  the  request  of  the  European  Commission  (EC)  under  Article  20  of Regulation (EC) No 726/2004.

The  recommendation  on  the  present  application  is  without  prejudice  to  the  final  conclusions  of the ongoing referral procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data.

## 3.8. Conclusions

The overall B/R of Tofacitinib is positive provided all conditions of the marketing authorisation are fulfilled.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of active ankylosing spondylitis for Xeljanz prolonged release tablets; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. In

<div style=\"page-break-after: always\"></div>

addition, editorial changes have been introduced throughout the PI. The Package Leaflet is updated in accordance. Version 28.1 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

This recommendation is without prejudice to the final conclusions of the ongoing referral procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular, the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion ' Xeljanz-H-C-004214-II0039'

## Attachments

1. SmPC, Package Leaflet (changes highlighted) as adopted by the CHMP on 19 May 2022.